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ABSTRACT 
Despite the success of current biological agents, achievement of broader 
efficacy and improved safety profile remains an unmet need in rheumatoid arthritis 
therapy. Neovasculogenesis plays a vital role in the progression and perpetuation of 
rheumatoid arthritis and significant evidence has demonstrated molecular 
heterogeneity within the endothelium (MVE) of different tissues. The heterogeneity 
of the synovial MVE can be exploited for the development of organ-specific 
therapeutic and diagnostic reagents. A novel recombinant antibody fragment, scFv 
A7, with specificity for human arthritic synovium, was isolated in our laboratory 
following in vivo phage display. The aim of the project described in this thesis is to 
characterise the antibody reactivity and develop a novel tissue specific therapeutic. 
 The scFv A7 antibody proved to specifically target the microvasculature of 
human arthritic synovium with no detectable reactivity in a comprehensive range of 
normal tissues. Furthermore, the detected reactivity was not a common feature of 
chronic inflammatory conditions. Hence, the A7 antibody represents a unique and 
versatile tool with great potential for the development of diagnostic and/or 
therapeutic agents.  
The unique properties of A7 were combined with the anti-TNF Adalimumab, 
forming a bispecific antibody with neutralising activity and synovial homing 
properties. The new construct was able to retain the synovial specificity and 
showed comparable TNF binding kinetics and biological activity to the parent 
Adalimumab antibody in vitro. 
In conclusion, these results demonstrate that scFv A7 reactivity is specific to 
the microvasculature of human arthritic synovium, suggesting that the target 
molecule may have potential as a biomarker in arthritis and applications as an 
immunotherapeutic target. The bispecific antibody format developed showed 
unaltered TNF blocking capacity and synovial specificity that may allow reduction in 
the dosage and/or administration frequency, with the ultimate goal to reduce the 
systemic exposure, achieve a better therapeutic index and decreasing health care 
costs. 
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Chapter 1 - Introduction 
 
1.1 Joint pathophysiology in health and disease 
1.1.1 Normal synovial joint environment  
In the normal human body, bones are connected in structures called joints 
that provide mechanical support and specific functional properties. The joints are 
classified structurally and functionally in three main groups: Fibrous joints 
(Synchondroses), Cartilaginous joints (Syndesmoses) and Synovial joints 
(Diarthrosis). Synovial joints are highly mobile articular structures composed of two 
bones linked by a fibrous capsule with a deeper synovium membrane, which lines 
the joints until the areas of articular cartilage, surrounding a synovial cavity (Figure 
1.1 A). 
The synovial membrane is characterised by two separate layers: the lining 
layer, called intima, consisting of condensed cells one- to four-cells thick and a 
sublining layer, sub-intima, formed by extracellular matrix, dispersed fibroblasts 
and macrophages, blood and lymphatic vessels. The presence of limited cell 
numbers embedded in the extracellular matrix makes the sublining an amorphous 
structure, consisting mainly of loose connective tissue that serves as a base for the 
lining layer. The lining, unlike regular epithelial layers, lacks a real basement 
membrane and the cells form an intricate network of compacted cells with regions 
of cell-to-cell contact where the cells and their processes are separated by wide 
intracellular spaces (1, 2). In the absence of a basal membrane, this function is 
provided by the matrix and the interdigitating cells of the lining themselves. The 
sublining allows for the transfer of protein, small molecules and cellular elements 
from the circulating blood to the lining layer where the reticular organisation of the 
cellular components and the extracellular matrix form a physical and chemical 
barrier respectively, influencing the passage of serum components into the joint 
cavity and provide nutrients to the avascular articular cartilage (1). In healthy 
conditions, the synovial lining layer contains two distinct cell types: macrophage-
like synoviocytes (MLS) and fibroblast-like synoviocytes (FLS). MLS present similar 
features to other tissue resident macrophages, they derive from a common bone 
marrow precursor and show active phagocytic ability, supporting their role in 
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clearance of debris from the synovial cavity and acting as sentinels for microbial 
encounters (3). FLSs are mesenchymal cells expressing common fibroblast markers 
e.g. collagen, vimentin, CD90, while additional markers such as CD55 (decay-
accelerating factor), CD106 (vascular cell adhesion molecule 1 VCAM-1), uridine 
disphosphoglucose dehydrogenase and lubricin have been detected only in the 
lining FLS, suggesting functional differences in the FLS subpopulations (4). FLSs play 
a critical role in normal joint homeostasis, maintaining the synovial extracellular 
matrix by producing matrix components (laminin, tenascin, fibronectin, collagen, 
elastin and proteoglycans), and by influencing matrix assembly via expression of 
integrins such as α5β1 and αVβ3 (5, 6).  
Synovial fluid levels and composition are also influenced by FLS. The synovial 
fluid derives from dialysed plasma filtered by the extracellular matrix in the 
sublining and lining layer and is influenced by the cellular components of the 
synovial membrane. Mature intimal FLS secret the glycoprotein lubricin in the joint 
cavity, contributing to synovial fluid viscosity, and hyaluronan, a long-chain 
glycosaminoglycan, involved in the control of synovial fluid levels. High hyaluronan 
concentrations cause an increase in the oncotic pressure in the joint, restoring the 
reduced synovial fluid levels. Via a negative feedback loop, the expanded synovial 
fluid volumes increases the mechanical stress on intimal FLS, causing a down-
regulation of hyaluronan production (7). 
In the internal cavity of the synovial joint, the articular cartilage protects the 
subchondral bone, providing stiffness to compression and the ability to distribute 
loads, minimising the peak stresses on the bone. The articular cartilage appears as a 
firm inert tissue composed primarily of extracellular matrix with a sparse 
population of cells and absence of blood vessels, lymphatic vessels or nerves (8). 
The chondrocytes are the only cell type present within normal articular cartilage, 
embedded in a hydrated extracellular matrix. Water is the principal component of 
the cartilage matrix, contributing up to 80% of the wet weight, whereas the 
chondrocytes represent only 1% of the total volume. However, chondrocytes are 
essential to maintain the structural integrity and function of the matrix, 
synthesising collagen, proteoglycans and other non-collagenous proteins. Collagens 
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are a family of secreted matrix proteins characterised by a triple-helical peptide 
structure, important for their tensile strength, and represent the most abundant 
macromolecule in the cartilage (9). Among the 14 types of collagen, type II, IX and 
XI are responsible for the cross-banded fibrils in the articular cartilage. 
Proteoglycans are large, negatively charged macromolecules, consisting of a protein 
core and one or more glycosaminoglycan side chains. The chondrocytes maintain a 
tight interaction with the matrix, with the latter protecting the cells from 
mechanical damage, maintaining their shape and phenotype, filtering and storing 
nutrients, substrates for matrix synthesis, metabolic waste products and 
stimulatory molecules. On the other hand, chondrocytes are responsible for matrix 
turnover. The mechanisms that control the balance between anabolic and catabolic 
activity are not fully understood, but aggrecan content of the matrix and cytokines 
appear to have an important role (10, 11). Zinc-dependent matrix 
metalloproteinases (MMP) are primarily responsible for matrix degradation. Stimuli 
such as interleukin (IL)-1 and tumour necrosis factor (TNF)-α induce the expression 
of MMPs, reducing synthesis and increasing catabolic activity, while growth factors 
such as transforming growth factor-beta (TGF-β) and insulin-like growth factor-1 
(IGF-1), promote cartilage synthesis (11). 
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1.1.2 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease 
affecting joints and extra-articular structures and is considered one of the most 
common and severe forms of inflammatory arthritis with significant associated 
morbidity and mortality (12, 13). The disease primarily affects the small diarthrodial 
joints of hands and feet in a symmetrical manner, causing a chronic inflammation of 
the synovium membrane characterised by hyperplasia and hypertrophy (14, 15). 
The major clinical symptoms associated with RA are swelling of the joints, stiffness 
and pain and can develop into profound disability caused by bone erosion and 
cartilage destruction. Systemic features of rheumatoid arthritis include 
cardiovascular alterations, with pericardial inflammation and vasculitis, pulmonary, 
psychological and skeletal disorders, generally associated with increased disability 
and shortened life expectancy (13, 14, 16, 17). RA is a relatively common disease, 
affecting approximately 1% of the adult population in Western Europe with an 
average age of onset of 40 years and an increase in incidence with rising age (18). 
Disease occurrence is generally higher in women than in men with a ratio of 3 to 1 
(18, 19). The burden caused by RA is not only confined to the affected patients, this 
severe chronic disease is also characterised by direct and indirect costs associated 
with primary medical costs, socio-economical costs such as sick leave and loss of 
productivity, and psychological costs represented by the deterioration of the quality 
of life of patients. The annual NHS cost is estimated to be around £560 million, with 
an average of £3500 per patient, and indirect costs amounting to £1.8 billion a year 
have been estimated (20-22). 
RA has a wide clinical spectrum ranging from mild joint symptoms to severe 
inflammation and joint erosion. Clinical symptoms, serological and radiological data 
are taken into consideration when RA diagnosis needs to be assessed. The first 
classification criteria was proposed by the American College of Rheumatology (ACR) 
in 1956 and then revised in 1958 and 1987, and more recently a new classification 
criteria has been developed by the ACR and the European League Against 
Rheumatism (EULAR) in 2010 (23). Patients that show at least one joint with 
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definite clinical synovitis (swelling) not better explained by another disease can be 
considered eligible for the scoring system.  
 
 Score 
Joint involvement 
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
>10 joints (at least 1 small joint) 5 
Serology (at least 1 test result is needed for classification) 
Negative rheumatoid factor (RF) and 
anti citrullinated protein antibody (ACPA) 
0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or High-positive ACPA 3 
Acute-phase reactants (at least 1 test result is needed for classification) 
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
Duration of symptoms 
<6 weeks 0 
≥6 weeks 1 
 
Table 1.1 2010 ACR/EULAR classification criteria for rheumatoid arthritis 
 
For classification purposes, a patient with a score ≥6 is indicative of the 
presence of definite RA. A patient with a score <6 cannot be classified as having 
definite RA, but might still fulfil the criteria at a later time point. This classification, 
compared to the earlier ACR 1987, includes also autoantibody status and acute 
phase response, showing a higher sensitivity but also a lower specificity, especially 
in patients aged ≥60 years (24). 
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1.1.2.1 Aetiology 
 The leading cause for rheumatoid arthritis remains elusive, however there is 
strong evidence linking genetic and environmental factors towards the 
development and progression of the disease. 
Genetic factors 
Hereditability seems to have an important impact on the risk of developing 
RA, several genetic regions have been associated with the disease using 
genomewide analyses. Twin studies have shown a concordance rate of 15-30% 
among monozygotic twins as opposed to 5% in dizygotic twins (25, 26). The region 
of the genome of greatest importance in all studies on RA is the major 
histocompatibility complex (MHC) locus which can account for 30-50% of the 
genetic susceptibility depending on the ethnic group. Human Leucocyte Antigen 
(HLA) class II is involved in antigen presentation to T-helper (Th) cells, which is in 
accordance with the hypothesis of a T-cell repertoire selection and/or antigen 
presentation in the onset of the autoimmune response in RA. In particular the HLA 
subclass HLA-DR1 and HLA-DR4 have shown higher frequency in RA patients who 
are positive for rheumatoid factor or ACPA than in the general population. The 
theory behind this genetic association is the presence of a shared epitope in the 
third hyper-variable region of the β chain. In particular, the HLA-DRβ1 molecules in 
RA share a sequence in position 70-74 (QRRAA or KRRAA or RRRAA) that constitute 
an α helical domain forming one side of the antigen binding site, likely affecting 
antigen presentation (27-29). In different ethnic groups the predominant RA-
associated alleles vary considerably with the alleles DRB1*0101, *0401 and *0404 
being more expressed in Caucasian population and *0405 and *0901 in Asia (27, 
30). Recently it has been demonstrated that the shared epitope is able to 
specifically interact with cell surface calreticulin (CRT), a protein important for 
cellular stress response in the innate immune system triggering increased levels of 
cellular reactive oxygen species. Interaction between the HLA alleles and CRT may 
aberrantly activate an innate immune system signal transduction pathway (31). 
Additionally, the shared epitope was able to trigger murine dendritic cells (DC) to 
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enhance Th17 differentiation and inhibit the generation of Treg cells (32). Other 
gene polymorphisms involved in RA susceptibility have a minor impact. The 
polymorphism R620W on PTPN22, a gene encoding a tyrosine phosphatase 
essential in signal transduction of the T cell antigen receptor (TCR), causes a 
reduced binding activity of the enzyme for the target protein leading to a reduced 
down-regulation of activated T cells (33). However, a more recent study proposed 
an alternative mechanism in which the mutation causes a gain of function resulting 
in an increased threshold level of stimulation for T cells activation, due to a 
decreased TCR mediated calcium mobilisation, leading to thymocyte 
hyporesponsiveness and failure to delete autoreactive T cells during thymic 
selection (34).  
Environmental factors 
Population studies have shown that hereditability can account only for a 
proportion of disease risk factors and genetically similar groups can exhibit marked 
differences in disease prevalence (35). Environmental factors may act as triggers 
rather than being directly involved in the disease process or may act as initiators of 
the disease in susceptible hosts. Smoking represents a key risk factor for RA. Heavy 
smokers (more than 40 pack a year) have a 2-fold increase in the risk of RA 
compared to non-smokers which persists after cessation (30, 36). The exact 
mechanism of action is still unknown, however smoking has been associated with 
an increased level of peptidylarginine deaminase 2 (PAD2) and citrullinated proteins 
in pulmonary cells (37). 
The presence of high levels of citrullinated proteins might trigger loss of 
tolerance towards these neoepitopes and elicit ACPA response, contributing to 
initiate the inflammatory response especially in those who carry the HLA-DRβ1 
shared epitope. Interestingly, alcohol consumption has been found to offer lower 
risk of developing ACPA-positive RA and a dose dependent effect was 
demonstrated in a study of two Swedish cohorts, EIRA and CACORA, and in a more 
recent English study, with heavy drinkers showing a decreased risk compared to 
non-drinkers of up to 50% (38, 39). In addition, carriers of the shared epitope were 
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found to have a more pronounced risk reduction. Infectious agents such as Epstein-
Barr virus (EBV), cytomegalovirus, Escherichia coli, have long been linked with 
rheumatoid arthritis. Molecular mimicry has been proposed as a possible 
mechanism of action (40). According to this model, a systemic infection with a 
microorganism bearing an antigen with enough similarity for a host antigen may 
trigger an immune response and break of tolerance towards the self-antigen, 
resulting in auto-antibodies production and autoimmune response (41). Viral 
infections may also influence and promote autoimmunity through a more direct 
mechanism. EBV is able to infect naïve B cells and allow them to enter the germinal 
centre (GC) in the tonsil where the cells will switch to the viral program called 
latency II and express EBNA-1, LMP-1 and LMP-2a, helping EBV to gain access to the 
memory B cell pool and enter the latent state. LMP-1 has been demonstrated to 
serve as a CD40 transduction signal initiated by CD4+ T cells (42), whereas LMP-2a 
mimics a constitutively activated B cell receptor (43). With these signals, an 
autoreactive EBV infected naïve B cell may be driven into latently infected memory 
B cells, escape apoptosis and ultimately migrate and persist in the target organ 
independently of T cell help.  
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1.1.2.2 Pathophysiology 
As mentioned earlier, the aetiology of rheumatoid arthritis is poorly 
understood and although many possible mechanisms have been suggested none 
has proved to be determinant. However, the pathogenesis and the role of the 
immune system in the disease progression are much better understood. This 
disease can be considered as a syndrome spanning several disease subsets that can 
lead to a common outcome: chronic inflammation of the synovium. Clinically RA 
development consists in several stages beginning with swelling and pain in a limited 
number of joints, slowly spreading to unaffected joints and finally leading to 
destruction of the articular cartilage and subchondral bone caused by the 
hyperplastic and hypertrophic synovium (Figure 1.1 B). A local hypoxic condition 
due to increased metabolic demand of the hypertrophic synovium and extensive 
infiltration, combined to cytokines presence, stimulates local angiogenesis fuelling 
and exacerbating the pathological condition. At the cartilage-bone interface, the 
inflamed synovium forms an aggressive pannus lesion formed mainly of 
macrophages, osteoclasts and fibroblasts, which infiltrate the adjoining articular 
cartilage promoting joint destruction. The mechanism for cartilage destruction is 
related to the expression of a variety of degrading enzymes, including MMPs, 
collagenases, serine and cysteine proteases and cathepsins, that together with pro 
inflammatory cytokines and down-regulation of physiological tissue inhibitor of 
metalloproteinases (TIMP) causes increased cartilage and bone resorption (44). 
The preclinical phase of the disease doesn’t involve joint alterations, 
however ACPAs and rheumatoid factors can be detected more than 10 years before 
RA clinical onset (45) and are usually associated with a more rapid radiographic 
progression and worse outcome of the disease (46). This indicates that 
immunological abnormalities can precede the appearance of clinical features of RA. 
As described in section 1.1.2.2, environmental factors such as smoking can trigger 
the formation of citrullinated peptides and the loss of tolerance resulting in ACPA 
production especially in patients carrying the HLA shared epitope. A second event 
in the synovium, caused by viral infection or trauma, could induce citrullination in 
the joint causing an immune response on the ground of a pre-existing 
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immunisation. When the disease clinically manifests, the synovium shows a 
thickening of the intimal layer with increased numbers of MLS and FLS, the 
sublining layer becomes infiltrated by leukocyte migrating through the synovial 
microvessels causing increased expression of adhesion molecules and chemokines. 
Levels of infiltrate can vary greatly between patients, ranging from low infiltrate 
levels, diffuse distribution across the synovium, to the presence of follicular 
structures that may appear only as lymphoid aggregates or may present features of 
secondary lymphoid structures with high-endothelial venules (HEV), segregation of 
T- and B-cells with a follicular dendritic cell network, acquiring the structure and 
function of ectopic lymphoid structure (ELS) also known as tertiary lymphoid 
structures (TLS) (47, 48) (Figure 1.2).  
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Figure 1.1 Healthy versus rheumatic joint 
Healthy diarthrodial joint with thin synovial membrane lining the non-weight bearing parts 
of the joint enclosing the joint cavity (A). Rheumatoid joint characterised by hyperplastic 
synovial membrane forming an aggressive and invasive pannus with joint cartilage and 
bone erosion. Local infiltration with immune cells contribute to the formation of an hypoxic 
environment stimulating angiogenesis and exacerbating the inflammatory condition (B) 
(Image adapted from Strand et al, 2007) (49).   
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Figure 1.2 Histomorphological features of RA synovium 
Diverse immune cell infiltrates in RA synovial tissue, showing pauci immune synovitis, 
diffuse and follicular distribution. Presence of B-cells (CD20), T-cells (CD3), macrophages 
(CD68) and plasma cells (CD138) showed via immunohistochemistry staining (figure taken 
from Pitzalis et al, 2013) (50). 
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FLS are the most abundant cell type in the synovium, accounting for up to 
two thirds of the total cell population, and characterised by an elongated 
phenotype and a prominent endoplasmic reticulum and Golgi apparatus, indicating 
a strong protein synthesis capacity (7). In disease conditions, this cell population 
undergoes hyperproliferation, possibly due to growth factors presence such as 
platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF) and 
TGF-β (51, 52). However, increased mitotic rates of FLS in RA synovium have not 
been definitively documented. On the other hand however, a decrease of the 
apoptotic rate has been reported despite the toxic environment of the rheumatoid 
synovium. A possible role of p53 mutations (53), Bcl-2 overexpression (54) and Fas 
ligand disregulation (55) have been suggested. The presence of FLS at the 
cartilage/pannus junction suggests an active role in cartilage degradation and 
invasion. Indeed, secretion of MMP-1,3,8,9,10,11 and 13 induced by IL-1, TNF and 
growth factors has been reported in the literature (7, 56). Recently, FLS have been 
recognised as functional inflammatory cells with direct interactions with T- and B-
cells. FLS are the principal source of IL-6 in the synovial intima and could promote 
Th17 differentiation and proliferation (57). In addition, FLS can directly promote B-
cell survival and activity via production of BAFF and APRIL and stimulating class-
switch recombination and IgG/IgA production (58). 
The adaptive immune system has a pivotal role in development and 
perpetuation of the disease. Historically RA has been considered a disease 
mediated by T-cells, specifically CD4+ type 1 helper T-cells (Th1), due to the 
relationship with the increased susceptibility in patients bearing the HLA shared 
epitope that could be responsible for antigen presentation of arthritogenic peptides 
to T-cells via antigen presenting cells (APC) interaction. T-cells are abundant in RA 
synovium, often found in close proximity to B-cells, follicular dendritic cells (FDc) 
and fibroblasts. Synovial T-cells show a highly differentiated phenotype CD45RO+ 
(memory), display markers of activation such as CD69, CD28 and CD40L and are 
characterised by a marked shift towards the Th1 phenotype with production of 
interferon (IFN) γ and inadequate production of Th2 cytokines such as IL-4. 
However, only a limited amount of synovial T-cell cytokine appears to be secreted, 
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probably impaired by a chronic exposure to TNF-α in the synovium that mediates a 
down-regulation of the TCRζ chain causing limited proliferation and effector 
responses (59-62). The paradigm of Th1/Th2 imbalance is not sufficient to explain 
the mechanisms of synovitis and in an animal model of arthritis where the Th1 Ifng 
and Ifngr genes are knocked out, collagen induced arthritis (CIA) results in a faster 
progression (63). Recently more attention has been focused around the role of 
Th17 cells as potential crucial effector cells in RA and the paradigm has now shifted 
from Th1/Th2 to Th17/Treg imbalance. Th17 are a subset of CD4+ T helper cells 
producing mainly IL-17, which differentiate from naïve T-cells upon stimulation with 
IL-6 and TGF-β. In a CIA mouse model of arthritis, onset of the disease in IL-17 
deficient mice was suppressed, while the administration of anti-IL-17 antibodies 
could reduce joint inflammation and damage after the onset of arthritis (64, 65). 
The role of Th17 in the RA pathogenesis could be related to the IL-17 induced 
expression of IL-1, IL-6, TNF-α, metalloproteinases and chemokines by stromal cells, 
in particular fibroblasts. Tregs are an additional T-cell subset that plays an 
important role in maintenance of immune tolerance. They exhibit the CD4+CD25+high 
phenotype and are characterised by the expression of the transcription factor 
Foxp3. Tregs have been described in vitro as able to suppress proliferation and 
cytokine production of CD4+ CD25- T cells (66) and suppression of macrophages 
(67), B-cells (68) and dendritic cells (69). Secretion of cytokines such as IL-10, IL-35 
and TGF-β and of cytotoxic factors such as perforin and granzyme B are at the basis 
of the suppressive activity of this cell population. In rheumatoid arthritis, the Treg 
function appears impaired, being unable to suppress pro-inflammatory cytokine 
release by T-cell and macrophages despite the inherent enhanced suppressive 
capacity of Tregs found in RA synovial fluid (70). This deficiency has been linked to a 
defective expression of cytotoxic T lymphocyte-associated protein (CTLA)-4 (71). 
Additionally, the elevated cytokine levels in the RA synovium, in particular TNF-α, 
IL-1 and IL-6, despite promoting an increased recruitment of Tregs at the site of 
inflammation, act as suppressor of their immune modulatory activity (70, 72).  
As mentioned above and shown in Figure 1.2, immune cells aggregates can 
occur in the synovium of patients with rheumatoid arthritis, with B cells mainly 
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localised in the T-cell/B-cell aggregates (47, 48). These structures can be functional 
and present typical secondary lymphoid characteristics such as follicular dendritic 
cell (FDC) network, HEV, peripheral lymph node addressin (PNAd), important for 
lymphocyte homing, and CCL21 expression which is usually produced by lymph 
node myofibroblasts. In addition, these structures have been demonstrated to be 
able to promote B cell survival and proliferation, stimulate class switch 
recombination via activation-induced cytidine deaminase (AID) expression, and 
promote active expression of human IgG ACPA and therefore contribute to the 
pathogenesis of rheumatoid arthritis (73). 
The synovial fluid and synovial tissue house a large number of innate 
effector cells, amongst which macrophages and neutrophils are the predominant 
cell type. Macrophages are found in the synovial membrane and represent, along 
with fibroblasts, the cellular constituent of the synovial lining layer in normal 
conditions (3). During RA, macrophages act as central effectors in synovitis 
development with a high efflux from the bone marrow directed to the synovium, 
following stimulation with macrophage colony-stimulating factor (M-CSF), 
granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (74). Their role in the pathogenesis of RA is further 
supported by the fact that conventional therapies act to reduce the levels of 
cytokines produced by macrophages (75). Macrophages are an important source of 
pro-inflammatory cytokines in the synovium, including TNF-α, IL-1, IL-6, IL-15, IL-18, 
IL-23 which suggests a predominant M1 phenotype (14), and produce short half-life 
mediators of inflammation, matrix-metalloproteinases, nitrogen intermediates and 
growth factors that promote cell survival in the rheumatoid synovium. Activated 
macrophages can be found at the cartilage-pannus junction and are important 
contributors in joint erosion. The second innate effector population is neutrophils, 
which is the most abundant cell type in synovial fluid. This cell type is known for 
producing a wide range of inflammatory mediators such as TNF-α, IL-1, IL-6, IL-15, 
IL-18 and BAFF, promoting synovial inflammation and joint destruction and 
contribute to synovitis by synthesis of prostaglandins, proteases and reactive 
oxygen intermediates (76). 
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1.1.3 Synovitis in Osteoarthritis 
 Osteoarthritis is the most common articular disorder worldwide consisting 
in a chronic disease resulting from biomechanical damage to the articular cartilage. 
Although initially considered as a simple disease arising from joint cartilage 
degradation due to advanced age, now it is considered a complex disorder with a 
substantial involvement of immunological factors in the synovium. This disease 
shows a similar prevalence in males and females during reproductive life, although 
post-menopausal women are subjected to an increased predisposition suggesting a 
role of sex hormones in disease modulation (77). Obesity is currently considered 
the strongest risk factor for OA development (78, 79), however, mechanical factors 
are considered the leading cause of the disease in which injury to the joint may 
cause disruption of joint biomechanics, accentuating pathological damage and 
increasing the risk of OA development (77). The OA synovium is often characterised 
by a thickened lining layer and the presence of perivascular and diffuse lymphocyte 
infiltrates (80). Macrophages are among the most abundant cells present in the OA 
inflamed synovium and are responsible for the expression of the two major pro-
inflammatory cytokines IL-1β and TNFα (81). IL-1β is overexpressed during OA and 
has been shown to up-regulate the expression of MMP catabolic enzymes 1, 3 and 
13, the aggrecanases ADAMTS-4 and 5 in human chondrocytes (82, 83) and inhibit 
the expression of type II collagen and proteoglycans (84, 85). TNFα acts in synergy 
with IL-1β stimulating cartilage resorption and inhibiting proteoglycan synthesis 
(86). The OA synovium is also characterised by the presence of T-cell infiltrates both 
CD8+ and CD4+, with a predominant Th1 phenotype (87). In addition, analysis of the 
α/β gene repertoire suggested an undergoing clonal expansion in response to 
synovial antigens (88). Oligoclonal expansion was also reported for activated B-cells 
and several groups described the presence of antibodies targeting cartilage 
components (89). 
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1.2 Neoangiogenesis 
 During organ development, growth and tissue remodelling, the vascular 
compartment undergoes reorganisation, characterised by vasculogenesis, defined 
as recruitment of endothelial progenitor cells and formation of new vessels, or 
angiogenesis, formation of new capillaries from pre-existing vessels. A 
subpopulation of CD34+ cells expressing the vascular endothelium growth factor 
(VEGF) receptor 2 has been identified as endothelial cell progenitors and is 
responsible for vasculogenesis following recruitment via stimulation of the CXCR4 
receptor with the chemokine SDF-1/CXCL12. Several factors can stimulate 
angiogenesis in vivo, including chemokines, matrix molecules, cell adhesion 
molecules, growth factors and cytokines. VEGF is one of the strongest stimulators 
of angiogenesis and can be upregulated in conditions of hypoxia, leading to 
enhanced blood vessel formation and the restoration of blood and oxygen supply to 
the affected tissues (90). In response to those stimuli, the vascular endothelial cells 
(EC) become activated and release proteases (such as MMPs) to digest the 
underlying basal membrane and allow the emigration of endothelial cells from the 
extracellular matrix in a mechanism called sprouting (91). The sprouting cells would 
then form a column of migrating and proliferating cells moving towards a VEGF 
gradient (92). When the destination is reached, the endothelial cells start forming 
the lumen of the newly formed vessel and secrete growth factors such as PDGFβ to 
attract pericytes that envelop the immature vessel, induce EC growth arrest and 
promote vessel maturation (93, 94) (Figure 1.3).  
Pericytes are important components of the microvasculature and are 
ubiquitously present in blood microvessels, extending the cytoplasmic processes 
along the surface of endothelial cells. Pericytes and ECs are generally separated by 
the basal membrane in which the pericytes are embedded, with occasional contacts 
of peg-socket type. The reason for tissue specific density and distribution is 
unknown but it is modulated by blood pressure levels, inflammation and hypoxia 
(95). Pericytes are responsible for vasoconstriction and vasodilation of capillaries, 
regulating diameter and blood flow in response to specific adrenergic stimuli, 
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angiotensin II and endothelin-1 (96). In addition, oxygen levels have been proven to 
influence cellular contraction. Specifically, hyperoxia increases pericyte contraction, 
causing vasoconstriction and blood flow reduction, while hypoxia and high levels of 
carbon dioxide cause relaxation and vasodilation increasing blood flow (93). Organ 
specific functions have been reported in the literature, pericytes are important for 
structural integrity of the blood-brain barrier (97) and for the glomerular capillaries 
in the kidney (98). 
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Figure 1.3 Angiogenesis 
Hypoxia induced vessel sprout characterised by degradation of basal membrane and 
extracellular matrix (orange lines) and endothelial cell (green cells) migration following a 
VEGF gradient. Endothelial expression of PDGFβ attracts pericytes (red cells) that provide 
support to the newly formed vessel and promote maturation (figure adapted from Bergers 
et al, 2005) (93). 
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1.2.1 Role of angiogenesis in rheumatoid arthritis 
 As previously described, rheumatoid arthritis is characterised by 
inflammation and extensive angiogenesis. During disease onset and progression, 
the synovium undergoes expansion with hyperproliferation of synoviocytes and 
leukocytes infiltration from peripheral circulation. This change in synovial cellularity 
causes an increased metabolic demand and oxygen consumption, leading to 
hypoxia. The oxygen pressure in the synovium can then drop from 9-12% in normal 
individuals to 2-4% in RA patients (99). The regulators of the oxygen tension are 
called hypoxia-inducible-factors (HIF). HIF is a heterodimeric transcription factor, 
formed of subunits HIF-α and HIF-β, able to bind to hypoxia-response elements 
(HRE) on target genes and activate transcription. Two isoforms of HIF-α are 
expressed in human arthritic synovium (100). VEGF is one of the best characterised 
HRE-containing genes and increased levels of VEGF/VEGF receptor in RA synovium 
have been described in the literature as a consequence of hypoxia (99, 101). Up-
regulation of SDF-1, proinflammatory cytokines (IL-6) and matrix 
metalloproteinases (MMP1 and MMP6) have also been associated with HIF 
activation in RA synovium (102, 103), suggesting a direct role of hypoxia in synovial 
angiogenesis, inflammation and cartilage degradation. Interestingly, 
proinflammatory cytokines such as IL-1β and TNFα are able to directly stimulate HIF 
expression in normoxia, further strengthening the relation between hypoxia and 
inflammation (104). However, despite the increased vascularisation, the synovial 
tissue remains hypoxic, which is possibly due to the formation of abnormal vessels 
and results in impaired perfusion and oxygenation (105). 
 During inflammation circulating immune cells are recruited in the affected 
tissue via interaction with the endothelial layer of blood vessels. This passage 
involves interaction of constitutive and inducible surface cell adhesion molecules 
(CAM) on endothelial cells and leukocytes and extravasation of the latter in the 
target tissue (Figure 1.4). In the first step, weak adhesion takes place between 
leukocyte and the vascular endothelium mediated by low affinity binding of 
selectins. In the presence of inflammation, the cells undergo activation/triggering 
induced by the presence of chemokines anchored to the EC via proteoglycans (106). 
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Following chemokine/chemokine receptor binding, the cells become activated, 
triggering the expression of integrins necessary for high affinity interaction with the 
endothelial layer (107). Finally, the adhered leukocytes initiate the extravasation 
process through the endothelium and the basal membrane. During this process the 
leukocytes engage specific immunoglobulin molecules, causing the opening of the 
endothelial barrier mediated by production of proteases, polarisation of chemokine 
receptors and migration towards the chemokine gradient (108-110).  
 General inflammation triggers the expression of E- and P-selectins on 
endothelial cells to facilitate the initial tethering phase, alongside ICAM-1 and 
VCAM-1 to induce firm adhesion with β2 integrins and stimulate trans-endothelial 
migration. Similarly, rheumatoid synovial endothelial cells express E- and P-selectins 
as well as ICAM-1 and VCAM-1 (111, 112). Notably, the integrin αVβ3 seems to play 
and important role in angiogenesis and disease progression (113) and blockade 
with αVβ3 antagonist provided reduction of angiogenesis and significant protection 
against cartilage erosion in animal models (114). However, very little efficacy was 
demonstrated in human RA trial (113). Chemokines and chemokine receptors have 
also been implicated in synovial inflammation and angiogenesis, where 
constitutively expressed chemokines important for homeostatic functions can drive 
and actively promote inflammation in the synovium. Hypoxia can stimulate the 
production of SDF-1/CXCL12 from synovial fibroblasts contributing to CXCR4+ T-cell 
retention and stimulation of angiogenesis (115, 116). CXCL13 chemokine, mainly 
expressed by FDCs, interacting with the CXCR5 receptor has been implicated in the 
formation of tertiary lymphoid structures in RA synovium, where organisation of T- 
and B-cell aggregates can support and promote local inflammation (117). Among 
other chemokines important during phase two of leukocyte migration, CCL2, 
CXCL8/IL-8 and CCL5 (RANTES) are overexpressed in RA synovium. CCL2, mainly 
expressed by macrophages, contributes to attraction of macrophages, T- and 
natural killer (NK)-cells on site; CXCL8 is important for neutrophil and monocyte 
attraction and CCL5, mainly expressed by synovial fibroblasts acts as a 
chemoattractant for monocytes and T-cells (118). 
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1.2.2 Organ tropism 
 The vascular endothelium represents the first barrier encountered by 
circulating leukocytes before they migrate into the target tissue. Direct interaction 
between CAMs expressed on the endothelial layer and on the migrating leukocytes 
is the basis of general translocation mechanism. However, there is evidence 
supporting organ specific signals that can direct specific leukocyte subsets to the 
target tissue. The organ tropism is mediated by the expression of homing receptors 
on circulating leukocytes that interact with specific vascular addressins expressed 
on the microvascular endothelium of the target organ and facilitated by chemokine 
gradient (119, 120). 
 Peripheral lymphoid organ tropism has been described in the past, L-selectin 
expression on naïve T-cells interacts with PNAd expressed on HEV in secondary 
lymphoid organs, necessary for peripheral lymphoid tissue homing (121). L-selectin 
knockout mice showed reduced leukocyte adhesion to HEV and smaller peripheral 
lymph nodes (PLN) structures, related to reduced PLN lymphocyte numbers (122). A 
second homing signal is dictated by CCR7 chemokine receptor expressed by PLN 
naïve T cells, which interacts with CCL19 and CCL21 chemokines expressed in the 
lymph nodes (123). 
 Intergrin α4β7 expression in T-cell subsets is important for interaction with 
gut mucosal venular endothelium MAdCAM-1 and homing to gut associated 
lymphoid tissues (GALT) (124). Mice deficient for α4 or β7 subunits or treated with 
α4β7 antagonists are characterised by underdeveloped GALT (125). CCL25 
expression further strengthens the homing capacity of CCR9 expressing α4β7+ T-
cells to gut mucosal tissues (126). 
 Another well characterised organ tropism is T-cell skin homing mechanism, 
where CLA expressing T-cells are able to bind to E-selectin on skin MVE (127). In 
conditions characterised by skin inflammation and patients affected by T-cell 
lymphoma, infiltrating T-cells are confined to CLA expressing subsets (128, 129), 
aided by CCL17 chemokine stimulation of CCR4 receptor on T-cell surface (127). 
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  There is thus evidence for molecular heterogeneity within the 
microvascular endothelium of different organs and tissues. In an attempt to identify 
such molecules, Rajotte and colleagues adopted intravenous in vivo phage display 
technology (described in section 1.4.1) to select several peptides able to selectively 
target lung, skin and pancreatic tissues among others, in murine models (130). For 
each organ different peptides were isolated, suggesting the presence of a variety of 
organ specific markers. Furthermore, they showed that specific peptide motifs 
preferentially recognised the vascular environment of different tissues. Similarly, 
Arap and colleagues used in vivo phage display in terminally ill human patients via 
intravenous administration of the phage library and recovery of bound phage clone 
from biopsies (131). More than 47000 motifs from 4716 phage clones were isolated 
showing specific organ localisation. More recently, the adaptation of the in vivo 
phage display assay using severe combined immunodeficient (SCID) mice grafted 
with human arthritic synovium allowed the isolation of peptides showing homing 
specificity for the synovial microvasculature (132). 
This heterogeneity can be exploited for the identification of tissue and/or 
disease specific markers to be used for targeted delivery approaches. Towards this 
goal, it has been demonstrated that specific peptides can be exploited for targeted 
drug delivery in an attempt to lower systemic doses and increase effectiveness 
(133-136). 
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1.3 Treatment of rheumatoid arthritis 
 With 1% of incidence in the Western population, rheumatoid arthritis is 
considered a relatively common disease (18) with a high impact on national health 
systems (20-22). From a commercial point of view, rheumatoid arthritis is one of 
the most lucrative markets for pharmaceutical industries, mostly related to 
monoclonal antibody therapies which generated revenues for US$ 23 billion in 2011 
and are expected to rise from US$ 11.5 billion in 2011 to US$ 15.7 billion in 2018 in 
US, Japan, Germany, France, Spain, Italy and UK markets (137). Despite the obvious 
success of the current therapeutic approaches in treatment of RA, clinical studies 
have shown that achievement of treatment-free remission, which is the ultimate 
goal for clinical practice, can be reached only by 9.4-15% of patients (138). 
Additionally, 20-40% of the patients do not respond to the available therapeutics 
(139, 140). To evaluate responsiveness to treatments and validate clinical outcome, 
the Disease Activity Score (DAS) in Europe and the ACR response criteria in North 
America have been adopted. The DAS28 is a composite outcome measure assessing 
how many joints in the hand, wrists, elbows, shoulders and knees are swollen or 
tender, the ESR and CRP in the blood to assess inflammation, and the patient’s 
visual analogue score to assess the patient’s feeling. A score below 2.6 indicates 
disease remission, while a score over 5.1 suggests high disease activity (141). For 
standard readout, the ACR score is set at three goal points, ACR20, ACR50 and 
ACR70, representing 20%, 50% and 70% improvement respectively, of the ACR 
criteria. These criteria involve number of swollen or tender joints, patient’s global 
assessment, pain assessment and physical assessment, physician’s global 
assessment, ESR and CRP values (142). 
1.3.1 Synthetic DMARD 
 The clinical approach to RA has changed over the past 30 years. In the 1980s 
a pyramid strategy was adopted, following the “go low go slow” philosophy with a 
gradually build up therapeutic intervention starting with non-steroidal anti-
inflammatory drugs (NSAIDs) and finishing with disease modifying anti-rheumatic 
drugs (DMARD) when erosion became evident. Often the therapy was maintained 
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unaltered for long periods of time. This approach has now been substituted by an 
inverted pyramid approach, characterised by the use of DMARDs early in the course 
of the disease with frequent therapy changes to tailor the therapy to the individual 
(143). 
Methotrexate is now the first-line DMARD for most patients. This molecule 
acts as a folate antagonist, blocking purine synthesis with cytostatic properties at 
high dosage. At the therapeutic dosage however, extensive cytotoxicity does not 
occur (143). The reason behind the success of this compound lies on the relatively 
fast onset of action, a considerable success rate with 50-80% clinical response 
compared to baseline and acceptable adverse side effects that translates increased 
patient’s tolerability (144). However, true remission has not been reported. 
Leflunomide is an inhibitor of dihydroorotate dehydrogenase, an enzyme 
required for pyrimidine synthesis, primarily used as an alternative to methotrexate. 
The specific mechanism of action in rheumatoid arthritis is not known but it has 
been shown to affect lymphocyte function (145). Leflunomide produced similar 
clinical results to methotrexate, with approximately 50% of patients achieving 
ACR20 and 34% achieving ACR50 (144). Due to the similar mechanism of action, the 
adverse effects of Leflunomide were comparable to methotrexate, however, due to 
the teratogenic effect observed in animals it is not recommended for women in 
childbearing potential. 
Sulfasalazine is a synthetic compound developed in the late 1940’s with the 
specific purpose of RA inflammation treatment, showing efficacy in reducing 
radiological damage and alleviating symptoms (143). 
Comparison of DMARD monotherapy in patients revealed an increased 
ACR20 success rate for methotrexate compared to leflunomide but a worse health-
related quality of life (146, 147). Leflunomide however, resulted in a higher 
percentage of patients achieving ACR20 and 50 compared to sulfasalazine in a 
double-blind randomised trial (147, 148), while three trials showed similar ACR20 
for methotrexate and sulfasalazine (147). Notably, triple combination of 
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methotrexate, sulfasalazine and hydroxychloroquine resulted more efficacious that 
single therapy or double therapy in randomised double blind trials (149, 150), 
stressing the importance of inhibiting different pathways to achieve better 
effectiveness. However, data are still insufficient to determine which combination 
outweighs another, especially when highly selected populations in different trials 
are compared, and a patient tailored therapeutic approach is still preferable.  
1.3.2 Biologic agents 
 Since the mid 1970’s production of rodent-derived monoclonal antibodies 
became accessible, opening the road for the magic-bullet dream and the beginning 
of the antibody therapy era (151). The new possibilities given by this technology 
radically changed the clinical management of RA with the raise of the biologic 
agents in the therapy or arthritis (Figure 1.4). Monoclonal antibodies developed for 
clinical purposes generally belong to the IgG class due to the effector functions 
exerted by the constant region of γ globulins (152). In particular, the IgG1 isotype is 
the most suited to trigger effector functions such as antibody-dependent cellular 
cytotoxicity (ADCC) and complement fixation (152). An IgG antibody is characterised 
by the presence of a heavy chain and a light chain. The heavy chain is composed of 
a variable region (VH) linked to three constant domains (CH) with a hinge region 
separating the CH1 from the Fc region (CH2 and CH3 domains), responsible for 
homodimerisation through the formation of two disulphide bonds. The light chain is 
constituted of a variable (VL) and a single constant domain (CL) which forms a 
disulphide bond with the CH1 domain, allowing heavy and light chain pairing (153). 
Two types of VL, defined as κ and λ light chain, are available, with the former being 
the most represented amongst functional natural IgG antibodies. Schematic of an 
IgG antibody is shown in Figure 1.6. 
By the mid 1980’s TNF had been described as a pleiotropic cytokine with 
clear contribution to synovitis and bone resorption in rheumatoid arthritis (154, 
155). CD4+ T-cells and macrophages are the main producers of this cytokine and the 
expanded population in the synovium can lead to an overproduction with 
deleterious effects. In addition, TNF inhibition was able to reduce the production of 
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pro-inflammatory cytokines such as IL-1, IL-6 and IL-8 as well as growth factor G-CSF 
(156) and showed to efficiently prevent joint destruction in animal models of 
arthritis (157, 158). These findings led to the notion that TNF plays a dominant role 
in the inflammatory cascade. TNF-α is initially expressed as a trans-membrane 
protein of 26 kDa (tmTNF) in a homotrimeric format with a total molecular weight 
of 78 kDa. The soluble form of TNF is created by cleavage of the extracellular 
domain by the TNF-converting enzyme TACE (or ADAM17). The final molecular 
weight of the soluble TNF is 17 kDa, present in a 51 kDa homotrimer. Once in 
soluble format, the TNF maintains the biological activity of the tmTNF without the 
localisation constriction (159). Two receptors are available for TNF: p55 (TNFR1) 
and p75 (TNFR2). Interestingly, the two forms of TNF are able to elicit distinct 
effects, which is to be put in relation with the differential binding capacity for the 
two receptors. Indeed, tmTNF was shown to be superior in activating the TNFR2 
compared to sTNF (160). In respect to rheumatoid arthritis, the p55 TNFR1 was 
shown to be more influential in disease onset and progression. Mice overexpressing 
TNF are characterised by the spontaneous development of inflammatory conditions 
such as erosive polyarthritis and bowel disease. Knockout of the p55 gene showed 
abrogation of arthritic condition and reduced gut involvement, while knockout of 
the p75 gene didn’t provide the same protection (161). Possibly, the pathologic role 
of p55 is to be linked to the downstream activation pathway that leads to NFkB 
activation, stimulating cell survival (162).  
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Figure 1.4 Biologics in rheumatoid arthritis 
Schematic demonstration of current biologic therapeutic targets. Anti-TNF biologics, 
Anakinra and Tocilizumab act as cytokine inhibitors, blocking TNFα, IL-1 and IL-6 
respectively. Abatacept, a CTLA-4 –Fc fusion protein, binds CD80/86 on APC, preventing co-
stimulation of CD28 and T-cell activation. Rituximab is an anti-CD20 antibody able to induce 
B-cell depletion, preventing antibody production such as ACPA and RF (figure adapted from 
van Vollenhoven 2009) (143). 
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In 1999 two anti-TNF molecules were almost simultaneously registered for 
the treatment of RA, Etanercept and Infliximab. Etanercept is a fusion protein 
consisting in the human IgG1 Fc domain and the TNFR2 (163). Infliximab is a 
chimeric monoclonal antibody characterised by human IgG1 constant domains and 
murine derived variable regions (164). A few years later a fully human anti-TNF 
antibody was developed under the name of Adalimumab and commercialised as 
Humira (165). Interestingly, Adalimumab is the first FDA approved antibody to be 
derived from phage display technology. Since then, two more anti-TNF agent have 
been produced, Golimumab and Certolizumab pegol. Golimumab is a human 
monoclonal IgG1κ antibody (166), while Certolizumab pegol is a PEGylated Fab 
(fragment antigen binding) of a humanised anti-TNF monoclonal antibody (167). No 
randomised controlled clinical trials comparing Etanercept, Infliximab and 
Adalimumab are available. However, two cohort studies reported a faster response 
for Etanercept, compared to Infliximab, but with no clinically relevant differences in 
efficacy (168, 169). Indirect comparison of the three anti-TNF biologics showed no 
difference in terms of ACR20 and ACR50 rates (147, 170). Furthermore, a patient 
who has failed to respond to an anti-TNF agent, has a probability of responding to a 
second anti-TNF agent of approximately 50% (ACR20 criteria) (139). Infliximab and 
Adalimumab proved to be effective in Crohn’s disease while Etanercept showed no 
efficacy (171-173). The reason behind this discrepancy may lie on the mode of 
administration and on the anti-TNF structure. Both Infliximab and Adalimumab are 
full IgG antibodies, while Etanercept contains only the Fc domain of an IgG. This 
might result in a differential ability to fix complement or induce ADCC. However, no 
real indication of complement or ADCC on Infliximab activity has yet been described 
(174). Most likely, the differential efficacy of anti-TNF agents derives from the 
interaction with TNF (Figure 1.5). Infliximab and Adalimumab are bivalent 
antibodies able to target two TNF monomers at the same time and potentially two 
TNF homotrimers as well (175, 176). Interestingly, the most thermodynamically 
stable complex was a 600 kDa macromolecule composed of three antibodies and 
three TNF homotrimers (Figure 1.5 B) (176). At the same time, Adalimumab and 
Infliximab are able to engage the tmTNF and act as a bridge, crosslinking two tmTNF 
trimers. In doing so, the tmTNF cytoplasmic domain is phosphorylated in a specific 
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serine residue, causing a reverse signalling transduction and inducing apoptosis 
(177, 178). Due to the monovalent format, Etanercept was not able to elicit the 
apoptotic signal through tmTNF, although the ability could be restored following 
crosslinking (178). However, the clinical importance of the apoptotic signal in RA 
therapy is still debated (159).  
Among the adverse effects related to anti-TNF therapy, injection site 
reactions are the most common. However, the most severe adverse effects are 
related to the mechanism of action of the drug. Increased incidence of infectious 
complications, from common or opportunistic pathogens, has been reported in 
clinical practice and reactivation of latent tuberculosis was reported early in the 
development of Infliximab (179). Screening for at-risk patients substantially reduced 
tuberculosis occurrence (180).  
Infliximab is a chimeric antibody, containing the murine variable domains 
and Etanercept is a fusion protein with a synthetic linker. Due to the exogenous 
amino acid sequences, immunogenicity is a concern. The production of anti-drug 
antibodies (ADA) against Infliximab, but also Adalimumab, has been described, with 
IgG1 and IgG4 subtypes as predominant ADA detected for the two biologics (181). 
Reduction of clinical efficacy might occur in some patients and increased frequency 
of minor and major clinical adverse effects has been linked to ADA levels (181). 
Difference in patients’ reaction is related to variable levels of circulating ADA which 
if in low concentration are insufficient to bind and inhibit the entire pool of 
therapeutic antibody. The proposed mechanism of action of ADA is neutralisation 
of the antibody by steric hindrance, blocking the binding to its target and 
preventing biological activity, and formation of immune complexes, resulting in 
faster clearance and reduced half-life (181).  
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Figure 1.5 Mechanism of action of anti-TNF agents 
Schematic representation of TNF neutralisation by anti-TNF biologics. The TNFR2-Fc fusion 
protein Etanercept is able to engage TNF in a monomeric fashion (A). Adalimumab and 
Infliximab IgG antibodies are able to bind two TNF monomer or trimers simultaneously. The 
stable soluble aggregate consists in three TNF trimers and three anti-TNF IgGs. Binding on 
trans-membrane TNF induces ligand cross-linking and reverse signalling through the 
cytoplasmic domain (B). Fab antibody fragment Certolizumab is able to bind TNFα only in a 
monomeric manner (C). (figure adapted from Rigby, 2007) (159).  
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Anakinra is an IL-1 receptor antagonist used in the treatment of moderate-
severe rheumatoid arthritis in patients that did not respond to the initial DMARD 
therapy. Animal models overexpressing IL-1 are characterised by joint 
histopathologic changes similar to RA and increased osteoclast differentiation (182, 
183). A double blind randomised clinical trial confirmed efficacy of Anakinra in 
comparison to placebo (184), although a lower efficacy and increased risk for 
injection-site reactions was observed when compared to anti-TNF biologics (ACR20 
and ACR50 criteria) (170, 185). 
 A third strategy is the inhibition of IL-6 activity. Tocilizumab is a humanised 
monoclonal antibody, characterised by the backbone of the human IgG antibody 
with murine CDR regions, targeting the IL-6 receptor (IL-6R). During RA, IL-6 binds 
the soluble or membrane-bound form of IL-6R, inducing angiogenesis and activating 
osteoclasts, T- and B-cells (186). Tocilizumab showed comparable efficiency to the 
anti-TNF agents with similar adverse effects (187). Most common side effects were 
infections of the upper respiratory tract and gastro-intestinal tract. Patients 
previously treated with anti-TNF agents were more prone to develop severe side 
effects such as pneumonia, gastroenteritis and urinary-tract infections but also 
malignancies and haematological disturbances with significant alterations in plasma 
lipid concentrations (187). 
 Rituximab, a chimeric monoclonal antibody against the membrane protein 
CD20 found on naïve, mature and memory B-cells but not on pro-B-cells, 
plasmablasts and long-lived plasma cells (188). Although the exact mechanism of 
action remains unknown, Rituximab appears to act via induction of apoptosis, 
ADCC, and complement–dependent cytotoxicity (189). Generally one month after 
single treatment the B-cell compartment appears depleted, with the exception of B-
cell precursors and long-lived plasma cells (190, 191). The depletion is reversible 
and peripheral B-cells start to repopulate to reach basal levels around 6-10 months 
post treatment (192). Interestingly, RF and ACPA serum titres were significantly 
decreased at 24 and 36 weeks respectively, while antibodies against common 
foreign antigens were not affected (192). Furthermore, clinical response was more 
pronounced in RF+ and ACPA+ patients, providing a biomarker for patients 
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stratification (193, 194). This suggests that Rituximab is able to selectively affect 
short-lived autoantibody secreting plasma cells. However, despite efficiently 
depleting B-cells in all the treated patients, a substantial percentage of patients do 
not respond to the treatment in clinical terms. Notably, synovial B-cells seem to be 
less affected by Rituximab treatment, probably due to environmental factors in the 
synovium, and patients with higher levels of clinical response are characterised by a 
more consistent B-cell depletion (195, 196). Following Rituximab treatment, many 
patients relapse when B-cell titres are still low, suggesting a more complex 
mechanism of action than the one described above (197). Genome-wide gene 
expression profiling revealed a clear distinction between responder and non-
responder patients. In patients responding to the therapy, the INF response gene 
expression was increased, while limited or no expression could be detected in non-
responding patients (197). Concern was raised for Rituximab therapy due to the 
prolonged B-cell depletion. Assessment of toxicity and impact of side effects in the 
long term are still preliminary but encouraging (198). Among the adverse effect 
described for Rituximab the most common are injection-site reaction and increased 
rate of infections (199). 
 The CD80/86 – CD28 interaction between antigen presenting cells and T-
cells respectively, is the target of Abatacept. This biologic agent is a fusion protein 
between the extracellular domain of CTLA-4 and the Fc region of human IgG1 (200). 
The CTLA-4 domain is able to bind CD80 and CD86, preventing co-stimulation of 
CD28 on T-cells and promoting anergy (201). In phase III studies Abatacept proved 
to be efficient in patients showing inadequate methotrexate response and TNF 
blockade failure with an average of 50% improvement for the ACR20 criteria 
compared to placebo (199). As mentioned for the other biologics, the main adverse 
effects were related to infusion reactions and increased infections rates but 
generally the drug is well tolerated (202). 
 Although the biologics have substantial impact as monotherapy, 
combination with methotrexate showed a better clinical response than 
Adalimumab, Infliximab, Etanercept or Rituximab alone (147). However, due to the 
immunosuppressive properties of each biologic agent, combination therapies 
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between biologics showed increased incidence of severe adverse effects and did 
not provide evidences for higher efficiency compared to biologic + DMARD co-
therapy (203, 204). 
1.3.3 Bispecific antibodies 
 Recently, bispecific antibodies (BsAb) are gaining momentum with 
increasing clinical success. Bispecific antibodies are an emerging class of biological 
therapeutics characterised by binding capacity to two distinct epitopes. This can 
potentially lead to simultaneous inhibition of two cell surface receptor or soluble 
molecules, cross-linking of two receptors and recruitment of effector cells in the 
proximity of a target expressing cell. This last aspect has been the reason for the 
success of bispecific antibodies in cancer therapy. BsAbs directed against the CD3 
antigen expressed on T-cells are able to redirect the T effector cells to the desired 
site when the second arm has the relevant specificity (205).  
Engineering of standard IgG antibodies has led to the development of 
several bispecific antibody construct strategies, combining different properties and 
characterised by variable success rates (Figure 1.6). Bispecific antibodies can be 
distinguished based on the dimerisation strategy employed and are generally a 
result of development by pharmaceutical companies. Efficacy of this constructs was 
first demonstrated against tumours using chemically cross-linked antibodies and 
hybrid hybridomas (or quadromas) however with little clinical success (206-208). 
The limiting step in bispecific antibody design is the efficiency of 
heterodimerisation. Quadromas approach was characterised by fusion of two 
distinct hybridomas, providing a mixture of parent monoclonal antibodies, 
bispecific antibodies and inactive antibodies due to the random coupling of heavy 
and light chains belonging to the two original antibodies (209). The use of mouse 
IgG2a and rat IgG2b developed by Trion Pharma (Triomab) demonstrated a 
preferential species-restricted heavy/light chain pairing, increasing the rates of 
functional bispecific antibodies (210). The EpCAM/CD3 bispecific antibody 
Catumaxomab proved to be efficient in the treatment of ovarian cancer with 
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malignant ascites obtaining the first marketing approval for a bispecific antibody 
(205). Additional antibodies with the same framework are currently in clinical trials. 
Several attempts to increase the heterodimerisation efficiencies have been 
reported in the literature. Of note is the “Knob-into-Holes” technology developed 
by Ridgway and colleagues at Genentech, based on the substitution of a small 
amino acid with a larger one in the CH3 domain of the first Fc region, and the 
substitution of a large amino acid with a small one on the second Fc (211). This 
design would create a knob and a hole in the two heavy chains, allowing a 
preferential heterodimerisation in order to accommodate the protruding side 
chain. Up to 92% of efficient heterodimerisation was reported for this strategy 
(211). A second strategy is the SEED platform developed by EMD Serono, consisting 
in strand-exchange engineered CH3 domains (212). This construct derives from 
dimerization of heavy chains carrying a chimeric IgG and IgA CH3 domain that allows 
preferential heterodimerisation, with less than 1% of contaminant homodimers, 
and unaltered Fc effector functions (212).  
The development of phage display (described in section 1.4.1) and scFv 
(single-chain variable-region antibody fragment), marked the advent of the 
recombinant antibody era. This antibody fragment, composed of the heavy and 
light chain variable domains linked with a small peptide linker, has been used as a 
building block for antibody engineering. Bispecific T-cell engagers (BiTE) are a 
simple form of tandem scFv antibodies showing bifunctional activity. Blinatumomab 
anti-CD3/CD19 was the first BiTE to be developed and is currently in clinical trials 
for lymphoma and leukaemia treatment. Additional non-standard bispecific 
antibodies have been reported in the literature, including among others the dual 
variable domain (DVD)-Ig developed by Abbott (213) and the mAB2 developed by F-
star (214). 
As mentioned above, cancer therapy has been the pioneer in bispecific 
antibody development. None of the available bispecific antibodies has yet been 
approved for rheumatoid arthritis. However, increasing reports are being published 
regarding development of bispecific molecules tailored to the needs of 
Page | 53  
 
Chapter 1 - Introduction 
 
autoimmune diseases. Recently, a bispecific antibody targeting IL-1β and IL-17A in 
tandem scFv format was adopted in a collagen induced arthritis (CIA) mouse model. 
The BsAb proved to significantly ameliorate the pathological lesions when 
compared to anti-IL1β or IL-17A monotherapy (215). Kanakaraj and colleagues 
adopted a bispecific antibody to target TNFα and Angiopoietin 2 (Ang2), adding 
anti-angiogenic properties to the well-established anti-TNF Adalimumab. The 
bispecific antibody was shown to maintain unaltered the functionalities of 
Adalimumab but was significantly more effective in controlling the progression of 
arthritis in Tg197 TNF transgenic mice (216). Lastly, Veri and colleagues developed a 
scFv diabody (DART technology) targeting the inhibitory CD32B and the CD79B on 
B-cells, negatively regulating B-cell activation and IgG production, resulting in 
delayed onset of arthritis in CIA mice (217). 
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Figure 1.6 Bispecific antibodies 
Schematic representation of bispecific antibody constructs. Various bispecific antibody 
strategies have been employed; strategies include symmetric IgG-like molecules such as 
the cross-linked mAbs developed by Karmanos Cancer Centre showing two antibodies 
cross-linked at the Fc region, the mAB² structure developed by F-star characterised by 
engineered CH3 domains containing additional VH regions, and the DVD structure by 
Abbott, with two extra Fv regions in series to the original IgG Fv domains. Asymmetric 
antybodies are design with two independent binding arms, including Triomab design by 
Trion Pharma, exploiting mouse IgG2a and rat IgG2b species-restricted heavy/light chain 
pairing, the Knob-into-holes technology developed by Genentech, characterised by steric 
stabilisation of heterodimers, and SEED bodies, EMD Serono, with preferential 
heterodimerisation obtained through IgA/IgG chimeric CH3 domains. 
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1.4 Synovium as target organ 
 As described in section 1.2.2, the vascular compartment can be exploited for 
the identification and isolation of tissue specific homing receptors or vascular 
addressins. To date the identification of a synovial specific homing antigen is still 
lacking. Our group described in 2002 the isolation of a synthetic peptide with 
preferential homing specificity for the human arthritic synovium. This peptide was 
able to accumulate in the synovial microvasculature in vivo, in a SCID mouse model 
double grafted with human arthritic synovium and normal human skin as control 
(132). Recently, the peptide has been fused to IL-4, demonstrating efficient delivery 
of the cytokine to human RA synovium, using the same SCID mouse xenograft 
model, and provide proof of concept for peptide-targeted tissue specific 
immunotherapy in RA (136).  
 There is therefore evidence of synovial specific antigens that can be used for 
targeted drug delivery or as diagnostic tools. Peptide based screening using phage 
display has already been proven efficient in identifying such vascular determinants 
(130-132). Monoclonal antibodies lend themselves well to the development of 
ligand based therapeutic strategies, they are notoriously efficient in screening for 
specific antigens, are characterised by high affinity targeting of both linear and 
conformational epitopes and are characterised by long retention times in vivo, 
providing better therapeutic capacities (218). Since the first publication by Kohler 
and Milstein, the hybridoma technology has been an inestimable tool for 
recombinant antibody production (151). Clinical studies, however, have been 
disappointing due to the murine origin of the monoclonal antibodies and the 
related immunogenicity (218). As mentioned earlier, reduction of immunogenicity 
could be achieved by substituting the constant regions with human IgG 
counterparts. Such constructs were defined as chimeric antibodies, human constant 
regions and murine variable domains, or humanised antibodies, when the murine 
sequences are restricted to the CDR regions. However, this process is laborious and 
not necessarily successful with reported anti-humanised and anti-chimeric antibody 
response in vivo (219). The use of transgenic mice expressing human 
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immunoglobulin loci superseded the mouse hybridoma technology, providing a 
more natural immune response including direct affinity maturation (220). However, 
the shortcomings of these technologies for the intended application described 
above lie on the fact that the animals need to be challenged with the foreign 
antigen to elicit an immune response. This requires for the antigen to be known and 
possibly purified. Alternatively, the animals can be immunised with a mixture of 
proteins extracted from the target tissue, therefore extrapolated from their natural 
environment, which may result in isolation of antibodies targeting regions not 
exposed in vivo and impair clinical efficacy. In order to avoid this problem and 
identify specific vascular determinants directly in vivo, our group adopted the 
antibody phage display technology in a SCID mouse xenograft model (described 
below).  
1.4.1 Phage display 
 The phage display technology developed in the late 80’s (221) is based on 
the expression of a foreign antigen on the surface of filamentous bacteriophage 
particles, via fusion to the gene III (gIII) or VIII (gVIII). The exogenous protein was 
efficiently produced (limited to the bacterial expression machinery) and exposed on 
the particle surface, allowing fast screening with interacting molecules. The 
technology has been further developed in the early 1990’s by Winter’s group and 
adapted to antibody display (222).  
The filamentous bacteriophage M13, and the relative fd bacteriophage, is 
the most commonly used vector for display purposes (223). This class of E.coli 
bacteriophage is characterised by a central cylindrical capsid containing the single-
stranded circular DNA genome encoding for non-structural proteins and for the five 
coat proteins: pIII, pVI, pVII, pVIII and pIX (Figure 1.7 A). The pVIII protein is most 
abundant with 2700 copies expressed; pIII, pVI, pVII and pIX are present only in 5 
copies each with apical distribution. The lifecycle of M13 starts with the infection of 
the E.coli host via interaction between the pIII coat protein and the bacterial F-pilus 
that retracts upon engagement, bringing the phage to the bacterial surface (224). 
Once in contact with the cell surface, the bacteriophage injects the DNA into the 
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host, disassembles and inserts the coat proteins in the bacterial membrane (225). 
At this point the phage takes control of the replicative machinery of the host and 
new phage particles are produced. The new phage are then released without cell 
lysis (223). 
The phage life cycle depends therefore on the bacterial host for protein 
expression and assembly. This represents a limitation for the applications of phage 
display. Specifically, only small proteins that do not require post-translational 
modification can be efficiently expressed. All coat proteins have been exploited for 
display purposes, however, pIII and pVIII are the most commonly used (223). By 
logic the highly represented pVIII protein would be the optimal target for fusion 
protein display, allowing high density of target protein on the phage surface. 
Though, the resulting “avidity effect” may cause the selection of low-affinity 
binders and cause a less efficient screening. The pIII coat protein represents a valid 
alternative and many expression libraries are designed to express the foreign 
protein at the N-terminus of the pIII gene (gIII).  
Full IgG antibodies are complex molecules that bacteria are not able to 
process, therefore for phage display antibody fragments are used instead. Both Fab 
and scFv have been successfully exposed on the surface of phage particles (226, 
227). The protein to be displayed is fused to the N-terminus of the pIII in a vector 
(phagemid) containing the M13 origin of replication (ori), an E.coli ori (for episomal 
vector amplification), an inducible promoter (e.g. LacZ) and an antibiotic resistance 
gene to allow screening (Figure 1.7 B). This phagemid vector is able to replicate in 
the E.coli host but it doesn’t produce phage particles due to the lack of the 
additional phage genes needed for virion packing. Transformed E.coli cells are then 
superinfected with a helper phage (227). This helper phage is a wild type 
filamentous phage engineered by disabling the packaging signal due to a defective 
M13 ori. This phage is therefore able to provide the necessary accessory genes to 
the phagemid carrying E.coli hosts, forming new phage particles preferentially 
containing the fusion pIII protein on the capsid. Helper phage pIII protein may still 
be incorporated, creating a mixed phage population. This is important to bear in 
mind because it could introduce a bias for wild type phage clones during E.coli 
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infection step and invalidate the system. In order to reduce this possible scenario, 
the helper phage used in the preliminary data for this thesis project was the KM13 
mutant, characterised by a trypsin cleavable site between the D2 and D3 domain of 
the pIII protein (228). Trypsin treatment of phage particles would render inactive 
the wild type pIII protein, preventing wild type phage infection, while maintaining 
active the fusion pIII protein. 
As a general protocol, a large repertoire of phage particles containing scFv 
or other peptides fused to the pIII are screened (panning) by affinity selection 
either in vitro against immobilised antigens, tissue samples, cell cultures or in vivo 
using animal models. Unbound non-specific clones are removed following extensive 
washes and bound phage are eluted using trypsin digestion. The trypsin step allows 
the removal of the fused scFv/peptide from the pIII protein, while at the same time 
inactivating the wild type pIII. The recovered phage particles are then used to infect 
E.coli bacteria in selective medium, allowing amplification of the phagemid vector 
containing the fusion protein gene. Phagemids are subsequently rescued via 
superinfection with helper phage and prepared for a second round of selection 
(228, 229). In libraries characterised by the presence of an amber codon between 
the peptide gene and the gIII gene, induced expression with IPTG in non-
suppressive E.coli strains promotes the production of soluble protein (229). 
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Figure 1.7 Phage display 
Schematic structure of filamentous bacteriophage composed of a circular single strand DNA 
genome and 2700 copies of pVIII protein coating the phage particle. Minor proteins include 
pIII, pVI, pVII and pIX, each present in 5 copies (A). Structure of the phagemid vector 
carrying the LacZ inducible promoter to express the scFv fused to the gIII gene. scFv is then 
exposed on the phage surface anchored to the pIII coat protein (B). 
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1.4.2 scFv A7 antibody fragment 
 Antibody phage display technology represents a unique opportunity for 
rapid selection of high affinity antibody clones. This technique was therefore 
adopted in our group for the identification of specific scFv antibody fragments 
interacting with the microvasculature of human arthritic synovium, isolating among 
others the scFv clone A7 which represents the main focus of the work presented in 
this thesis (230).  
 As mentioned above, screening antigens in vitro or using cell lines may 
impair the chances to identify a scFv antibody with applications in vivo. Animal 
models are able to mimic the human pathology but are characterised by the 
expression of murine antigens that may not find counterpart in humans or with 
only low sequence homology and may therefore not be directly applicable to 
humans. In order to obviate this limitation, screening in humans would be the ideal 
solution. Ethical considerations, however, prohibit the use of humans in research 
unless in strictly regulated circumstances. The work carried out in our group 
provided an elegant solution to these boundaries, pioneering a chimeric mouse 
model using SCID mice grafted with human tissues (231, 232). In this human/mouse 
chimeric model the grafts are sustained by the murine vasculature via functional 
anastomoses with the resident human vessels (232). Furthermore, intragraft 
injection of TNF-α in synovium grafted SCID mice was able to upregulate ICAM-1 
and VCAM-1 expression, causing intravenously injected human lymphocytes to 
migrate in the tissue (232). Additionally, in a PLN grafted SCID mouse model, 
stimulation with CXCL12 promoted human lymphocytes migration in the grafted 
tissue (231). These results confirm the validity of the model in which the grafted 
tissue is sustained by the murine host while maintaining the human vasculature 
environment and supporting the natural tissue specific response. This model has 
been previously adopted for the isolation of synovium specific antigens via phage 
display (132), providing proof of concept for the validity of this investigation.  
 The synthetic Tomlinson scFv library, developed in Greg Winter’s group, was 
chosen for the presented screening (233). This library is based on the common VH3 
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(1-3) and Vk (2-1-1) framework, with diversified CDR3 and CDR2 regions. SCID mice 
double grafted with human arthritic synovium and normal human skin as control, 
were injected with the unchallenged library via the tail vein and allowed to 
recirculate for 15 minutes in order to distribute across the mouse vasculature and 
the grafted tissues. Synovial grafts were then harvested and bound phage eluted to 
be used for a second round of selection. A total of 4 enrichment cycles were used 
for the screening (Figure 1.8 A). Randomly picked colonies from E.coli infected with 
phage clones from the last round of selection were screened for efficient scFv 
production. 24 clones showed high protein expression and were subsequently 
shown to encode for the same scFv sequence (scFv clone A7). The soluble scFv A7 
was isolated in two independent screenings and was shown to retain synovium 
specificity in vivo. Xenograft SCID mice were injected with the scFv A7, scFv anti-hen 
egg lysozyme (scFv HEL) as negative control and anti-vWF/CD31 antibodies to stain 
the vasculature. The scFv A7 was able to target the synovial microvasculature with 
no cross-reactivity with the human skin tissue or mouse tongue tissue (Figure 1.8 
B). Additionally, radiolabeled scFv A7 showed statistically significant differential 
reactivity between synovium and skin grafts up to 24h post-injection in vivo (Figure 
1.8 C), further confirming the synovium-specific reactivity of the scFv A7 antibody 
(230) (Paper attached). 
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Figure 1.8 in vivo antibody phage display 
A phage library was injected in double grafted SCID mice with human arthritic synovium 
and normal human skin. After 15 minutes of recirculation, synovium was harvested and 
phage eluted to use in a second round for a total of 4 enrichment cycles (A). In vivo 
recirculation of soluble scFv A7 describing specific reactivity with microvasculature of 
arthritic synovium as shown in HRP immunohistochemistry. No reactivity shown in skin 
sample of mouse tongue (B). In vivo retention of ¹²⁵I labelled scFv A7 showing significant 
accumulation in human synovium compared to skin graft up to 24h post injection (C). 
(figure B and C taken from Kamperidis, Kamalati et al, 2011)(230).  
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1.5 Rationale and aims of the project  
Despite the obvious success of the biologic agents used in the treatment of 
rheumatoid arthritis, many patients fail to respond to the available therapies and 
although true remission is achieved only by a minority, a “cure”, that is treatment 
free remission still remains an unmet goal for most. The specific mechanism of 
action of the currently available biologic therapies in RA involves a systemic 
targeting of cytokines or immune effector cells, increasing the risk of developing or 
re-emergence of bacterial and viral infections. There is therefore room for the 
development of tissue specific agents able to circumvent or reduce systemic side 
effects, increase the potency and possibly decrease the cost inherent to disease 
management in patients. 
Several lines of evidence suggest that neoangiogenesis plays a crucial role in 
the development and progression of rheumatoid arthritis, furthermore the 
presence of molecular heterogeneity in the microvascular environment of different 
tissues and/or disease conditions has been correlated with the capacity to target 
and direct circulating leucocytes subpopulation, contributing to local enrichment 
and selecting for specific response. The synovial microvasculature, with the 
presence of post-capillary vessels reminiscent of lymphoid HEV morphology, 
represents therefore a unique opportunity to identify synovium specific vascular 
addressins that may be used as tools for tissue specific drug delivery and disease 
tissue imaging.  
However, to date the identification of such specific microvascular addressin 
in the joint still remains elusive. Our group has pioneered the development of a 
chimeric SCID mouse model able to sustain long-term survival of human tissue 
xenografts, maintaining the natural human environment and overcoming the 
problem of in vitro culturing dedifferentiation of the microvascular endothelium 
and loss of antigen expression. Combining this platform with the in vivo phage 
display technology, our group has successfully isolated several peptides showing 
preferential homing specificity for the arthritic human synovium. Additionally, the 
same strategy has been used to isolate scFv antibody fragments showing specificity 
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for the human arthritic synovium compared to the control normal human skin 
tissue. In particular, a scFv clone named A7 has shown a great homing specificity for 
the human arthritic synovium and represents the main focus of this thesis. 
On the basis of the evidence reported above, the main aim of my project 
was to develop a reagent with selective synovial specificity to be used as a 
therapeutic tool for tissue specific drug delivery in the treatment of arthritic disease 
conditions. Specifically, the hypothesis that scFv A7 binds to a unique synovial 
microvascular antigen, or one preferentially expressed at high levels in this tissue, 
able to efficiently discriminate between disease and normal state will be tested in 
this thesis.  This hypothesis will be addressed in detail in chapters 4 and 5.  In 
addition, experiments in this thesis are designed to test the hypothesis that the 
scFv A7 antibody can be developed as a building block for the generation of 
bispecific antibodies for tissue specific drug delivery in the context of arthritis, to 
circumvent the adverse biological effects caused by systemic administration of the 
current biological therapies.  This hypothesis will be specifically addressed in 
chapter 6. 
Results organisation and experimental design of the work are summarised below. 
- Chapter 3 is focused on the optimisation of scFv A7 and the IgG-like A7 scFv-
Fc fusion protein production, comparing purification systems, assessing the 
purity and quality of the obtained antibody and optimising the 
immunohistochemistry protocol necessary for the work presented in 
Chapter 4. 
 
- Chapter 4 describes the scFv A7 in vitro reactivity in human tissues, aiming 
at characterising the tissue, disease and species specificity of the antibody 
and defining the localisation of A7 binding capacity. 
 
- Chapter 5 is centred on the identification of A7 target antigen, involving 
identification of cell lines expressing the antigen, proteomic approaches 
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towards the isolation of the putative target protein and phage library 
screening. 
 
- Chapter 6 represents the translational application of the project with the 
development of a novel bispecific antibody combining the A7 synovial 
homing capacity to the anti-TNF properties of the Adalimumab antibody. In 
this chapter the strategy adopted for the bispecific antibody design is 
reported along with A7 quality assessment and characterisation and 
Adalimumab tissue reactivity and biological functions. 
 
- In Chapter 7 the significance of the findings will be analysed and discussed, 
including the implications and future work arising from this investigation. 
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2.1 scFv production and purification 
A single colony of E.coli strain HB2151 expressing the scFv clone of interest 
(vector map can be found in Figure 3.1) was picked from a 2TY agar plate and 
inoculated in 20 ml 2TY, 1% glucose, 100 μg/ml ampicillin and left at 37 ⁰C 
overnight shaking at 200 rpm. On day 2, 2 ml of overnight subculture was diluted in 
40 ml 2TY 0.1% glucose, 100 μg/ml ampicillin and grown at 37 ⁰C 200 rpm shaking 
until an optical density (OD) of 0.8 was reached. The bacteria were then incubated 
with 1 mM IPTG to induce antibody expression and incubated overnight at 30 ⁰C 
200 rpm shaking. Following overnight induction of expression of scFv A7 from E.coli 
strain HB2151, the bacteria were pelleted by centrifugation at 5000 rpm for 30 
minutes at 4 ⁰C. The media containing secreted antibody was store at 4 ⁰C as 
supernatant. The bacterial pellet was resuspended in 6.4 ml ice-cold TES buffer and 
added 13.6 ml dH2O (ice cold), mixed by inversion and incubated on ice for 30 
minutes to release proteins from the periplasmic compartment. The bacterial cells 
were then spun to a pellet at 13000 rpm for 20 minutes at 4 ⁰C and the supernatant 
containing scFv protein removed and stored at 4 ⁰C as periplasmic extract. In order 
to remove bacterial particles from the protein extracts, supernatant and 
periplasmic extract were filtered separately, using a 0.22 μm filter unit. To remove 
salt contained in the medium, the filtered supernatant and periplasmic extract were 
dialysed using dialysis tubing with molecular weight cut off of 10000 Da against 10 
litres of PBS for 2 hours at room temperature with stirring. To increase the 
efficiency of dialysis, the buffer was changed every 2 hours and finally left to dialyse 
at 4 ⁰C overnight.  
2.1.1 Purification of scFv by affinity chromatography 
2.1.1.1 Protein A Sepharose 
Following supernatant and periplasmic extract dialysis, the samples were 
retrieved from the tubing and placed in a sterile bottle and allowed to bind with 
200 mg of rehydrated protein A Sepharose CL-48 beads (GE Healthcare, Amersham 
UK) for 30 minutes at room temperature with gentle mixing. The beads were then 
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loaded into Econo Column Chromatography columns and packed by gravity flow. 
The packed column was washed with 50 ml PBS, then with 50 ml PBS + 0.5 M NaCl 
and finally with 100 ml 0.2 M Glycine pH6. To elute the bound antibody protein, 20 
ml of 0.2 M glycine pH 2.8 was added to the column and fractions to the volume of 
1 ml collected. Low pH was neutralised with Tris 1 M pH 9 using 200 μl for 1 ml 
fractions. The protein concentration in each fraction was assessed by OD analysis 
via spectrophotometry at 280 nm. Protein fractions with similar OD were pooled 
and dialysed overnight at 4 °C against PBS for buffer exchange using 10000 Da 
Slyde-A-Lyser dialysis cassettes (Thermo Fisher scientific, Loughborough UK). 
Proteins were then aliquoted and stored at -80 ⁰C. 
 Purification of periplasmic extract and supernatant from empty HB2151 host 
cells was processed as above. Since no detectable protein was present in the 
elution fraction, a concentration step was introduced. Fractions were incubated 
with 20 μl Strataclean resin (Agilent Technologies, Berkshire UK) to non-selectively 
bind proteins, and lysed in Laemmli lysis buffer (0.5 M DTT, 10% glycerol, 0.44 M 
Tris pH 6.8, 0.04% Bromophenol Blue, 10% SDS) for further analysis. 
 
2.1.1.2 Talon® metal affinity resin 
Periplasmic protein extract and bacterial supernatants were prepared as 
above. The samples were then retrieved from the tubing, placed in a sterile bottle 
and allowed to bind to 8 ml of pre equilibrated Talon® metal affinity resin (Clontec, 
Mountain View, CA USA) for 30 minutes at room temperature with gentle mixing. 
The resin was then packed by gravity flow into Econo Column Chromatography 
columns. Subsequently two serial washes with 20 bed volumes of dialysis buffer (50 
mM NaH2PO4, 300 mM NaCl, pH 7) were performed. The antibody protein was 
eluted with 150 mM imidazole pH 7, collected in 1 ml fractions and the protein 
concentration assessed by spectrophotometry at 280 nm. Protein fractions with 
similar OD were pooled and dialysed overnight at 4 °C in PBS for buffer exchange 
using 10000 Da Slyde-A-Lyser dialysis cassettes (Thermo Fisher scientific, 
Loughborough UK). Proteins were then aliquoted and stored at -80 ⁰C. 
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Purification of periplasmic extract and supernatant from empty HB2151 host 
cells was processed as above. Since no detectable protein was present in the 
elution fraction, a concentration step was introduced. Fractions were incubated 
with 20 μl Strataclean resin (Agilent Technologies, Berkshire UK) to non-selectively 
bind proteins, and lysed in Laemmli lysis buffer (0.5 M DTT, 10% glycerol, 0.44 M 
Tris pH 6.8, 0.04% Bromophenol Blue, 10% SDS) for further analysis. 
 
2.1.2 FPLC 
2 ml of concentrated Talon® purified protein was loaded on a Superdex 75 
10x300 mm Sepharose column with a size exclusion limit of 200 kDa and a 
resolution power between 3 kDa and 70 kDa. 1 ml fractions were collected at a flow 
rate of 0.5 ml/min in PBS and the protein concentration assessed by OD 280 nm 
measurements. The relative molecular masses of fragments present in the sample 
were compared to standard proteins used to calibrate the machine. Specifically, 
thyroglobulin (MW 670 kDa), bovine-globulin (MW 158 kDa), chicken ovalbumin 
(MW 44 kDa) equine myoglobin (MW 17 kDa) and vitamin B12 (MW 1.35 kDa). 
Protein fractions were aliquoted and stored at -80 ⁰C. 
 
2.1.3 HPLC 
 100 μg of Talon® purified protein in 100 μl final volume was loaded on 
Phenomenex silica-based size exclusion column BIOSEP-SEC-S-2000 300x7.8 mm, in 
an automated chromatograph, using a 0.5 ml/minute flow rate. The relative 
molecular masses of fragments present in the sample were compared to standard 
proteins used to calibrate the machine. Specifically, thyroglobulin (MW 670 kDa), 
bovine-globulin (MW 158 kDa), chicken ovalbumin (MW 44 kDa) equine myoglobin 
(MW 17 kDa) and vitamin B12 (MW 1.35 kDa). scFv antibody monomer generally 
eluted between 18 and 19 minutes. 
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2.2 scFv-Fc production and purification 
2.2.1 pHygro scFv-Fc vector cloning 
A modified version of pCDNA3.1/Hygro(+) from Invitrogen, carrying a XbaI 
restriction site instead of NheI and HindIII in the place of PmeI, was provided by 
Professor D. Sblattero, University of Eastern Piedmont, Novara, Italy, and was used 
as base vector (referred as pHygro vector). This vector also contained the human 
IgG1 CH2 and CH3 domains gene amplified from lymphocyte cDNA and the SV5 tag 
at the 3’ end (234). scFv A7 VH and VL sequences were obtained from the clone 
isolated by phage display. Codon usage was optimised for CHO expression and 
synthesised using GeneArt gene synthesis service (Life Technologies, Paisley UK). 
The original VH-L-VL structure was maintained unaltered (vector map for pHygro A7 
scFv-Fc can be found in Figure 3.11). Adalimumab sequence for VH and VL domains 
was obtained from the original patent (165). V regions in VH-VL orientation were 
linked using the scFv A7 15 amino acids linker and codon optimised for CHO 
expression using GeneArt gene synthesis service (Life Technologies, Paisley UK). 
NheI and BssHII restriction sites were included at the 3’ and 5’ respectively of both 
sequences, to facilitate insertion in pHygro vector (vector map for pHygro 
Adalimumab scFv-Fc can be found in Figure 6.1).  
1 μg of scFv A7 or scFv Adalimumab optimised insert and pHygro vector 
were digested using NheI restriction endonuclease (New England BioLabs, Herts UK) 
at 37 °C for 1 h in NEB buffer 2, followed by incubation with BssHII restriction 
enzyme (New England BioLabs, Herts UK) at 50 °C in NEB buffer 2 for 1 h. Reaction 
was then resolved in 0.8% agarose gel and purified following gel extraction of the 
relevant bands using PCR clean-up Gel extraction kit (Macherey-nagel, Düren 
Germany) following manufacturer recommendations. Briefly, bands were excised 
from the gel and dissolved in buffer NT at 50 °C. Sample was then loaded in 
Nucleospin columns, washed in buffer NT3 and eluted in buffer NE. Digested insert 
and vector were ligated to reconstitute the expression plasmid using T4 DNA ligase 
(New England BioLabs, Herts UK). A 3:1 molar ratio between insert and vector was 
used and incubated at 16 °C overnight. The ligase reaction was transformed in 
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competent DH5α E. coli bacteria, leaving the reaction for 15 minutes in ice to allow 
optimal plasmid distribution, incubating 30 seconds at 42 °C and finally 2 minutes in 
ice. Bacteria were left recovering in 2TY culture medium with 1% glucose at 37 °C at 
200 rpm for 1 h. Finally, bacteria were plated in 2TY agar plates containing 100 
μg/ml ampicillin and left overnight at 37 °C. Grown colonies represented efficiently 
transformed cells. Single colonies were screened for presence of the correct 
plasmid via polymerase chain reaction (PCR) using pHygro SEQ sense (5’-
CTGCTTACTGGCTTATCG-3’) and pHygro SEQ antisense (5’-
CAGATGGCTGGCAACTAG-3’) and sequenced to confirm protein identity.  
2.2.2 Transfection in cell line 
2.2.2.1 CHO-S transfection 
Vector showing correct nucleotide sequence was used to transfect CHO-S 
cell line. Cells were grown in serum free medium OptiPRO SFM (Life Technologies, 
Paisley UK) without selective agents and transfected using FreeStyleTM Max 
Reagent (Life Technologies, Paisley UK) according to manufacturer’s conditions. 
37.5 μg of plasmid DNA were mixed with 37.5 μl of FreeStyle Max Reagent in a final 
volume of 1.2 ml OptiPRO SFM and incubated 15 minutes at room temperature to 
allow DNA-lipid complex to form. The DNA-lipid complex was slowly added to CHO-
S cells at a density of 1x106 cells/ml in 30 ml of medium in T175 flasks and 
incubated at 37°C in humid environment with 5% CO2. In order to select for 
efficiently transfected cells, cells were re-suspended in serum free ProCHO 5 
medium (Lonza, Slough UK) supplemented with 100 U/ml penicillin, 100 μg/ml 
streptomycin and the selective agent hygromycin B at 200 μg/ml and cultured at 37 
°C in humid environment with 5% CO2. The selective agent will allow survival only of 
the cells expressing the hygomycin resistance gene present in the pHygro vector.  
In order to achieve a monoclonal cell population, transfected cells were 
diluted to limiting dilution obtaining single cell suspension in selective medium. 
Cells were grown in 96 well plates in 100 μl of medium and cell growth rate was 
monitored via cell count. Protein production was assessed via Enzyme-Linked 
Immunosorbent Assay (ELISA), coating with cell culture supernatant and probing for 
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the SV5 tag. Cell clones showing highest growth rate and protein production were 
selected for antibody expression. 
2.2.2.2 HEK-293T transfection 
 Vector showing correct nucleotide sequence was used to transfect HEK-
293T cell line. Cells were grown in Dulbecco’s modified Eagle medium (DMEM) (Life 
Technologies, Paisley UK) supplemented with 10% foetal calf serum (FCS), 100 U/ml 
penicillin and 100 μg/ml streptomycin. Cells at 60-70% confluence were transfected 
with JetPRIME reagent (Polyplus, Illkirch France) according to the manufacturer’s 
protocol. 6x106 cells were grown in 20 ml of complete medium in 15 cm petri 
dishes, with overnight incubation at 37 °C in humid environment with 5% CO2. 20 
μg of plasmid DNA were mixed with 40 μl JetPRIME reagent in 1 ml JetPRIME buffer 
and incubated at room temperature (RT) for 10 minutes before adding the mixture 
to the cells. After 4 h incubation the medium was replaced with serum free DMEM 
supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin and Nutridoma-SP 
(Roche, Indianapolis USA) and incubated for 48 h to allow protein production. 
Media containing the antibody was then collected and cells incubated with fresh 
media for 48 h for a second harvest.  
2.2.3 scFv-Fc protein purification 
2.2.3.1 Protein A Sepharose 
Supernatant from transfected cells was filtered using 0.22 μm filter units to 
remove remaining cells and cell components. The suspension was then dialysed 
overnight at 4 °C against 2 L of PBS using dialysis tubing with 10000 Da molecular 
weight cut-off (MWCO) to remove contaminant low molecular weight proteins and 
remove detergent present in the CHO-S medium. Dialysed supernatant was 
incubated with protein A Sepharose CL-4B (GE Healthcare, Amersham UK) for 2 
hours at 4 °C with gentle rotation. Beads were then loaded in Econo Column 
Chromatography columns and packed by gravity flow. Columns were washed twice 
with 20 bed volumes of PBS or dialysis buffer, eluted with IgG Elution Buffer 
(Thermo Fisher Scientific, Loughborough UK) and buffered with 1 M Tris pH 9 using 
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50 μl for 400 μl fraction, to obtain a final solution at pH 7. The protein 
concentration in each fraction was assessed by OD analysis via spectrophotometry 
at 280 nm. Protein fractions with similar OD were pooled and dialysed overnight at 
4 °C in PBS for buffer exchange using 10000 Da Slyde-A-Lyser dialysis cassettes 
(Thermo Fisher Scientific, Loughborough UK). Proteins were then aliquoted and 
stored at -80 ⁰C. 
2.2.3.2 Supernatant concentration 
 Supernatant from transfected cells was filtered using 0.22 μm filter units to 
remove remaining cells and cell components. The suspension was then dialysed 
overnight at 4 °C against 2 L of PBS using dialysis tubings with 10000 Da MWCO to 
remove contaminant low molecular weight proteins and remove detergent present 
in the CHO-S medium. Antibody content was assessed via ELISA assay coating with 
cell culture supernatant and probing with anti-Human Fc HRP conjugated antibody 
(Jackson ImmunoResearch, Pennsylvania USA). Concentration was determined via 
comparison with standard curve of human IgG1 antibody. Dialysed supernatant was 
concentrated using Millipore Centricon system 10000 Da MWCO (Millipore, 
Massachusetts USA). Centricon filter units were spun at 4000 g to remove excess 
medium and low molecular weight protein. Suspension volume was reduced in 
order to achieve a 1 mg/ml antibody concentration. Concentrated supernatant was 
dialysed again overnight at 4 °C against 2 L of PBS using dialysis tubings with 10000 
Da MWCO for buffer exchange.  
2.3 Bispecific antibody production 
 The pHygro plasmid described in section 2.2.1 was used as a base expression 
vector. CH2 and CH3 domains were amplified from the pHygro CD59-CD20 
bispecific plasmid (kindly provided by Professor D. Sblattero, University of Eastern 
Piedmont, Novara Italy) in two steps (for schematic refer to Figure 6.8 and 6.9).  
To generate the pHygro 407 human vector (pHygro 407 opt), the starting Fc 
region was amplified using the forward primer NheI 407 senso (5’-
AGCTGCTAGCGACAAGACCCACACCTGT-3’) and reverse primer AgeI-HindIII 407 anti 
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(5’- ACGTAAGCTTTCACACCGGTGCCCTCTTGGCTCT-3’). The 769 bp amplified 
fragment consisted in the CH2-CH3 domain (with Y407T mutation) containing the 
NheI restriction site at 5’ end, the SV5 tag and the first fraction of the 2A peptide 
and the AgeI and HindIII at the 3’ end. In addition, the sequence contained the stop 
codon TGA before the HindIII restriction site. The amplified region was then cloned 
inside a pHygro vector containing the Adalimumab scFv sequence, using NheI and 
HindIII restriction sites.  
Similarly, the pHygro 366 human vector was obtained amplifying the 
starting vector with primer forward NheI 366 sense (5’-
AGCTGCTAGCGATAAGACACATACCTGC-3’) and primer reverse pHygro SEQ 
antisense (5’-CAGATGGCTGGCAACTAG-3’). The 751 bp fragment amplified 
consisted in the CH2-CH3 domain (with the T366Y mutation) containing the NheI 
site at 5’, the 6-His tag and the HindIII site at 3’. The amplified region was then 
cloned inside a pHygro vector containing the A7 scFv or E2 scFv sequence, using 
NheI and HindIII restriction sites. A sequential PCR was used to introduce the 
second portion of the 2A peptide. First the primer forward XbaI-AgeI 366 1 senso 
(5’- 
TGCTGAAGCTGGCCGGCGACGTGGAATCCAACCCTGGCCCTATGGGCTGGAGCCTGATC-
3’) and the primer reverse CH2 Human anti (5’-CGGTCCCCCCAGGAGTTCAGGTGC-3’) 
were used to introduce the first part before the leader sequence and then the 
primer forward XbaI-AgeI 366 2 senso (5’- 
AGCTTCTAGAGCACCGGTGAAGCAGACCCTGAACTTCGACCTGCTGAAGCTGGCCGGCG-
3’) and primer reverse CH2 Human anti (5’-CGGTCCCCCCAGGAGTTCAGGTGC-3’) 
were used to complete the second part of the 2A peptide. The newly amplified 
XbaI-AgeI-2A-scFv sequence was cloned in the pHygro vector before the CH2-CH3 
(T366Y)-HIS region to complete the pHygro 366 human vector (pHygro 366 opt). 
Finally, the bispecific antibody vector was obtained by cloning the XbaI-AgeI 
region from pHygro 407 opt into the pHygro 366 opt in order to introduce the first 
scFv-Fc molecule and reconstitute the full 2A peptide linking the second scFv-Fc 
sequence. The bispecific vector obtained is referred as pDuo-opt. 
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Protein production from CHO was carried out as described in Section 2.2.2.1 
and protein purified using Talon® metal affinity chromatography as described in 
Section 2.1.1.2 using CHO supernatant and 2 ml of Talon® resin. 
2.3.1 Bispecific scFv-Fc truncated for heterodimerisation assessment 
 Truncated bispecific antibody showing single Adalimumab scFv domain was 
obtained from A7/Adalimumab pDuo-opt vector following PCR removal of A7 scFv 
region. The A7 scFv-Fc region was first amplified using primer forward pHygro AgeI 
sense (5’-TTAGATACCGGTGAAGCAGACCCTG-3’) and primer reverse pHygro SEQ 
antisense (5’-CAGATGGCTGGCAACTAG-3’). The PCR product was the purified using 
the PCR clean-up Gel extraction kit (Macherey-nagel, Düren Germany) and used for 
a second round of amplification. The PCR template was used to amplify the 2A-
leader-intron region using the forward primer pHygro AgeI sense and the reverse 
primer pHygro BssHII mini-intron antisense (5’-GGCATGCGCGCCACCTGT-3’). At the 
same time hinge-CH2-CH3-6His region was amplified using forward primer pHygro 
BSSHII mini-intron/Hinge overlapping sense (5’-
ACAGGTGGCGCGCATGCCGATAAGACACATACCTGCCCC-3’), characterised by a 
complementary region to the pHygro BssHII mini-intron antisense at 5’, and the 
reverse primer pHygro SEQ sense. The resulting PCR products were then used for 
an overlapping PCR exploiting the complementary portions at 3’ for PCR 1 and at 5’ 
for PCR 2, using the forward primer pHygro AgeI sense and reverse primer pHygro 
SEQ sense. The resulting PCR product consisted in the 2A-Leader-Hinge-CH2-CH3-
6His region that was cloned in the pHygro 407 opt using the AgeI and HindIII 
restriction sites (for vector map refer to Figure 6.13).  
 The truncated bispecific antibody was produced by transiently transfected 
HEK-293T cells (as described in Section 2.2.2.2) and purified from supernatant using 
protein A (as described in Section 2.2.3.1) followed by Talon® metal affinity 
chromatography (as described in Section 2.1.1.2 using 2 ml of resin). 
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2.4 Antibody biotinylation 
Biotinylated scFv or scFv-Fc proteins were generated using the Pierce EZ-
link® Sulfo-NHS-SS-Biotinylation kit (Thermo Fisher scientific, Loughborough UK). 
Protein at the desired concentration was diluted in 0.5-2 ml PBS. Immediately 
before use, a 10 mM Sulfo-NHS-SS-Biotin dilution was prepared in filtered ultrapure 
water. The protein was mixed with a 10 fold molar excess of biotin reagent and the 
reaction incubated for 1 hour at 4 °C. Unincorporated free biotin in the reaction 
mixture is removed by a desalting column or by dialysis using a MWCO 10 kDa 
cassette. Desalting columns were pre-equilibrated via 3 washes in PBS intercalated 
by 2 minutes 1000 g centrifugation. Sample was applied directly to the resin bed 
and recovered via centrifugation at 1000 g for 2 minutes. Dialysis cassettes were 
pre-equilibrated in dialysis buffer (50 mM NaH2PO4, 300 mM NaCl, pH 7) or PBS for 
2 minutes and sample loaded in the inner chamber. Sample was recovered 
following 2 hours dialysis against 2 L of dialysis buffer or PBS. Biotin incorporation 
was estimated using HABA (4’-hydroxyazobenzene-2-carboxylic acid) assay, 
following manufacturer specifications. Briefly, HABA/avidin complex is dissociated 
by biotin causing a proportional decrease in 500 nm absorbance, allowing 
quantitation of protein conjugated biotin. 100 μl of solution containing the 
biotinylated scFv was added to 900 μl HABA/Avidin solution and change in OD 
measured at 500 nm. Biotin/protein ratio was calculated using the HABA calculator 
(www.piercenet.com/haba/habacalccuv.cfm). 
2.5 SDS-PAGE 
Polyacrylamide gel electrophoresis was performed on Novex Tris-Glycin 
precast polyacrylamide-based gel at 10% or in gradient 8-16% (Life Technologies, 
Paisley UK). The gels were characterised by a stacking (4%) and resolving (10% or 8-
16%) acrylamide concentration and comprised Tris, HCl, acrylamide, bisacrylamide, 
Ammonium persulfate (APS) and ultrapure water. Occasionally, homemade gels 
were employed. In this case, resolving gel at 10% was made with 250 mM Tris pH 
8.8, 10% Protogel (National Diagnostics, Hessle UK), 0.05% APS and 0.2% N,N,N´,N´-
Page | 78  
 
Chapter 2 – Materials and Methods 
 
tetramethylethylenediamine (TEMED) in ultrapure water. Stacking gel was made 
with 250mM Tris pH 6.8, 4% Protogel, 0.05% APS and 0.2% TEMED. 
For reduced conditions, samples were diluted at the desired concentration 
in 5x Laemmli lysis buffer (0.5 M DTT, 10% glycerol, 0.44 M Tris pH 6.8, 0.04% 
Bromophenol Blue, 10% SDS), to achieve a 1x solution, and boiled at 95 °C for 5 
minutes on heating block to obtain complete denaturation and reduction of the 
proteins. For non-reduced conditions, samples were diluted at the desired 
concentration in non-reducing LDS Sample Buffer (Thermo Fisher scientific, 
Loughborough UK) without boiling.  
Samples were then loaded onto SDS-PAGE gels and run immersed in running 
buffer (25 mM Tris, 192 mM glycine 0.1% SDS) at a constant rate of 50 mA. A 
standard molecular weight ladder was included in each run. The gel was then 
washed in dH2O for 10 minutes to remove excess SDS and soaked in Coomassie 
Brilliant Blue (Coomassie Blue R250 0.25%, methanol 42%, acetic acid 16% and 
dH2O 42%) for 2 h at RT or overnight at RT with gentle rocking. Excess of dye was 
removed via multiple washings in de-stain solution (isopropanol 12.5%, glacial 
acetic acid 10% dH2O 77.5%) until optimal staining was achieved. Alternatively, the 
gel was soaked in colloidal Coomassie Blue EZ-Blue reagent (Sigma, Dorset UK) for 1 
h at RT with gentle rocking and de-stained in dH2O until optimal staining was 
reached. Stained gels were then washed in dH2O and soaked in gel drying solution 
(20% ethanol, 4% glycerol in water) for 15 minutes or 5 minutes for colloidal stain. 
The gel was subsequently included in two cellophane sheets and left to air dry. 
Once dry the gel could be stored at RT. 
Alternatively, the gel was soaked twice in 100 ml of fix solution (50% 
methanol, 7% acetic acid) for 30 minutes, and then stained with 60 ml of SYPRO® 
Ruby protein gel stain (Life Technologies, Paisley UK) overnight with gentle rocking 
in a dark chamber. Gel was then washed in 100 ml of wash solution (10% Methanol, 
7% Acetic acid) for 30 minutes at RT followed by wash in dH2O in dark chamber. 
Presence of protein bands was then assessed when exited under UV light in a 
standard bench top transilluminator (UV 300 nm). Occasionally the ruby stained gel 
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was post-stained with Coomassie Brilliant Blue as described above. Molecular 
weight markers were always present in Commassie Brilliant Blue and Sypro® ruby 
protein gel stained gels but cropped from the figures presented in this thesis. 
2.5.1 Analysis of SDS-PAGE gels 
 Gels stained with Ruby protein gel stain were exited with UV light (300 nm) 
and scan of the gel acquired using UVItec gel station (Uvitec, Cambridge UK). Jpeg 
pictures of exited gels were analysed with the image analysis tool ImageJ 1.44 (NIH, 
Maryland USA) (235). First, the gel pictures were colour inverted and specific lanes 
to be analysed were highlighted and the plot profile created using the gel analysis 
plugin. Relative proportion of peaks was measured by the program with Label peaks 
function. 
2.5.2 Western Blot 
Subsequent to protein separation, the gel was soaked in tris-glycine transfer 
buffer (25 mM Tris, 192 mM glycine and 20% methanol) for 10 minutes at room 
temperature. Protein transfer was performed at 400 mA for 1 hour at room 
temperature (236) using a nitrocellulose membrane (GE Healthcare, Amersham 
UK). For detection of proteins of interest the blotted nitrocellulose membrane was 
blocked with 5% dried milk powder (Marvell, Dublin Ireland) in PBS at 4 ⁰C 
overnight with constant shaking. The membrane was then washed 3 times with PBS 
for 5 minutes and incubated with the appropriate primary antibody for 1 h at room 
temperature with shaking. The membrane was subsequently washed 3 times for 10 
minutes in PBS 0.05% Tween 20 and incubated with a secondary antibody HRP 
conjugated for 1 h at room temperature with shaking. The membrane was then 
further washed 3 times for 10 minutes in PBS 0.05% Tween, followed by 5 minutes 
in dH2O. To detect the Horse Radish Peroxidase (HRP) activity, the membrane was 
incubated with ECL reagent (GE Healthcare, Amersham UK) for 1 minute at room 
temperature and developed by exposure on X-ray film (GE Healthcare, Amersham 
UK). 
For scFv detection: 
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Primary antibody mouse anti-HIS (clone HIS-1, Sigma, Dorset UK) diluted 
1:3000 in PBS 0.5% BSA or mouse anti-cMyc (clone 9E10 Sigma, Dorset UK) 
diluted 1:3000 in PBS 0.5% BSA. 
Secondary antibody goat anti-mouse HRP (SantaCruz, California USA) diluted 
1:2000 in PBS 0.5% BSA. 
For scFv-Fc detection: 
 Primary antibody mouse anti-SV5 (kindly provided by Professor D.Sblattero 
University of Eastern Piedmont, Novara Italy) diluted 1:5000 in PBS 0.5% 
BSA. 
Secondary antibody goat anti-mouse HRP (SantaCruz, California USA) diluted 
1:2000 in PBS 0.5% BSA or anti-mouse AP conjugated antibody. 
For bispecific scFv-Fc: 
Primary antibody mouse anti-SV5 (kindly provided by Professor D.Sblattero 
University of Eastern Piedmont, Novara Italy) diluted 1:5000 in PBS 0.5% 
BSA, or mouse anti-HIS (clone HIS-1, Sigma, Dorset UK) diluted 1:3000 in PBS 
0.5% BSA. 
Secondary antibody goat anti-mouse HRP (SantaCruz, California USA) diluted 
1:2000 in PBS 0.5% BSA or anti-mouse AP conjugated antibody. 
For E-cadherin detection: 
 Primary antibody mouse anti-E-cadherin (clone 36/E-Cadherin, Becton 
Dickinson, Oxford, UK) 1μg/ml in PBS 0.5% BSA. 
Secondary antibody goat anti-mouse HRP (SantaCruz, California USA) diluted 
1:2000 in PBS 0.5% BSA or anti-mouse AP conjugated antibody. 
For α-tubulin detection: 
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 Primary antibody mouse anti-α-tubulin (clone 236-10501, Life technologies, 
Paisley UK) at 1μg/ml in PBS 0.5% BSA. 
Secondary antibody goat anti-mouse HRP (SantaCruz, California USA) diluted 
1:2000 in PBS 0.5% BSA or anti-mouse AP conjugated antibody. 
For ICAM1 detection: 
 Primary antibody rabbit anti-ICAM1 (clone EP1442Y, Abcam, Cambridge UK) 
at 1:2000 dilution in PBS 0.5% BSA. 
 Secondary antibody goat anti-rabbit IgG H+L (Jackson ImmunoResearch, 
Pennsylvania USA) at 1μg/ml in PBS 0.5% BSA.  
2.6 Staining on tissue sections 
 Synovial tissues were obtained from patients with RA and OA that attended 
the Royal London Hospital/Barts & The London NHS Trust, Mile End Hospital/Barts 
NHS Trust and St Bartholomews Hospital/Barts & The London NHS Trust after 
informed consent, either by ultrasound-guided joint biopsy, total joint replacement 
or following synovectomy (NRes No 07/Q0605/29).  
Non-arthritic synovial tissues were kindly provided by M.D. Smith (Repatriation 
General Hospital, Adelaide Australia). 
Skin tissues were obtained from healthy individuals or RA/OA patients that 
attended the Guys & St Thomas Hospital, NHS Foundation Trust after informed 
consent (NRes No 07/Q0605/29). 
Tonsil tissues were obtained from patients undergoing tonsillectomy at the St 
Bartholomews Hospital/Barts & The London NHS Trust after informed consent 
(NRes No 07/Q0605/29). 
AccuMax normal tissue array was purchased from Isu Abxis (Isu Abxis, Seoul Korea). 
Crohn’s disease, ulcerative colitis and colon cancer tissues were kindly provided by 
Dr P. Biancheri (Queen Mary University of London, London UK). 
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Malignant melanoma tissue sections were kindly provided by Professor R. Cerio 
(Queen Mary University of London, London UK). 
2.6.1 Preparation of formalin fixed paraffin embedded tissues 
Tissue samples were fixed with 4% paraformaldehyde (PFA) in PBS for 1 
hour with rocking at room temperature. The fixed samples were then processed in 
a LEICA TP1050 tissue processor overnight before being embedded in wax and 
stored at room temperature until use. The samples were cut at 3 μm thickness 
using a microtome and mounted on Superfrost-Plus glass slides (VWR, 
Leicestershire UK), dried for 2 hours at room temperature and baked at 55-60 ⁰C for 
2 hours. Slides were then stored at RT until needed. 
2.6.2 Preparation of frozen tissue samples 
Tissue samples were snap frozen in liquid nitrogen cold iso-pentane and 
then embedded in Optimal cutting temperature compound (OCT) (Miles, California 
USA) supported on 1 cm3 cork disk, frozen in liquid nitrogen and stored at -80 ⁰C. 
Frozen tissue sections were then cut at 3 μm thickness using a cryostat and 
mounted on Superfrost-Plus glass slides (VWR, Leicestershire UK) and stored at -80 
°C until needed.  
2.6.3 Immunohistochemistry 
2.6.3.1 Paraffin embedded sections 
Slides were de-waxed by immersion in xylene twice for 7.5 minutes followed 
by two washes in 96% ethanol for 7.5 minutes. The slides were then rehydrated in 
dH2O for 3 minutes at room temperature. Antigen retrieval was carried out 
according to the specification of each individual antibody (see below). The 
endogenous peroxidase activity was blocked by adding 3% H2O2 in methanol for 20 
minutes at RT. The sections were then washed in dH2O and soaked in PBS for 5 
minutes. Sections were blocked with Avidin-Biotin block (Vector, Peterborough UK) 
to block endogenous avidin or biotin reactivity. Serum free protein block (Dako, 
Cambridgeshire UK) was added to the sections for 30 minutes at RT in order to 
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prevent unspecific antibody binding and then washed 3 times in PBS for 3 minutes 
with gentle rocking. The sections were incubated with 100 μl of the primary 
antibody at the desired concentration (2 hours for scFv and 1 hour for commercial 
antibodies), with matching concentrations of the isotype control antibody, at room 
temperature in humid environment. Unbound antibodies were removed by 3 
washes in PBS for 3 minutes with gentle rocking. The sections were then incubated 
with 100 μl of the appropriate secondary antibody for 1 h at RT in humid chamber, 
washed 3 times in PBS for 3 minutes and followed by incubation with avidin-HRP 
conjugate (Vector, Peterborough UK or Dako, Cambridgeshire UK) for 30 minutes at 
room temperature and washed 3 times in PBS for 3 minutes to remove excess of 
reagent. Diaminobenzidine (DAB) chromogenic substrate was used to reveal HRP 
activity. Reaction was stopped by immersion in dH2O when optimal intensity was 
reached. To reveal nuclei presence, the sections were counterstained in 
haematoxylin for 2 minutes and washed in dH2O, followed by tap water. The 
sections were then dehydrated in ethanol twice for 3 minutes followed by xylene 
twice for 3 minutes, mounted in DPX and covered using glass coverslips. The 
stained sections were stored at RT. 
 Antigen retrieval procedures varied according to the primary antibody used. 
For scFv A7 the preferred retrieval procedure was proteinase K proteolytic-induced 
epitope retrieval (PIER). Tissue sections following de-waxing and rehydration were 
incubated with 100 μl of proteinase K (Dako, Cambridgeshire UK) pre-warmed 10 
minutes at 37 °C, for 4 minutes at room temperature followed by serial washes in 
PBS. Digest-All3 retrieval (Life technologies, Paisley UK) required 10 minutes 
incubation with 100 μl of the solution at 37 °C, followed by serial washes in PBS. 
When in combination with Proteinase K, the latter was performed as first 
procedure, followed by Digest-All3 digestion. Chondrotinase ABC (Sigma, Dorset UK) 
was used at 1 U incubating 100 μl over the tissue section for 1 h at 37 °C, followed 
by serial washes in PBS. When in combination with proteinase K, it was performed 
as last retrieval. EDTA Heat-induced epitope retrieval (HIER) was performed at pH 9. 
Buffer was heated to boiling point and sections immersed in the solution for 3 or 20 
minutes and allowed to cool in water bath for 20 minutes. Sections were then 
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washed in dH2O and PBS. Trisodium citrate HEIR procedure was conducted using 
0.01% trisodium-citrate buffer at pH 6. Buffer was heated to boiling point and 
sections immersed in the solution for 3 or 20 minutes and allowed to cool in water 
bath for 20 minutes. The 3 minutes incubation protocol was used as standard 
retrieval procedure for anti-vWF, anti-CD31, anti-CD34 and anti-α actin stainings. 
Finally, HCl retrieval was performed with 2 M HCl with 100 μl of buffer per tissue 
section for 10 minutes at RT, followed by serial washes in PBS.  
Concentration of biotinylated scFv and biotinylated scFv-Fc antibody was 
assay dependent. When not specified, a concentration of 10 μg/ml was used. As 
detecting agent was used avidin-HRP complex (Vector, Peterborough UK) via mixing 
1:1 volumes of reagent A and reagent B in PBS and allowed to form HRP-biotin-
Avidin complexes with a 30 minutes incubation. 100 μl of the avidin-HRP complex 
was added to each section for 30 minutes at RT in humid chamber. Commercial 
antibodies anti-vWF (clone F8/86 - Dako, Cambridgeshire UK), anti-CD31 (clone 
1D2-1A5 - Sigma, Dorset UK), anti-CD34 (clone QBEnd-10 - Dako, Cambridgeshire 
UK) and anti-α actin (clone 1A4 - Sigma, Dorset UK) were used at 1 μg/ml with 1h 
incubation at RT in humid environment. Sections were then treated with 
biotinylated anti rat/mouse antibody (Dako, Cambridgeshire UK) and followed by 
incubation with avidin-HRP complex (Vector, Peterborough UK) as described above. 
2.6.3.2 Frozen sections 
Slides were defrosted at RT for 30 minutes, fixed in ice-cold acetone for 10 
minutes and air dried for 30 minutes at RT. The slides were then rehydrated in PBS 
for 10 minutes at RT. The endogenous peroxidase activity was blocked by adding 
0.3% H2O2 in methanol for 20 minutes at RT and the sections processed as 
described above. No antigen retrieval was required for frozen tissue section. 
2.6.4 Immunofluorescence 
Frozen tissue slides were defrosted at RT for 30 minutes, fixed in ice-cold 
acetone for 10 minutes and air dried for 30 minutes at RT. Serum free protein block 
(Dako, Cambridgeshire UK) was added to the sections for 30 minutes at RT in order 
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to prevent non-specific antibody binding and then washed 3 times in PBS for 3 
minutes. 100 μl of primary antibody was applied to the sections and incubated at 
room temperature before washing 3 times with PBS for 3 minutes to remove 
unbound antibody. The primary antibody was detected with 100 μl of fluorochrome 
conjugated secondary antibody upon incubation for 1 h at RT in dark chamber and 
humid environment. The sections were washed as above and incubated with 100 μl 
DAPI 1:1000 solution in PBS for 10 minutes at RT in humid chamber away from the 
light. Slides were then washed once in PBS, mounted with 20 μl Mowiol (Sigma, 
Dorset UK) per section and closed with glass coverslips. In order to prevent 
mounting medium evaporation or diffusion, the sections were sealed with nail 
varnish and stored at 4 °C or -20 °C for longer storage. 
Concentration of scFv or scFv-Fc biotinylated and non-biotinylated 
antibodies was assay dependent. When not specified a concentration of 10 μg/ml 
was used. As detecting agent for biotinylated antibodies was used avidin-Texas red 
conjugated molecule (Life technologies, Paisley UK) diluted 1:1000 in PBS 0.5% BSA. 
Anti-vWF (clone F8/86 - Dako, Cambridgeshire UK), anti-CD31 (clone 1D2-1A5 - 
Sigma, Dorset UK), anti-α actin (clone 1A4 - Sigma, Dorset UK), anti-NG2 (Millipore, 
Massachusetts USA), anti-CD248 (clone B1/35 – Millipore, Massachusets USA) and 
anti-CD31 biotinylated (clone MEM-05 – Abcam, Cambridge UK) were used at 1 
μg/ml in PBS 0.5% BSA. Bound antibodies were detected with anti-mouse IgG 
(Isotype specific) antibody directly conjugated to Alexa Fluor 488 (green) or 594 
(red) (Life Technologies, Paisley UK) at a concentration of 1 μg/ml or avidin-Texas 
red (for biotinylated antibodies) in PBS 0.5% BSA. When in dual fluorescence 
staining the antibody were chosen with different IgG subclass and detected with 
the relevant isotype specific conjugated antibody. 
2.6.5 Image analysis 
Pictures from DAB staining were acquired using Cell-P imaging software 
(Soft Imaging System, Münster, Germany) in bright field with Olympus microscope 
unit. UV fluorescent pictures were acquired using Cell-P imaging software using UV-
light at the required excitation wavelength with Olympus microscope unit. Alexa 
Page | 86  
 
Chapter 2 – Materials and Methods 
 
Fluor 488 was excited at 488 nm and emission detected at 519 nm, Alexa Fluor 594 
was excited at 591 nm at emission detected at 618 nm, Texas red was excited at 
589 nm and emission detected at 615 nm.  
Quantification of HRP/DAB staining intensity was performed on digitally 
captured colour images, saved as tiff files and analysed using ImageJ 1.44 (NIH, 
Maryland USA) after using the colour deconvolution algorithm as described 
previously (237). DAB layer was thresholded using ImageJ 1.44, for consistency 
samples included in the same analysis were thresholded to a fixed value. 
Thresholded pictures were converted in grey scale and the mean grey value, which 
is the sum of the grey values of all the pixels in the selection divided by the number 
of pixels, was calculated for vascular regions (positive staining region) and 
comparable size areas in a non-relevant portion of the tissue (background value) 
using ImageJ 1.44 analysis tool. A total of 5 regions per sample or category were 
calculated and expressed as mean ± standard deviation (SD) and compared using 
unpaired non parametric statistical analysis. 
ImageJ 1.44 (NIH, Maryland USA) colocalization indices plugin was used to 
perform thresholded Pearson’s Correlation Co-efficient analysis of images in order 
to accurately quantify and correlate overlap of image pixels from 2 different 
channels (238, 239). A value of +1 indicates complete pixel-to-pixel overlap 
between the two chosen channels. A value of 0 indicates no overlap or correlation 
of pixels from two different channels, and −1 indicates complete disparity/exclusion 
of pixels from the two channels that have been compared. 
2.7 In vitro cell culture 
 Cell cultures were grown in plastic tissue-culture flasks (Corning, 
Massachusetts USA) in Binder CO2 incubators (Binder, Tuttlingen Germany) at 37 °C 
with 5% CO₂ and humid environment. 
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2.7.1 Cell line culture 
Prostate cancer cell line (PC3), Epithelial cancer cell line JU77 and human 
embryonic kidney cell line (HEK-293) were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Life Technologies, Paisley UK) supplemented with 10% foetal calf 
serum (FCS), 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. 
HEK-293 SV40 transformed (HEK-293T) cell line was cultured in DMEM 
supplemented with 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.5 
mg/ml geneticin and 2 mM L-glutamine. IE7 cell line was cultured in M200 medium 
(Life Technologies, Paisley UK) supplemented with Low Serum Growth Supplement 
(LSGS) (foetal bovine serum, 2% v/v; hydrocortisone, 1 mg/ml; human epidermal 
growth factor, 10 ng/ml; basic fibroblast growth factor, 3 ng/ml; and heparin, 10 
mg/ml), 100 U/ml penicillin and 100 μg/ml streptomycin and 2 mM L-glutamine. 
Monocyte cell line U937 was cultured in RPMI medium (Life Technologies, Paisley 
UK) supplemented with 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin and 
2mM L-glutamine.  
2.7.2 Primary fibroblast culture 
 Rheumatoid arthritis synovial fibroblasts (RASF) kindly provided by Dr Ngar-
woon Kam (Queen Mary University of London, London UK), were derived and 
maintained as previously described (58). Briefly, after discarding fat and dense 
fibrous tissues, synovium was minced, mashed under a 70 μm nylon mesh cell 
strainer (Becton Dickinson, Oxford, UK) and digested overnight at 37 °C with 1.5 
mg/ml dispase II in DMEM supplemented with 10% FCS, 50 U/ml penicillin-
streptomycin and 10 mM HEPES buffer (Life technologies, Paisley UK). The resulting 
suspension was passed through a cell strainer, centrifuged and the cell pellet was 
re-suspended in culture medium and incubated in T75 tissue-culture flasks. When 
90% confluent, fibroblasts were passaged at a ratio of 1:3 using 0.25% trypsin/EDTA 
(Sigma, Dorset UK). Synoviocytes were used between passages 4 and 8 (240). 
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2.7.3 Immunocytochemistry 
3x104 cells were seeded in 13 mm round autoclaved coverslips (VWR, 
Leicestershire UK), in 24 well plates with 1ml of appropriate medium and incubated 
overnight at 37 °C. 500 μl of medium were then removed and 500 μl of 1% 
formaldehyde in PBS added and incubated at RT for 5 minutes with gentle rocking. 
The medium was then completely removed from the wells via aspiration and 
replaced with 1ml of 1% formaldehyde and left for 10 minutes at RT with gentle 
rocking. The wells were then washed extensively in PBS to remove excess of fixing 
agent. 0.1 M glycine was used for 10 minutes at RT to quench the reactive aldehyde 
groups. When permeabilisation of the cells was required, 1 ml of 0.1% Triton X-100 
in PBS was used for 5 minutes followed by extensive washes with PBS. Primary 
antibody was then applied to coverslips and incubated for 2 hours at 37 °C in a 
humidified chamber. 100 μl of antibody was used when applied directly on the 
coverslip surface and 500 μl if the incubation was performed in 24 well plates. 
Three washings with PBS were performed to remove unbound antibody. The 
primary antibody was detected with a fluorochrome conjugated secondary 
antibody in a dark chamber. The cells were washed as above and incubated with 
100 μl DAPI 1:1000 solution in PBS for 10 minutes at RT in humid chamber away 
from the light. Slides were then washed once in PBS, mounted with 20 μl Mowiol 
(Sigma, Dorset UK) per section and closed with glass coverslips. In order to prevent 
mounting medium evaporation or diffusion, the sections were sealed with nail 
varnish and stored at 4 °C or -20 °C for longer storage. 
Concentration of scFv biotinylated and non-biotinylated antibodies was 20 
μg/ml. As detecting agent for biotinylated antibodies, anti-c-Myc antibody (clone 
9E10 – Sigma, Dorset UK) was used at 1 μg/ml concentration in PBS 0.5% BSA, 
followed by anti-mouse IgG Alex Fluor 488 (green) conjugated antibody at a 
concentration of 1 μg/ml. Biotinylated antibodies were detected with streptavidin 
Alexa Fluor 488 conjugated molecule (Life technologies, Paisley UK) at a 
concentration of 1 μg/ml. Anti-ICAM1 antibody (clone EP1442Y - Abcam, Cambridge 
UK) was detected with anti-Rabbit IgG Alexa Fluor 488 (Green) conjugated antibody 
(Life Technologies, Paisley UK). 
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2.7.4 Image analysis 
 Image acquisition was performed as described in section 2.5.5. Additionally, 
image acquisition was also performed using Leica confocal microscope (Leica, 
Wetzlar Germany) using Leica Application Suite Advanced Fluorescence (LAS AF) 
software platform (Leica, Wetzlar Germany). 
2.7.5 Cellular ELISA 
Cells were seeded at a concentration of 5x103 cells/well in 100 μl of complete 
medium in 96 well plates and incubated overnight at 37 °C. If needed cells were 
stimulated with 10 ng/ml TNFα for 24 hours. Culture medium was aspirated and 
cells washed in PBS (pre-warmed at 37 °C). Cells were then fixed in 2% PFA in PBS 
for 12 minutes at 37 °C. Cells were washed twice in PBS 0.1% BSA, ensuring that the 
cells were not dislodged. 1% BSA in PBS was used to block reactive aldehyde groups 
for 30 minutes at 37 °C. Blocking solution was aspirated and 100 μl of primary 
antibody was added to the wells and incubated for 1 h at 37 °C. 50 μg/ml was used 
as first scFv concentration with serial 1:2 dilutions in duplicate in PBS 0.1% BSA. 
Unbound antibodies were removed by three washes in 0.1% BSA in PBS. Anti-cMyc 
secondary antibody (clone 9E10, Sigma, Dorset UK) was incubated for 1 h at 37 °C. 
Three washes were performed as described above to remove antibody excess. Anti-
mouse IgG HRP conjugated antibody (SantaCruz, California USA) was used as 
detection agent and incubated for 1 h at 37 °C. Cells were washed as previously 
described and incubated with 70 μl of TMB substrate according to manufacturer’s 
conditions (Becton Dickinson, Oxford UK) for 5 minutes at room temperature. 
Reaction was stopped with 35 μl 1N H2SO4 and absorbance read at 450nm in Genios 
Tecan plate reader (Tecan, Mannedorf Switzerland). 
2.8 Protein extracts 
Cells were seeded at a density of 3x106 in 10 cm petri-dishes and incubated 
overnight at 37 °C. Alternatively, 90% confluent T75 flasks were lysate in 1 ml 
buffer.  
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RIPA buffer (150 mM NaCl, 10 mM Sodium Phosphate pH 7.2, 1% Na 
deoxycholate, 1% Triton X-100, 0.1% SDS, 5.2 mM 4-(2-Aminoethyl)benzenesulfonyl 
fluoride hydrochloride (AEBSF), 4 μM Aprotinin, 200 μM bestatin, 70 μM E-64, 100 
μM leupeptin, 75 μM pepstatin) extraction was performed as follows: cells were 
washed twice in ice cold PBS, 1 ml of RIPA buffer was added and cells scraped from 
the plate. The lysed cells were then left to incubate on ice for 30 minutes with 
gentle mixing and centrifuged at 10000 rpm using a table top centrifuge for 10 
minutes at 4 °C. The supernatant was collected and stored at -80 °C. 
For extraction in OTG buffer (1% w/v octylglucopyranoside in Tris-buffered 
saline pH 7.4, 2 mM EDTA, 5.2 mM AEBSF, 4 μM aprotinin, 200 μM bestatin, 70 μM 
E-64, 100 μM leupeptin, 75 μM pepstatin) cells were washed as above and 1ml of 
OTG buffer added and the cells scraped from the plate. The lysed cells were then 
left to incubate on ice for 1 hour with gentle mixing and centrifuged at 10000 rpm 
in a table top centrifuge for 10 minutes at 4 °C. The supernatant was collected and 
stored at -80 °C. 
To prepare cell lysates using saponin (0.2% saponin in PBS, 5.2 mM AEBSF, 4 
μM aprotinin, 200 μM bestatin, 70 μM E-64, 100 μM leupeptin, 75 μM pepstatin) 
the cells were washed as above, 1 ml of saponin added and the cells incubated on 
ice for 30 minutes with gentle rocking. The saponin buffer was then gently removed 
and stored at -80 °C. The cells were then lysed by scraping into 1ml Triton X-100 
(1% v/v Triton X-100, 20 mM Tris pH 8, 150 mM NaCl, 5.2 mM AEBSF, 4 μM 
aprotinin, 200 μM bestatin, 70 μM E-64, 100 μM leupeptin, 75 μM pepstatin). The 
lysed cells were incubated on ice for 30 minutes with frequent gentle agitation and 
then centrifuged at 10000 rpm for 10 minutes in a table top centrifuge at 4 °C. The 
supernatant was collected and stored at -80 °C. 
Triton X-114 (1.5% v/v Triton X-114, 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM 
MgCl2, 1 mM CaCl2, 5 mM EDTA, 5.2 mM AEBSF, 4 μM aprotinin, 200 μM bestatin, 
70 μM E-64, 100 μM leupeptin, 75 μM pepstatin) extraction was performed by 
washing the cells as above. 1ml of Triton X-114 buffer was then added and cells 
scraped from the plate. The lysed cells were left to incubate on ice for 1 hour with 
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frequent vortexing and then centrifuged at 10000 rpm in a table top centrifuge for 
10 minutes at 4 °C to pellet unbroken cells and nuclei. The supernatant was 
transferred in a clean tube and incubated at 37 °C for 3 minutes. The solution was 
then centrifuged at 3000 rpm for 10 minutes and the two phases (detergent phase 
[bottom] and aqueous phase [top]) separated and stored at -80 °C. 
To prepare cell lysates using hypotonic shock buffer (10 mM Tris pH 7.5, 200 
μM MgCl2, 5.2 mM AEBSF, 4 μM aprotinin, 200 μM bestatin, 70 μM E-64, 100 μM 
leupeptin, 75 μM pepstatin) the cells were washed twice in ice cold hypotonic 
buffer, incubated with 1 ml ice cold hypotonic buffer for 10 minutes on ice. The 
cells were then scraped from the dishes and mechanically disrupted in a Dounce 
homogeniser (50 strokes). The lysed cells were transferred to a clean tube, 
centrifuged at 500 g for 5 minutes at 4 °C and the supernatant transferred to a new 
tube and centrifuged at 20000 g for 30 minutes at 4 °C. The supernatant containing 
the cytoplasmic fraction was stored at -80 °C. 
 Lysate buffer for cell lysate ELISA (100 mM Tris pH 7.4, 150 mM NaCl, 1 mM 
EGTA, 1 mM EDTA, 1% IGEPAL, 5.2 mM AEBSF, 4 μM aprotinin, 200 μM bestatin, 70 
μM E-64, 100 μM leupeptin, 75 μM pepstatin) extraction was performed as follows: 
cells were washed once in ice cold PBS, 1 ml of lysis buffer was added and cells 
scraped from the flask and collected in pre-chilled tubes. The lysate was agitated on 
vortex briefly, incubated on ice for 30 minutes and centrifuged at 13000 rpm for 10 
minutes in bench top centrifuge at 4 °C to pellet insoluble content. The supernatant 
was collected and stored at -80 °C. 
 Cell extracts were analyse in Western blot (as described in section 2.4.2), in 
cell lysate ELISA (as described in section 2.7.1) and in Immunoprecipitation assays 
(as described in section 2.8). 
2.8.1 Cell lysate ELISA 
 A 96 well plate was coated with cell lysate diluted in equal volume of PBS 
and incubated overnight at 4 °C. Plate was then emptied, washed once in PBS and 
blot dry. 200 μl of PBS 4% milk was added as blocking solution for 1 h at 30 °C. 
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Blocking solution was removed after the incubation, washed once in PBS and blot 
dry. 100 μl of primary antibody in 0.5% BSA in PBS was added to each well and 
incubated for 1 h at 30 °C. For biotinylated scFv was used a concentration of 10 
μg/ml or 20 μg/ml, while for mouse anti-αtubulin (clone 236-10501 Life 
Technologies, Paisley UK) a concentration of 1 μg/ml was used. Plate was then 
washed three times in PBS 0.05% Tween 20 and PBS, blot dry and incubated with 
100 μl/well of secondary antibody. For biotinylated scFv, avidin-HRP conjugate 
(Vector, Peterborough UK) was used with 15 minutes incubation at 30 °C. For 
mouse antibodies, anti-mouse IgG HRP conjugate (SantaCruz, California USA) was 
incubated for 1h at 30 °C. Plate was then washed as described above and incubated 
with 70 μl of TMB substrate according to manufacturer’s conditions (Becton 
Dickinson, Oxford UK) for 5 minutes at room temperature. Reaction was stopped 
with 35 μl 1 N H2SO4 and absorbance read at 450 nm in Genios Tecan plate reader 
(Tecan, Mannedorf Switzerland). 
2.9 Immunoprecipitation 
2.9.1 scFv, scFv-Fc and IgG IP using protein A/G agarose beads 
 50 μl of protein A/G agarose beads (Sigma, Dorset UK) were resuspended in 
PBS and centrifuged at 2500 g for 1 minute to remove suspension buffer. The 
washing step was repeated twice to equilibrate the buffer. 500 μl of protein extract 
(RIPA or Lysate ELISA lysis buffer) were incubated with the protein A resin for 10 
minutes at 4 °C to pre-clear the lysate and reduce non-specific binding of the 
proteins to the agarose beads. Pre-cleared lysate was recovered by centrifugation 
at 13000 rpm on bench top centrifuge for 5 minutes. The lysate was then incubated 
with 10 μg of scFv (Figure 5.11) or 5 μg of scFv, scFv-Fc and IgG antibody (Figure 
5.12 and 5.14 B) for 2 h at room temperature with rotation. Antibody-lysate 
complex was then incubated with the resin overnight at 4 °C with tilting rotation to 
allow antibody binding to the resin. The resin was washed twice in 1 ml of PBS with 
2500 g centrifugation for 1 minute. Bound antibody-antigen complex was recovered 
via elution in 50 μl of Laemmli lysis buffer boiled at 95 °C for 5 minutes. Samples 
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were resolved in SDS-PAGE as described in section 2.4 and processed for Western 
blot (section 2.4.2) or stained with Ruby protein gel stain (section 2.4). 
2.9.2 scFv IP with CNBr activated agarose beads 
 To prepare the covalently coupled scFv-cyanogen bromide (CNBr) activated 
Sepharose beads, 0.05 g of lyophilised Sepharose beads (GE Healthcare, Amersham 
UK) were resuspended in 1 mM HCl and washed for 15 minutes in a 2 ml disposable 
gravity column with 20 ml of 1 mM HCl dispensed in several aliquots. 1 mg of scFv 
antibody was concentrated to 100 μl using Ultracel YM3000 MWCO (Millipore, 
Massachusetts USA) and re-diluted in coupling buffer (0.1 M NaHCO3 pH 8.3 and 0.5 
M NaCl) to a final concentration of 1 mg/ml. Concentration of antibody was 
measured after buffer exchange to evaluate effective protein content and protein 
loss, using a spectrophotometer at 280 nm. The antibody solution was added to the 
medium suspension in a stoppered vessel and incubated overnight at 4 °C with end 
over end rotation. Following incubation, the unbound antibody suspension was 
aspirated and beads were washed with 5 bed volumes of coupling buffer. Unbound 
antibody solution was measured to determine quantity of unbound antibody and 
determine coupling efficiency. Remaining active groups of the resin were blocked in 
0.1 M Tris-HCl buffer pH 8 for 2 h. Resin was then washed with three cycles of 
alternating pH, consisting in 5 bed volumes of 0.1 M acetic acid/sodium acetate pH 
4 containing 0.5 M NaCl, followed by wash with 0.1 M Tris-HCl pH 8 containing 0.5 
M NaCl.  
 500 μl of cell lysate was incubated with 10 μl of scFv coupled Sepharose 
beads for 2 h at 4 °C with end over end rotation. The suspension was centrifuged at 
3000 rpm on a bench top centrifuge for 2 minutes and the unbound lysate was 
discarded. Aliquot of unbound lysate, or flowthrough, was kept for analysis. Beads 
pellet was resuspended in 500 μl of PBS to wash and remove remaining lysate 
proteins. The suspension was spun a second time at 3000 rpm for 2 minutes and 
resuspended in 10 μl of Laemmli lysis buffer (0.5 M DTT, 10% glycerol, 0.44 M Tris 
pH 6.8, 0.04% Bromophenol Blue, 10% SDS) and boiled at 95 °C for 5 minutes. 
Similarly, flowthrough and wash samples were prepared in Laemmli lysis buffer for 
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further analysis. Samples were run on 8-16% polyacrylamide gels and stained with 
Ruby protein gel stain as described in section 2.4. 
2.9.3 IgG and scFv-Fc IP using protein A Dynabeads 
To prepare protein A Dynabeads resin (Life Technologies, Paisley UK), 50μl 
of the resin (1.5 mg beads) were transferred to a 1.5 ml tube and placed on a 
magnet. The magnetic field would retain the Dynabeads allowing the removal of 
the suspension buffer without resin loss. The tube was then removed from the 
magnet support and beads resuspended in 200 μl of PBS 0.05% Tween 20 
containing 5 μg of scFv-Fc antibody and incubated at RT for 10 minutes with tilting 
rotation. After the coupling step, the tube was placed on the magnet and the 
supernatant containing unbound antibodies was discarded. Aliquot of the 
flowthrough was kept for further analysis. Beads were washed by resuspention in 
200 μl of PBS 0.05% Tween 20. 400 μl of PC3 cell lysate or 500 μl of RASF protein 
extract were added to the beads - scFv-Fc complex and gently resuspended by 
pipetting. Cell lysate was allowed to interact with the beads for 25 minutes at RT 
with tilting rotation. The tube was placed on the magnet to remove the supernatant 
containing unbound lysate proteins and resuspended in 200 μl of PBS for a total of 
3 washes. Resuspended beads were then transferred to a clean tube to reduce 
carry-over of lysate and washing buffer, and supernatant removed. Dynabeads 
were then gently resuspended in 20 μl of Laemmli lysis buffer to elute the bound 
antigens and incubated at 85 °C for 10 minutes. Elution fraction, flowthrough and 
total cell lysate were resolved in SDS-PAGE with 8-16% polyacrylamide gels and 
stained with Ruby protein gel stain as described in section 2.4. 
2.9.3 scFv-Fc IP using cross-linked protein A Dynabeads 
 50 μl of protein A dynabeads suspension (1.5 mg resin) was transferred to a 
tube and placed under magnetic field to remove supernatant as described in 
section 2.8.2. The beads were then removed from the magnetic support and 
resuspended in 200 μl of PBS 0.05% Tween 20 containing 4.2 μg of scFv-Fc antibody 
and incubated for 10 minutes at RT with tilting rotation. Unbound antibodies were 
removed and the beads washed with 200 μl of PBS 0.05% Tween 20.  
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 In order to chemically cross-link the antibodies to the protein A Dynabeads, 
bis-sulfosuccinimdyl-suberate (BS3) was prepared by making a 100mM solution in 
conjugation buffer (20 mM sodium phosphate, 0.15 M NaCl at pH 7-9) and diluting 
to a final 5 mM concentration. scFv-Fc coupled protein A Dynabeads were washed 
twice in 200 μl of conjugation buffer, placed on a magnet and removed 
supernatant. The beads were then resuspended in 250 μl of 5 mM BS3 and 
incubated at room temperature for 30 minutes with tilt rotation. Cross-linking 
reaction was quenched by adding 12.5 μl of quenching buffer (1 M Tris-HCl pH 7.4) 
with 15 minutes incubation at RT with tilting rotation. Cross-linked beads were 
washed three times with 200 μl PBS 0.05% Tween 20 and IP performed as described 
in section 2.8.2. 
2.10 TNF cytotoxicity assay 
 The TNF cytotoxicity test was conducted on mouse fibroblast cell line L929. 
The L929 cells (1.5·104) were placed in each well of 96 well plates (Corning, 
Massachusetts USA) in 100 µl of DMEM medium supplemented with 10% FCS in the 
presence of 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine and 
incubated for 18 h at 37 °C 5% CO2. The medium was then removed and 100 µl of 
complete medium with 1µg/ml actinomycin D, 0.45 ng/ml TNFα or TNFα and the 
antibody of interest, were added to the cell monolayer and incubated 24 h at 37 °C 
in a CO2 incubator. Test antibody was used at a starting concentration of 18.8 nM 
with 1:2 serial dilutions. 10 µl of 5 mg/ml thiazolyl blue tetrazolium bromide in PBS 
(Sigma, Dorset UK) was added to the wells and incubated for 3 h at 37 °C. The 
medium was then removed and the cells resuspended in 100 µl 90% isopropanol 
10% DMSO for 15 minutes. Optical absorption was measured at 560 nm or 595 nm 
with a TECAN GENios plate reader (Tecan, Mannedorf Switzerland). 
2.11 TNF ELISA 
 Nunc 96 well immunosorbent plates (Thermo Fisher Scientific, 
Loughborough UK) were coated overnight at 4 °C with 100 ng/ml TNFα in PBS. 
Medium was then discarded, wells washed once in PBS and incubated with 200 μl 
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2% BSA in PBS to block non-specific reactive sites for 1 h at RT. Blocking solution 
was discarded after incubation and wells rinsed in PBS. 100 μl of primary antibody 
diluted in PBS 0.5% BSA was added per well and incubated for 2 h at RT. Test 
antibody was used at a starting concentration 6.8 nM with 1:3 serial dilutions. 
Unbound antibodies were removed via three repeated washes in PBS 0.05% Tween 
20. Secondary goat anti-Human IgG (Jackson ImmunoResearch, Pennsylvania USA) 
was used at 1:3000 dilution in PBS 0.5% BSA and incubated for 1 h at RT. Washes 
were repeated as described above and plate incubated with 70 μl per well of TMB 
substrate (GE Healthcare, Amersham UK) for 5 minutes and reaction stopped with 
35 μl 1 N H2SO4. Optical absorption was measured at 450 nm with a TECAN GENios 
plate reader (Tecan, Mannedorf Switzerland). 
2.12 DPP6 ELISA 
 DPP6 ELISA assay was performed as described in section 2.11 with the 
following difference: Nunc 96 well immunosorbent plates were coated with 100 
ng/ml of recombinant DPP6, kindly provided by Professor D. Sblattero (University of 
Eastern Piedmont, Novara Italy), overnight at 4 °C.  
2.13 Biacore 
 Set up of the Biacore T200 instrument was carried out according to Biacore 
procedure manual. A CM5 chip (GE healthcare, Amersham UK) carrying a 
carboxymethylated dextran matrix covalently attached to the gold sensor surface 
was used to covalently bind the capture mouse anti-human Fc antibody (GE 
healthcare, Amersham UK). The carboxyl groups were activated with a mixture of 
0.4 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 0.1 M N-
hydroxysuccinimide (NHS) (flow rate 10 μl/min for 7 minutes) to form succinimide 
esters. The capture antibody at a concentration of 25 μg/ml in immobilisation 
buffer (GE Healthcare, Amersham UK) was applied to the chip at a flow rate of 10 
μl/min for 7 minutes, in order to allow the exposed succinimide ester groups to 
react spontaneously with the amine groups of the capture antibody. Immobilisation 
of the antibody resulted in 2000 response units (RU). 1 M Ethanolamine-HCl pH 8.5 
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was used to deactivate excess reactive groups in the chip (flow rate 10 μl/min for 7 
minutes). To measure kinetic interactions of the test antibodies with TNF-α, the 
antibodies were injected at a concentration of 1 μg/ml with a flow rate of 30 μl/min 
for a contact time of 60 seconds. TNF-α was then injected at different 
concentrations starting at 20 nM with 1:2.5 serial dilutions at a flow rate of 30 
μl/min for a total contact time of 180 seconds, followed by 700 seconds of 
dissociation time. The chip was then regenerated via two injections of 3 M MgCl2 
(30 μl/min 60 seconds), removing all trace amounts of captured ligand and TNF-α 
from the chip surface. After successful regeneration, the capture and kinetic studies 
were repeated as described above. 
2.14 Phage library screening 
 The cDNA phage expression library obtained from mRNA of human colon 
carcinoma, human lung fibroblasts and human pancreatic islets was kindly provided 
by Professor D. Sblattero (University of Eastern Piedmont, Novara Italy). The library 
was characterised by 18000 genes present in multiple copies with fragments 
varying from 200 to 700 bp (241). Phage library in DH5αF’ was rescued from 
glycerol stock and grown in 2TYAG bacterial medium (for 1 L 16 g bactotryptone, 10 
g bacto-yeast, 5 g NaCl, 100 μg/ml ampicillin, 2% glucose in dH2O pH 7) at 250 rpm 
for 1.5-2 h at 37 °C until reached an OD 600 nm of 0.5. At this OD the bacterial cells 
should have reached a concentration of 3x108 cells/ml. 20 fold excess of helper 
phage was used to trigger phage expression for 45 minutes incubation at 37 °C with 
occasional agitation. Bacterial culture was spun at 4000 g for 10 minutes to pellet 
the infected cells. The pellet was then resuspended in a volume 5 times greater 
than the initial culture volume in 2TYAK (for 1 L 16 g bactotryptone, 10 g bacto-
yeast, 5 g NaCl, 100 μg/ml ampicillin, 25 μg/ml kanamycin in dH2O pH 7), grown at 
30 °C with 250 rpm agitation overnight. The following day the bacteria were 
centrifuged at 7000 rpm for 25 minutes at 4 °C to pellet the cells, and the 
supernatant was collected and subjected to PEG precipitation. 
 1/5 volumes of PEG/NaCl solution was added to the cleared phage 
supernatant and incubated for 30-60 minutes on ice. The solution was centrifuged 
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at 4000 g for 15 minutes at 4 °C and the phage pellet resuspended in 1/10 of the 
original volume with PBS. The solution was then spun in a microcentrifuge to 
remove remaining bacterial cells and the supernatant was transferred to a new 
tube. 
 1 ml of scFv or scFv-Fc antibody at a concentration of 5-10 μg/ml was used 
to coat Nunc immunotubes (Thermo Fisher scientific, Loughborough UK) and left 
overnight at 4 °C in rotation to allow antibody binding to the plastic surface. The 
following day the immunotubes were washed twice in PBS to remove unbound 
antibodies and blocked with 2% milk in PBS for 45 minutes at RT with rotation. The 
blocking step was necessary to block non-specific reactive sites of the plastic tubes. 
At the same time, the PEG precipitated phage pool was blocked with 2% milk in PBS 
in a final volume of 1 ml. After the blocking step the immunotubes were washed 
twice with PBS 0.05% Tween 20 and twice in PBS and incubated with the phage mix 
for 30 minutes at room temperature. Tubes were then washed 20 times in PBS 
0.05% Tween 20 and 20 times in PBS by pouring buffer in and out of the tubes. 
Bound phage clones were then eluted by adding 1ml of DH5αF’ at OD 600 nm of 0.5 
and left for 45 minutes at 37 °C. Infected bacteria were plated on 2TY agar plates 
with 100 μg/ml ampicillin as selective agent and incubated at 30 °C overnight. This 
plate represents the phage output of the first selection. Titration of the phage 
output was performed by colony count on 2TY agar plates. 
 Following rounds of selection were performed as described above with 
doubled washing steps to increase stringency. The inverted third round of selection 
was performed as above by using the output of scFv selection as input for scFv-Fc 
selection and vice versa. 
2.14.1 Phage ELISA 
 Individual colonies were picked from the phage selection. 100 μl of 2TYAG 
medium was added to each well of a 96 well plate and single colony was inoculated 
in each well. The bacteria were allowed to grow at 30 °C with 250 rpm agitation 
overnight. The following day 2 μl of each well was transferred in 120 μl of 2TYAG 
medium in a new 96 well plate with round bottom and grown at 37 °C with 250 rpm 
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agitation until reached OD 600 nm of 0.5. To each well was added 50 μl of 2TYAG 
medium containing 1x109 pfu helper phage (ratio of 20:1 phage to bacteria) and 
incubated for 30 minutes at 37 °C. Plate was then spun at 1700 rpm for 10 minutes 
to pellet the bacterial cells and the supernatant was discarded. Pellet was 
resuspended in 150 μl of 2TYAK and grown overnight at 28 °C with agitation.  
 Immunosorbent 96 well plates were coated with 100 μl of 10 μg/ml scFv or 
scFv-Fc antibody in PBS overnight at 4 °C. Antibody solution was discarded and 
plate washed once in PBS and incubated with 120 μl of 2% milk in PBS for 45 
minutes at RT to block remaining reactive sites of the plate. Plate was then washed 
twice in PBS. 50 μl of 4% milk in PBS and 50 μl of culture supernatant containing the 
phage clones were added to each well and incubated 1 h at RT with gentle 
agitation. Solution was discarded and plate washed three times in PBS 0.05% Tween 
20 and PBS. 100 μl of HRP conjugated mouse anti-M13 antibody was added to each 
well and incubated for 1h at RT. Plate was washed as described above and 70 μl of 
TMB substrate solution (Becton Dickinson, Oxford UK) was added in each well. The 
reaction was left for 5-20 minutes or until a suitable signal was detected, and 
quenched with 35 μl of 1 N H2SO4. Absorbance was read at 450 nm in a Genios 
Tecan plate reader (Tecan, Mannedorf Switzerland). 
2.14.2 Soluble protein expression from phage clone 
 Single infected DH5αF’ colonies were inoculated in 100 μl of 2TY medium 
supplemented with 100 μg/ml ampicillin and 2% glucose in each well of a 96 well 
plate and allowed to grow overnight at 30 °C with 250 rpm shaking. The following 
day, 2 μl from each well was transferred in a new 96 well plate with 100 μl 2TY with 
100 μg/ml of ampicillin and 0.1% glucose per well. Cells were grown at 37 °C until 
OD 600 nm was 0.6. 50 μl of 2TY with 100 μg/ml ampicillin and 1.5 mM IPTG (final 
concentration 0.5 mM IPTG) was added in each well and incubated at 28 °C 
overnight with 250 rpm shaking. The following day the plate was spun at 1700 rpm 
for 10 minutes and the supernatant containing the soluble protein was collected for 
ELISA screening. In addition, the bacterial pellet was resuspended in PPB solution 
(200 mg/ml sucrose, 1 mM EDTA, 30 mM Tris-HCl pH 8) and incubated for 45 
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minutes on ice. The solution was then centrifuged at 13000 rpm at 4 °C for 20 
minutes and the periplasmic extract collected for ELISA screening. 
2.15 Target antigen validation 
2.15.1 LTBP2 soluble protein expression 
In collaboration with the University of Eastern Piedmont in Novara, the 
vector coding for LTBP2 cDNA fragment was amplified and digested using NheI 
restriction endonuclease (New England BioLabs, Herts UK) at 37 °C for 1 h in NEB 
buffer 2, followed by incubation with BssHII restriction enzyme (New England 
BioLabs, Herts UK) at 50 °C in NEB buffer 2 for 1 h. Reaction was then resolved in 
1% agarose gel and purified following gel extraction of the relevant band using PCR 
clean-up Gel extraction kit (Macherey-nagel, Düren Germany) as described in 
section 2.2.1. A modified version of the pGEX 4T-1 vector (GE Healthcare, 
Amersham UK), containing the NheI and BssHII restriction sites and the glutathione 
S-transferase (GST), was used as expression plasmid and digested as described 
above to accommodate the insert. Digested insert and vector were ligated to 
reconstitute the expression plasmid using T4 DNA ligase (New England BioLabs, 
Herts UK). A 3:1 molar ratio between insert and vector was used and incubated at 
16 °C overnight. Ligase reaction was transformed in competent DH5αF’ E. coli 
bacteria, leaving the reaction for 15 minutes in ice to allow optimal plasmid 
distribution, incubating 30 seconds at 42 °C and finally 2 minutes in ice. Bacteria 
were left recovering in 2TY culture medium with 1% glucose at 37 °C at 200 rpm for 
1h. Finally, bacteria were plated in 2TY agar plates containing 100 μg/ml ampicillin 
and left overnight at 37 °C. Grown colonies represented efficiently transformed 
cells. Single colonies were screened for presence of the correct plasmid via 
polymerase chain reaction (PCR) using primer sense (5’-
GGGCTGGCAAGCCACGTTTGGT-3’) and primer antisense (5’-
GGTGAAAACCTCTGACACATGCAGCTCCCGG -3’) and sequenced to confirm correct 
gene insertion.  
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Transformed bacteria were grown in 2TY medium with 100 μg/ml ampicillin 
with agitation at 37 °C until OD 600 nm reached 0.6. Bacteria were then induced 
with 0.5mM IPTG with overnight incubation at 30 °C to stimulate protein 
expression. Bacteria were collected following centrifugation at 4000 rpm for 20 
minutes and resuspended in 1% Triton X-100 in PBS at 4 °C with agitation until 
solution appeared clarified, in the presence of 200 μg/ml of lysozyme and 20-50 
μg/ml DNAase. Clarified lysates were centrifuged at 8500 rpm for 20 minutes at 4 
°C and supernatant purified by affinity chromatography with 25 μl of settled GSH 
agarose resin (Sigma, Dorset UK). The suspension was incubated with gentle mixing 
for 30 minutes at 4 °C, loaded on filter column and allowed to settle by gravity flow. 
Resin was washed three times in 0.05% Tween 20 in PBS and once in PBS and eluted 
with 100 μl of elution buffer (50 mM GSH reduced, 100 mM NaCl, PBS pH 8). 
Protein fractions were dialysed overnight against PBS for buffer exchange at 4 °C, 
recovered and stored at -80 °C. 
2.15.2 C19 ORF 10 soluble protein expression 
 pCMV6 plasmid containing the C19 ORF 10 519 bp gene, cloned with SgfI-
MluI restriction sites, was purchased from OriGene (OriGene, Washington D.C. 
USA). HEK-293T cells were grown on the surface of glass coverslips, previously 
degreased and autoclaved, in 24 well plates at a concentration of 5x104 cells/ml for 
24 h at 37 °C in 1 ml of complete medium. Cells were then transfected with the 
pCMV6-C19 ORF 10 plasmid using the JetPrime reagent (Polyplus, Illkirch France) 
following manufacturer’s recommendations. Briefly, a mixture of 50 μl JetPrime 
buffer with 0.5 μg of plasmid DNA and 1 μl JetPrime reagent was left to incubate for 
10 minutes and applied drop-wise to the cells. Transfection was protracted for 4 h 
at 37 °C before medium was replaced and incubated for 24 h. The supernatant was 
then collected, centrifuged at 1500 rpm and filtered to remove cells and cellular 
debris. 
2.15.3 ELISA on soluble proteins 
 Nunc immunosorbent 96 well plates (Thermo Fisher Scientific, 
Loughborough UK), were coated with 100 μl 10 μg/ml of soluble protein in PBS or 
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100 μl of C19 ORF 10 transfected or non-transfected HEK-293T supernatant 
overnight at 4 °C. Coating solution was discarded and plate washed once in PBS and 
incubated with 200 μl of 4% milk in PBS for 1 h at RT to block remaining reactive 
sites of the plate. Plate was then washed once in PBS and wells incubated with 100 
μl of primary antibody at 10 μg/ml (or 1 μg/ml for commercial antibodies) in PBS 
0.5% BSA for 1 h at RT with agitation. Solution was discarded and plate washed 
three times in PBS 0.05% Tween 20 and once in PBS. 100 μl of secondary antibody 
HRP conjugated was added per well and incubated for 1 h at RT. For scFv 
antibodies, a mouse anti-cMyc antibody followed by anti-mouse IgG HRP 
conjugated antibody was used. For scFv-Fc it was used an anti-SV5 antibody 
followed by anti-mouse IgG HRP conjugated antibody. Plate was washed as 
described above and 70 μl of TMB substrate solution (Becton Dickinson, Oxford UK) 
was added in each well. The reaction was left for 5-20 minutes or until a suitable 
signal was detected, and quenched with 35 μl of 1 N H2SO4. Absorbance was read at 
450 nm in a Genios Tecan plate reader (Tecan, Mannedorf Switzerland). 
2.15.4 PDGFR fusion protein 
The LTBP2 gene fragment was amplified from the phagemid plasmid using 
PCR using the primer LTBP2 BglII Display sense (5’-
AGCTAGATCTGGCGCGCCTGGCTTCGT-3’) and primer LTBP PstI Display anti (5’-
CGACCTGCAGCCGCTCGTCAATATCCA-3’) and including the restriction sites BglII and 
PstI to allow cloning in the pDisplay vector (Life Technologies, Paisley UK). Similarly, 
the C19 ORF 10 gene sequence was amplified from pCMV6-C19 ORF 10 plasmid, 
described in section 2.10.2, following PCR using the primer ORF BglII Display (5’-
AGCTAGATCTATGGCGGCGCCCAGCGG-3’) and antisense ORF PstI Display anti (5’-
CGACCTGCAGCAGCTCAGTGCGCGATGA-3’). 1 μg of pDisplay vector and PCR 
products were digested with restriction enzymes BglII and PstI at 37 °C for 1 h in 
NEB buffer 3 (New England BioLabs, Herts UK). Digestion products were resolved in 
0.8% agarose gel and purified following gel extraction of the relevant band using 
PCR clean-up Gel extraction kit (Macherey-nagel, Düren Germany) as described in 
section 2.2.1. Digested insert and vector were ligated to reconstitute the expression 
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plasmid using T4 DNA ligase (New England BioLabs, Herts UK) and transformed in 
competent DH5α as described in section 2.10.1. 
Plasmid coding for PDGFR-LTBP2 or PDGFR-C19 ORF 10 were transfected in 
HEK-293T cells grown on glass coverslips on 24 well plates as described in section 
2.10.2. Transformed cells were stained in immunofluorescence as described in 
section 2.6.3. Biotinylated scFv antibodies were used at 50 μg/ml concentration in 
PBS 0.5% BSA and detected with streptavidin-Alexa 488 conjugated molecule (Life 
Technologies, Paisley UK). Mouse anti-HA (clone HA-7 Sigma, Dorset UK) and mouse 
anti-cMyc (clone 9E10 Sigma, Dorset UK) were used at 1μg/ml in PBS 0.5% BSA and 
detected with anti-mouse IgG Alexa 594 conjugate antibody (Life Technologies, 
Paisley UK) at 1 μg/ml.  
2.16 Polymerase chain reaction 
 Polymerase chain reaction (PCR) was generally performed with Herculase II 
Fusion DNA polymerase (Agilent Technologies, Berkshire UK) using 10 ng DNA 
template, 0.5 μl DNA polymerase, 5% DMSO, 0.25 μM of each primer and 250 μM 
of each dNTP, in a total volume of 50 μl. Reaction was performed in GeneAmp PCR 
system 9700 (Life Technologies, Paisley UK). PCR cycle was performed as follows: 95 
°C 2 minutes; 2 cycles of 95 °C 10 seconds, 62 °C 30 seconds and 72°C 2 minutes; 2 
cycles of 95 °C 10 seconds, 60 °C 30 seconds and 72 °C 2 minutes; 2 cycles of 95 °C 
10 seconds, 58 °C 30 seconds and 72 °C 2 minutes; 15 cycles of 95 °C 10 seconds, 56 
°C 30 seconds and 72 °C 2 minutes; final extension at 72 °C for 10 minutes. 
2.17 Statistical analysis 
 Statistical analysis was performed using GraphPad Prism version 5 for 
Windows OS (GraphPad, California USA). Specifically, Mann-Whitney test was used 
for unpaired non-parametric quantitative variables when comparing two groups; 
Kruskal-Wallis test was used when comparing more than two groups of unpaired 
non-parametric quantitative variables; Paired or unpaired T-test was used to 
compare paired or unpaired quantitative variables respectively; 2 way ANOVA with 
Bonferroni’s post-test to compare more than two groups of unpaired quantitative 
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variables. A p value <0.05 was considered statistically significant. # or *= p value 
<0.05, **= p value <0.01, ***= p value <0.001. 
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3.1 Introduction 
Phage display library screening in vivo using a SCID mouse model double 
transplanted with human arthritic synovium and normal human skin as control 
tissue, has allowed the isolation of the phage clone A7, as described in section 
1.4.2, showing high homing specificity for the arthritic synovium. In order to 
express a soluble scFv antibody, the HB2151 non suppressor E.coli strain was 
infected with phages carrying the scFv gene of interest. The HB2151 strain, as 
opposed to the TG1 strain, is able to recognise the Amber (TAG) codon present in 
the sequence between the scFv and the pIII phage protein. This step is crucial to 
allow the scFv antibody fragment to be expressed as an independent protein and 
evaluate its binding capacity and tissue reactivity. However, the production 
efficiency of a heterologous protein in a bacterial host is highly variable, mainly 
being a direct consequence of the primary sequence and the propensity to form 
insoluble aggregates during the folding process, leading to low yields (242). Despite 
yield being an important aspect when it comes to large scale antibody preparation, 
protein sequence can also influence the stability and determine the propensity to 
aggregate during storage conditions. For the past 20 years periplasmic expression in 
E. coli has been the standard approach to functional antibody fragments production 
(243), ensuring good yields and correct protein folding. In particular three different 
types of folding modulators with chaperone activity have been discovered in the 
periplasmic compartment of E.coli and may have a role in the correct folding and 
expression of foreign proteins. Such folding modulators include the disulphide-
bond-forming machinery (244), periplasmic proteins with peptidyl prolyl cis/trans 
isomerase (245) and the protease DegP that shows chaperone activity at low 
temperatures (246).  
Due to the variability observed among different antibodies and expression 
systems, it is important to thoroughly evaluate the protein production efficiency 
and reactivity of each antibody. In this chapter it will firstly be described the 
production method adopted for scFv expression, comparing different strategies for 
protein purification and assessing protein purity and quality. Subsequently the 
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development of biotinylated reagents and the evaluation tissue reactivity in vitro 
will be presented. In the second part of the chapter the development of a scFv-Fc 
fusion protein, characterising production efficiency, quality assessment and tissue 
reactivity in vitro will be described. 
3.2 scFv A7 protein production 
Achieving a successful protein production with correct expression, high 
purity and optimal reactivity, is the critical limiting step towards the 
characterisation of a potential therapeutic molecule. As described in detail in 
section 2.1, the expression of the scFv antibody of interest from the HB2151 E.coli 
strain can be triggered by IPTG induced Lac promoter activation in the pIT2 plasmid. 
A schematic of the expression vector used for scFv expression is shown in Figure 
3.1. The pelB leader sequence provides the necessary signal for bacterial 
periplasmic expression from which the protein can then be isolated and purified in 
a more efficient way compared to whole cell lysate (247). However, the purification 
strategy adopted for protein isolation can determine the yield of recovered protein. 
Two purification systems, specifically protein A Sepharose purification procedure 
and Talon® metal affinity resin purification, were compared in order to determine 
which was the most efficient.  
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Figure 3.1 pIT2 vector and scFv A7 protein structure 
Schematic of pIT2 vector encoding the scFv gene with the pelB leader sequence under the 
control of the inducible lac promoter (A). Schematic of the expressed scFv protein showing 
the VH and VL domains linked by a serine-glycine linker and carrying the 6-His and c-myc 
tags (B). 
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3.2.1 Optimisation of scFv protein purification 
The Staphylococcus aureus protein A is a protein able to interact with the Fc 
portion of IgG1 and IgG2 and therefore is the method of choice for isolation of IgG 
isoforms from complex medium. Additionally, protein A has been proven to interact 
with the variable region of the VHIII subgroup (248). Since the Tomlinson library, 
used for the phage display scFv isolation, is based on the VHIII gene frame work 
(VHIII 1-3), antibody clones derived from this library can be purified using this 
method. Further, antibody clones derived from the Tomlinson library carry a c-myc 
and a 6-Histidine (6-His) tag (Figure 3.1). The presence of a 6-Histidine tag can be 
exploited with use of an immobilised metal affinity resin. Specifically, the metal 
affinity resin Talon® is composed of Sepharose beads bearing a tetradentate 
chelator for the metal ion Cobalt that, under conditions of physiological pH, allows 
the binding of histidine to the resin that can then be released by competition with 
free imidazole (249, 250). Both resins are loaded in chromatography columns 
following incubation with the medium containing the scFv protein to be purified.  
Direct comparison of the two purification strategies using the same bacterial 
culture divided in equal measure, showed Talon® purification to be more efficient 
than protein A, generating a 1.8 fold increase in protein yield and was able to purify 
up to 3 mg scFv A7 from 100 ml culture (Table 3.1). 
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Purification 
system 
Supernatant 
Periplasmic 
extract 
Total 
protein 
Culture 
volume 
Protein A 0.34 (±0.001) mg 1.30 (± 0.05) mg 1.65 mg 100 ml 
Talon® 0.83 (± 0.01) mg 2.17 (± 0.23) mg 3 mg 100 ml 
 
Table 3.1 scFv A7 protein yields 
Protein yields obtained through Protein A and Talon® metal affinity purification of 100ml 
bacterial culture. Supernatant purification and periplasmic extract are shown as separate 
values as a mean of 3 independent purifications (± SD), quantified using spectrophotometry 
at OD 280 nm and densitometry analysis of Coomassie stained SDS-PAGE. Total protein 
obtained from 100 ml bacterial culture has been calculated by sum of supernatant and 
periplasmic mean yield. 
 
SDS-PAGE and Western blot analysis of the purified scFv A7 showed no 
difference in terms of purity between the two methods compared. A specific band 
at 30 kDa could be detected with both purification systems and the scFv identity 
was confirmed in a Western blot targeting the 6-His tag (Figure 3.2). The presence 
of a lower molecular weight band was detected in the Talon® purification which 
represents a breakdown product of the purified protein at the linker region. This 
breakdown product is most likely the VL carrying the 6-His tag which can thus be 
pulled down using the metal affinity chromatography. In the same way, the VH 
region could be pulled down using protein A and the fact that it is not detectable in 
the Coomassie stained SDS-PAGE in Figure 3.2 is ascribed to lower protein content 
in the protein A purified fractions below the coomassie sensitivity limit. In order to 
further confirm the specificity of both Talon® and protein A resins for the scFv 
protein, parent (empty) HB2151 bacteria were grown and processed using the 
above techniques. The results obtained, showed that no detectable protein could 
be measured by spectrophotometry (OD280nm), SDS-PAGE and Western blot analysis 
even after concentrating the material 10 fold (Figure 3.3).  
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Talon® purification appeared to be more efficient in scFv purification. The 
optimised purification procedure was used to purify a second scFv targeting hen 
egg lysozyme (scFv HEL), kindly provided by Dr. Ahuva Nissim. The scFv HEL was 
isolated from the Tomlinson phage library and therefore shares the same 
framework of scFv A7, representing an ideal control antibody. Figure 3.4 shows the 
efficient purification of scFv HEL using Talon® metal affinity resin. 
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Figure 3.2 scFv A7 production and purification 
Optical density analysis of scFv A7 eluted fractions from supernatant and periplasmic 
extracts using protein A or Talon® purification systems (A). SDS-PAGE resolved scFv A7 
fractions from protein A or Talon® stained with Coomassie brilliant blue (B) or probed with 
anti 6-HIS and anti-mouse HRP conjugated antibody (Western blotting) (B). 
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Figure 3.3 Purification control on empty HB2151 host 
Optical density analysis of eluted fractions from supernatant and periplasmic extracts using 
protein A or Talon® purification system (A). SDS-PAGE resolved protein from 10 times 
concentrated fractions eluted from protein A or Talon® stained with Coomassie brilliant 
blue (B) or probed with anti 6-HIS and anti-mouse HRP conjugated antibody (Western 
blotting) (B).  
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Figure 3.4 scFv HEL production and purification 
SDS-PAGE resolved scFv HEL fractions from Talon® metal affinity purification stained with 
Coomassie brilliant blue (A) or probed with anti 6-HIS and anti-mouse HRP conjugated 
antibody (Western blotting) (B). 
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3.2.2 Quality assessment of scFv A7 protein production 
As described in the previous section, analysis of the purified scFv A7 
antibody protein by Coomassie blue staining of SDS-PAGE gels and Western blots, 
shows the presence of a main band at approximately 30 kDa corresponding to the 
intact scFv antibody, and a minor band at approximately 20 kDa corresponding to a 
breakdown product of the protein (Figure 3.2). Staining of the gel using a high 
sensitive colloidal Coomassie brilliant blue reagent (EZBlue), shows the presence of 
several minor bands appearing at 60 kDa and above that did not appear in 6-His 
targeted Western blots (Figure 3.5). These high molecular weight bands most likely 
correspond to bacterial chaperone proteins, like the hsp60 GroEL, that are retained 
during the purification steps (251). 
Since achieving good quality, highly pure protein production is essential to 
characterise the antibody reactivity, an additional analysis step was performed to 
clearly define the protein constituents of the HB2151 purified periplasmic extracts. 
Specifically, HPLC size exclusion chromatography was performed on a freshly Talon® 
purified scFv A7 batch. The UV detection plot showed the predominant protein to 
be the monomeric form of the scFv A7, eluting between 18 and 19 minutes and 
corresponding to a putative molecular weight of 30 kDa, a small portion of dimers, 
eluting between 16 and 17 minutes (60 kDa), and no detectable contaminant 
proteins within the resolution power of the column (Figure 3.6 A). FPLC size 
exclusion chromatography performed on freshly Talon® purified scFv A7 confirmed 
the result obtained in HPLC, showing the monomeric form of scFv A7 as the 
predominant protein and only a limited amount of dimers and contaminant 
proteins (Figure 3.6 B). 
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Figure 3.5 Analysis of scFv A7 protein purity 
Talon® purified scFv A7 protein fractions resolved in SDS-PAGE gel and stained with 
colloidal Coomassie brilliant blue (EZBlue) (A) or probed with anti 6-His and anti-mouse HRP 
conjugated antibody following Western blotting (B). The gels show the presence of a 
predominant band at 30 kDa corresponding to scFv A7 and breakdown products of lower 
molecular weight. The presence of high molecular weight contaminant proteins in the 
Coomassie stained gel probably correspond to bacterial contaminants as they do not show 
His reactivity in Western blot. 
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Figure 3.6 HPLC and FPLC analysis of scFv A7 
HPLC analysis of scFv A7 Talon® purified using phenomenex silica-based size exclusion 
column biosep-sec-S-2000. The elution plot shows the presence of a predominant peak at 
18-19 minutes corresponding to a predicted molecular weight of 30 kDa, consistent with 
the size of the monomeric form of scFv A7. A small amount of contaminant proteins can be 
detected at 16-17 minutes corresponding to 60 kDa (putative scFv A7 dimers) and 12-13 
minutes corresponding to proteins over 200 kDa (A). FPLC analysis of scFv A7 Talon® 
purified using Superdex 75 size exclusion column. The elution plot shows the presence of a 
predominant peak corresponding to the monomer format of scFv A7 at 30 kDa with small 
amount of scFv dimers at 60 kDa and contaminant proteins.  
Page | 118  
 
Chapter 3 – Optimisation of scFv A7 and A7 scFv-Fc production and quality control 
 
3.2.3 Optimisation of immunohistochemistry and assessment of synovial 
reactivity 
Immunohistochemistry (IHC) is a method used to demonstrate the 
distribution of proteins in tissue sections. This technique is less sensitive than 
conventional immunoassays, such as Western blot and ELISA, however, IHC 
combined with optical microscopy allows the assessment of the binding capacity of 
the test antibody in the context of an intact tissue and provides information on 
antibody reactivity such as tissue distribution and cellular localisation. Despite a 
relatively straightforward experimental method, many variables can influence the 
outcome and the best possible protocol conditions need to be determined for each 
antibody tested. In particular, the fixation step of fresh tissue was performed using 
4% formaldehyde, preserving tissue morphology by protein crosslinking and 
preventing autolysis and necrosis of the tissue. This step may cause a masking of 
the target antigen that needs to be retrieved prior to staining procedure. The 
optimisation of IHC conditions are discussed in this section. 
3.2.3.1 Biotinylation of scFv antibody 
 After purity and quality assessment of the soluble scFv antibody produced, 
the proteins were conjugated to biotin according to the protocol described in 
section 2.4. The coupling with biotin allows an amplification of the signal, due to a 
high molar ratio of biotin to scFv, to be detected using avidin conjugated HRP 
reagent. The pre- and post-biotinylation scFv antibodies were resolved on 
coomassie stained SDS-PAGE gel and analysed by HPLC where no loss in protein 
purity or quality could be detected (Figure 3.7) 
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Figure 3.7 Analysis of scFv A7 biotinylation 
SDS-PAGE resolved scFv A7 pre- and post-biotinylation stained with colloidal Coomassie 
brilliant blue (EZBlue) (A) and HPLC analysis (B) show no loss of protein purity or increased 
aggregation due to the biotinylation procedure. 
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3.2.3.2 Antigen retrieval procedures in paraffin embedded tissue sections 
The process of sample fixation can lead to protein crosslinking that can 
cause masking of the target antigen, reducing or completely blocking the binding to 
the specific antibody. In order to remove this artificial alteration of the tissue and 
restore antigen availability, two different approaches can be used: Proteolytic-
induced Epitope Retrieval (PIER) or Heat-induced Epitope Retrieval (HIER). The PIER 
approach uses the proteolytic activity of an enzyme to partially digest the tissue 
and unmask the target antigen. The HIER approach utilises heated buffers with 
different composition and pH to unmask epitopes. Table 3.2 describes a list of PIER 
and HEIR buffers used to test scFv A7 activity in synovial tissue sections.  
The most suitable retrieval procedure to reveal scFv A7 reactivity in human 
arthritic synovium was assessed via IHC staining in formalin fixed paraffin 
embedded tissue sections as described in section 2.6.3.1. Briefly, paraffin was 
removed from the sections via a xylene – ethanol exchange buffer and rehydrated 
in PBS. Subsequently the sections were incubated with a spectrum of antigen 
retrieval buffers as listed in Table 3.2. Varying degrees of background noise could 
be detected between the different buffers. In general proteolytic retrieval appeared 
to be more efficient while procedures involving heat inactivation showed increased 
tissue degradation especially at long incubation times (Figure 3.8). Proteinase K 
retrieval was more convenient due to a combination of a short incubation time (4 
minutes) and efficient retrieval of the scFv A7 target antigen with a good signal to 
noise ratio that did not improve when used in conjunction with other proteolytic 
enzymes. 
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PIER Incubation time 
Proteinase K 4 minutes 37 °C 
Digest-All3 (pepsin) 10 minutes 37 °C 
Digest-All3 (pepsin) + proteinase K 10 minutes 37 °C + 4 minutes 37 °C 
Chondrotinase 1 hour 37 °C 
Chondrotinase + proteinase K 1 hour 37 °C + 4 minutes 37 °C 
HIER  
EDTA pH 9 3 minutes boiling in water bath 
EDTA pH 9 20 minutes boiling in water bath 
0.01% trisodium-citrate pH 6 3 minutes boiling in water bath 
0.01% trisodium-citrate pH 6 20 minutes boiling in water bath 
Additional procedure  
HCl 2 M 10 minutes room temperature 
 
Table 3.2 Antigen retrievals 
List of buffers tested in antigen retrieval procedure for scFv A7 staining in arthritic 
synovium tissue sections. 
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Figure 3.8 Comparison of retrieval procedures in arthritic synovium 
RA synovial tissue sections treated with PIER, HIER or HCl retrieval procedures. Staining 
obtained with biotinylated scFv A7 and detected with ABC-HRP. Various degrees of signal 
to noise ratio were detected among the different procedures tested. Proteinase K showed 
a significant difference between positive staining and background signal when mean grey 
value was compared between vessel area and a comparable region in a non-relevant 
portion of the tissue. A total of 5 vessels and 5 non-vascular areas were counted per 
sample, values expressed as mean ± SD. (Mann-Whitney test ** = p value <0.01, ns = not 
significant). Scale bar = 100 μm. 
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3.2.3.3 Analysis of scFv monomer reactivity in human arthritic synovium 
FPLC was performed as an additional purification step in order to increase 
the purity of the protein and isolate the monomeric form of scFv A7. To do this, 1 
mg of purified antibody protein was loaded on a Superdex 75 size exclusion column, 
eluted and single fractions collected, obtaining a separation of the total protein 
content of purified periplasmic extract (Figure 3.9 A). The protein fractions were 
pooled together in groups and analysed by SDS-PAGE and Western blot analysis in 
reducing conditions (Figure 3.9 B and C). In order to characterise the role of the 
monomeric form of scFv A7 in the reactivity observed in arthritic synovium, the 
fractions comprising the main peak and corresponding to the monomer were 
pooled so as to generate three fractions. Each fraction pool was then biotinylated 
according to the protocol described in section 2.4, reaching comparable protein to 
biotin ratio (generally 2 biotin molecules per protein). Their reactivity was assessed 
by immunohistochemistry on OA samples and compared to that of the protein 
before FPLC purification. The reactivity and signal to noise ratio observed in the 
monomeric peak proved to be significantly different between the central fraction 
(yellow) and the third fraction (red) but no statistically significant difference was 
shown between the central fraction (yellow) and the scFv pre-FPLC (Figure 3.10). 
These results therefore demonstrate that the bacterial protein contaminants and 
the breakdown products present in scFv A7 preparations (Figure 3.5) do not 
contribute or substantially interfere with the specific interaction between this 
antibody and its antigen in IHC. 
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Figure 3.9 Analysis of scFv A7 protein fractions from FPLC 
Pooled fractions from FPLC purification of scFv A7 depicted by colour visualisation (A). SDS-
PAGE analysis of FPLC purified fractions of scFv A7 stained with colloidal Coomassie brilliant 
blue (EZBlue) (B) or probed with anti 6-His and anti-mouse HRP conjugated antibody 
(Western blotting) (C). 
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3.3 A7 scFv-Fc protein production 
In collaboration with the University of Eastern Piedmont in Novara, Italy, the 
scFv A7 antibody was fused with the CH2 and CH3 domain of a human IgG, as 
described in detail in section 2.2, to form a mini antibody defined as scFv-Fc (234). 
As a scFv-Fc fusion protein, this IgG-like structure differs from the conventional 
IgG1 form due to the missing CH1 and CL domains. The natural IgG1 format is 
characterised by the expression of a separate light and a heavy chain, linked by a 
disulphide bond at the CH1-CL interface, and by the presence of a hinge region 
connecting two heavy chains in a homodimer fashion through the formation of two 
disulphide bonds (153, 252). However, the role of the missing C1 domain of both 
heavy and light chain in the scFv-Fc construct is played by the small peptide linker 
between the VH and VL domains. Using this strategy, the heavy and light chains are 
expressed as a single chain, and the presence of the IgG1 hinge region allows the 
formation of disulphide bonds linking the two chains forming a homodimeric 
structure. In addition, the presence of the CH2 and CH3 domains allows N-
glycosylation, promoting and stabilising the Fc dimerisation (252-254). The vector 
map used to produce the molecule and a schematic of the scFv-Fc structure is 
described in Figure 3.11. The nucleotide sequence encoding for the scFv A7 has 
been optimised for mammalian expression systems prior to cloning in the Fc 
containing vector.  
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Figure 3.11 pHygro vector and A7 scFv-Fc protein structure 
Schematic of pHygro vector encoding the scFv-Fc gene with the IgG leader sequence 
containing a mini intron (A). Schematic of the expressed A7 scFv-Fc protein showing the 
scFv domain linked to the IgG1 Fc domain and carrying the SV5 tag (B). 
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In order to ensure the correct dimerization of the A7 scFv-Fc protein and a 
correct Fc effector function, it is of pivotal importance to promote efficient 
glycosylation of the Fc domain (254). The bacterial expression system used for the 
scFv antibody fragment is extremely efficient, allowing the production of large 
protein quantities. However, bacteria are not able to perform post-translational 
modifications on the produced proteins. This shortcoming would not allow 
glycosylation of the Fc region potentially resulting in protein mis-folding and low 
yields (255). In order to overcome this limitation, a mammalian expression system 
was adopted for efficient scFv-Fc protein production. Specifically, a Chinese 
Hamster Ovary (CHO) derived cell line able to grow in suspension in serum free 
medium (CHO-s) was used as a primary expression system. The absence of serum in 
the culture medium eliminates the possibility of contaminant bovine 
immunoglobulins during antibody purification. CHO-s cells were transfected with 
the scFv-Fc pHygro vector, as described in section 2.2.2.1, in a culture medium 
containing the selective agent Hygromycin B to select for efficiently transfected 
cells. The surviving cell population was then diluted to a single cell suspension in 
order to monitor growth and protein production of a single clone and select the 
most efficient (Figure 3.12). The presence of the A7 scFv-Fc antibody in the culture 
medium was confirmed by Coomassie stained SDS-PAGE and Western blot (Figure 
3.13). 
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Figure 3.12 Selection of A7 scFv-Fc CHO-s expressing clone 
ELISA assay on culture supernatant of transfected CHO-s clones carrying the A7 scFv-Fc 
construct. ELISA performed on anti-Human Fc coated plates and presence of scFv-Fc 
antibody detected using anti-SV5 and anti-mouse HRP conjugated antibody. Positive clone 
(C+) and negative clone (C-) included as control (A). Comparison of correlation between cell 
number and scFv-Fc protein content in the supernatant of CHO-s clone 12 detected at 
different time points (B). 
  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
clone
7
clone
12
clone
13
clone
15
C+ C-
O
D 
45
0 
nm
 
A7 scFv-Fc 
0 1 2 3 4 5 6 7 8
0.0
0.5
1.0
1.5
2.0
0
20
40
60
80
100
CHO A7 clone 12 cell count
A7 scFv-Fc
Days
Ce
ll 
co
un
t x
10
6
Ab
µ g/m
l
B 
A 
Page | 131  
 
Chapter 3 – Optimisation of scFv A7 and A7 scFv-Fc production and quality control 
 
 
 
 
Figure 3.13 A7 scFv-Fc production from CHO-s 
SDS-PAGE resolved A7 scFv-Fc from CHO-s clone 12 stained with Coomassie brilliant blue 
(A) or probed with anti-SV5 and anti-mouse AP conjugated antibody following Western 
blotting (B). Positive clone (C+) included as control. 
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3.3.1 Optimisation of A7 scFv-Fc purification 
 The high efficiency observed in Talon® purification of scFv antibodies cannot 
be applied to the purification of the scFv-Fc fusion protein due to the absence of a 
6-His tag. However, protein A purification is an established method for IgG 
purification (256) and was used as primary purification system in this context. 
Culture supernatant from stably transfected CHO-s cells bearing the A7 scFv-Fc 
encoding vector, was collected, incubated with protein A Sepharose beads, as 
described in detail in section 2.2.3.1, and the purification was carried out with the 
same principle as applied for scFv protein A purification in section 3.2.1. Analysis of 
the eluted fractions with a spectrophotometer at 280 nm showed high readings in 
the first elution fractions (Figure 3.14 A). Fractions showing similar readings were 
pooled and dialysed overnight in PBS for buffer exchange. Presence of the A7 scFv-
Fc protein was assessed through Coomassie stained SDS-PAGE and Western blot 
probing with an anti-SV5 tag antibody, showing the prevalence of a single band at 
60 kDa corresponding to the size of the scFv-CH2-CH3 chain under reducing 
conditions without detectable contaminant proteins and with only minor protein 
loss in the flowthrough and washing steps (Figure 3.14 B and C). This purification 
protocol was able to purify up to 20 mg/L.  
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Figure 3.14 A7 scFv-Fc production and purification via CHO-s 
Optical density analysis of A7 scFv-Fc eluted fractions from CHO-s supernatant using 
protein A purification system (A). SDS-PAGE resolved purified A7 scFv-Fc fractions from 
CHO-s stained with Coomassie brilliant blue (B) or probed with anti-SV5 and anti-mouse 
HRP antibody following Western blotting (B).  
0 1 2 3 4 5 6 7 8 9 10 11 12
0.0
0.5
1.0
1.5
2.0
2.5
 A7 scFv-Fc
Fractions 0.4 ml
O
D
 2
80
 n
m
250 kDa 
150 kDa 
100 kDa 
75 kDa 
50 kDa 
37 kDa 
25 kDa 
A 
C B 
72 kDa 
55 kDa 
36 kDa 
28 kDa 
17 kDa 
95 kDa 130 kDa 
250 kDa 
Page | 134  
 
Chapter 3 – Optimisation of scFv A7 and A7 scFv-Fc production and quality control 
 
Protein A purification requires an acidic elution step at pH 2.8 that may not 
be well tolerated by some antibodies, leading to conformational changes and often 
causing degradation and formation of insoluble aggregates (257). To overcome this 
possible scenario, a simple culture supernatant concentration step was adopted as 
an alternative purification procedure as described in section 2.2.3.2. In this case, to 
reduce the carryover of detergents contained in the culture medium, the 
supernatant was dialysed in PBS before and after concentration. Analysis in 
Coomassie stained SDS-PAGE and Western blot in Figure 3.15, show the presence of 
the predominant band at 60 kDa, confirming the presence of A7 scFv-Fc with little 
detectable contaminant proteins. 
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Figure 3.15 Concentration of CHO-s culture medium 
300 ml of CHO-s stably transfected with A7 scFv-Fc concentrated using Millipore centricon 
filter unit (MWCO 10 kDa). 3 μl of supernatant and concentrated supernatant resolved in 
10% SDS-PAGE and stained with Coomassie brilliant blue, showing a single band at 60 kDa 
corresponding to the A7 scFv-Fc protein (A). 1 μl of supernatant and concentrated 
supernatant resolved in 10% SDS-PAGE and detected with anti-SV5 and anti-mouse HRP 
conjugated antibody, showing the presence of a predominant band at 60 kDa 
corresponding to the A7 scFv-Fc antibody and several breakdown products at lower 
molecular weight (B). 
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3.3.2 Quality assessment of A7 scFv-Fc protein production 
 Protein A purified A7 scFv-Fc from CHO-s cells showed the presence of a 
marked band at 60 kDa with no detectable contaminant proteins (Figure 3.14). In 
order to further investigate the protein composition of the purified batch from CHO 
cell line, SDS-PAGE resolved protein batch was stained with Sypro® Ruby protein gel 
stain, as described in section 2.5, characterised by a limit of detection of 0.25 ng. 
The plot profile of A7 scFv-Fc purified from CHO-s cells analysed with ImageJ, 
showed the presence of a single peak at 60 kDa accounting for 87% of signal above 
background (Figure 3.16 A and B).  
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Figure 3.16 Quality assessment of CHO-s produced A7 scFv-Fc 
SDS-PAGE resolved A7 scFv-Fc produced in CHO-s (A) stained with Sypro® ruby protein gel 
stain. Analysis of plot profile from the purified A7 scFv-Fc lane produced in CHO-s (B) 
reveals a high purity of produced antibody with little detectable contaminant proteins. 
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3.3.3 Assessment of A7 scFv-Fc reactivity in human arthritic synovium 
  Prior to IHC staining on human arthritic synovium, the A7 scFv-Fc antibody 
was biotinylated with the same procedure that was applied to the scFv antibody 
and described in section 2.4. SDS-PAGE resolved protein pre- and post-biotinylation 
showed no loss of purity and protein quality (Figure 3.17) with a biotin to protein 
molar ratio over 2.  
 A critical point to the development of an IgG-like version of the scFv A7 is 
the retention of A7 specific synovium reactivity. The ability of the scFv-Fc fusion 
protein to target the human arthritic synovial tissue was assessed using the 
optimised protocol adopted for scFv staining and described in section 2.6.3.1. The 
pictures presented in Figure 3.18 show a similar staining pattern between the scFv 
and the scFv-Fc antibodies. This result confirms the retention of the scFv A7 
reactivity in the new antibody format. In addition, since the acidic elution step 
included in the protein A purification procedure may cause conformational changes 
in the protein leading to loss of activity (257), the reactivity of the protein A purified 
A7 scFv-Fc protein was compared to the reactivity of the A7 scFv-Fc obtained 
through supernatant concentration. The results in Figure 3.19 show a stronger 
reactivity of the concentrated protein. However, an increased background level 
could be detected at high antibody concentrations, probably due to the presence of 
contaminant proteins in the pool that can be processed during the non-selective 
biotinylation step contributing to background noise. 
  
Page | 139  
 
Chapter 3 – Optimisation of scFv A7 and A7 scFv-Fc production and quality control 
 
 
 
 
 
Figure 3.17 Biotinylation of A7 scFv-Fc antibody 
Coomassie stained SDS-PAGE of A7 scFv-Fc pre- and post-biotinylation, resolved in 10% 
polyacrylamide gel. No increase in breakdown products could be detected after 
biotinylation process. 
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Figure 3.19 Comparison of protein A purified and supernatant concentrated A7 
scFv-Fc 
IHC on OA synovium stained with protein A purified A7 scFv-Fc – biotin and supernatant 
concentrated A7 scFv-Fc – biotin. Both antibodies were able to target the synovium with a 
similar pattern (red arrows). The supernatant concentrated A7 scFv-Fc showed stronger 
reactivity compared to the protein A purified protein but showing also showed a higher 
background at high concentrations. Scale bar = 50 μm. 
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3.4 Discussion 
 The aims of the experiments presented in this chapter were to characterise 
the production efficiency of the scFv A7 and the A7 scFv-Fc fusion protein in terms 
of protein yield and quality. In addition, an effort was made towards the 
optimisation of the procedures for immunohistochemistry to be used for 
assessment of tissue, disease and species specificity of A7 described in the next 
chapter. 
The first important step when working with antibody fragments isolated 
through phage display is to verify the ability of the clone to produce a soluble 
protein. The Tomlinson library adopted for the scFv A7 isolation consists of a vector 
carrying the scFv gene fused to the gIII phage gene by the presence of the Amber 
stop codon. Phages are produced via transformation of a permissive E.coli strain 
that will translate the amber codon, allowing the formation of the scFv-pIII fusion 
protein. In order to produce the soluble scFv protein, phages carrying the clone of 
interest are used to infect a non-permissive host that will recognise the stop codon 
and produce only the scFv protein. However, due to the nature of the high diversity 
of the library which guarantees the production of a high number of different scFv 
with different specificities, it is possible that the amber stop codon would be 
present in the scFv sequence itself, impeding the production of a soluble scFv 
protein. This possible scenario, together with the unpredictability of protein 
properties due to the primary antibody sequence itself, requires a careful 
characterisation of production efficiency and protein reactivity. The scFv A7 clone 
was readily produced by the HB2151 E.coli strain upon IPTG stimulation. The 
protein recovered from culture supernatant or from the periplasmic compartment 
was purified using two approaches: protein A purification, exploiting the ability of 
protein A to bind the VH3 framework, and the Talon® metal affinity purification, 
exploiting the 6-His tag. Both resins were used in gravity flow column 
chromatography. The use of a column system is important because it ensures a 
more efficient washing step and the retention of bead particles. In addition, column 
based chromatography guarantees a better separation of the protein mixture 
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present in the starting medium, due to the Theoretical Plate Model. This plate 
model supposes that the chromatographic column contains a large number of 
separate layers, called theoretical plates. Separate equilibrations of the sample 
between the stationary and mobile phase occur in these "plates", moving the 
analyte down the column by transfer of equilibrated mobile phase from one plate 
to the next. The resolution between two peaks, in this case two proteins with 
similar molecular weights, depends on the number of theoretical plates, with this 
number varying according to the length of the column and the tightness of the 
packed bead volume. A higher number of theoretical plates increases the resolution 
power of the column (258). Talon® proved to efficiently purify the scFv A7 with 
higher yield compared to protein A. Analysis of protein purity and quality in SDS-
PAGE, HPLC and FPLC showed the monomer of scFv A7 as the predominant protein 
following Talon® purification, with little detectable contaminants. Purification with 
Talon® metal affinity resin has been therefore chosen as the primary purification 
strategy for scFv A7. 
In order to optimise the conditions to be used in IHC for tissue staining, a 
comprehensive panel of retrieval procedures was used to identify the best 
candidate. Proteinase K was able to provide a good signal to background noise ratio 
and was selected as standard protocol for IHC. Furthermore, an in-depth analysis 
was made on the reactivity of the components of the scFv A7 purified protein 
content. Specifically, the main peak corresponding to scFv A7 monomer was divided 
in 3 groups following FPLC purification and the reactivity in human arthritic 
synovium was determined for each of them in comparison to the full scFv A7 pool. 
Despite a significant difference in the reactivity of the central fraction and the one 
showing a lower molecular weight, compared to the total scFv A7 pool the 
reactivity was not significantly different, meaning that the presence of contaminant 
proteins and background products do not inhibit or impair the scFv A7 reactivity 
and therefore it can be safely used following Talon® purification without need of 
further purification steps. 
The increasing interest that has been focused on scFv development in recent 
years is to be attributed mainly to the extreme efficiency of phage display 
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technology in isolating in vivo specific peptides and antibody fragments allowing the 
characterisation of new organ specific antigens (130, 259, 260). Another key 
characteristic of this class of antibody fragments, is the high versatility of these 
molecules, allowing a large spectrum of functionalisation strategies with effector 
moieties including conjugation with cytokines, therapeutic radionuclides, 
photosensitisers and established therapeutic molecules (261). This high versatility 
can also be exploited to convert the scFv fragment into an IgG-like molecule by 
fusing the IgG Fc domain to the protein (234). By fusing the scFv to the CH2 and CH3 
domain of an IgG1, the protein acquired the structural and functional 
characteristics of a native IgG molecule. In particular, this format allows having a 
bivalent molecule with increased avidity, higher molecular weight, determining 
higher serum half-life, and introduction of Fc effector functions (153, 252, 262). 
Since bacteria are not equipped for post-translational modifications and 
glycosylation exerts a pivotal role in IgG structural integrity and functions (254), the 
mammalian CHO expression system was chosen as the primary production 
platform. The use of mammalian expression systems for biopharmaceutical 
molecules is well accepted (263), furthermore, CHO cells have been demonstrated 
as safe hosts for the past two decades, with several FDA approved derived 
products, and are capable of efficient post-translational modifications that are 
compatible and bioactive in humans, making them the cell line of choice in 
biopharmaceutical production (264).  
CHO demonstrated an efficient production of the scFv-Fc fusion protein at 
high yield and with high purity levels following protein A purification. The staining 
pattern of the scFv-Fc molecule was comparable to the one observed with the 
parent scFv antibody fragment. However, the acidic elution step necessary for 
antibody recovery in protein A purification, seemed to partially impair the reactivity 
of the A7 scFv-Fc. When compared to a concentrated supernatant preparation of 
the antibody showing very low contaminant proteins, the protein A purified protein 
needed a concentration 5 times higher to obtain a detectable signal. The use of 
concentrated supernatant may be acceptable for in vitro testing of the antibody 
reactivity but a purified antibody preparation will be necessary for in vivo testing. 
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Although the reactivity of the protein A purified antibody does not seem to be 
inhibited but only partially impaired and can therefore be used as standard 
approach for protein production, testing alternative elution buffers requiring less 
stringent pH conditions remains an important aspect to investigate (257). 
In summary, this chapter provides the ground base conditions for functional 
characterisation of both the scFv A7 and the A7 scFv-Fc antibodies described in the 
following chapters. 
  
Page | 147  
 
Chapter 4 – Characterisation of scFv A7 reactivity 
 
 
 
 
 
Chapter 4 
Characterisation of  
scFv A7 reactivity 
  
Page | 148  
 
Chapter 4 – Characterisation of scFv A7 reactivity 
 
4.1 Introduction 
 Phage display has proven a potent tool to select and identify new vascular 
determinants showing organ specificity in vivo that may have an impact in the field 
of targeted drug delivery (130, 259). The scFv A7 antibody fragment isolated via in 
vivo phage display in SCID mouse model double transplanted with human arthritic 
synovium and normal human skin (described in section 1.4.2), showed a 
preferential homing specificity for the synovium compared to the control human 
skin tissue. The 4 enrichment cycles employed, have guaranteed the bias towards 
clones showing high specificity for the synovium compared to the skin control 
tissue, confirmed by the in vivo recirculation experiment using the soluble scFv 
fragment (described in section 1.4.2 introduction). The preferential homing capacity 
of this clone for the human synovium may suggest the targeting of a synovium 
specific molecule or a molecule subjected to overexpression in arthritic conditions. 
However, the presence of the target antigen in other human tissues or disease 
conditions still remains to be assessed. In order to develop the scFv A7 antibody 
into a therapeutic tool for the treatment of rheumatoid arthritis and related 
arthritic conditions, it is crucial to investigate the two main aspects that may have 
an impact on the antibody efficacy: tissue specificity and disease specificity. 
Towards the first aspect, it is important to thoroughly investigate the tissue 
distribution of the target antigen and evaluate the scFv A7 reactivity in normal 
human tissues. As a therapeutic tool for arthritic conditions, the disease specificity 
of the antibody plays a pivotal role. The inflammatory condition underlying 
rheumatoid arthritis can influence the expression of selective cell adhesion 
molecules in the microvasculature to direct circulating lymphocytes (265). 
However, the expression of such molecules in the inflamed synovial tissue may be 
due to the inflammatory condition rather than being a disease specific feature and 
therefore it is important to verify the antibody reactivity in diseases that show 
similar characteristics.  
 In the previous chapter the purification of a soluble scFv A7 and 
optimisation of conditions for IHC were optimised, showing specific reactivity of the 
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antibody for the human arthritic synovium. In this chapter characterisation of the 
disease, tissue and species specificity of the scFv A7 antibody will be assessed 
through immunohistochemistry on tissue sections. In addition, the localisation of 
the antibody binding, defining the target cell population and distribution, will be 
discussed. 
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4.2 Disease specificity of scFv A7 reactivity 
 As mentioned above, characterisation of the disease specificity of scFv A7 is 
a crucial aspect for this project. In this section the reactivity of the scFv A7 will be 
characterised in the target tissue, the arthritic synovium, and compared to other 
inflammatory disease conditions such as inflammatory bowel disease, colorectal 
cancer, psoriasis and melanoma skin cancer. 
4.2.1 Reactivity in RA and OA synovium 
 Analysis of the staining pattern in grafted synovial tissue following an in vivo 
recirculation assay in SCID mice, showed a vascular reactivity of the scFv A7 
antibody (Figure 1.8 B). The specificity of reactivity of scFv A7 within synovial tissue 
was further characterised using immunohistological analysis on a considerable 
number of synovial samples from osteoarthritic patients (n=16) and patients 
suffering from rheumatoid arthritis (n=8), including normal human skin tissue (n=5) 
as a negative control. In Figure 4.1 is shown a representative staining pattern. scFv 
A7 was able to specifically target both the RA and OA synovium but no reactivity 
could be detected in the control skin tissue. Staining of sequential tissue sections 
with a control scFv (scFv HEL) and sections with no primary antibody (Negative 
control) confirmed the specificity of the staining observed with scFv A7. In addition, 
staining with an antibody targeting the vascular marker von Willbrand Factor (vWF), 
showed a similar staining distribution, confirming the vascular targeting of scFv A7. 
Since the original phage clone was isolated using in vivo phage display in which the 
phage library was injected into the tail vein of SCID mice and thus selected against 
vascular determinants, this result further confirms the specificity of the scFv A7 
reactivity. The image analysis software ImageJ was used to quantify the intensity of 
staining and evaluate whether the scFv A7 antibody reactivity was specific and 
significantly above background. The data presented in Figure 4.2 demonstrate that 
as measured by the Mean Gray Value, scFv A7 antibody had substantial reactivity in 
the blood vessels of RA and OA tissue and significantly above background (p value 
<0.01). Further, the reactivity of control scFv antibody (scFv HEL) was minimal and 
very close in value to the corresponding tissue background and negative control. As 
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expected, in all tissues examined vWF antibody showed substantial reactivity with 
blood vessels that was significantly above background, reflecting the specificity of 
reactivity of this antibody with the endothelial layer in the blood vessels. 
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Figure 4.1 Immunohistochemical analysis of scFv A7 antibody reactivity with 
human arthritic synovial tissue 
The reactivity of scFv A7 with sections of human arthritic synovial and skin tissue was 
examined using biotinylated scFv A7. Biotinylated scFv HEL was used as antibody negative 
control. The presence of blood vessels in tissue samples was visualised with anti-human 
vWF antibody. Biotinylated scFv antibodies were detected with avidin-biotin complex HRP 
conjugated (ABC-HRP) application whilst vWF antibody reactivity was detected using an 
HRP labeled antibody. Scale bar = 100 μm. 
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Figure 4.2 Quantification of intensity of immunohistochemical staining 
Immunoreactivity of scFv A7, scFv HEL and vWF found in the vessels presented in Figure 4.1 
was quantified using the image analysis tool ImageJ (plain) and compared to a matched 
area size in a non-relevant tissue area representing the background (checked). Intensity of 
staining is represented by the mean grey value (mean ± SD) of 5 vessels and 5 non-vascular 
areas per sample. Mann Whitney test ** = p value < 0.01.  
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Other than synovial lining layer hypertrophy and neo-angiogenesis, a third 
characteristic feature of RA/OA synovitis is infiltration of immune cells of both 
innate and adaptive immune system. The spatial distribution of these cells can vary 
greatly among different patients. The immune cells infiltrating the synovium can 
display from a disperse distribution with no clear organisation, to a highly organised 
aggregated structure reminiscent of secondary lymphoid organ follicles (50). The 
functional implication of such structures in the progression of the disease or 
therapeutic response is still unclear (48, 266). However, cell type distribution and 
specific cytokine/chemokine expression have been shown to vary depending on the 
presence or absence of the follicular structures (267). To investigate the role that 
different degrees of cell infiltrate within the synovium may exert on the A7 target 
antigen expression, tissues ranging from non-infiltrated (OA n=7), diffuse infiltrate 
(OA n=5), 1 to 5 cells thick perivascular aggregates (grade 1) (OA n=2), 5 to 10 cells 
thick perivascular aggregates (grade 2) (OA n=2) and more than 10 cells thick 
perivascular aggregates (grade 3) (OA n=3 and RA n=5) were screened for scFv A7 
reactivity. The results presented in Figure 4.3 demonstrate that scFv A7 is able to 
target the arthritic synovium independently of the degree and organisation of 
immune infiltrates within the tissue (Figure 4.4).  Furthermore, scFv A7 recognises 
the microvasculature of both OA and RA synovium with no significant difference in 
reactivity when comparing the two diseases (Figure 4.4). 
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Figure 4.3 Immunohistochemical analysis of scFv A7 antibody reactivity with OA 
and RA synovium 
10 μg/ml biotinylated scFv A7 IHC staining in inflamed OA and RA sections with varying 
degrees of infiltrate. Bound biotinylated scFv A7 antibody was detected using ABC-HRP 
conjugate. Scale bar = 100 μm. 
 
 
  
Page | 157  
 
Chapter 4 – Characterisation of scFv A7 reactivity 
 
 
 
 
Figure 4.4 Quantification of intensity of immunohistochemical staining 
Immunoreactivity of scFv A7 found in the vessels presented in Figure 4.3 was quantified 
using the image analysis tool ImageJ. Intensity of staining is represented by the Mean grey 
value (mean ± SD). 5 comparable vascular regions were counted spanning the tested 
tissues of each category. Kruskal-Wallis test ns = p value > 0.05. 
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4.2.2 Reactivity in inflammatory bowel disease 
 Inflammatory bowel disease (IBD) is a group of inflammatory conditions of 
the colon and small intestine with unknown etiology, associated to an increase risk 
of developing colorectal cancer (CRC). The two major types of IBD are Crohn’s 
disease and ulcerative colitis. The first is generally absent from the upper 
gastrointestinal tract and affects mainly the terminal ileum and the proximal colon, 
the lesions are generally separated by uninvolved “skip areas” and characterised by 
the presence of granulomas, mucosal lesions and a transmural inflammation 
causing a thickened bowel wall involving submucosa and muscularis propria. The 
second starts from the rectum and spreads proximally involving a variable length of 
the colon, is characterised by an inflammatory reaction with special distribution and 
structural abnormalities of the mucosa (268). Both of these diseases are associated 
with an initial physiological angiogenesis to supply nutrients and oxygen to the 
regenerating bowel mucosa and remove waste products. However, this 
physiological remodelling is soon turned into a pathological process due to aberrant 
expression of angiogenic molecules (269). 
Among the 12 Crohn’s disease sample tested, 9 showed no reactivity with 
scFv A7 while 3 showed a minor reactivity confined to the muscular layer. The 
ulcerative colitis sample tested proved to be non-reactive with scFv A7 while the 2 
CRC samples showed staining in the muscular layer. Five healthy control samples 
were included in the experiment and none of them showed detectable reactivity 
with scFv A7 at any concentration tested (Figure 4.6). 
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Figure 4.5 Reactivity of scFv A7 antibody with the microvasculature of 
inflammatory bowel disease 
The reactivity of scFv A7 with normal colon, Crohn’s colon, ulcerative colitis and epithelial 
tumour was assessed. The presence of microvasculature was visualised using anti-human 
vWF antibody and α-actin for the stromal compartment. Biotinylated scFv A7 was detected 
with ABC-HRP. vWF and α-actin antibody reactivity were detected using an HRP labeled 
secondary antibody. The images shown are representative of the 9 negative Crohn’s 
disease samples, 1 ulcerative colitis, 5 healthy colon and 2 CRC samples. Scale bar = 200 
μm. 
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4.2.3 Reactivity in psoriatic skin 
Psoriasis is a chronic, autoimmune disease that appears in the skin and is 
characterised by overgrowth of skin cells with rapid accumulation. There are five 
main forms of psoriasis: plaque, guttate, inverse, pustular and erythrodermic. This 
disorder can also cause inflammation of the joints, a condition which is known as 
psoriatic arthritis (270). Due to its correlation with the arthritic diseases subject of 
this study, the reactivity of scFv A7 was tested in 3 psoriatic skin tissue samples. The 
results presented in Figure 4.6 show that scFv A7 had no detectable reactivity with 
this tissue.  
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Figure 4.6 Reactivity of scFv A7 antibody with the microvasculature of psoriatic 
skin 
The reactivity of scFv A7 with normal skin and psoriatic skin was assessed. The presence of 
microvasculature was visualised using anti-human vWF antibody. Biotinylated scFv was 
detected with ABC-HRP conjugate. vWF antibody reactivity was detected using an HRP 
labeled secondary antibody. The images shown are representative of the 5 skin samples 
and 3 psoriatic skin tissues examined. Scale bar = 100 μm. 
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4.2.4 Reactivity in melanoma skin cancer 
Melanoma is the most serious type of skin cancer, with a good chance of 
regression only if surgically removed at an early stage. If not treated, metastasis 
may be found mainly at lymph node sites, lungs, liver, brain and bones. Three 
tissues from one patient with melanoma skin cancer, presenting metastasis in 
sigmoid colon and axillary lymph nodes, were tested for reactivity with scFv A7. The 
results presented in figure 4.7 show that scFv A7 had no detectable reactivity with 
this tissue despite the presence of vasculature as depicted by anti-vWF staining. 
Clearly larger numbers of samples need to be examined before firm conclusions can 
be derived.  
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Figure 4.7 Reactivity of scFv A7 antibody with the microvasculature of melanoma 
skin cancer 
The reactivity of scFv A7 melanoma skin cancer, lymph node and colon metastasis was 
assessed. The presence of microvasculature was visualised using anti-human vWF antibody. 
Biotinylated scFv were detected with ABC-HRP conjugate. vWF antibody reactivity was 
detected using an HRP labeled secondary antibody. Scale bar = 100 μm.  
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4.3 Tissue specificity of scFv A7 reactivity 
The overall aim of this project is the development of a therapeutic tool for 
arthritic disease, able to selectively target the synovium and reduce possible 
systemic adverse effect. In order to achieve these goals, the ideal candidate 
antibody should not exhibit reactivity with normal healthy tissues.  
As shown in Figures 4.1, 4.5 and 4.6, the scFv A7 antibody does not show 
reactivity with normal skin and healthy colon. However, a more comprehensive 
analysis on normal human tissues derived from various organs is required to clearly 
define the tissue distribution of the target antigen. In order to do so, a whole-body 
tissue microarray was screened for scFv A7 reactivity. As shown in Figure 4.8, scFv 
A7 did not exhibit reactivity with the vasculature or cellular components of the 
tissues represented in the array despite the presence of microvasculature detected 
using anti-vWF antibody.  
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Figure 4.8 Immunohistochemistry of scFv A7 in normal human tissues 
The reactivity of scFv A7 antibody with normal human tissues was assessed using paraffin 
embedded whole body survey tissue microarray. Bound biotinylated scFv A7 antibody was 
detected using avidin HRP conjugate. The presence of blood vessels in tissue samples was 
visualised with anti-human vWF antibody and an HRP labeled secondary antibody. 
Representative areas in selected samples (          ) are presented at higher magnification for 
clarity. Scale bar = 100 μm. 
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From the data presented in section 4.2, it is clear that the scFv A7 target 
antigen is expressed by both RA and OA synovium and may represent a common 
feature of arthritic conditions in the synovium. To confirm the disease specificity of 
this antibody fragment, it is important to verify whether the normal synovium 
tissue retains the same antigen expression and scFv A7 reactivity as the arthritic 
tissue. Because of obvious ethical implications, it is very difficult to obtain normal 
synovium from healthy patients. One way to overcome this limitation is to collect 
tissues post-mortem or from limb amputations of patients with osteosarcoma or 
injuries. The samples used in this project were obtained using arthroscopy from 
patients with prolonged unexplained knee pain that did not develop arthritic 
conditions in a 5 years follow up survey (271). IHC staining with scFv A7 antibody, 
showed no significant reactivity with the microvasculature in 11 samples of normal 
(non-arthritic) human synovium (Figure 4.9). The intensity of staining in the OA 
sample run at the same time as a positive control was comparable to what was 
seen in the previous experiments. 
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Figure 4.9 Reactivity of scFv A7 antibody with the microvasculature of normal 
synovium 
The reactivity of scFv A7 with normal synovium was assessed. Biotinylated scFv A7 
reactivity was detected with ABC-HRP conjugate. The images shown are representative of 
11 normal synovium tissues (A). Higher magnification of normal synovium showing 
vasculature (red arrows) depicted by anti-vWF and anti-smooth muscle α-Actin (B). Scale 
bar = 50 μm. 
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4.4 Species specificity of scFv A7 reactivity 
 One important aspect to be considered is that the expression of the antigen 
may not be restricted to human tissue. Therefore, the reactivity of scFv A7 with 
mouse tissues was tested using paw and knee sections of CIA mice. This mouse 
model is an extensively studied animal model sharing both immunological and 
pathological features of human RA. In this model, injection of type II collagen in 
susceptible mice strains, such as DBA/1, elicits a T- and B-cell response causing 
proliferative synovitis, cartilage degradation and bone erosion (272). The data 
presented in Figure 4.10, demonstrate that despite the presence of prominent 
lymphoid infiltrates and neo-vasculogenesis in the CIA mouse synovium (assessed 
by CD34 staining), no detectable scFv A7 staining was observed in the arthritic 
mouse joint or in the blood vessels of the neighbouring joint tissues. In addition, no 
scFv A7 reactivity was detected in normal non inflamed DBA/1 knee. 
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Figure 4.10 Reactivity of scFv A7 antibody with the microvasculature of CIA mice 
joints 
10 μg/ml biotinylated scFv A7 IHC staining in normal DBA/1 knee and CIA inflamed 
knee and paw. CD34 staining included to highlight joint microvasculature. 
Biotinylated scFv A7 was detected with ABC-HRP. CD34 antibody reactivity was 
detected using an HRP labeled secondary antibody. The images shown are 
representative of 4 CIA mice joints analyzed. Scale bar = 100 μm. 
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4.5 Comparison between scFv A7 and current vascular markers 
 The immunohistochemistry performed with scFv A7 in Figures 4.1 and 4.3, 
shows a vascular staining in the human arthritic synovium. However, arteries and 
veins are characterised by the presence of three layers: the tunica intima 
characterised by the presence of endothelial cells forming the internal wall of the 
vessel; the tunica media, characterised by smooth muscle cells with varying degrees 
of thickness depending on the type and calibre of the vessel; and the tunica 
adventitia made of connective tissue which may present nerves and capillaries in 
the larger vessels. The main cell types constituting the vessels are therefore 
endothelial cells and smooth muscle cells. In the small blood vessels there is also 
the presence of a cell population called pericyte, generally one cell thick, 
surrounding and providing structural stability to the vessels (273, 274). In order to 
determine which cell type within the microvasculature was able to react with scFv 
A7, a dual immunofluorescent staining using scFv A7 and the endothelial markers 
vWF and CD31 was performed. The data presented in Figure 4.11 shows no overlap 
between the scFv A7 staining and the endothelial cell layer. However, when stained 
in combination with NG2, a pericyte specific marker, and smooth muscle α-Actin, a 
marker for the smooth muscle layer, a complete overlap in the pattern of cellular 
staining was observed (Figure 4.11). In order to quantify the degree of co-
localisation, the Pearson’s correlation coefficient was used to provide a numerical 
and non-subjective analysis (275). The Pearson correlation ranges from +1 to −1, 
whereby a correlation of +1 indicates complete overlap of pixels from two different 
channels. A value of 0 indicates no overlap and, a correlation of −1 indicates 
complete pixel disparity/exclusion between the two channels being compared. The 
Pearson’s co-localisation analysis of scFv A7 reactivity (red pixels) and vWF-CD31 
(green pixels) resulted in a correlation (r) of 0.09, demonstrating no co-localisation 
of scFv A7 and the endothelial layer. Similarly, Pearson’s co-localisation analysis of 
NG2 or α-actin (red pixels) with vWF-CD31 (green pixels) resulted in a correlation of 
0.05 and 0.03 respectively, demonstrating no colocalisation. However, staining with 
scFv A7 (red pixels) in combination with NG2 or α-actin (green pixels) showed a co-
localisation index of 0.7 and 0.74 respectively, demonstrating that the reactivity of 
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scFv A7 is specific for the stromal component of the microvasculature in the 
synovium. 
Further, staining of a broad spectrum of normal human tissues and 
inflammatory disease tissue samples with scFv A7 showed that the reactivity of this 
antibody is specific for the microvasculature of arthritic synovium only and 
therefore doesn’t represent a universal marker for the stromal compartment 
(Figure 4.1, 4.5, 4.6, 4.7 and 4.8). In order to further confirm the specificity of scFv 
A7, a dual immunofluorescent staining of human tonsil was performed using scFv 
A7 and NG2. The data presented in Figure 4.12 shows the presence of NG2 positive 
cells in the stromal compartment of the vessels while no scFv A7 reactivity could be 
detected. This result clearly demonstrates that scFv A7 is not merely a new 
common marker of pericytes. 
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Figure 4.11 Characterisation of cellular reactivity of scFv A7 within synovial 
microvasculature 
The reactivity of biotinylated scFv A7 with cellular components of synovial 
microvasculature was examined by dual staining of frozen human synovial tissue from RA 
patients and compared with staining for the endothelial markers vWF and CD31, the 
pericyte specific marker NG2 and the smooth muscle marker α-actin. Bound scFv A7 was 
detected using Texas Red – Avidin conjugate. vWF, CD31, NG2 and α-actin binding were 
detected using Alexa 488 (green) or Alexa 594 (red) labelled secondary antibodies. Sections 
were counter stained with DAPI to depict nuclei (blue). Correlation coefficient (r) calculated 
using Pearson’s correlation coefficient in the image analysis tool ImageJ. Scale bar = 100 
μm. 
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Figure 4.12 Co-staining of human tonsil tissue 
The reactivity of scFv A7 antibody with cellular components of human tonsil 
microvasculature was examined by co-staining of frozen human tonsil tissue with the 
pericyte specific marker NG2 and endothelial marker CD31. scFv A7 antibody binding was 
detected using Texas Red – Avidin conjugate. CD31 and NG2 binding were detected using 
Alexa Fluor 488 (green) or Alexa Fluor 594 (red). Sections were counter stained with DAPI 
to depict nuclei (blue). Scale bar = 100 μm. 
NG2  +  scFv A7 CD31 +  scFv A7 NG2  +  CD31 
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More recently, endosialin (CD248), a transmembrane glycoprotein with a C-
type lectin-like domain, has been implicated as a marker of mural (pericyte/smooth 
muscle) cells and fibroblasts associated with tumour blood vessels (276, 277). 
Further, expression of endosialin has been observed in rheumatoid fibroblast-like 
synoviocytes and in a subset of fibroblasts involved in the remodelling of lymphoid 
tissues (276, 278). In order to investigate the potential correlation between CD248 
and scFv A7 staining in RA and OA synovial tissues, dual immunofluorescent 
stainings were performed comparing CD248, smooth muscle α-actin, CD31, NG2 
and scFv A7 reactivity. The data presented in Figure 4.13 show that in both RA and 
OA synovial tissue, CD248 could be detected in the fibroblast-like synoviocytes 
surrounding the microvasculature but not in the pericytes nor in the smooth muscle 
compartment of these blood vessels as demonstrated by the lack of overlap in the 
staining of CD248 with that of NG2 and smooth muscle α-actin, respectively. 
Similarly no co-localisation was observed between scFv A7 staining and that of 
CD248. CD248 pattern of staining was comparable between the RA and the OA 
synovial tissue samples (Figure 4.13). Further comparison between scFv A7 and 
markers of pericytes will not be pursued in this project since the primary aim of this 
study is identification of the target molecule for this antibody.  
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Figure 4.13 Comparison between scFv A7 reactivity and CD248 
Characterisation of CD248 (Alexxa 488 green) cellular reactivity in OA synovium (A) and RA 
synovium (B), in a dual immunofluorescent staining with biotinylated scFv A7 (Avidin - 
Texas red), α-actin (Alexxa 594 red), NG2 (Alexxa 594 red) and CD31 (Avidin – Texas red) 
respectively. Scale bar = 100 μm 
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4.6 Discussion 
 The chimeric SCID mouse model adopted for the isolation of the scFv A7 
using in vivo phage display, has the advantage of overcoming the limitations of a 
mouse environment allowing the selection of phage with homing specificity for 
human tissue determinants. The scFv A7 showed preferential homing specificity for 
human arthritic synovium compared to normal human skin both as a phage and as 
a soluble antibody fragment in in vivo recirculation assays. However, the 
characterisation of the reactivity in terms of tissue specificity and cellular 
localisation, disease specificity and species specificity is important to clearly define 
the potential of the molecule as a diagnostic or therapeutic tool. To answer this 
question and define the possible applications of the antibody fragment, a 
comprehensive screening was carried out in human arthritic tissues, normal tissues, 
disease tissues and in an animal model of arthritis. 
 The evaluation of synovial reactivity was assessed using 
immunohistochemistry on synovial tissue sections. The scFv A7 was able to 
specifically target the microvasculature of both OA and RA synovium but not the 
normal human skin tissue included as a control (Figure 4.1). Although phage display 
screening was performed in SCID mice transplanted with human OA synovium, the 
capacity to target both OA and RA is not unheard of. A previous project within our 
group showed that peptides isolated through phage display from RA synovium 
grafted SCID mice had the ability to target also OA synovium both in vivo and in 
vitro (279). This may be due to the targeting of synovium specific antigens 
expressed on the vascular compartment of the tissue or may be due to the 
presence of antigens that are expressed or up-regulated in arthritic conditions. The 
possibility of shared antigens driven by the arthritic disease condition in OA and RA 
is in line with recent findings showing an overlap in synovitis and inflammatory 
processes between the two conditions (86). In addition, the targeting of the 
microvasculature within the synovium is consistent with the isolation of a scFv from 
a phage library injected through the blood stream and confirms the specificity of 
the reactivity observed. Further, scFv A7 did not show reactivity with other 
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inflammatory disease conditions such as inflammatory bowel disease and psoriatic 
skin (Figure 4.5 and 4.6) both characterised by neo-angiogensis and inflammation, 
and with a melanoma skin cancer tissue with related metastasis characterised by 
extensive neo-angiogenesis, strengthening the disease specificity of the scFv A7 
molecule.  
 Analysis of reactivity in a large panel of normal human tissues from various 
organs showed no reactivity with the vasculature or other cellular components of 
the tissues tested (Figure 4.8). Most importantly no reactivity could be detected in 
normal human synovium (Figure 4.9), further strengthening the disease specificity 
of this antibody. However, it may be argued that the normal synovium tissues used 
in this study were from patients with knee pain and therefore not entirely normal. 
Nonetheless, since the donors of these samples did not develop arthritis in a follow 
up survey of 5 years (271), it can be concluded that the expression of the target 
antigen for scFv A7 is absent in non-arthritic synovial tissues or up regulated in 
arthritic conditions.  
 The collagen induced arthritis model is one of the most commonly studied 
models of arthritis and has been intensively researched for its immunological and 
pathological features. CIA is primarily an autoimmune disease involving both T- and 
B-cells in susceptible mice strains. This model is based on injection of heterologous 
type II collagen in the joint eliciting a break of tolerance, developing a Th1 response 
and production of autoantibodies. The reactivity of scFv A7 for CIA mice joints 
proved to be negative despite the presence of large lymphoid infiltrates and the 
presence of extensive neo-vasculogenesis (Figure 4.10). This result may be 
dependent on a masking of the antigen not retrieved with the proteinase K but may 
also suggest the identification of a human specific synovial antigen not shared by 
other species. Although this finding may represent a limitation for the preclinical 
assessment of a potential therapeutic activity of the antibody, the identification of 
a human specific synovial antigen over-expressed in arthritic conditions would have 
a great impact in the understanding of pathological processes during disease onset 
and progression. However, the fact that CIA mice do not share the antigen 
expression is not conclusive to rule out the possibility of homologous protein 
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expression in other mice strains or other species. Different animal models of 
arthritis are currently used in research and due to the fact that none of them 
perfectly duplicates the pathological condition and implications of human RA, it is 
possible that different stimuli and pathways could lead to different protein 
expression profiles. There is therefore the need to screen additional animal models 
of arthritis for scFv A7 reactivity. 
 Using double immunofluorescent staining combining scFv A7 with known 
vascular markers such as vWF, CD31, α-Actin and NG2, allowed the identification of 
the target cell population for scFv A7. Von Willebrand Factor is a glycoprotein 
constitutively produced by the endothelium and megakaryocytes (280) and is used 
as a marker for endothelial cells in mature vessels. CD31 or Platelet endothelial cell 
adhesion molecule (PECAM)-1 is a protein normally found on the surface of 
platelets, neutrophils, monocytes and is responsible for endothelial cells 
intercellular junctions (281, 282). NG2 is a chondroitin sulphate proteoglycan that is 
expressed by pericytes but not shared by the smooth muscle cells, allowing a clear 
discrimination between the two populations (283). Smooth muscle α-Actin is 
important for muscle cell architecture and therefore is a shared feature of smooth 
muscle cells and pericytes (284, 285). Analysis of co-localisation showed no 
correlation between scFv A7 and vWF (r <0.1) and a significant correlation (r >0.6) 
with NG2 and α-Actin. scFv A7 specifically targets the microvasculature of arthritic 
synovium and localises to the stromal compartment rather than the endothelial 
layer as demonstrated by the dual immunofluorescent staining with NG2, 
CD31/vWF and α-Actin (Figure 4.11), showing reactivity to both pericytes and 
smooth muscle cells. Since it is well established that pericytes are multipotent cells 
and retain the capacity to differentiate into vascular smooth muscle cells (286) our 
data could suggest that scFv A7 may represent a marker for pericytes. In this 
context, staining of a broad spectrum of normal human tissues and inflammatory 
disease tissue samples with scFv A7 showed that the reactivity of this antibody is 
specific for the microvasculature of arthritic synovium only and therefore doesn’t 
represent a universal marker for pericytes (Figure 4.1, 4.5, 4.6, 4.7, 4.8, 4.9 and 
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4.12). Further, since NG2 shows no reactivity with the smooth muscle cells of the 
microvasculature, it is unlikely that NG2 represents the scFv A7 target molecule.  
The stromal targeting may seem in contrast with the design of an in vivo bio-
panning of a phage library in which the most obvious target compartment would be 
the endothelial layer (130, 259, 279). However, the mechanism of phage selection 
in vivo requires the antigen to be accessible at the moment of bio-panning to a 
probe much larger than the scFv i.e. the phage carrying multiple copies of the scFv. 
The xenograft SCID mouse model adopted in this project allows the graft to remain 
viable, maintaining human vasculature and expression of related protein (287). In 
this context, the inflammatory environment of the grafted arthritic synovium may 
allow the extravasation of large molecules through permeable vessels and promote 
the targeting of stromal antigens (118).  
 In conclusion, the scFv A7 displays all the properties of an arthritic synovium 
specific antibody and is the ideal candidate for a targeted therapeutic tool to be 
used in the treatment of rheumatoid arthritis. 
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5.1 Introduction 
 The scFv A7 isolated from in vivo phage display has demonstrated a synovial 
specific reactivity (section 4.2). Most importantly, the antibody was also able to 
discriminate between healthy and arthritic synovium (section 4.3). All the 
information provided in chapter 4 points towards the targeting of a synovium 
specific antigen or an antigen undergoing up-regulation in arthritic conditions. In 
both cases, the A7 target antigen displays potential as diagnostic tool. Furthermore, 
the accessibility of this antigen, demonstrated by the in vivo phage display and 
recirculation assay of soluble scFv A7, makes it an ideal candidate for targeted drug 
delivery. The isolation and characterisation of the target antigen remains a primary 
goal of this project and is vital for further development of the antibody and 
translation in clinical practice. Two main approaches can be used to determine the 
nature and identity of the target antigen: a standard proteomic approach and a 
peptide library based screening.   
 The classical proteomic approach consists of the identification of a suitable 
source of the target protein such as cell lines, tissues or body fluids, to be used as a 
bulk protein producer from which the antigen of interest can be extracted for 
subsequent analysis. A well characterised and commonly adopted method of 
analysis is antigen solubilisation from the original source using detergents. Protein 
extracts are then resolved in two dimensional gel electrophoresis (2DE) and probed 
with the relevant antibody to identify the candidate target antigen (288-290). 
Alternatively, the protein mixture can be incubated with the antibody of interest, 
forming antibody-antigen complexes that can be pulled down using standard 
immuno-precipitation (IP) procedures and resolved in 2DE gels (291). The 2DE 
allows the separation of the proteins based on molecular weight and isoelectric 
point (pI), providing resolution of proteins within a mixture. Mass spectrometry 
analysis of the individual reactive spots will then provide information on the 
molecular weight and amino acid composition of the protein and determine protein 
identity by comparison with comprehensive protein databases (292, 293). Efficient 
protein solubilisation vastly depends on the detergent adopted and on the 
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biophysical properties of the protein itself. It is rare that a protein profile 
representative of the entire proteome can be obtained. Highly hydrophobic 
proteins and high molecular weight proteins for example tend to precipitate 
especially during isoelectric focusing and can be poorly resolved in 2DE (292). 
Extensive optimisation of the solubilisation buffer conditions are therefore required 
when looking for an unknown antigen. 
 The second approach involves the use of cDNA peptide libraries for antigen 
screening. Recently, the increased knowledge of the human genome and proteome 
has allowed the development of cDNA peptide libraries encoding virtually all 
putative human proteins. Screening of these libraries against the tested antibody 
will allow the isolation of the relative DNA sequence and identification of the target 
antigen. Several efficient methods have been described in the recent years for 
cDNA library screening, such as phage display, ribosome display and yeast two 
hybrids. Phage display, already described in section 1.4.2 for scFv isolation, can be 
applied to peptide library screening against a known antibody, selecting specific 
reactive phage clones and rapidly identifying the protein encoding DNA sequence 
(294). In ribosome display technology, the open reading frame (ORF) sequences 
contained in the library are transcribed and translated by the ribosomal machinery. 
However, due to the absence of a stop codon, the complex mRNA-ribosome-
protein remains stable. Panning of these ribosome complexes against the test 
molecule allows the isolation of the protein and the coding mRNA at the same time. 
The mRNA isolated can then be reverse transcribed and sequenced for gene 
identification (295, 296). In contrast to phage display, which requires bacterial 
protein expression, and ribosome display, which is characterised by in vitro protein 
expression, the yeast two-hybrid technology allows post-translational modifications 
on the coded proteins. In this system, the antibody (bait) is used to screen 
expressed proteins (prey) from the library. Antibody antigen complexes can then 
reconstitute a transcription activator and promote the expression of a reporter 
gene. This method has been successfully used in the past to identify the targets for 
several scFv antibodies (297, 298). However, cDNA library expression is inherently 
limited by the translation efficiency of the host organism. Despite high titre of 
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putative ORF in the library, proteins can be expressed at different levels, 
introducing a bias for antigen copy number in the screening procedure. 
Furthermore, expression in a heterologous environment can cause protein 
precipitation or altered protein folding, inhibiting or impairing antibody-antigen 
binding (292).  
 More recently, synthetic protein microarrays have been successfully used 
for antibody profiling in autoimmune diseases (299, 300). In this technique, 
immobilised proteins synthesised or extracted from various sources can be rapidly 
screened for antibody interaction. This technique however, despite allowing high-
throughput screening, is subjected to protein expression efficiency, relatively low 
antigen representation and is characterised by generation of false positive and false 
negative results. 
 In this chapter the strategies adopted towards A7 target antigen isolation 
and validation of target candidates will be presented. 
  
Page | 186  
 
Chapter 5 – Towards the identification of scFv A7 target antigen 
 
5.2 Proteomic approach 
 Conceptually, the most suitable source of A7 target antigen would be the 
arthritic human synovium. However, low availability of fresh synovium represents a 
limiting factor for this approach. In addition, the staining observed with scFv A7 in 
human synovium is confined in the perivascular region (Figure 4.1 and 4.3) and 
therefore can account only for a minor fraction of the total tissue. Protein extracts 
obtained from total tissue digest would therefore provide only low concentration of 
the antigen and may not be detected in a conventional proteomic approach. 
Identification of an antigen expressing cell line would provide a significant amount 
of protein and represent a more stable antigen source. 
5.2.1 Identification of cells expressing the target antigen 
 Several available cell lines were screened in order to identify one showing 
reactivity to A7 antibody. This resulted in two cell lines with reactivity to scFv A7 
being identified. Specifically, PC3 cells (prostate cancer cell line) and IE7 cells (SV40 
transformed primary, human umbilical cord vein endothelial cell line) appeared to 
express the target molecule. Immunofluorescent staining was performed on non-
permeabilised conditions to detect cell surface signals as described in detail in 
section 2.7.3. Two additional cell lines, human embryonic kidney (HEK)-293 and the 
human monocytic cell line u937, were screened. As shown in Figure 5.1, both PC3 
and IE7 expressed the target antigen for scFv A7 on the cell surface, however only a 
minor percentage of the cell population was positive. Among the HEK-293 and 
u937, no reactivity with scFv A7 was detected. Confocal imaging on positive cells 
confirmed the presence of the staining on the cellular membrane as shown in Z-
stack imaging in Figure 5.2. In order to evaluate the presence of the target antigen 
in the intracellular compartment, cells were permeabilised with Triton X-100 (as 
described in section 2.7.3) prior to the standard staining procedure. The data 
shown in Figure 5.1, demonstrate that PC3, IE7 and HEK-293 cells displayed strong 
intracellular reactivity with scFv A7 in 100% of the cells examined, while staining 
remained undetectable on the u937 cell line. Confocal imaging on permeabilised 
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PC3 cell line showed indeed a distinct staining pattern compared to the non-
permeabilised condition (Figure 5.2). 
 These data indicate that the above mentioned cell lines may serve as a good 
protein source for characterisation of the target molecule for scFv A7. 
  
Page | 188  
 
Chapter 5 – Towards the identification of scFv A7 target antigen 
 
 
 
 
Figure 5.1 scFv A7 reactivity in cell lines 
Immunofluorescent staining in PC3, IE7, HEK 293 and u937 cell lines with biotinylated scFv 
A7 and biotinylated scFv HEL as control, detected by α-myc antibody (Alexa 488 green). 
Cells were stained in non permeabilised condition as well as in permeabilised condition 
after treatment with Triton X-100. Scale Bar = 20 μm. 
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Figure 5.2 scFv A7 reactivity in PC3 cell line 
Immunofluorescent staining in PC3 cell line with biotinylated scFv A7 detected by α-myc 
antibody (Alexa 488 green). Cells were stained in non permeabilised condition as well as in 
permeabilised condition after treatment with Triton X-100. Pictures show confocal imaging 
Z-stack of positive cells. Scale Bar = 25 μm. 
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The staining observed in the endothelial cell line IE7 is in contrast with the 
data presented in Figure 4.11, in which the staining pattern showed stromal rather 
than endothelial involvement. However, it is now well established that the 
expression of cell type specific markers is disregulated once cells are removed from 
the three dimensional context of tissue (301, 302). This may reflect in loss of 
differentiation specific antigens but also acquired expression of previously silenced 
genes. Since the IE7 cell line is derived from endothelial cells of the umbilical cord 
vein, the endothelial layer of fresh human umbilical cord veins were examined to 
determine whether they exhibited reactivity with scFv A7. Using IHC and 
immunofluorescence analysis, three umbilical cord samples were tested for 
reactivity with scFv A7. The results presented in Figure 5.3 A, demonstrate that scFv 
A7 exhibits reactivity with the stromal components of the vessels found in the 
umbilical cord. Specifically, dual immunofluorescent staining using vWF and scFv 
A7, further confirmed that the reactivity of scFv A7 localises in the stromal 
compartment with no detectable signal in the endothelial cell layer (Figure 5.3B). 
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Figure 5.3 scFv A7 reactivity in umbilical cord vein endothelium 
Biotinylated scFv A7 IHC staining in umbilical cord vein detected with ABC-HRP conjugate 
(A). Immunofluorescent double-staining with biotinylated scFv A7 (Texas Red – Avidin) and 
vWF-CD31 (Alexa 488 green) in umbilical cord vein with DAPI negative control (B). Scale bar 
= 50 μm. 
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In order to screen a cell population more closely related to the target tissue 
for scFv A7, the reactivity of this antibody was examined with primary synovial 
fibroblasts derived from RA synovial tissue (RASF) (240). Additionally, primary 
dermal fibroblasts derived from RA patients’ skin (RADF) were used as control. 
Examination of scFv staining with these two primary fibroblast cell populations in 
vitro has shown that scFv A7 exhibits strong reactivity with the cell surface of both 
population tested (Figure 5.4) both of which obtained 100% positive cell staining. 
Further, both cell types showed positive cytoplasmic reactivity with scFv A7 (Figure 
5.4). Confocal analysis of RASF stained with scFv A7 confirmed membrane and 
cytosol staining in non-permeabilised and permeabilised conditions respectively 
(Figure 5.5).  
The synovial tissue in rheumatoid arthritis exists in the context of active 
inflammation. Cytokines are known to play an important role in the pathogenesis of 
rheumatoid arthritis with an imbalance towards proinflammatory cytokines (14, 
30). In this context, cytokine stimulation may have a role in A7 target antigen 
expression. In order to evaluate the effect of cytokine stimulation in relation to A7 
target antigen expression and scFv A7 binding, RASF cells were stimulated for 24h 
with human TNF-α. Staining was performed in non-permeabilised conditions as 
described in section 2.7.5. scFv A7 showed a dose-dependent increase in signal with 
both stimulated and unstimulated cells, significantly higher than the control scFv 
HEL (Figure 5.6 A). TNF stimulated RASF showed a significant increase in signal 
intensity of scFv A7 compared to unstimulated cells while maintaining a comparable 
curve profile, suggesting analogous binding kinetics and a possible role for 
cytokines in A7 target antigen up-regulation (Figure 5.6 B). 
These results are in contrast with our earlier data where no detectable scFv 
A7 reactivity was observed with synovial fibroblast when sections of RA/OA synovial 
tissue were examined. Similarly, no detectable scFv A7 reactivity was observed with 
dermal fibroblasts when sections of human skin were examined (section 4.2). As 
mentioned above, in vitro culturing conditions might alter the protein expression 
profile of primary cells. In this light, reactivity of scFv A7 with primary synovial and 
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dermal fibroblasts in culture may represent promiscuous expression of proteins due 
to lack of signals from surrounding cells within the tissue matrix. 
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Figure 5.4 scFv A7 reactivity in cultured RA fibroblasts 
Biotinylated scFv A7 IF staining in dermal and synovial fibroblast with scFv HEL staining as 
control, detected by α-myc antibody (Alexa 488 green). Cells were stained in non-
permeabilised as well as in permeabilised condition after treatment with Triton X-100. 
Scale bar = 20 μm. 
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Figure 5.5 scFv A7 reactivity in RASF 
Immunofluorescent staining in primary RASF with biotinylated scFv A7 detected by 
streptavidin-Alexa fluor 488 (green). Cells were stained in non-permeabilised as well as in 
permeabilised condition after treatment with Triton X-100. Pictures show confocal imaging 
Z-stack of positive cells. Scale Bar = 25 μm. 
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Figure 5.6 reactivity of scFv A7 in TNF stimulated RASF 
Cellular ELISA on TNF stimulated and unstimulated RASF with scFv A7 and scFv HEL. Starting 
antibody concentration 1.85 μM with 1:2 serial dilution (A). Comparison of signal intensity 
between stimulated and unstimulated RASF with scFv A7 or HEL at 1.85 μM (B). Bound 
antibodies were detected with anti c-myc and anti-mouse IgG-HRP coupled antibody. 
Conversion of TMB substrate read in standard plate reader at 450 nm. (A) Unpaired t test # 
= p value <0.05. (B) Paired t test * = p value <0.05 (B).  
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5.2.2 Protein extraction from selected cell lines 
The data previously described, demonstrate that scFv A7 shows reactivity 
with the cell surface of a number of cells grown in culture. These cells therefore, 
may represent a useful resource for identification of the target antigen for scFv A7 
through a proteomics approach combining Western blot analysis, 
immunoprecipitation and protein sequencing. Towards this aim, the initial efforts 
sought to identify a detergent which best solublised the target molecule for scFv A7 
in cells, for preparation of cell lysates for use in Western blot and 
immunoprecipitation studies. 
Membrane bound and transmembrane proteins account for a high number 
of genes in the human genome, however, analysis of membrane proteins is 
aggravated by their low abundance in cells and low copy numbers of each individual 
protein (303). It is therefore crucial when aiming at isolating membrane proteins 
from live cells, to enrich for this class of proteins. A common feature of 
transmembrane proteins, is the presence of hydrophobic regions. Depending on the 
degree of hydrophobicity, a suitable detergent must be used in order to solubilise 
the antigen efficiently. To avoid cytosolic proteins contaminants and to enrich for a 
selected class of transmembrane protein, it is recommended to proceed with a 
multi-step purification process using detergents with specific properties (304). 
However, this procedure is time consuming and not applicable when aiming at the 
isolation of an unknown antigen. 
The best strategy for protein enrichment was to select a number of 
detergents with different properties, in order to identify one able to better 
solubilise the unknown target antigen for scFv A7 in cells grown in culture. Since 
each detergent chosen would preferentially solubilise proteins with specific 
properties, this approach may also yield information regarding characteristic 
properties of the protein of interest. Specifically the following detergents were 
selected: 
Triton X-100, a non-ionic detergent, most commonly used in protein 
extraction from cytoplasm, membrane and nucleus.  
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n-Octyl-β-D-thioglucopyranoside (OTG), a non–ionic, mild detergent 
used for solubilisation of membrane proteins.  
Saponin, a non-ionic detergent able to remove cholesterol from the 
membrane. Treatment with saponin will facilitate subsequent 
solubilisation by Triton X-100 of the membrane proteins that would 
otherwise be inaccessible and insoluble in the same detergent. 
Triton X-114, a non-ionic detergent used to solubilised highly 
hydrophobic proteins. Treatment with Triton X-114 will give two 
fractions: an aqueous phase rich in hydrophilic or mild hydrophobic 
proteins, and a detergent phase rich in highly hydrophobic proteins.  
Radio Immunoprecipitation Assay (RIPA) buffer, a mild ionic detergent 
for efficient solubilisation of membrane-bound and soluble proteins 
avoiding protein degradation and interference with proteins’ 
immunoreactivity. 
The final approach used a hypotonic shock, where no detergent is used 
in preparation of cellular protein extract. 
Although both endothelial cell line IE7 and prostate cancer cell line PC3 cell lines 
showed reactivity with scFv A7, this study focused initially on PC3 due to the rapid 
growth rate and easier culturing conditions. To this end, PC3 cell lysates prepared in 
the above listed detergents were resolved by SDS-PAGE, transferred onto 
nitrocellulose membrane and probed with anti E-cadherin and anti α-tubulin 
antibodies to examine the efficiency of extraction. As shown in Figure 5.6, E-
cadherin, a trans-membrane protein of 124 kDa, was efficiently solubilised in all 
preparations with the only exception of the hypotonic shock and the supernatant 
from the saponin treatment. This is as expected since the hypotonic preparations 
should contain predominantly cytosolic proteins, while the saponin supernatant can 
contain some cytoplasmic proteins which are present in abundance and “leak” as 
the cell membrane is made more fluid due to removal of cholesterol. Indeed, this is 
seen with α-tubulin, an abundant intracellular protein with a molecular weight of 
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approximately 55 kDa (Figure 5.7).  Similarly, presence of α-tubulin in the detergent 
phase of Triton X-114, which represents hydrophobic proteins, is most likely due to 
the abundance of this protein. As mentioned above, these one step protein 
extraction procedures are not sufficient to purify proteins but are useful for crude 
enrichment of specific classes of proteins. 
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Figure 5.7 Western blot analysis of PC3 cell extracts 
Western blotting of PC3 cell extracts probed with anti E-cadherin (124 kDa)/α-tubulin (55 
kDa) as controls. Reactivity detected with HRP conjugated secondary antibody and ECL 
reagent. 
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5.2.2.1 Western blot analysis 
Having established that the solubilisation protocols were functional and 
efficient in isolating transmembrane and cytosolic proteins, the above cell lysates 
were probed with scFv A7 in order to determine whether this antibody had 
applications in Western blot analysis. ScFv HEL was used as control. ScFv A7 and 
scFv HEL showed a similar staining pattern, highlighting protein bands at 35/37 kDa 
and 60 kDa (Figure 5.8). Since probing with secondary and tertiary antibodies 
(primary Ab omission) or tertiary antibody alone (secondary Ab omission) gave 
clean negative result, the reactivity detected with both A7 and HEL antibodies is 
probably a non-specific interaction due to the framework on the scFv format. Same 
result was obtained when lysates from IE7, HEK-293 and u937 cell lines were 
analysed by Western blot and probed for scFv A7 or control scFv HEL antibody 
(Figure 5.9).  
ScFv antibodies are by definition single variable domains, despite 
maintaining comparable specificity and affinity to the parent IgG they are 
inherently limited by low avidity due to the monovalency of the antibody fragment. 
Since high avidity plays an important role in the stability of antibody-antigen 
complexes with a reduced dissociation rate resulting from multiple binding to 
antigen molecules (305), the use of the scFv-Fc construct described in section 3.3 
could increase the chances of detecting the antigen in Western blot. Total cell 
lysate from PC3, HEK-293 and u937 cell lines using Laemmli lysis buffer (306) were 
resolved in SDS-PAGE and probed with A7 scFv-Fc and a control scFv-Fc antibody. 
No specific protein band could be detected in the A7 scFv-Fc blot when compared 
to the control antibody (Figure 5.10). 
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Figure 5.8 Western blot analysis of PC3 cell extracts with scFv A7 
Western blotting of PC3 cell extracts probed with scFv A7 and scFv HEL as a control, at 5 
μg/ml. Reactivity detected with anti c-myc and anti-mouse IgG-HRP conjugated antibody 
followed by incubation with ECL reagent. 
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Figure 5.9 Western blot analysis of PC3, 1E7, HEK-293 and u937 cell extracts with 
scFv A7 
Western blotting of PC3 cell extracts probed with scFv A7 or scFv HEL as control, at 5 μg/ml. 
Reactivity detected with anti c-myc and anti-mouse IgG-HRP conjugated antibody and ECL 
reagent. 
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Figure 5.10 Western blot analysis of PC3, HEK-293 and u937 cell extracts with A7 
scFv-Fc 
Western blotting of PC3, HEK-293 and u937 cell extracts probed with A7 scFv-Fc or control 
scFv-Fc at 5 μg/ml. Reactivity detected with anti-human Fc-HRP conjugated antibody and 
ECL reagent. 
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5.2.2.2 Immunoprecipitation analysis 
 Western blot analysis using protein extracts from PC3 cell line did not 
provide a target candidate, showing only non-specific reactivity. Low antigen 
concentration in the cell lysate can often be the reason for lack of specific reactivity 
in Western blot. Protein concentration using filter systems is not suitable for 
antigens with unknown molecular weight. Immunoprecipitation, however, is a well-
established method for isolating protein-protein complexes (291). The traditional 
method includes incubation of the test antibody with the antigen mixture, in this 
case the protein extract from the cell line, and subsequent binding to protein A 
beads. The resin containing protein A is able to selectively bind the Fc region of 
human IgG and the variable region of the VHIII subgroup (248, 256). In this context, 
protein A will be able to pull down the antibody and the bound protein.  
In the first attempt, cell lysates obtained from the PC3 cell line using RIPA 
buffer were incubated with the test scFv A7 or control scFv as described in section 
2.9.1. Antibody-antigen complexes were then isolated from the total protein pool 
using agarose protein A/G. Resin-antibody-antigen complex was destabilised by 
using Laemmli lysis buffer and resolved by SDS-PAGE followed by Western blotting 
probing with scFv A7 or control scFv antibody. Data presented in Figure 5.11 show 
the presence of an intense band at 30 kDa corresponding to the scFv, a lower 
molecular weight band at 15 kDa corresponding to the scFv breakdown products 
and a high molecular weight band at approximately 65 kDa, visible also in the beads 
alone lane, which most likely corresponds to protein A/G leakage during elution. No 
specific band was detected with scFv A7 when compared to control scFv HEL.  
Combined with the results described in section 5.2.2.1, the lack of reactivity 
with any specific protein band might be due to the fact that a conformational 
epitope is required for antibody-antigen binding. The SDS-PAGE and Western blot 
employed in the previous experiments involved boiling of the cell lysate in Laemmli 
lysis buffer containing DTT and SDS. These procedures cause reduction of 
disulphide bonds and denaturing of the proteins. Antibodies requiring 
conformational epitopes for antigen binding are therefore precluded from Western 
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blot application. Immunoprecipitation does not necessarily require identification of 
the precipitated proteins via Western blot. In this context, immunoprecipitation 
from cell lysate using A7 antibody should remove most of the non-specific proteins 
and then when resolved in SDS-PAGE should show enrichment of the target antigen 
that can be visualised using non-specific protein dyes. The IP procedure was 
repeated using scFv A7 and A7 scFv-Fc antibody formats, in parallel with the 
respective control antibodies, using lysates from PC3, HEK-293 cell line and primary 
RASF cells. SDS-PAGE resolved antibody-antigen complexes were stained with 
Sypro® ruby protein gel stain in order to detect total protein content and determine 
whether any protein enrichment was obtained in the A7 IP assays. In Figure 5.12, 
stained gels from PC3, HEK-293 and RASF are shown. Bands at approximately 60 
kDa and 30 kDa could be detected in all gels and corresponded to the scFv-Fc and 
scFv molecules, respectively. Minor bands present in the gels were mirrored by the 
scFv-Fc and scFv alone lane and represented antibody breakdown products. No 
detectable protein enrichment was observed in any of the cell lines tested following 
IP.  
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Figure 5.11 Immunoprecipitation analysis of PC3 cell extracts with scFv A7 
Immunoprecipitation of PC3 RIPA cell lysates with scFv A7 and scFv HEL used as a control, 
at 10 μg. Recovered bound material analysed in Western blot and probed with scFv A7 or 
control scFv HEL. Reactivity detected with anti c-myc and anti-mouse IgG-HRP conjugated 
antibody and ECL reagent. 
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Figure 5.12 Immunoprecipitation analysis of PC3, HEK-293 and RASF cell extracts 
with scFv A7 
Immunoprecipitation of PC3, HEK-293 and RASF RIPA cell lysates with A7 scFv-Fc, control 
scFv-Fc, scFv A7 and scFv HEL as control at 5 μg/ml. Recovered bound material resolved in 
SDS-PAGE and stained with Sypro® ruby protein gel stain.  
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Although the detergent approach used was able to efficiently solubilise the 
trans-membrane protein E-cadherin and the cytosolic protein α-tubulin (section 
5.2.2), no direct proof of A7 target antigen solubilisation was obtained. In order to 
do so, a new lysis buffer optimised for cell lysate ELISA assay was used for PC3 
protein extracts and screened for scFv A7 reactivity in ELISA. Data presented in 
Figure 5.13 show a dose dependent reactivity of scFv A7 with PC3 cell lysates. This 
result strongly indicates the presence of A7 target antigen in the protein extract. 
In order to validate the IP procedure with the new lysis buffer, the trans-
membrane protein ICAM-1 was chosen as a target for a proof of concept IP. The 
JU77 epithelial cell line expresses high levels of ICAM-1 upon 24 h TNF-α stimulation 
(Figure 5.14 A). The presence of ICAM-1 can be detected in stimulated JU77 cell 
lysates following Western blotting (Figure 5.14 B). To test the capacity to isolate 
ICAM-1 from TNF stimulated JU77 lysates, protein extracts were incubated with 
anti-ICAM 1 antibody and immune-precipitated using protein A/G beads. The 
elution profile shown in Figure 5.14 C, demonstrates the capacity to specifically 
isolate ICAM-1 using the immune-precipitation procedure.  
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Figure 5.13 PC3 cell lysate ELISA with scFv A7 
ELISA assay on PC3 cell lysate with scFv A7 or control scFv HEL. α-tubulin antibody included 
as positive control. Signal detected with streptavidin-HRP. Two tailed unpaired T-test ***= 
p value < 0.001. 
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Figure 5.14 ICAM IP on JU77 protein extracts 
JU77 stimulated with 10 ng/ml TNF-α for 24 h stained with anti-ICAM-1 antibody (green) 
and DAPI (blue) to depict nuclei (A). Scale bar 400 μm. Western blot on JU77 and TNF 
stimulated JU77 cell lysates probed with anti ICAM-1 antibody. Recombinant human ICAM-
1 was used as a positive control (B). IP on TNF stimulated JU77 cell lysates using anti ICAM-
1 antibody (C).    
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As previously described, protein A is able to bind the variable antibody 
region of the VHIII subgroup (248). However, as shown in section 3.2.1, protein A is 
not as efficient as Talon in purifying scFv antibody fragments which may be due to 
low affinity for the variable region and suboptimal antigen retention compared to 
the interaction of Talon® for the 6His tag. In order to prevent early dissociation, 
scFv A7 and control scFv HEL were directly coupled to CNBr-activated agarose 
beads. In this process, CNBr reacts with the hydroxyl groups on agarose beads 
forming cyanate esters. These groups are able to react with primary amines under 
very mild conditions. The result is a covalent coupling of proteins/peptides to the 
agarose beads. Since this process is non-specific and will covalently bind any given 
protein, a pure antibody preparation has to be used in order to avoid unwanted 
contaminant protein coupling which can reduce the binding capacity of the resin 
and increase background noise. As demonstrated in section 3.2.2, the scFv 
purification process yielded a high quality pure antibody with limited breakdown 
contaminant products. Coupling efficiency of scFv A7/HEL with CNBr-activated 
agarose beads was measured via quantification of free scFv pre- and post-coupling 
(Figure 5.15). A coupling efficiency greater than 97% was obtained for both scFv 
antibodies. 
The coupled agarose beads were used in an immunoprecipitation assay to 
identify interacting partners within the PC3 cell line. PC3 protein extract that 
showed positivity for scFv A7 in ELISA (Figure 5.13) was used as the antigen source. 
In order to include a positive control for the IP procedure and confirm functionality 
of the setup, recombinant hen egg lysozyme was added to the PC3 protein extract. 
IP was performed as described in section 2.9.2. Briefly, PC3 protein extract was 
incubated with the coupled resin to allow antibody-antigen interaction. The beads 
resin was then washed to eliminate non-specific and low affinity protein 
interactions and subsequently eluted in Laemmli lysis buffer to recover bound 
material. This final fraction should contain the antibody coupled to the resin and 
any protein that showed sufficient binding interaction. The recovered bound 
material was then resolved in SDS-PAGE and stained with Sypro® ruby protein gel 
stain to highlight protein content. In Figure 5.16 A is shown the resolved fractions 
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obtained from scFv A7 and scFv HEL IPs, including loaded material, flowthrough, 
washing steps and eluted bound material. Visual comparison between the resolved 
PC3 loaded material and the flowthrough fraction, containing the unbound protein 
from scFv A7 IP, does not show any significant protein depletion. The reduction in 
intensity of a band in the flowthrough compared to the total protein load would 
indicate a selective retention of the antigen in the coupled resin. Low protein 
content can be detected in the washing step fractions of both scFv A7 and scFv HEL 
and represents antigens with low affinity for the coupled resin. Finally, the elution 
fractions of both A7 and HEL show the presence of a marked band at 30 kDa 
corresponding to the molecular weight of the scFv molecule. However, high 
background is visible in both scFv A7 and scFv HEL recovered bound material. 
Analysis of the elution plot profile (Figure 5.16 B) shows the presence of several 
proteins with different intensity (peaks) but with no clear distinction between scFv 
A7 and the control scFv HEL samples. No detectable specific protein was isolated in 
the scFv A7 IP. Despite high protein contaminants in the elution fractions, the scFv 
HEL was able to selectively retain the recombinant hen egg lysozyme antigen which 
is represented by a peak at 14 kDa with considerably higher intensity compared to 
the scFv A7 elution fraction. 
  
Page | 214  
 
Chapter 5 – Towards the identification of scFv A7 target antigen 
 
 
 
 
 
Figure 5.15 Agarose beads coupling efficiency 
ScFv coupling efficiency on CNBr-activated agarose beads. Free scFv measured via 
spectrophotometric analysis at 280nm. Paired t test * = p value <0.05, ** = p value <0.01.  
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Figure 5.16 SDS-PAGE of scFv A7 IP with PC3 protein extract 
SDS-PAGE resolved samples from PC3 protein extracts using scFv A7 and scFv HEL coupled 
agarose beads (A). Plot profile analysis of elution fraction of scFv A7 and scFv HEL using the 
image analysis tool ImageJ (B).  
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As already mentioned above, scFv antibodies may be limited in their binding 
capacity and antibody-antigen complex stability by low functional affinity and 
avidity (305). Since no clear antigen enrichment was obtained using scFv A7 and 
PC3 protein extracts, the scFv-Fc bivalent A7 antibody format was adopted in the 
subsequent experiments. In this IP setup, the scFv-Fc antibody obtained from 
concentrated CHO-S supernatant (section 3.3.1), was coupled to protein A beads. 
Unlike scFv antibody fragments, full human IgG molecules have shown high binding 
capacity to staphylococcal protein A (256), making protein A resin suitable for this 
purpose. In addition, to ensure a better washing step and limit the carry-over of 
unbound material, magnetic protein A coupled beads were used as binding resin. 
The use of a magnetic resin confers an advantage over classical protein A agarose 
beads, the beads can be separated from the liquid phase by applying a magnetic 
field to the suspension reducing the carry-over of unwanted sample/washing 
buffer, reducing loss of resin during washing steps and resulting in fewer 
interference bands and lower backgrounds (307). Subsequently, beads-protein A-
antibody complex was added to the PC3 cell lysate or to the RASF cell lysate to 
allow antibody-antigen binding. After 3 washing steps, bound antigens were eluted 
in Laemmli lysis buffer following incubation at 90 °C. 
As shown in Figure 5.17 A, most of the A7 scFv-Fc was successfully coupled 
to the beads with only limited uncoupled material left in the flowthrough (lane A7 
scFv-Fc uncoupled FT). Similarly to what was observed in Figure 5.16, no clear 
protein depletion was identified between total PC3 lysate material and flowthrough 
following incubation with A7 scFv-Fc coupled resin. Analysis of the elution fraction 
obtained from PC3 lysate with A7 scFv-Fc or control scFv-Fc antibody, shows the 
presence of a predominant band at 60 kDa which corresponds to the reduced scFv-
Fc molecule (Figure 5.17 A). Comparing plot profiles of A7 scFv-Fc loaded material, 
PC3 cell lysate and elution fraction from control and A7 scFv-Fc antibodies can help 
distinguish protein peaks deriving from the scFv-Fc loaded material and peaks 
deriving from the PC3 cell lysate (Figure 5.17 B). Several peaks are visible in the 
elution profile of A7 scFv-Fc, mostly shared by the control antibody elution profile 
and A7 scFv-Fc loaded sample plot. A peak at around 180 kDa was very intense in 
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the A7 elution sample compared to control (Figure 5.17 B dashed line). However, 
the same peak was present also in the A7 scFv-Fc loaded sample, indicating 
therefore a possible antibody aggregate. A second protein peak at around 50 kDa 
was more pronounced in the A7 scFv-Fc elution plot while being absent in the A7 
scFv-Fc sample plot, suggesting a protein that is not a breakdown product of the 
antibody itself but rather a specific protein enrichment (Figure 5.17 B dotted line 
and blue arrow).  
IP on RASF cell lysates showed a similar pattern when compared to PC3 IP 
(Figure 5.17 A). No clear protein depletion was visible between RASF lysate and 
flowthrough following incubation with A7 scFv-Fc coupled resin. Interestingly, the 
elution profile of IP performed with A7 scFv-Fc was remarkably similar with the one 
obtained in PC3 IP (Figure 5.17 B). An intense peak at 180 kDa was visible in the A7 
elution profile (Figure 5.17 B dashed line) but was shared with both A7 scFv-Fc 
loaded sample and control antibody elution profiles and therefore representing 
most likely an antibody aggregate. The possible specific band observed at 50 kDa in 
PC3 IP was present also in the RASF IP. The peak was marked in the A7 elution 
sample while being undetectable in both control IP elution and A7 scFv-Fc loaded 
sample (Figure 5.17 B dotted line and blue arrow).  
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Figure 5.17 SDS-PAGE of A7 scFv-Fc IP with PC3 and RASF protein extracts 
SDS-PAGE resolved samples from IP of PC3 and RASF protein extracts using A7 scFv-Fc 
coupled to protein A dynabeads (A). Plot profile analysis gel lanes using the image analysis 
tool ImageJ (B). Peak specific for scFv-Fc A7 elution marked with blue arrow and dotted 
line. 
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The IP experiments described so far were characterised by the elution of the 
IP antibody with the partner antigen. The Laemmli lysis buffer used to recover the 
bound antigens from the affinity purification resin contains SDS and DTT reagents, 
causing protein denaturation. While this is important for optimal band resolution in 
SDS-PAGE, together with the boiling step it also causes uncoupling of the antibody 
from the resin. Since the antibody is likely the most abundant protein in the IP 
mixture, its presence in the elution fraction might mask other proteins, preventing 
detection in standard SDS-PAGE analysis. In order to prevent antibody leakage 
during the elution step, a possible solution is cross-linking the protein to the resin. 
 For this purpose, A7 scFv-Fc antibody derived from concentrated 
supernatant of CHO-s cells was coupled to protein A beads and cross-linked using 
bis-sulfosuccinimdyl-suberate (BS3) as described in section 2.9.3. The BS3 is a water 
soluble molecule containing amino reactive sulfo-NHS esters on both ends that can 
be used to covalently orient antibody to immobilised protein A resin. Subsequently, 
the resin-antibody complex was added to the PC3 protein extract to allow antibody-
antigen interaction. In order to limit possible antibody leakage, the elution step was 
conducted without Laemmli lysis buffer but using a pH 2.8 elution buffer instead. 
Before loading on SDS-PAGE for resolution, the elution fraction was equilibrated to 
pH 7.4 via buffer exchange in PBS using filter spin columns. The data presented in 
Figure 5.18 A, confirm the efficient coupling of scFv-Fc to the protein A beads, 
visible as a depleted 60 kDa band in the uncoupled flowthrough fraction in the 
stained SDS-PAGE. The scFv-Fc 60 kDa band was efficiently retained by the cross-
linked protein A resin with no detectable leakage in the elution fractions of both A7 
and control scFv-Fc. Virtually no proteins were eluted from the control IP, while two 
main bands could be detected in the A7 scFv-Fc IP elution. The presence of a smear 
in the A7 elution sample is reflected in the plot profile analysis in Figure 5.18 B by 
an elevated background noise. However, two main peaks are clearly visible at 95 
kDa and 15 kDa, not being shared by the control elution sample and representing 
specific A7 scFv-Fc interactions (dotted line in Figure 5.18 B). A peak at 60 kDa, 
corresponding to the A7 scFv-Fc, was visible in the A7 scFv-Fc loaded sample but 
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not in the A7 or control IP elution, confirming the efficient retention of the antibody 
by the cross-linked protein A resin. 
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Figure 5.18 SDS-PAGE of cross-linked A7 scFv-Fc IP with PC3 protein extracts 
SDS-PAGE resolved samples from IP of PC3 protein extracts using A7 scFv-Fc cross-linked to 
protein A dynabeads (A). Plot profile analysis gel lanes using the image analysis tool ImageJ 
(B). Peak specific for scFv-Fc A7 elution marked with dotted line. Peak corresponding to 
scFv-Fc antibody marked with dashed line. 
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5.3 Phage library screening 
 The second approach used for antibody target antigen identification was the 
screening of cDNA expression libraries. cDNA libraries have been successfully used 
to isolate protein-protein interactions over the years and phage display proved to 
be a versatile technology for large library screening (294, 308, 309). As already 
described in section 1.4.2 for scFv phage display isolation, phage libraries were 
expressed in permissive host E.coli strains allowing the formation of a full 
bacteriophage vehicle containing the foreign (test) antigen fused to the phage coat 
proteins. The test antigen is therefore exposed on the surface of the bacteriophage 
and free to interact with partner antigens during library biopanning. For the 
purpose of this project, a phage display cDNA expression library was used as a 
screening tool to identify interacting molecules to the A7 antibody.  
 Since phage libraries require amplification and expression in bacterial hosts, 
protein expression is characterised by the absence of post-translational 
modifications. This aspect represents a limitation for identification of protein-
protein interactions when modifications such as glycosylation are important for 
protein activity and/or folding. In order to establish whether the glycosylation was 
required for scFv A7 binding to its target antigen, in collaboration with the 
University College of London the positive cell line IE7 (characterised in section 5.2.1) 
was treated with tunicamycin, PNGase F and benzyl-GalNAc. Tunicamycin is an 
antibiotic that blocks the reaction of UDP-GlcNAc in the first step of glycoprotein 
synthesis, inhibiting N-linked glycoprotein formation. PNGase F is an amidase able 
to cleave between GlcNAc and asparagine residues of complex oligosaccharides 
from N-linked glycoproteins. Benzyl-GalNAc inhibits glycosyltransferase 
incorporation of glucosamine into O-glycans, suppressing O-linked glycosylations. 
The data shown in Figure 5.19 suggest that the glycosylation is not required for scFv 
A7 binding. However, it doesn’t exclude the presence of glycosylation in the target 
antigen. 
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Figure 5.19 scFv A7 reactivity in IE7 cell line following inhibition of glycosylation 
Immunofluorescent confocal microscopy was used to examine the reactivity of scFv A7 
with the cell surface of 1E7 cells after treatment with tunicamycin together with the 
glycosidase PNGase F, for removal of N-linked carbohydrates (I), and benzyl-GalNAc for 
inhibition of O-linked glycosylation (II). Reactivity with the cell surface was examined using 
non-permeabilised cells. Bound scFv A7 was detected through anti c-myc antibody followed 
by Alexa fluor 488. DAPI was used to depict nuclei.  
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The cDNA library used for the proposed screening was developed and 
extensively characterised by Di Niro et al. (241). Briefly, the library was obtained 
from mRNA of human colon carcinoma, human lung fibroblasts and human 
pancreatic islets. The mRNA molecules were fragmented, reverse transcribed in 
cDNA, cloned into an appropriate vector and filtered for clones encoding for open 
reading frames (ORF). Massive sequencing of the entire cDNA library demonstrated 
the presence of over 18000 different human genes. In addition, the random 
fragmentation of the source mRNA provides the possibility to identify the minimum 
region required for protein-protein binding and determine the epitope recognised 
by the test antibody. 
 The phage display cDNA expression library screening was performed in 
collaboration with the University of Eastern Piedmont in Novara, Italy. Figure 5.20 
shows a schematic for phage library biopanning on scFv A7. Briefly, in the first 
round of selection 4 μg/ml scFv A7 was coated on immunotubes, as described in 
section 2.14, and incubated with the phage library (1013 phage clones) in order to 
allow antibody-antigen interaction. Phage clones showing no specificity or low 
affinity for the scFv A7 were removed by serial washing steps using 0.1% tween 20 
in PBS to increase stringency. Bound clones were then recovered via incubation 
with E.coli DH5α bacteria strain and plated for amplification. In Figure 5.21 an 
agarose gel analysis of PCR products from random clones derived from the first 
round of selection is shown. The PCR confirmed the selection of cDNA fragments 
from 200 to 700 bp which indicates a correct selection performance (Figure 5.21 A). 
Recovered infected bacteria were then infected with helper phage and phage 
clones harvested for a second round of selection. The second round of selection 
was performed using the same protocol adopted for the first round. One important 
characteristic that differentiates the first round from the second is the fact that this 
selection will start with a total phage population containing only phage clones 
showing high binding capacity for the test antibody. A total of 1012 phage were used 
for the second biopanning and in order to increase the stringency of the assay, the 
washing steps were doubled in number. The increased washing steps would allow 
the elimination of phage clones that showed moderate affinity for the scFv A7 
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during the first round of selection, contributing to enrich for the clones showing 
high binding capacity. The second round of selection gave a titre of 104 phage 
clones. Starting from a total of 1013 phage from the non-selected library, the output 
showed a 109 reduction in phage number which indicates positive selection and 
enrichment for specific phage clones. Random colonies from DH5α E.coli bacteria 
infected with the output from the second round of selection were screened in 
phage ELISA to confirm the specificity for scFv A7. In this assay, coated scFv A7 in a 
96 well plate was challenged with phage obtained from the random colonies 
selected. Bound phage molecules were detected using an anti-M13 antibody 
(Figure 5.21 B). One clone (F2/B6) showed a good signal with scFv A7 and 6 showed 
only a moderate reactivity. When expressed as soluble protein extracted from the 
periplasmic compartment of infected bacteria, only the clone F2/B6 showed good 
expression and reactivity for scFv A7 (Figure 5.21 C). Sequencing analysis and BLAST 
alignment identified the clone F2/B6 as Latent-transforming growth factor beta-
binding protein 2 (LTBP2), a human extracellular matrix associated protein with 
multi-domain structure.  
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Figure 5.20 Phage display screening of cDNA expression library with scFv A7 
Schematic of cDNA expression library biopanning on scFv A7 using phage display. 
Immobilised scFv antibodies in immunotubes were incubated with the phage library, 
unbound and low affinity phages removed by washing steps. Bound phage clones 
recovered via infection of DH5α E.coli strain and plated for amplification. The total output 
was then harvested and used for successive rounds of enrichment. 
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Figure 5.21 Analysis of phage clones from first phage display selection 
PCR screening on random clones from the first round of selection on scFv A7. Fragment 
length from 200 to 700 bp, consistent with cDNA library characteristics (A). Analysis of 
selected phage clones from second round of selection on scFv A7. Phage ELISA on coated 
scFv A7 detected with anti-M13 HRP conjugated antibody (B). ELISA on periplasmic extract 
of selected clones on coated scFv A7 detected with anti SV5 tag and anti-mouse HRP 
conjugated antibody (C). 
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The phage display library screening was performed a second time using both 
scFv A7 and A7 scFv-Fc immobilised in immunotubes. The screening protocol was 
conducted in the same way as described above with the following modifications: 10 
μg/ml of antibody was immobilised on a plastic surface and incubated with the 
phage library for a shorter time at room temperature (30 minutes standing and 1 
hour on rotation). The output from the first round of selection was then amplified 
via infection of DH5α and used as input for a second round of selection against the 
same antibodies. As for the previous phage display selection, washing steps were 
increased in the second round. 50 random colonies were picked for both scFv A7 
and A7 scFv-Fc selection and screened in phage ELISA as previously described 
(Figure 5.22 A). Clones that were shown to have a good signal on phage ELISA were 
screened by PCR to analyse insert length (Figure 5.22 B) and sequenced to 
determine identity via BLAST alignment on human nucleotide database (Table 5.1). 
Phage ELISA of clones that showed strong signal for A7 scFv-Fc (n=3) or scFv A7 
(n=1) was repeated using two different concentrations and including the control 
scFv-Fc antibody as negative control (Figure 5.22 C). None of the selected clones 
gave a similar result for both scFv A7 and A7 scFv-Fc, while non-specific reactivity 
for the control scFv-Fc was detected for half of the samples. 
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Table 5.1 Sequence identity of selected phage clones (round 2) 
  
phage coating N° cycle clone Sequence identity 
output 
1°cycle vs 
A7 scFv-Fc  
A7  
scFv-Fc 2 A5 
Homo sapiens ras homologous gene family member B 
(RHOB) 
   B4 Homo sapiens ring finger protein 1 (RING1) 
   C2 
serpin peptidase inhibitor, clade A  
(alpha-1 antiproteinase, antitrypsin) 
   E4 
Homo sapiens brain abundant, membrane attached signal 
protein 1 (BASP1) 
   F2 
Homo sapiens ras homologous gene family member B 
(RHOB) 
   F5 TOP1 
   G4 
Homo sapiens nuclear receptor subfamily 1, group H, 
member 2 (NR1H2) 
   G5 
Homo sapiens serrate RNA effector molecule homolog 
(Arabidopsis) (SRRT) 
output  
1° cycle vs 
scFv A7 
scFv A7 2 F7 Homo sapiens adenylate cyclase 5 (ADCY5) 
   F9 
Homo sapiens GABA(A) receptor-associated protein like 1 
(GABARAPL1) 
   H8 
Homo sapiens GABA(A) receptor-associated protein like 1 
(GABARAPL1) 
   H12 Homo sapiens GABA(A) receptor-associated protein like 1 (GABARAPL1) 
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Figure 5.22 Analysis of second phage display screening 
Analysis of selected phage clones from second round of selection on scFv A7 and A7 scFv-
Fc. Phage ELISA on coated scFv A7 and A7 scFv-Fc detected with anti-M13 HRP conjugated 
antibody (A). PCR screening on clones from the second round of selection on scFv A7 and 
A7 scFv-Fc that showed good signal on phage ELISA (B). Phage ELISA on 4 high reactive 
phage clones at two different concentrations on coated scFv A7, A7 scFv-Fc or control scFv-
Fc. Bound phage detected with anti-M13 HRP conjugated antibody (C). 
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Since no clear specific reactivity for either scFv A7 or A7 scFv-Fc was proved 
with the outcome of the previous phage selection, a third round of selection was 
performed inverting the input of the scFv A7 and A7 scFv-Fc screening. The output 
of the second round of selection for scFv A7 was incubated with coated A7 scFv-Fc 
and vice versa. This inverted selection should eliminate phage clones showing 
specificity for the framework of either antibody. In this selection round, the binding 
time was further reduced to retain only high affinity clones and washings increased 
to have more stringent conditions. 100 clones were randomly picked for each 
selection and screened against scFv A7 or A7 scFv-Fc in phage ELISA (Figure 5.23 A). 
Phage clones showing highest reactivity for scFv A7 or A7 scFv-Fc after the third 
round of selection were sequenced and the result is shown in Table 5.2. The Homo 
sapiens myeloid leukemia factor 2 (MLF2) and Homo sapiens GABA (A) receptor-
associated protein like 1 (GABARAPL1) were the most represented among the 
selected phage clones. In order to determine the specificity of both enriched phage 
clones for A7, the phage ELISA was repeated on scFv A7 and A7 scFv-Fc, including 
the control scFv-Fc antibody (Figure 5.23 B). High reactivity could be detected with 
scFv A7. However, A7 scFv-Fc and control scFv-Fc antibodies gave similar results, 
suggesting a non-specific reactivity for the scFv format. 
 
 
 
 
 
 
 
 
 
 
  
Page | 233  
 
Chapter 5 – Towards the identification of scFv A7 target antigen 
 
 
Table 5.2 Sequence identity of selected phage clones (round 3) 
  
phages coating N° cycle clone Sequence identity 
output 
2°cycle vs 
A7 scFv-Fc 
scFv A7 3 A3 Homo sapiens myeloid leukemia factor 2 (MLF2) 
   A12 
Homo sapiens GABA(A) receptor-associated protein like 1 
(GABARAPL1) 
   B9 Homo sapiens myeloid leukemia factor 2 (MLF2) 
   B12 Homo sapiens myeloid leukemia factor 2 (MLF2) 
   C12 
Homo sapiens GABA(A) receptor-associated protein like 1 
(GABARAPL1) 
   D6 Homo sapiens myeloid leukemia factor 2 (MLF2) 
   D8 
Homo sapiens GABA(A) receptor-associated protein like 1 
(GABARAPL1) 
   E7 
Homo sapiens GABA(A) receptor-associated protein like 1 
(GABARAPL1) 
   E8 
Homo sapiens GABA(A) receptor-associated protein like 1 
(GABARAPL1) 
   E9 
Homo sapiens GABA(A) receptor-associated protein like 1 
(GABARAPL1) 
output 2° 
cycle vs 
scFv A7 
A7  
scFv-Fc 3 B1 Homo sapiens integral membrane protein 2C (ITM2C) 
   G9 Homo sapiens myeloid leukemia factor 2 (MLF2) 
   H3 Homo sapiens myeloid leukemia factor 2 (MLF2) 
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Figure 5.23 Phage ELISA on clones from inverted selection 
Analysis of selected phage clones from the third round of selection on scFv A7 and A7 scFv-
Fc via phage ELISA (A). Phage clones MLF2 and GABARAPL1 were tested in phage ELISA on 
coated scFv A7, A7 scFv-c or control scFv-Fc (B). Phage ELISA detected with anti-M13 HRP 
conjugated antibody.  
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5.3.1 Validation of LTBP2 as target antigen 
 The first phage display selection against scFv A7 identified LTBP2 as a 
putative interacting protein. Although the following round of selections against scFv 
A7 and A7 scFv-Fc failed to reproduce the same result, this protein represented a 
valid candidate as target antigen. LTBP2 is a protein belonging to the LTBP family, 
that has been previously described in synovium of OA and RA patients and 
associated with chondrocyte dedifferentiation (310-312). Furthermore, staining for 
LTBP2 on RA, OA and SLE synovium was reminiscent of the staining pattern 
obtained with scFv A7 (Figure 5.24 A) (310).  
In order to produce a purified soluble LTBP2 protein, in collaboration with 
the University of Eastern Piedmont, the cDNA obtained from the phage clone F2/B6 
(Figure 5.22) was subcloned in an expression vector containing the GST tag, forming 
a GST-LTBP2 fusion protein that can be easily purified using GSH resin. LTBP2 is a 
large protein of 1821 amino acids and 195 kDa. The design of the cDNA library does 
not allow the presence of the entire protein and therefore the selected phage clone 
contained only a fraction of the original protein. This fraction was characterised by 
a small 200 bp sequence coding for a 40 kDa peptide as visible in the purified 
protein fractions in Western blot or Coomassie stained gels (Figure 5.24 B). ELISA 
assay was used to validate the specificity of A7 for LTBP2. The LTBP2 fusion protein 
was coated on a 96 well plate along with the non-relevant protein DPP6 and the 
LTBP2 containing the SV5 tag obtained from supernatant and periplasmic extract of 
infected DH5α (Figure 5.24 C). ELISA was performed via incubation with scFv A7, 
scFv HEL, A7 scFv-Fc, control scFv-Fc and anti-GST or anti-SV5 as positive controls. 
Signal derived by anti-GST or anti-SV5 antibodies demonstrated efficient coating 
with the fusion proteins. No reactivity was detected with any test antibody on GST 
purified protein. Minor reactivity was detected with scFv A7 and A7 scFv-Fc on 
LTBP2-SV5 fusion protein. However, a similar signal was obtained using the 
corresponding control antibody.  
As already mentioned above, the cDNA sequence obtained from the phage 
library contains only a fragment of the original LTBP2 gene. The absence of large 
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portions of the original protein and specific domains or secondary structures may 
impair proper protein folding and inhibit antibody-antigen interaction. During 
phage library screening the protein is expressed on the surface of the 
bacteriophage, fused to the g3p minor coat protein. Since in this format the 
antibody was able to target and retain the phage clone, a possible strategy was to 
clone the protein in fusion with a trans-membrane domain in order to express it on 
the cell surface of a mammalian cell line. This strategy has the dual advantage of 
providing a fast screening for protein expression and of exploiting the mammalian 
expression machinery. The peptide was then fused with the single trans-membrane 
domain of the platelet derived growth factor receptor (PDGFR) using the pDisplay 
vector (313). This vector contains the Ig κ-chain leader sequence at the N-terminus 
to direct the protein to the secretory pathway. In addition, the protein is fused to 
the hemagglutinin A (HA) epitope at the N-terminus and c-myc tag at the C-
terminus to help identification of efficiently transfected cells. This construct was 
transfected in HEK-293T SV40 transformed cell line and screened in 
immunocytochemistry for scFv A7 reactivity. Transfected cells were stained for scFv 
A7 or control scFv HEL in a dual IF approach in combination with anti-HA antibody. 
HEK-293T cells were efficiently transfected with the LTBP2-PDGFR construct as 
shown from staining with anti-HA antibody. scFv A7 showed reactivity with the 
transfected cell line, however, the staining did not co-localise with the anti-HA 
signal and therefore was not related to the expression of the fusion protein. 
Furthermore, the reactivity of scFv A7 antibody could be detected also in the 
control non-transfected HEK-293T cells (Figure 5.25).  
These results indicate that the LTBP2 protein is unlikely the target antigen 
for A7. 
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Figure 5.24 Analysis of A7 reactivity with LTBP2 
Staining pattern on OA, RA and SLE synovium reported by Nzeusseu Toukap et al. 2007 
(310) (A). SDS-PAGE of purified LTBP2-GST analysed in western blot using anti-GST HRP 
conjugated antibody (left) or stained with coomassie brilliant blue (right) (B). ELISA on 
coated purified LTBP2-GST, supernatant concentrated or periplasm extracted LTBP2-SV5 
with scFv A7, scFv HEL, A7 scFv-Fc and control scFv-Fc (C).  
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Figure 5.25 IF staining on LTBP2 transfected HEK-293T 
HEK-293T transfected cells with PDGFR-LTBP2 construct. Dual IF staining with scFv A7 or 
scFv HEL (green) in combination with anti-HA tag (red) on transfected and non-transfected 
cells. Nuclei depicted with DAPI stain. Scale bar = 50 μm. 
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5.4 Literature survey and validation of C19 ORF 10 
 Analysis of the RASF proteome has provided insights on possible synovial 
specific markers or antigens that are characterised by over expression in stress 
conditions such as the inflammatory environment of arthritic synovium (314). 
Among those proteins, one in particular has raised interest: the product of C19 ORF 
10. The mRNA of the C19 ORF 10 gene is widely expressed and does not appear to 
be lineage restricted. However, the role and biological activity of this protein still 
remains unclear. Further, analysis of tissue distribution of C19 ORF 10 in both OA 
and RA synovium has shown a perivascular localisation of the protein with 
occasional involvement of the lining layer (315). Due to the similarity of tissue 
distribution between the reported C19 ORF 10 and the staining pattern obtained 
with scFv A7, this protein represents an ideal target antigen candidate. 
 A vector for C19 ORF 10 was purchased from Origene. This vector coded 
for the C19 ORF 10 protein fused to the green fluorescent protein (GFP) at the C-
terminus under the control of the CMV promoter. The GFP protein serves as a 
reporter protein to determine transfection efficiency and protein production. The 
vector was transfected in HEK-293T cell lines in parallel with a control GFP only 
plasmid. The cell line transfected with the control plasmid showed green 
fluorescence when stimulated with UV light, in over 80% of transfected cells. The 
cells transfected with C19 ORF 10-GFP plasmid showed a fluorescent signal only 
slightly increased compared to the non-transfected cells (Figure 5.26 A). When 
analysed using the SignalP 4.1 server protein analysis tool, the C19 ORF 10 is shown 
to have a putative signal peptide at the N-terminus consisting of 31 amino acids 
(MAAPSGGWNGVGASLWAALLLGAVALRPAEA) with a cleavage site between position 
31 and 32 (316). The presence of a signal peptide suggests that the protein might 
be secreted by the transfected cell line in the culture media. Since GFP is a cytosolic 
protein, the secretory pathway causes improper folding of the protein and 
inhibition of fluorescent activity (317). For this reason, the presence of secreted C19 
ORF 10 protein was evaluated in culture supernatant of transfected cells. 
Supernatant of both transfected and non-transfected HEK-293T cells were screened 
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in ELISA for scFv A7 or control scFv HEL reactivity (Figure 5.26 B). scFv A7 showed a 
stronger signal compared to scFv HEL and most importantly, the signal obtained in 
transfected supernatant was significantly higher than the supernatant from non-
transfected cells. However, anti-GFP antibody tested did not confirm the presence 
of the target protein in the supernatant. 
 
  The experiment reported above gave the first indirect indication of a 
possible interaction between C19 ORF 10 and scFv A7. In order to further 
investigate the interaction between the two proteins, the protein was fused to the 
PDGFR trans-membrane domain using the pDisplay vector (313). As mentioned in 
section 5.3.1 for the LTBP2-PDGFR fusion protein, this construct carries the HA and 
the c-myc tags. Transfected HEK-293T cells were stained with scFv A7 or scFv HEL as 
control, in combination with anti-HA tag antibody (5.27). The presence of the signal 
peptide is further confirmed by the low intensity of staining with anti-HA tag. The 
HA tag was positioned at the N-terminus of the C19 ORF 10 protein and therefore 
gets cleaved when the signal peptide is removed. Efficient transfection and protein 
expression is confirmed by staining for the c-myc tag. scFv A7 showed reactivity for 
both transfected and non-transfected cells in a minor percentage of the cell 
population suggesting a signal not related to the expression of C19 ORF 10. 
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Figure 5.26 scFv A7 reactivity for C19 ORF 10 
HEK-293T transfected cells with C19 ORF 10-GFP construct. Bright field and UV imaging of 
C19 ORF 10-GFP transfected cells, non-transfected and transfected with GFP control 
plasmid (A). ELISA assay on supernatant from transfected and non-transfected HEK-293T 
cells with scFv A7, control scFv HEL and including anti-BSA and anti-GFP as positive controls 
(B). 2 way ANOVA with Bonferroni post-test ***= p value <0.001.  
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5.5 Discussion 
 The aim of this chapter was to identify the target antigen for the scFv A7. 
This is particularly important because of the tissue and disease specificity 
demonstrated for the scFv A7 in chapter 4 that suggest the targeting of an arthritic 
synovium specific marker with potential applications for imaging, drug targeting or 
as a diagnostic tool. The work reported in this chapter represents an on-going effort 
towards this goal.  
 The proteomic approach was used as a first strategy to isolate the target 
antigen. The classical method would involve the identification of a suitable source 
of the protein to be analysed for reactivity with the test antibody. However, this 
approach has the disadvantage of requiring large quantities of the target molecule. 
In this project the ideal antigen source would be the human arthritic synovium. 
Unfortunately, as mentioned earlier in this chapter, the limited availability of this 
tissue does not allow the employment of this source. Furthermore, the vascular 
localisation of the A7 target antigen suggests that the antigen is expressed only in a 
small area of the tissue, making a total synovium lysate an inefficient source of 
protein. Several cell lines were screened in order to identify a potential source of 
antigen. Interestingly, the scFv A7 showed reactivity with both intracellular and 
surface compartment of the positive cell lines PC3 and IE7 (Figure 5.1). Some 
protein can be kept in vesicles in the intracellular front of the membrane until a 
stimulus promotes secretion. However, the staining pattern of scFv A7 in 
permeabilised cells does not comply with a vesicle localisation. Several proteins 
have been reported to exhibit the phenomenon of dual localisation through a 
process of retrotranslocation or altered localisation signals (318). Of particular 
interest was also the reactivity of scFv A7 for the SV40 transformed endothelial cell 
line derived from the human umbilical cord vein, IE7. Since localisation experiments 
described in Figure 4.11 pointed towards perivascular reactivity, involving pericyte 
and smooth muscle layer but not the endothelial cells, examination of umbilical 
cord reactivity was necessary. Sections of human umbilical cord stained for scFv A7 
in IHC and IF showed a strong reactivity with the stromal compartment of the 
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umbilical cord vein but not with the endothelial layer (Figure 5.3). As has been 
reported in the literature, an inflammatory environment may trigger the expression 
of oncofoetal antigens normally absent in adult tissues. Such is the case for the 
splicing variant of fibronectin containing the extra domain B (EDB) which has been 
shown to be re-expressed in arthritic synovium (319, 320). In this context, the A7 
target antigen may be an oncofoetal protein up-regulated or re-expressed in 
disease conditions and therefore may be expressed in other foetal tissues such as 
the umbilical cord.  
 Primary synovial fibroblasts from RA patients were screened for A7 
reactivity in order to analyse a cell population closely related to the target tissue. 
RASF showed strong reactivity with scFv A7 in both intracellular and membrane 
compartment (figure 5.4). Since synovial tissue in rheumatoid arthritis is subjected 
to extensive inflammation and normal synovium does not share the A7 target 
antigen (Figure 4.9), the expression of the target protein might be regulated by the 
inflammatory environment and specific cytokine stimuli. Although no sensible 
difference was detected in tissues with varying degree of cell infiltrates when 
screened for scFv A7 reactivity (Figure 4.3), no assumption could be made on the 
levels of cytokine present. In vitro TNF stimulation was able to increase the 
intensity of staining of scFv A7 on RASF, suggesting a role for cytokine tuning of A7 
target antigen expression. 
 As a first approach, protein extracts obtained from cell lysis using detergents 
with different properties were resolved in SDS-PAGE and analysed in Western blots 
for scFv A7 reactivity. The rationale behind a multi detergent approach is to ensure 
protein enrichment and increase the chances of detection. Membrane bound 
proteins in particular are characterised by low abundance and often contain highly 
hydrophobic regions difficult to solubilise in conventional buffers (303). Both scFv 
A7 and the A7 scFv-Fc bivalent format did not provide a specific reactivity with any 
protein band. The detected bands in Western blots were shared by the respective 
control antibody and therefore represented non-specific interactions (Figures 5.8 to 
5.10). The reason for this negative result may be attributed to the requirement of a 
conformational epitope for antibody-antigen interaction which is denatured in the 
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presence of DTT and SDS. A possible solution would be to run a gel in native 
conditions in which the protein is not subjected to denaturation prior to gel 
resolution. However, motility of proteins when exposed to electric field depends 
mainly on protein hydrodynamic size and superficial charge (321). The presence of 
SDS ensures a uniform negative charge and allows the resolution solely depending 
of protein size, moving from cathode to anode. Gel electrophoresis in native 
conditions of unknown proteins would probably convey a confusing picture with 
antigens potentially migrating in both directions and may therefore not be 
informative.  
 The IP strategy involves co-precipitation of antibody-antigen complex via 
use of an affinity resin. This is the method of choice for antigen isolation from 
complex protein solutions (291). The classical method involves isolation of the 
antibody-antigen complex from the protein solution, in this case the cell lysate, 
using protein A beads, resolution of the purified antigens in SDS-PAGE and analysis 
in Western blot. However, as reported for the Western blot approach described 
above, no specific protein isolation was detected (Figure 5.11). This result further 
indicates the requirement for a conformational epitope for antibody-antigen 
interaction to take place. In order to overcome this limitation, the proteins pulled 
down using IP were resolved in SDS-PAGE and stained with Sypro® ruby protein gel 
stain, able to non-selectively highlight the total protein content of the gel. Using a 
colorimetric or UV gel stain could allow the identification of an enriched protein 
band that can then be excised and analysed in mass spectroscopy to determine 
identity. No enriched band was detected in the IP experiment shown in Figure 5.12, 
suggesting low concentration of the target antigen in the cell lysate. Identification 
of a lysis buffer able to efficiently solubilise the target protein is therefore essential 
to increase the chances of isolation. One of the lysis buffers tested showed dose 
dependent reactivity with scFv A7, indicating efficient solubilisation of the target 
antigen and maintaining antibody binding capacity (Figure 5.13). This buffer was 
then used as standard lysis buffer for the subsequent experiments. Several 
strategies were studied to achieve efficient antigen isolation, using covalently 
coupled scFv antibodies to agarose beads (Figure 5.16), agarose-protein A coupled 
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scFv-Fc antibodies (Figure 5.17) or cross linked scFv-Fc antibodies to magnetic 
protein A beads (Figure 5.18). However, despite the fact that the system has shown 
to be able to selectively isolate ICAM-1 from JU77 cell lysates, no clear and 
unequivocal protein isolation could be claimed for A7 antibody in either format. 
Antibody efficiency in immunoprecipitation procedures can be affected by various 
factors: detergents in the lysis buffer may prevent antibody binding or retention, 
washing steps need to be optimised in order to reduce background but not remove 
specific antigen and finally antibody affinity plays a crucial role in antigen targeting. 
Antibodies isolated through phage display in scFv format are by design 
characterised by low avidity and scFv with a moderate affinity around 102 nM have 
been reported in the literature (322, 323). The range of this affinity is far from the 
high affinity values of affinity matured antibodies that are generally in the low pM 
range as is the case for Adalimumab (165, 324). If the koff rate is the limiting factor 
in this approach, a possible solution would be by chemically cross-linking the 
antibody on the surface of positive cells to prevent dissociation and then 
immunoprecipitate the complex. 
 The second approach adopted for antigen identification was cDNA library 
screening. Since the removal of glycosylation from the positive cells did not impact 
on scFv A7 reactivity, it could be assumed that post-translational modifications are 
not required for antigen targeting (Figure 5.19). This is important because the 
phage display technique adopted in this screening requires bacterial expression of 
the phage clone (325). Although the cDNA library adopted was not derived from 
synovial tissue but from colon carcinoma, lung fibroblasts and pancreas, it had been 
characterised in the past and successfully employed for isolation of specific 
antigens (241). The library was shown to express nearly 18000 human genes. Most 
importantly, the library was expressing only true ORF sequences with different 
lengths (ranging from 200 to 700 bp) with multiple copies per antigen. This last 
characteristic allows the presence of different overlapping fragments for each 
antigen. In this context, isolation of multiple phage clones coding for the same 
protein but with different fragments can be used to identify the minimum binding 
region and potentially determine the target epitope. The first selection on scFv A7, 
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with two enrichment cycles, identified the LTBP2 antigen as the most reactive clone 
(Figure 5.21). This protein has been previously reported in the literature to be 
expressed in arthritic synovium, representing a potential target candidate (310). 
However, further characterisation of the putative target as a purified protein or in a 
cell surface expression system did not confirm the specificity (Figures 5.24 and 
5.25). The second selection performed on both scFv A7 and A7 scFv-Fc did not 
produce the same outcome as the first screening. In order to reduce possible 
selection due to the framework, output from both selections were inverted and 
used for a third round of selection. Several low binding antigens were identified; 
with GABARAPL1 and MLF2 being the most represented clones (Table 5.2). 
GABARAPL1 antigen was reported to be expressed in brain, liver, kidney, heart, 
placenta and skeletal muscle (326), while the MLF2 was found to be ubiquitously 
expressed at mRNA level (327). Since no correlation with arthritic synovium 
appeared evident, further validation of these antigens was not performed. It has to 
be mentioned that the main limitation of phage display library screening resides on 
the time consuming step of random picking for assessment of individual clones. The 
screening procedure in the assays reported in this chapter was characterised by 
limited clone analysis, generally limited to 96 well plate format, and may not be 
representative of the total phage output. Massive sequencing of the total outcome 
pool can be performed using the deep-sequencing system 454 pyrosequencing 
(328). This strategy would allow a more comprehensive analysis of the phage 
outcome and identify the most represented clone population, potentially 
identifying previously missed clones (241). 
 Additionally, a potential target candidate was identified via literature 
screening. The C19 ORF 10 is a secreted protein that has been associated with 
arthritic synovium (314, 315). Tulin and colleagues suggested a role in cellular 
proliferation and identified the C19 ORF 10 as a murine bone marrow stroma-
derived growth factor (SF20/IL-25) (329). However, proliferation data could not be 
reproduced and the paper was withdrawn (330). Further, the C19 ORF 10 was 
reported to be over expressed in hepatocellular carcinoma (HCC), activating the 
Akt/MAPK pathway and contributing to proliferation (331), and in preadipocyte 
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cells (332). The staining pattern reported by Weiler and colleagues in rheumatoid 
and osteoarthritic synovium was strikingly similar to the staining obtained with A7, 
involving the perivascular compartment and showing occasional involvement of the 
synovial lining layer (315). Transfection of HEK-293T cells with a vector coding for 
the C19 ORF 10 protein fused to the reporter GFP antigen showed a significantly 
higher signal in the supernatant from transfected cells compared to non-
transfected counterpart (Figure 5.27). This result indicates the specific targeting of 
a soluble antigen in the culture medium. However, anti-GFP antibody failed to 
confirm the presence of the recombinant protein in the supernatant. Due to the 
variety of GFP proteins available on the market, the negative reactivity of the anti-
GFP antibody could be blamed on the non-specificity of the antibody clone used in 
the assay. To further characterize the reactivity with scFv A7, the protein has been 
fused with the PDGFR transmembrane domain to be exposed on the cell surface of 
transfected HEK-293T cells (Figure 5.28). The presence of a putative signal peptide 
at the N-terminus of the protein was detected with the SignalP 4.1 server tool (316) 
and confirmed by the cleavage of the HA tag domain on the fusion protein. Efficient 
transfection was confirmed by the presence of c-myc reactivity. However, no 
specific reactivity was detected with scFv A7. To finally validate the antigen and 
determine whether or not it represents the long sought target antigen, analyses 
using the soluble recombinant protein need to be performed in ELISA and IP. 
 The strategies employed for target antigen identification described in this 
chapter did not provide a suitable identity. The proposed approaches that will be 
evaluated in the future will be described in chapter 7. 
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6.1 Introduction 
 In the therapy for arthritis, biologic agents have acquired increasing interest 
over the years. In particular, anti-cytokine therapy, specifically anti-TNF agents, 
have proved to be the most promising therapeutics currently available for 
rheumatoid arthritis (139). Good clinical response can be achieved for the majority 
of patients after treatment with any of the 5 available TNF inhibitors, showing pain 
control, reduction of inflammation and prevention of joint damage (333, 334). 
However, an inadequate number of patients can actually achieve treatment free 
remission and loss of efficacy over time is not rare (139). Despite being generally 
well tolerated, systemic toxicity can still be devastating for individuals with side 
effects mainly involving increased risk of infectious complications (335). In addition, 
costs related to biologic therapy in the treatment of arthritis are high and constitute 
a considerable burden for national health systems (20-22).  
 In this project we aimed at the development of a novel tissue specific 
therapeutic for rheumatoid arthritis. Lately, bispecific antibodies have gained 
momentum especially in cancer treatment, with one FDA approved antibody and 
many other showing promising results in clinical trials, demonstrating good 
pharmacological capacities and improved potency compared to a standard antibody 
approach (205). The scFv A7 antibody described in chapters 3 and 4 displayed all 
the characteristics of a synovium specific antibody that most importantly was able 
to discriminate between arthritic and non-arthritic tissue. In this chapter the 
development of a new therapeutic agent combining the tissue specific properties of 
the A7 antibody with the gold standard for anti-TNF therapy Adalimumab in a 
bispecific antibody format will be described. Bispecific antibody design and 
characterisation of in vitro reactivity will be described in the following sections. 
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6.2 Adalimumab conversion in IgG-like scFv-Fc format 
 In order to obtain an IgG-like molecule equivalent to the one presented in 
section 3.3, characterised by a scFv fused to the Fc domain of human IgG1, the anti-
TNF antibody Adalimumab was converted into a scFv format using the VH and VL 
sequences published in the original patent and available in the public domain (165). 
Cloning strategy and rational for the development of a scFv-Fc fusion protein are 
described in section 2.2.1 and 3.3. Briefly, VH and VL nucleotide sequences obtained 
from the Adalimumab patent application were optimised for CHO expression and 
linked via the same Serine-Glycine peptide linker used for scFv A7, in a VH-L-VL 
orientation. This construct was cloned in the pHygro vector in frame with the hinge, 
CH2 and CH3 domains of human IgG1, ensuring efficient homodimerisation and 
correct glycosylation pattern of the IgG-like antibody (153, 252-254). This scFv-Fc 
format displays the same characteristics and properties of the parent Adalimumab 
IgG, maintaining bivalency for TNF binding capacity and normal Fc effector 
functions. Figure 6.1 presents a schematic of Adalimumab scFv-Fc antibody 
construct and pHygro vector structure. 
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Figure 6.1 pHygro vector and Adalimumab scFv-Fc protein structure 
Schematic of pHygro vector encoding the scFv-Fc gene with the IgG leader sequence 
containing a mini intron (A). Schematic of the conversion of Adalimumab from full IgG to 
scFv to scFv-Fc format showing the scFv domain linked to the CH2-CH3 Fc IgG1 domain and 
carrying the SV5 tag (B). 
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6.2.1 Adalimumab scFv-Fc expression and quality control 
 The CHO expression system proved to efficiently produce the A7 scFv-Fc 
construct with high yields and high purity (section 3.3.1 and 3.3.2). The optimised 
expression protocol used for A7 scFv-Fc was applied to Adalimumab scFv-Fc 
production. CHO-s cells able to grow in suspension in serum free medium were 
transfected with the pHygro vector carrying the Adalimumab scFv-Fc construct, in a 
culture medium containing the selective agent hygromycin B to select for efficiently 
transfected cells, as described in section 2.2.2.1. The surviving cell population was 
diluted to a single cell suspension and protein production capacity was evaluated in 
culture supernatant via ELISA assay (Figure 6.2 A). The clone 17 proved to efficiently 
produce the antibody with higher yields compared to the clone 12 selected for scFv 
A7 (shown in Figure 3.12 A). However, the selected clone gradually lost production 
capacity over time and frozen vials kept in liquid nitrogen for 1 year showed a high 
growth rate but a low antibody expression (Figure 6.2 B) and as a result was less 
efficient when compared to the A7 scFv-Fc CHO clone 12 (Figure 3.12 B). The 
presence of Adalimumab scFv-Fc was further confirmed by Coomassie stained SDS-
PAGE and Western blot analysis (Figure 6.3).  
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Figure 6.2 Selection of Adalimumab scFv-Fc CHO-s expressing clone 
ELISA assay on culture supernatant of transfected CHO-s clones carrying the A7 scFv-Fc 
construct. ELISA performed on anti-Human Fc coated plates and presence of scFv-Fc 
antibody detected using anti-SV5 and anti-mouse HRP conjugated antibody. Positive clone 
(C+) and negative clone (C-) included as control (A). Correlation between cell number and 
scFv-Fc protein content in CHO-s clone 17 supernatant after 1 year from transfection. Cell 
count and protein content detected at various time points (B). 
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Figure 6.3 Adalimumab scFv-Fc production from CHO-s 
SDS-PAGE resolved Adalimumab scFv-Fc from protein A stained with Coomassie brilliant 
blue (A) or probed with anti-SV5 and anti-mouse AP antibody following Western blotting 
(B). Positive clone (C+) included as control. 
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Protein A Sepharose beads were used as purification system due to the 
ability for IgG targeting (256) and the efficiency demonstrated in A7 scFv-Fc 
purification (section 3.3.1). Culture supernatant from CHO-s clone 17 transfected 
with Adalimumab scFv-Fc encoding vector was incubated with protein A resin, as 
described in section 2.2.3.1, and purification performed using gravity flow 
chromatography. Analysis of the eluted fractions using UV detection at 280 nm 
showed that the majority of the bound antibody was eluted within the first 
fractions collected (Figure 6.4 A). Presence of Adalimumab scFv-Fc was confirmed in 
Coomassie stained SDS-PAGE (Figure 6.4 B) and Western blot probing with anti-SV5 
tag antibody (Figure 6.4 C). The SDS-PAGE confirmed the presence of a 
predominant band at 60 kDa, consistent with the expected molecular weight of the 
reduced scFv-Fc fusion product. A minor proportion of breakdown products at 
around 30 kDa was visible in the Western blot and represents the Fc portion 
bearing the SV5 tag. This purification protocol was able to purify up to 5 mg/L, 
however, frozen vials kept in liquid nitrogen for 1 year showed a decrease in 
antibody production down to 1.6 mg/L. 
To further characterise and quantify the purity of Adalimumab scFv-Fc 
production from CHO-s cells, a SDS-PAGE resolved protein batch was stained using 
the high sensitive Sypro® ruby protein gel stain reagent. The plot profile of 
Adalimumab scFv-Fc purified from CHO-s cells analysed using the image analysis 
tool ImageJ, showed the presence of a predominant band at 60 kDa accounting for 
71% of signal above background (Figure 6.5 A and B).  
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Figure 6.4 Adalimumab scFv-Fc production and purification via CHO-s 
Optical density analysis of Adalimumab scFv-Fc eluted fractions from CHO-s supernatant 
using protein A purification system (A). SDS-PAGE resolved protein A purified Adalimumab 
scFv-Fc fractions from CHO-s stained with Coomassie brilliant blue (B) or probed with anti-
SV5 and anti-mouse HRP antibody following Western blotting (C). 
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Figure 6.5 Quality assessment of CHO-s produced Adalimumab scFv-Fc 
SDS-PAGE resolved Adalimumab scFv-Fc produced in CHO-s (A) stained with Sypro® ruby 
protein gel stain. Analysis of plot profile from the purified Adalimumab scFv-Fc lane (B) 
reveals a high purity in the CHO-s produced protein (71%). 
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6.2.2 Characterisation of Adalimumab scFv-Fc specificity 
 As reported in the previous section, the new Adalimumab scFv-Fc format 
proved to be efficiently produced using CHO-s expression system (Figure 6.4 and 
6.5). A key element in the design of this approach is that the Adalimumab antibody 
currently used in the clinic was isolated using phage display, therefore in scFv 
format, and subsequently converted into a fully human IgG antibody (324). In 
addition, when expressed in scFv format, Adalimumab maintains similar binding 
kinetics, affinity and potency in neutralising TNF as the parent antibody (336, 337). 
Based on this, the scFv-Fc fusion construct created in our lab should display optimal 
TNF binding and neutralising properties. However, every new construct may cause 
unforeseen structural changes and binding to target antigen may be blocked or 
impaired by protein mis-folding or steric hindrance.  In order to assess the capacity 
to bind human TNF-α, an ELISA assay was employed in which varying 
concentrations of Adalimumab IgG or Adalimumab scFv-Fc were added to the 
coated TNF (detail in section 2.11). The results presented in Figure 6.6 show an 
almost identical dose-response curve with similar EC50 when comparing the two 
antibody formats, while no binding could be detected with the control antibody A7 
scFv-Fc. 
 Further, the capacity of the Adalimumab scFv-Fc antibody to neutralise the 
biological effects of human TNF-α was assessed in a TNF induced cytotoxicity assay 
as described in section 2.10. Briefly, a murine fibroblastic cell line was incubated for 
24 hours in complete medium with the presence of the protein synthesis inhibitor 
actinomycin D, 0.45 ng/ml human TNF-α and varying concentrations of the test 
antibodies. Cell viability was assessed by measuring the production of a violet dye 
visible at 560 nm after incubation with MTT substrate. Results presented in Figure 
6.7 show a similar dose-response curve between Adalimumab and Adalimumab 
scFv-Fc antibodies while no rescue could be detected with A7 scFv-Fc (Figure 6.7 A). 
Comparison of half maximal inhibitory concentration (IC50), the concentration at 
which the antibody exerts 50% inhibition of TNF induced cytotoxicity, Adalimumab 
scFv-Fc shows a significant 2 fold increase compared to the parent antibody, rising 
from 0.17 nM to 0.34 nM (Figure 6.7 B). The IC50 value obtained with the IgG 
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Adalimumab is in line with reported values in literature (216, 337). On the basis of 
this last result, the Adalimumab scFv-Fc format shows good inhibitory capacity with 
only a minor increase in the IC50. 
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Figure 6.6 TNF binding assay 
ELISA assay on 100 ng/ml coated human TNF-α. 6.8 nM starting antibody concentration 
with 1:3 serial dilution. Bound antibodies detected using anti-human Fc HRP conjugated 
antibody. Intensity of converted TMB substrate detected at 450 nm. Values presented as 
Mean ± SEM. 
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Figure 6.7 TNF induced cytotoxicity assay on L-929 
3x10⁴ L-929 cells seeded in a 96 well plate in complete DMEM medium. Cells were 
incubated with 1 μg/ml actinomycin D and 0.45 ng/ml TNF-α in the presence of varying 
concentrations of test antibodies for 24 hours. Antibody starting concentration 18.8 nM 
with 1:3 serial dilutions. Viability measured upon conversion of 5 μg/ml MTT substrate in a 
violet dye and measure at 560 nm in standard plate reader. Values are representative of 5 
independent experiments expressed as Mean ± SEM (A). IC50 values of 5 independent 
cytotoxicity assay (B). Mean IC50 for Adalimumab = 0.17 nM. Mean IC50 for Adalimumab 
scFv-Fc = 0.34 nM. Mann-Whitney test * = p value <0.05. 
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6.3 Bispecific antibody development 
 Bispecific antibodies are a class of antibody molecules able to specifically 
target two different antigens at the same time. Several engineering strategies are 
available for bispecific antibody development, including small scFv based diabodies, 
symmetric and asymmetric IgG-like antibodies and IgG fusion molecules (205, 338). 
For the purpose of this project, a scFv-Fc fusion bispecific antibody format was 
employed. The strategy adopted to ensure efficient heterodimerisation is an 
adaptation of the well characterised knobs-into-Holes technology developed by 
Ridgway and colleagues in 1996 (211). In this section the cloning strategy adopted 
for A7/Adalimumab bispecific antibody production and characterisation of the 
expression efficiency, purity and in vitro functionality will be described. 
6.3.1 Cloning strategy 
 The knobs-into-Holes technology is based on the replacement of a small 
amino acid with a larger one in the CH3 domain of human IgG of the first heavy 
chain, specifically the residue 366 will be converted from threonine to tyrosine 
(T366Y) creating a knob. On the paired heavy chain, a large amino acid is converted 
into a smaller one, in this case the residue 407 will be converted from a tyrosine to 
a threonine (Y407T) creating a hole (211). With this strategy, the chain containing 
the T366Y mutation will preferentially dimerise in a heterodimer fashion with the 
chain containing the Y407T mutation. Homodimerisation of either chain is impaired 
due to steric hindrance and protein instability. The cloning procedure employed for 
the development of the pHygro bispecific vector is described in detail in section 2.3. 
Briefly, the T366Y and Y407T mutations were inserted in the CH3 sequence via site 
directed mutagesis. The two mutated heavy chains were cloned in separate vectors 
in order to allow the insertion of the desired scFv sequence independently. The first 
vector, containing the Y407T mutation carries also the Simian-virus 5 (SV5) tag and 
a portion of the 2A peptide sequence. The second vector containing the T366Y 
mutation carries the second part of the 2A peptide sequence at 5’ end and the 6-His 
tag at 3’. After cloning of the suitable scFv sequences in the two heavy chain 
mutated vectors, the two vectors were fused into one, reconstituting the entire 2A 
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peptide sequence and generating a single open reading frame sequence encoding 
both chains. The final vector construct (pDuo-opt) will encode both chains 
separated by a short peptide sequence. The most important features of the vector 
will be discussed in this section. Figure 6.8 shows a schematic representation of the 
cloning strategy adopted. 
  The vector encoding the bispecific construct carries a Kozak consensus 
sequence at the 5’ end of the sequence, important for the initiation of the 
translation process (339). The coding sequence starts with a human Ig leader 
sequence of 20 amino acids including a mini-intron sequence that while not 
transcribed is able to increase transcription efficiency. The leader sequence allows 
the translocation of the first antibody chain to the endoplasmic reticulum and 
subsequent release in the culture medium (340). The first scFv sequence in VH-VL 
orientation is linked to the Fc sequence carrying the CH3 Y407T mutation via the 
human IgG hinge region. At the end of the Fc region, a short 14 amino acid 
sequence (GKPIPNPLLGLDST) derived from the SV5 is added as a tag in order to 
allow a selective targeting of the first antibody chain. The first peptide chain is 
linked to the second scFv-Fc chain via the presence of a 2A peptide. First a furin 
protease cleavage site of 4 amino acids (RAKR) is present at the end of the SV5 
region. The following 24 amino acids (APVKQTLNFDLLKLAGDVESNPGP) constitute 
the 2A peptide sequence derived from the Foot-and-Mouth Disease Virus. The 
characteristic of this peptide is the ability to separate the previous and the 
subsequent peptide chains. The mechanism of action of this short sequence does 
not involve mRNA processing or proteolytic activity but rather a ribosomal skip 
during translation process in a stop codon-independent manner. In this mechanism, 
the nascent peptide chain will undergo hydrolysis at the -N-P-G sequence at the C-
terminus of the 2A sequence, releasing the first chain and allowing the ribosome to 
continue the synthesis of the second peptide chain without being released from the 
mRNA (341). The furin cleavable site located after the SV5 tag will allow the 
removal of the remaining amino acid residues. Since the 2A peptide determines the 
processing of the peptide chain at the moment of translation, a second Ig leader 
sequence is required to produce and release the second encoded scFv-Fc chain. 
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This second leader is equivalent to the one present at the 5’ end of the first scFv-Fc 
chain and contains the same mini-intron sequence. Following, the second scFv 
sequence is linked to the Fc domain carrying the CH3 T366Y mutation via the human 
IgG hinge region. At the end of the Fc, a 6 times repeated histidine is added as a tag 
to allow specific targeting of the second scFv-Fc chain. In Figure 6.9 is shown a 
schematic representation of the pDuo-opt vector and bispecific antibody construct 
with the first scFv Adalimumab fused to the Fc region containing the Y407T 
mutation and SV5 tag, while the second scFv A7 is fused to the Fc domain 
containing the T366Y knob mutation and 6-His tag. 
  
Page | 266  
 
Chapter 6 – Development of a novel tissue specific therapeutic 
 
  
Page | 267  
 
Chapter 6 – Development of a novel tissue specific therapeutic 
 
Figure 6.8 Schematic of cloning strategy for pDuo-opt 
Vector pHygro 407 generated via cloning of the first leader-scFv-Fc region using XbaI-NheI 
restriction sites to the Y407T mutated Fc region carrying the SV5 tag and the first part of 
the 2A peptide using NheI-HindIII restriction sites in the original pHygro vector. Vector 
pHygro 366 generated via cloning of the second leader-scFv-Fc region using XbaI-NheI 
restriction sites to the T366Y mutated Fc region carrying the 6-His tag and the second part 
of the 2A peptide using NheI-HindIII restriction sites in the original pHygro vector. pDuo-opt 
vector formed by cloning the second leader-scFv-Fc-6 His sequence to the pHygro 407 via 
AgeI-HindIII restriction sites. 
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Figure 6.9 pDuo-opt vector and bispecific A7-Adalimumab protein structure 
Schematic of pDuo-opt vector encoding the bispecific scFv-Fc gene with the IgG leader 
sequence containing a mini intron (A). Schematic of the bispecific A7/Adalimumab antibody 
carrying the knobs-into-Holes mutation in the CH3 domain and carrying the SV5 and 6-His 
tags (B). 
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6.3.2 Antibody expression and quality control 
 The CHO-s expression system adopted for A7 scFv-Fc and Adalimumab scFv-
Fc protein production was employed for the A7/Adalimumab bispecific antibody 
expression and for the control bispecific antibody E2/Adalimumab (section 3.3 and 
6.2.1). The E2 scFv antibody fragment used in the control antibody is specific for the 
intracellular domain of the dipeptidyl aminopeptidase-like protein 6 (DPP6) a 
protein implicated in ion channel modulation in human neuronal and heart tissue 
(342, 343). As described in section 6.3.1 for the bispecific antibody A7/Adalimumab, 
the scFv E2 antibody fragment was cloned in the pDuo-opt vector in the position 
previously occupied by scFv A7, generating the E2/Adalimumab bispecific antibody.  
6.3.2.1 Bispecific antibody production 
Stably transfected CHO-s cells with the two bispecific antibodies were grown 
in serum free medium containing the selective agent hygromycin B to bias for 
efficiently transfected cells. Since the bispecific antibody bears both the SV5 and 
the 6-His tags, the Talon® metal affinity purification system can be employed to 
purify the antibody from the culture supernatant. Due to the higher protein yield 
obtained with Talon® purification over protein A approach in scFv isolation, 
described in section 3.2.1, and to the reduced activity observed in A7 scFv-Fc 
antibodies purified using protein A compared to culture medium concentration, as 
described in section 3.3.3, the Talon® purification was chosen as the primary 
purification system.  
Analysis of the eluted fractions of A7/Adalimumab under UV 280 nm 
showed high readings, demonstrating the presence of protein in the collected 
fractions (Figure 6.10 A). Fractions showing similar protein content, calculated 
through OD absorbance, were pooled and dialysed O/N in PBS to remove excess 
free imidazole and equilibrated in standard buffer. Yields of up to 12 mg/L were 
obtained for A7/Adalimumab bispecific antibody. SDS-PAGE analysis of reduced 
protein, showed the presence of two distinct bands around 60 kDa (Figure 6.10 B). 
The difference in apparent molecular weight between A7 scFv-Fc and Adalimumab 
scFv-Fc was already observed in the bivalent monospecifc antibody, described in 
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sections 3.3 and 6.2.1, and is probably due to a different glycosylation pattern. No 
detectable contaminant proteins were present in the purified antibody pool. 
Western blot analysis of anti 6-His or anti-SV5 probed membranes show the 
presence of the A7 scFv-Fc and Adalimumab scFv-Fc band respectively (Figure 6.10 
C). 
 Analysis of eluted fractions of E2/Adalimumab under UV 280 nm, showed a 
good protein production although lower than the one obtained with 
A7/Adalimumab, with a yield of up to 8.5 mg/L (Figure 6.11 A). SDS-PAGE analysis 
of reduce protein previously dialysed in PBS, showed the presence of two bands 
around 60 kDa representing the two scFv-Fc chains (Figure 6.11 B). A difference in 
the apparent molecular weight between the two chains can be appreciated also in 
this bispecific construct. This time however, the E2 scFv-Fc chain appears smaller 
than the Adalimumab portion. Western blot analysis confirms the specificity of the 
bands detected in Coomassie stained SDS-PAGE, showing reactivity in anti-6-His and 
anti-SV5 probed membranes (Figure 6.11 C). 
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Figure 6.10 A7/Adalimumab bispecific antibody production and purification via 
CHO-s 
Optical density analysis of A7/adalimumab bispecific antibody eluted fractions from 150ml 
CHO-s supernatant using Talon® purification system (A). SDS-PAGE resolved purified 
A7/Adalimumab fractions from CHO-s stained with Coomassie brilliant blue (B) or probed 
with anti-6-His (A7 chain) or anti-SV5 (Adalimumab chain) and anti-mouse HRP antibody 
following Western blotting (C).  
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Figure 6.11 E2/Adalimumab bispecific antibody production and purification via 
CHO-s 
Optical density analysis of E2/adalimumab bispecific antibody eluted fractions from 150 ml 
CHO-s supernatant using Talon® purification system (A). SDS-PAGE resolved purified 
E2/Adalimumab fractions from CHO-s stained with Coomassie brilliant blue (B) or probed 
with anti-6-His (E2 chain) or anti-SV5 (Adalimumab chain) and anti-mouse HRP antibody 
following Western blotting (C). 
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6.3.2.2 Heterodimerisation efficiency 
 A key element in the production of an efficient and optimal bispecific 
antibody is the degree of heterodimerisation. The knobs-into-holes technology 
employed for bispecific antibody production in this project, has reported up to 92% 
of efficient heterodimerisation (211). However, the reproducibility of this 
dimerisation efficiency varies depending on the protein synthesis strategy and 
antibody structure. The antibody format used in this project significantly differs 
from the IgG format adopted in the original knobs-into-holes publication. It is 
therefore pivotal to determine the degree of heterodimerisation obtained and rule 
out the possibility of any effect being due to the presence of homodimers of either 
chain.  
 The production of bispecific antibodies, independently of the technology 
used, can potentially produce antibodies in heterodimer format, homodimer for the 
first chain and homodimer for the second chain. The data presented in Figure 6.10 
B, SDS-PAGE resolved reduced A7/Adalimumab antibody, shows a similar 
concentration of the two chains. This is due to the efficient 1:1 ratio obtained using 
the 2A peptide self-processing sequence. This analysis, however, is not informative 
with regard to the degree of dimerisation. In order to investigate this, bispecific 
antibodies were resolved in SDS-PAGE under non-reducing conditions and stained 
with the highly sensitive colloidal Coomassie brilliant blue stain (EZBlue). The 
Adalimumab IgG antibody shows a molecular weight of about 150 kDa, consistent 
with the IgG format. Adalimumab scFv-Fc shows an approximate molecular weight 
of 120 kDa. The bispecific antibodies show a molecular weight smaller than the IgG 
but higher than the Adalimumab scFv-Fc, however, due to the limitations in the 
resolution power of the acrylamide gel electrophoresis, it is difficult to discriminate 
subtle differences in size (Figure 6.12). 
In order to overcome this limitation and have a clear distinction between 
the three possible dimer molecules, the bispecific antibody encoding vector was 
engineered to remove the second scFv sequence as described in detail in section 
2.3.1. In doing so, the first chain maintained the correct Adalimumab scFv-hinge-Fc 
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sequence, while the second chain displayed only the hinge-Fc region 
(Adalimumab/Fc truncated). In this way the three possible dimers displayed a 
molecular weight size of 120 kDa, 60 kDa and 90 kDa, representing the homodimer 
for Adalimumab, the homodimer for the truncated chain and the heterodimer, 
respectively. Figure 6.13 shows a schematic of the vector and the antibodies 
structure.   
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Figure 6.12 SDS-PAGE analysis of bispecific antibodies 
SDS-PAGE analysis in non-reducing conditions of bispecific antibodies compared to original 
Adalimumab and Adalimumab scFv-Fc. Gel stained with colloidal Coomassie brilliant blue 
(EZBlue). 
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Figure 6.13 pDuo-mod vector and bispecific antibody protein structures 
Schematic of pDuo-mod vector encoding the bispecific scFv-Fc antibody with deletion of 
the second scFv (A). Schematic of the possible bispecific antibody dimer structures (B). 
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HEK-293T cell line was transiently transfected with the pDuo-mod vector 
and incubated in serum free medium. Culture supernatant was purified using a 
double purification step. First the medium was dialysed overnight in PBS and then 
incubated with protein A Sepharose beads as described in section 2.2.3.1. Protein A 
Sepharose beads are able to purify antibodies by targeting the Fc region. By doing 
so, the protein A will purify the antibody from the supernatant mixture without 
discriminating between the three different possible dimers. The second purification 
step employed is the Talon® metal affinity resin, the standard approach used for 
the bispecific antibody isolation. This resin by being able to selectively target the 6-
His tag, will discriminate in favour of the 90 kDa heterodimer and the 60 kDa 
homodimer. Both resins were able to purify the antibody as shown in Figure 6.14. 
 The asymmetric antibody construct created carried only one scFv domain 
and it was chosen to maintain the Adalimumab scFv order to be able to determine 
correct antibody function in a convenient ELISA assay. The ability to bind TNF was 
then assessed in comparison to the Adalimumab scFv-Fc antibody previously 
described (section 6.2). Both antibodies purified with protein A or Talon® were able 
to selectively target the TNF-α with only a slight increase in the EC50 values when 
compared to Adalimumab scFv-Fc to be ascribed to the monovalency of the 
asymmetric antibody construct (Figure 6.15). 
 Western blot analysis of non-reduced antibody derived from protein A or 
Talon® purification and probed for anti-6His tag showed as expected no change in 
the protein content between the two, figuring the 90 kDa and 60 kDa molecules. 
When probed for anti-SV5 however, the lane corresponding to protein A 
purification showed the bands at 120 kDa and 90 kDa while the lane from Talon® 
purification showed predominantly one band at 90 kDa (Figure 6.16 A). This data 
signifies that Talon® purification can significantly reduce the concentration of one 
of the two contaminating homodimers. 
 In order to quantify the relative proportion of the three dimer forms 
potentially present in the purified antibody pool and define the degree of purity of 
the functional heterodimeric antibody, SDS-PAGE resolved antibody from protein A 
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or Talon® purification were resolved in non-reducing conditions and stained with 
colloidal Coomassie brilliant blue (Figure 6.16 B). Analysis of the plot profile 
obtained from the protein A lane, showed the presence of the three molecular 
weight products with a relative proportion of 8.5%, 79.2% and 12.2% for the 120 
kDa homodimer, 90 kDa heterodimer and 60 kDa homodimer respectively. Analysis 
of the Talon® lane, showed a reduction of the 120 kDa homodimer down to 3.2%, 
and increase of the 90 kDa heterodimer format to 85.1% of the total protein pool 
and maintaining unaltered the 60 kDa homodimer with 11.7% (Figure 6.16 C). This 
result demonstrates that an efficient heterodimerisation rate of 85% can be 
achieved using our construct following Talon® purification.  
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Figure 6.14 Adalimumab/Fc truncated bispecific antibody production 
Optical density analysis of Adalimumab/Fc truncated antibody eluted fractions from 80 ml 
HEK-293T supernatant using protein A purification system and 1 mg antibody purified using 
Talon® metal affinity chromatography (A). SDS-PAGE resolved reduced purified 
Adalimumab/Fc truncated antibody from protein A and Talon® stained with Coomassie 
brilliant blue (B). 
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Figure 6.15 Reactivity of Adalimumab/Fc truncated antibody for TNF 
ELISA on coated 100 ng/ml TNF-α. Antibody starting concentration 6.8 nM with 1:3 serial 
dilutions. Bound antibodies detected using anti-human Fc HRP conjugated antibody. 
Intensity of converted TMB substrate measured at 450 nm in a standard plate reader. 
Values expressed as Mean ± SEM. 
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Figure 6.16 Quality analysis of Adalimumab/Fc truncated antibody 
Western blot of non-reduced Adalimumab/Fc truncated antibody probed with anti 6-His or 
anti-SV5 antibody and detected with anti-mouse HRP conjugated antibody (A). SDS-PAGE 
resolved Adalimumab/Fc truncated antibody in non-reduced condition stained with 
colloidal Coomassie brilliant blue (B). Analysis of plot profile of protein A and Talon® 
purified antibody resolved in SDS-PAGE (C). 
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6.3.3 Characterisation of bispecific antibody specificity 
 A bispecific antibody is by definition an antibody able to target two different 
antigen epitopes at the same time. The bispecific antibodies developed for this 
project are designed to target human TNF-α and either the A7 target antigen or 
DPP6. In order to define whether the scFv domains in the new antibody format 
were able to retain their original antigen specificity, each antibody was tested for 
their specific reactivity in vitro. 
6.3.3.1 A7 specificity 
 The specificity for synovium conferred by the scFv A7 domain was assessed 
in IHC and immunofluorescence on human arthritic synovium as described in 
sections 2.6.3 and 2.6.4. When compared to A7 scFv-Fc, the bispecific 
A7/Adalimumab antibody showed the classical perivascular staining characterised 
for scFv A7. Additionally, staining in sparse cell population across the tissue section 
could be detected in both A7/Adalimumab and E2/Adalimumab bispecific 
antibodies. This staining pattern was mirrored by Adalimumab scFv-Fc antibody and 
probably represents TNF-α targeting in TNF producing cells (Figure 6.17).   
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Figure 6.17 Reactivity in human arthritic synovium 
IHC on OA synovium stained with biotinylated A7 scFv-Fc, Adalimumab scFv-Fc, bispecific 
A7/Adalimumab and bispecific E2/Adalimumab at 20 μg/ml (n=3). Binding of antibody to 
the tissue section detected with ABC-HRP conjugated. Blue arrows showing A7 staining. 
Red arrows showing Adalimumab staining (A). Immunofluorescent staining on OA synovium 
with biotinylated A7 scFv-Fc, Adalimumab scFv-Fc, bispecific A7/Adalimumab and bispecific 
E2/Adalimumab at 20 μg/ml in combination with anti-vWF. Biotinylated antibody detected 
with streptavidin-Alexa fluor 488 (green). Anti-vWF detected with anti-mouse Alexa 555 
(red) (B). 
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6.3.3.2 E2 specificity  
Staining with E2/Adalimumab bispecific antibody on synovium showed a 
light reactivity in the vascular compartment and extracellular matrix. The presence 
of DPP6 protein has not yet been reported in the human synovium, while being 
documented in neuronal and heart tissues (342, 343). In order to further evaluate 
the reactivity in human arthritic synovium, a bivalent mono-specific version of scFv 
E2 using the same scFv-Fc format adopted for A7 and Adalimumab was developed. 
Staining in OA and RA synovium shows a distinct staining pattern compared to A7 
or Adalimumab, targeting the endothelial layer of the vessels and sparse cells 
within lymphoid infiltrates (Figure 6.18). 
E2/Adalimumab bispecific antibody reactivity for DPP6 was evaluated in an 
ELISA assay showing specific dose dependent reactivity for its target (Figure 6.19). 
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Figure 6.18 E2 scFv-Fc reactivity in human arthritic synovium 
IHC on RA synovium (A) and OA synovium (B) stained with biotinylated A7 scFv-Fc, E2 scFv-
Fc and Adalimumab scFv-Fc at 50 μg/ml. Binding of antibody to the tissue section detected 
with ABC-HRP conjugate. 
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Figure 6.19 Analysis of DPP6 reactivity 
ELISA on coated 1 μg/ml DPP6. Antibody starting concentration 6.8 nM with 1:3 serial 
dilutions. Bound antibodies detected using anti-human Fc HRP conjugated antibody. 
Intensity of converted TMB substrate measured at 450 nm in standard plate reader. Values 
expressed as Mean ± SEM. 
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6.3.3.3 Adalimumab specificity 
 Adalimumab reactivity for human TNF-α was assessed using an ELISA assay 
in which varying concentrations of the test antibodies were added to TNF coated 
plates. Dose dependent reactivity was detected for the antibodies carrying the scFv 
Adalimumab domain, while no reactivity could be detected with the control 
antibody A7 scFv-Fc (Figure 6.20). Both the A7/Adalimumab and the 
E2/Adalimumab antibodies showed an EC50 of 0.06 nM, in a similar range to the 
Adalimumab scFv-Fc and the parent Adalimumab antibody (0.04 nM and 0.025 nM 
respectively). In addition, when the E2/Adalimumab bispecific antibody was added 
to the TNF coated plates in the presence of the E2 specific target antigen DPP6, no 
change in EC50 value could be detected, indicating that the Adalimumab scFv arm 
remains active when the second scFv is engaged. 
 In order to further characterise the TNF binding kinetics of the newly 
produced antibodies and determine association (kon) and dissociation (koff) rates, 
surface plasmon resonance data are required (344). This method allows the 
measurement of the rates at which soluble TNF binds and dissociates from single 
antigen-binding regions of the antibody. The CM5 sensor chip, with a matrix of 
carboxymethylated dextran covalently attached to the gold surface, was used to 
covalently couple the anti-human Fc antibody, exploiting the primary amine groups 
(described in detail in section 2.13). An anti-human Fc antibody was used as a 
capture molecule for the test antibodies (ligand), with the advantage of allowing 
efficient and reproducible chip regeneration for serial experimental cycles. Test 
antibody was then added to the sensor chip to be captured by the anti-Fc antibody. 
Finally, the human TNF-α substrate (analyte) at five different concentrations (20, 8, 
3.2, 1.28 and 0.512 nM) was injected over the sensor surface in separate cycles for 
accurate kinetic measurements. The data obtained with the Biacore T200 were 
analysed using the BIAevaluation software adopting the 1:1 Langmuir binding 
model (Figure 6.21). The kinetic parameters obtained showed consistency with 
previously published data, with a KD of 23.3 pM  and 31.6 pM  for Adalimumab scFv-
Fc and A7/Adalimumab bispecific antibody respectively (Table 6.1) (345). When 
sensograms from Adalimumab scFv-Fc and A7/Adalimumab antibodies challenged 
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with 20 nM TNF-α are compared, a clear decrease in RU is visible in the bispecific 
antibody plot (Figure 6.22). This discrepancy can be partially explained by the 
reduced TNF binding capacity of the bispecific antibody in which only one arm is 
dedicated to the task. This characteristic translates to fewer bound TNF molecules 
and, as a consequence, a reduced signal. The similar KD values obtained with both 
antibodies suggest unaltered TNF binding kinetics, therefore confirming the 
functionality of the bispecific antibody construct. 
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Figure 6.20 Analysis of TNF-α reactivity 
ELISA coated on 100 ng/ml TNF-α. Antibody starting concentration 6.8 nM with 1:3 serial 
dilutions. Bound antibodies detected using anti-human Fc HRP conjugated antibody. 
Intensity of converted TMB substrate measured at 450 nm in a standard plate reader. 
Values expressed as Mean ± SEM. 
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Figure 6.21 Biacore analysis of TNF-α reactivity 
Biacore data analysed using Bia-evaluation software tool. Sensogram fitted with Langmuir 
binding model for (A) Adalimumab scFv-Fc antibody (TNF 20 nM dark blue, 8 nM green, 3.2 
nM orange, 1.28 nM pink and 0.512 nM light blue) and (B) A7/Adalimumab bispecific 
antibody (TNF 20 nM light blue, 8 nM pink, 3.2 nM dark blue, 1.28 nM green and 0.512 nM 
orange). Residuals included to indicate degree of discrepancy between experimental data 
points and the 1:1 Langmuir model fit.  
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Curve kon (1/Ms) [SE] 
koff (1/s) 
[SE] KD (M) 
Rmax (RU) 
[SE] 
Chi2 
(RU2) 
 
Adalimumab 
scFv-Fc 
 4.193E+6 [3.1E+3] 
9.768E-5 
[3.1E-7] 2.330E-11  0.127 
TNF 20 nM    64.42 [0.01]  
TNF 8 nM    62.42 [0.01]  
TNF 3.2 nM    57.84 [0.01]  
TNF 1.28 nM    58.17 [0.02]  
TNF 0.512 nM    54.56 [0.03]  
       
 
Bispecific 
A7/Adalimumab 
 3.739E+6 [3.5E+3] 
1.181E-4 
[3.9E-7] 3.157E-11  0.075 
TNF 20 nM    40.42 [0.01]  
TNF 8 nM    38.85 [0.01  
TNF 3.2 nM    37.19 [0.01]  
TNF 1.28 nM    38.68 [0.02]  
TNF 0.512 nM    38.21 [0.03]  
Adalimumab 
(345)  1.69E+6 4.71E-5 3.04E-11   
 
Table 6.1 Kinetics of Adalimumab scFv-Fc and A7/Adalimumab binding with TNF-α 
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Figure 6.22 Biacore sensogram analysis on anti-TNF constructs 
Sensograms from Biacore analysis of Adalimuab scFv-Fc, A7/Adalimumab and A7 scFv-Fc 
challenged with 20 nM TNF-α compared to reveal change in magnitude of response. A7 
scFv-Fc shows no interaction with TNF while the A7/Adalimumab bispecific antibody shows 
30-40% of RU detected with Adalimumab scFv-Fc, suggesting a monovalent capacity of TNF 
binding in the bispecific construct. 
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6.3.4 Pharmacodynamics of bispecific antibody in vitro 
 As already mentioned in section 6.2.2, the ability to target TNF in vitro is 
important but not sufficient to determine inhibition of the biological activity of TNF 
in a cell based environment. This ability is pivotal in the mechanism of action of 
Adalimumab (346). In order to evaluate the capacity to inhibit TNF induced 
cytotoxicity, a murine fibroblastic cell line was incubated for 24 hours in complete 
medium with the presence of the protein synthesis inhibitor actinomycin D, 0.45 
ng/ml human TNF-α and varying concentrations of the test antibodies. Cell viability 
was assessed by measuring the production of a violet dye visible at 560 nm after 
incubation with MTT substrate as described in section 2.10. Data presented in 
Figure 6.23 confirm the ability of the bispecific antibodies produced to inhibit the 
TNF induced cytotoxicity in a dose dependent manner. The bispecific antibodies 
showed an increase in the IC50 values compared to the original Adalimumab 
antibody. 
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Figure 6.23 TNF induced cytotoxicity assay on L-929 
3x10⁴ L-929 cells seeded in a 96 well plate in complete DMEM medium. Cells were 
incubated with 1 μg/ml actinomycin D and 0.45 ng/ml TNF-α in the presence of varying 
concentrations of test antibodies for 24 hours. Antibody starting concentration 18.8nM 
with 1:3 serial dilutions. Viability measured upon conversion of 5 μg/ml MTT substrate in a 
violet dye and measure at 560 nm in standard plate reader. Values expressed as Mean +- 
SEM (A). IC50 values of 5 independent cytotoxicity assay (B). Mean IC50 for Adalimumab = 
0.17 nM, Adalimumab scFv-Fc = 0.34 nM, A7/Adalimumab = 0.5 nM and E2/Adalimumab 
0.4 nM. Mann-Whitney test * = p value <0.05, **= p value <0.01.  
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6.4 Discussion 
 In this chapter the development of a synovium specific molecule with 
potential application as a therapeutic agent in the field of arthritis was presented. 
Following the results described in chapter 3, the scFv A7 antibody fragment proved 
to be able to specifically target the human arthritic synovium with little if any 
reactivity with other human tissues both in healthy and disease condition. This 
remarkable capacity has led us to further develop the molecule into a therapeutic 
agent. Ligand-based vascular targeting of disease is a new attractive strategy for 
treatment of conditions characterised by extensive neo-angiogenesis and vascular 
remodelling. This approach is likely to improve the therapeutic index of available 
therapeutic agents and increase safety. By targeting disease specific antigens in the 
vascular compartment, a selective drug localisation can be achieved in vivo, sparing 
healthy organs and decreasing systemic toxicity. Recently, antibodies specific for 
alternatively spliced extra-domain of fibronectin, up-regulated in tumour and 
inflammatory conditions, have been successfully conjugated with effector moieties, 
showing improved functionalities (261, 320, 347). As a proof of concept, the gold 
standard for anti-TNF therapy Adalimumab (Humira) (139) was chosen as the 
molecule for A7 functionalization in this project. In order to do so, it was chosen to 
use a bispecific antibody approach adopting the well characterised knobs-into-
Holes technology (211). 
 First, the original Adalimumab IgG antibody had to be converted into a 
format suitable for efficient production and rapid engineering. The same scFv-Fc 
antibody format (described in section 3.3) has been adopted for Adalimumab. This 
strategy is made possible by the fact that originally Adalimumab derives from a scFv 
molecule isolated through phage display (324).  Adalimumab has already been 
shown in the literature to be able to maintain binding specificity and 
pharmacokinetics in scFv format (336, 337), a characteristic that is crucial to 
assume similar therapeutic efficacy. The new antibody format adopted is 
structurally identical to the one presented in section 3.3 for A7, characterised by a 
scFv domain fused to the human IgG hinge and CH2 – CH3 domains, restoring Fc 
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effector functions, dimerization capacity and increased serum half-life to the scFv 
molecule (153, 252, 262). The results presented in section 6.2.1, demonstrate that 
the new Adalimumab scFv-Fc antibody can be readily produced by stably 
transfected CHO-s cell line with high efficiency and high purity following protein A 
purification (Figure 6.4 and 6.5). However, a reduction in protein production was 
detected following long term storing of transfected clones (Figure 6.2). Decreased 
protein production over time is an issue that can affect small scale laboratory based 
antibody production as well as large industrial facilities. Protein expression rates 
depend on numerous factors, such as transcriptional regulatory elements and DNA 
sequence, and can be altered by change in surrounding chromatin structure or 
specific DNA methylation (348). These changes can occur rapidly and are difficult to 
foresee. Often the only way to recover protein expression is by repeating the 
transfection step. A possible way to overcome this limitation and maintain a more 
stable and prolonged protein expression would be by using of vectors containing 
specific ubiquitous chromatin-opening elements (UCOEs), that are characterised by 
methylation-free CpG islands preventing heterochromatin formation and transgene 
silencing (348). Despite yield fluctuations, the Adalimumab scFv-Fc was fully 
functional and able to specifically target TNF in vitro as observed in ELISA essay 
(Figure 6.6). EC50 value comparison with the original Adalimumab antibody showed 
an almost identical binding capacity. Additionally, Adalimumab scFv-Fc was able to 
efficiently block TNF biological activity in a TNF induced cytotoxicity assay. This 
assay is the standard approach for in vitro determination of anti-TNF activity in a 
biological environment (165, 349). Results presented in Figure 6.7 showed an 
efficient inhibition of TNF induced cytotoxicity with Adalimumab scFv-Fc with a 
small, although significant, increase in IC50 value compared to the commercial 
Adalimumab antibody. This increase is likely due to the presence of impurities in 
the produced scFv-Fc protein deriving from in-house production and protein 
handling. Production of the antibody under good manufacturing practice (GMP) 
conditions and in dedicated facilities would probably ameliorate the quality and 
reactivity of the product. 
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 Many strategies are currently available to produce bispecific antibodies (as 
described in section 1.3.3), ranging from chemically cross-linked antibodies to 
tandem scFv and scFv-IgG fusion proteins (205). The approach used in this project 
was the knobs-into-Holes, one of the first described methods for efficient 
heterodimerisation of bispecific antibodies (211). The rational for choosing this 
method lies on the fact that it requires little engineering of the Fc region by 
introducing single amino acid substitutions. These mutations consist of the 
substitution of a small amino acid side chain with a larger one on the first peptide 
chain to create a knob and substitution of a large amino acid with a smaller one on 
the second chain creating a hole. Among the different possible mutations reported 
in the literature, the T366Y and Y407T were chosen. Recently, mutations on the 407 
residue with charged amino acids or glutamine have been proven to influence the 
degree and nature of glycosylation, leading to dimer destabilisation and impaired 
activity (350). However, substitution with a polar non-charged amino acid has 
shown to conserve functionality of the heterodimer by retaining the Fc effector 
functions, eliciting ADCC and complement-mediated cytotoxicity (CMC) (211). The 
knobs-into-Holes method was adapted to the scFv-Fc fusion construct already 
described in section 3.3 for A7 bivalent molecule. Having adopted a scFv-Fc fusion 
approach allowed a more efficient antibody expression. In this context, other 
bispecific antibody strategies, such as the Quadromas approach in which two 
monoclonal antibody producing hybridomas are fused (351) or the TriomAbs 
approach in which rat IgG2b and mouse IgG2a are used to create bispecific 
constructs (210), have the inherent limitation of heavy-light chain mis-pair. The 
scFv-Fc fusion construct developed overcomes this limitation by directly linking the 
heavy and light variable regions and preventing mismatch. The bispecific 
A7/Adalimumab and control E2/Adalimumab antibodies were efficiently expressed 
and secreted by CHO-s cells as described in Figure 6.10 and 6.11. SDS-PAGE analysis 
confirmed correct expression of the two chains in comparable levels; however, 
heterodimerisation efficiency could not be assessed using this format. Correct 
heterodimerisation is the limiting step in bispecific antibody efficacy. The knobs-
into-Holes technology has been reported to provide up to 92% of correct 
dimerization by inherent instability of the homodimers due to steric hindrance. 
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However, efficient heterodimerisation is often dependent on molecules expression 
performance. In order to improve our chances of obtaining a 1:1 ratio between the 
two chains, the vector construct described in Figure 6.9 contains the 2A peptide 
sequence. As previously mentioned this sequence allows a ribosomal skip during 
protein translation, causing the release of the first peptide chain before continuing 
with the second part (341). This self-processing peptide does not require ribosome 
release and re-attachment using internal ribosome entry sequences (IRES) and 
should therefore provide a better efficiency in chain expression. However, 
contrasting reports are described in the literature, showing both higher 2A peptide 
performance and higher IRES efficiency (352, 353). Probably these contrasting 
reports are influenced by host environment and primary protein sequence. To 
determine the degree of heterodimerisation that can be obtained with the 
developed construct described in this chapter, an asymmetric version of the 
bispecific antibody was engineered by removing one of the two scFv but 
maintaining both hinge and Fc region (Figure 6.13). This engineered version of the 
bispecific antibody allowed for a clear MW distinction between the three possible 
dimer formats. Analysis of the HEK-293T expressed protein purified with protein A 
or Talon®, the standard approach used for bispecific antibody purification in this 
project, revealed up to 85% of heterodimer formation with the latter (Figure 6.16). 
In addition, the Talon® purification could discriminate for the heterodimer and the 
dimer containing the 6-His tag (85% and 12% in comparison to 3% for the SV5 
tagged homodimer). Since the A7/Adalimumab antibody has the SV5 tag on the 
Adalimumab arm and the 6-His tag on the A7 side, the Talon® purification will 
preferentially purify the heterodimer and the homodimer for A7, reducing the 
quantity of homodimer for Adalimumab. This is important for the in vivo 
characterisation of the bispecific antibody functionality in which the presence of a 
full Adalimumab antibody contaminant in the bispecific antibody mixture should be 
minimised. Further, characterisation of in vitro functionality of the two scFv 
domains constituting the bispecific antibodies showed an unaltered binding 
capacity for their target antigen. This was demonstrated via synovial staining for A7 
scFv portion (Figure 6.17), DPP6 ELISA assay for E2 scFv (Figure 6.19) and TNF ELISA 
for Adalimumab scFv domain (Figure 6.20). Of particular interest is the notion that 
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bispecific E2/Adalimumab antibody can target TNF in the presence of DPP6 without 
altering the EC50 value. This indicates that the bispecific scFv-Fc format does not 
suffer from competitive binding between the two arms due to steric hindrance. 
Biacore analysis of Adalimumab scFv-Fc and A7/Adalimumab bispecific antibody 
binding kinetics with TNF-α showed consistent KD values with previously reported 
measurement for the commercial Adalimumab in the literature (345). These data 
further confirm the functionality of the scFv format of Adalimumab, providing 
additional proof to the validity of the developed bispecific antibody format. Lastly, 
both bispecific antibodies were able to efficiently rescue the L-929 murine cell line 
from TNF induced cytotoxicity with only a slightly elevated IC50 compared to the 
original Adalimumab antibody (Figure 6.23). This variation is likely to be due to the 
monovalency of the bispecific construct for TNF binding. By developing a bispecific 
but monovalent antibody for each functional domain, the construct in our hands 
probably displays a reduced avidity and an altered binding potential, translating 
into a reduced inhibitory efficiency. In this context, it has been demonstrated that 
Adalimumab is able to form complex multimeric structures with soluble TNF with 
the most stable binding configuration consisting of three separate TNF 
homotrimers and three Adalimumab antibodies (176). Furthermore, the data 
obtained from the Biacore analysis of anti-TNF kinetics (Figure 6.21) fit in the 
Langmuir 1:1 binding model when TNF is considered as a homotrimer, suggesting 
that each anti-TNF arm is able to interact with one TNF trimer (345).  
In conclusion, the conversion of Adalimumab into scFv-Fc format didn’t 
significantly alter the biological activity of the antibody. Coupling with the A7 scFv-
Fc molecule allowed the formation of a bispecific antibody construct with high 
efficiency and high quality. The in vitro characterisation demonstrated the 
functional properties of the newly generated bispecific antibody, providing 
excellent ground bases for further preclinical studies as a biotherapeutic in the 
treatment of rheumatoid arthritis. 
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7.1 General discussion 
Rheumatoid arthritis is a common autoimmune disease affecting 
diarthrodial joints and causing chronic inflammation and profound disability (14, 
15). Over the past decades, the introduction of recombinant antibodies targeting 
inflammatory cytokines, has rapidly transformed the established treatments for RA. 
However, a high-magnitude response and treatment-free remission remain an 
elusive goal. One explanation for the failure to achieve remission routinely could be 
due to the fact that they all target inflammatory cytokines or cells involved in 
immune inflammation rather than the actual cause of the disease. Therefore new 
therapeutics with higher effectiveness and improved safety profiles are still needed 
in the treatment of arthritic diseases. An interesting approach would be the 
development of targeting tools able to selectively deliver drugs to the site of 
interest, improving the levels of pharmaceuticals where needed, prolonging the 
local activity and limiting the systemic influence of the current anti-cytokine 
therapeutics.  
Towards this goal, identification of synovial specific antigens is of 
paramount importance and may have significant commercial impact. The ability of 
migrating leukocytes to preferentially accumulate in specific tissues has further 
sustained the notion of organ specific antigens expressed by the vascular 
endothelium. Indeed, in vivo phage display screenings have successfully isolated 
peptides able to specifically target vessels of different tissues, confirming the 
heterogeneity of the tissue microvasculature and the possibility to exploit such 
markers for targeted delivery approaches (130, 131, 133). With the same intent, 
our group has pioneered a chimeric mouse model using SCID mice grafted with 
human arthritic synovium, demonstrating the viability of the grafted tissue and the 
preservation of the natural human homeostatic and disease responses in the 
murine context (231, 232). This model was adopted to identify short peptides with 
specificity for the human arthritic synovium microvasculature, with potential as 
drug delivery vectors in vivo (132, 136). More recently, we adopted this model for 
the isolation of scFv antibody fragments showing preferential homing specificity for 
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the arthritic synovial tissue (230). Antibodies are evolutionally designed for antigen 
binding and retention, providing a unique opportunity for the identification of 
synovial specific markers to be used as diagnostic tools or for targeted drug 
delivery. Hence, the main goal of this project was to provide a direct translational 
application for the isolated scFv A7 antibody fragment, moving from the bench to 
the clinic by developing a targeted therapeutic agent with synovial specificity for 
the treatment of rheumatoid arthritis.  
Specifically, there were four objectives in this project and these were 
described in chapters three, four, five and six: 
1. Optimisation of scFv A7 antibody fragment production and quality 
assessment of the soluble antibody were the ground base conditions for 
further characterisation of the target antibody. In addition, a scFv-Fc 
IgG-like molecule was produced to take advantage of the increased 
avidity and Fc effector functions. 
 
2. Characterisation of scFv A7 reactivity was evaluated using 
immunohistochemistry, with an emphasis on tissue, disease and species 
reactivity, to provide supporting evidences for the human arthritic 
synovial specificity of the selected antibody. This investigation was 
pivotal to the development of the A7 antibody into a therapeutic tool. 
 
3. Subsequently, chapter five was centred on the efforts towards 
identification of the target antigen, providing an overview of the 
methods employed for A7 target antigen isolation and characterisation. 
This step would be important to provide information on the arthritic 
synovium specific marker targeted by A7. 
 
4. Finally, the well-established anti-TNF antibody Adalimumab was 
combined with scFv-Fc A7 to form a bispecific antibody with synovium 
specificity and TNF inhibiting properties. Both production optimisation 
and quality control were assessed, alongside characterisation of tissue 
reactivity, providing excellent ground bases for in vivo evaluation of 
antibody potency. 
Page | 304  
 
Chapter 7 – Discussion and future plans 
 
7.1.1 Optimisation of scFv A7 and A7 scFv-Fc production and quality control 
 The phage display technology has allowed the isolation of a selective agent 
with specificity for the microvasculature of human arthritic synovium. One of the 
most important characteristics of this technology when applied to antibody 
isolation, is the ability to express a small antibody fragment (such as scFv or Fab) on 
the surface of the phagemid particle via fusion with the pIII or pVIII coat protein 
(226, 227). Complex multi-domain molecules such as full IgG antibodies require 
glycosylation and disulphide bond formation for efficient folding and function. This 
post-translational modification is not provided by bacterial hosts, making the 
antibody fragments the optimal solution to allow fast antibody screening and 
production in bacteria.  
 Two approaches are available for bacterial protein production, either 
directing the protein to the reducing cytoplasmic compartment of the cell or to the 
oxidising environment of the periplasmic compartment between the cytoplasmic 
membrane and the outer membrane. Cytoplasmic expression has both advantages 
and disadvantages: when directed by a strong promoter high yields can be 
achieved, however, the absence of disulphide bond formation (due to the reducing 
environment) and the presence of high protein content often causes the formation 
of insoluble inclusion bodies, characterised by mis-folded protein precipitates. 
These protein aggregates can be easily separated from the cellular components due 
to their size and density but need to be converted into their natural conformation 
via laborious, time-consuming and complex in vitro renaturation. This step has 
variable success rates, depending on the protein sequence, and by the additional 
need to separate the correctly folded proteins (354, 355). Alternatively, the protein 
can be directed towards the periplasmic compartment mimicking the IgG secretion 
pathway in eukaryotic cells. In this instance, a leader signal is required to direct the 
nascent molecule towards the periplasm (234, 247). In this compartment, the 
presence of an oxidising environment and chaperone proteins ensures a more 
efficient protein folding, yielding functional proteins (244-246). An additional 
limiting step during production is inherent to the protein itself. Efficiency in the 
transfer to the periplasm can influence the yields of functional proteins and lengths 
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and composition of the linker can determine expression and formation of insoluble 
aggregates (355).  
 For the purpose of isolating a human antibody able to target human arthritic 
synovium, the use of naïve and immune libraries was excluded since autoreactive 
clones would not be included in the pool. The Tomlinson library however, is a 
synthetic library based on the common VHIII framework with diversified CDR2 and 
CDR3, high clone diversity (1.47x108) and good antibody production (233). 
However, the synthetic nature of the CDR2 and CDR3 sequences introduce an 
unknown variable in the antigen that can result in clone dependent expression 
efficiency. Presence of an amber codon is the most common yield limiting factor in 
scFv expression since it is not detected by the permissive E.coli host used for phage 
expression but is then recognised by the non-suppressive E.coli strains used for 
soluble scFv production, resulting in the abrupt termination of protein synthesis 
(356). 
 The scFv A7 antibody however, proved to be efficiently produced by the 
E.coli strain HB2151 following IPTG stimulation and using pelB driven periplasmic 
transfer. The soluble protein showed the expected 30 kDa molecular weight and 
presence of both c-myc and 6-His tags, indicating full protein length. Two 
purification methods were compared: staphylococcal protein A and the cobalt 
based metal affinity chromatography Talon®. The design of the Tomlinson library 
allows the use of protein A for a fast and easy purification, exploiting the VHIII 
framework in the absence of the more conventional Fc binding region. Targeting 
the 6-His tag proved to be more efficient, with a 1.8 fold increase in protein yield 
and up to 3 mg from 100 ml shake flask cultures, in line with the 0.1-100 mg/L yield 
for antibody fragments reported in the literature (355). Importantly, the purified 
scFv antibody showed limited contaminant proteins and breakdown products as 
detected by SDS-PAGE analysis, HPLC and FPLC. Furthermore, synovial reactivity of 
the scFv A7 purified antibody separated via size exclusion chromatography in FPLC 
showed no difference between the total scFv pool and the pure monomeric form. 
These results indicate not only that the scFv A7 was readily produced by E.coli using 
standard laboratory equipment, but also that the method adopted was able to 
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efficiently purify the scFv antibody from the bacterial culture with a single 
purification step. 
 ScFv antibody fragments have revolutionised the field of recombinant 
antibody development, providing small molecules with binding capacity that can 
easily be expressed by eukaryotic as well as prokaryotic hosts and have been 
successfully adapted to phage display technology for fast screening (205, 222, 227). 
ScFvs are by design small monovalent molecules with low avidity and fast blood 
clearance. However, these characteristics may offer several advantages over 
conventional full-length IgG antibodies. Generally scFvs have a molecular weight of 
30 kDa, below the kidney filtration limit which translates in fast renal clearance and 
short serum half-life. In specific circumstances however, this property is more than 
welcome: functionalization with effector moieties such as radionuclides for imaging 
or radiotherapy requires fast clearance rates to minimise the risk of healthy tissue 
exposure (357, 358). In addition, the small size allows a better and faster tissue 
penetration (359). For other applications though, longer half-life and increased 
antigen retention via high avidity may be preferable. Due to their plasticity, scFv 
have been extensively used as building blocks for the full IgG development, 
resulting in 13 antibodies currently in clinical trials (205).  
In order to increase avidity and restore Fc effector functions, we designed a 
scFv-Fc fusion protein linking the scFv domain to the CH2-CH3 regions, acquiring the 
structural and functional characteristics of a native IgG molecule. This new format 
was not compatible with the bacterial expression machinery due to the 
requirement of Fc glycosylation for homodimer stability and effector functions 
(153, 252, 254). Although bacteria are still considered the most efficient and cost 
effective way of producing recombinant proteins, 32 among the 58 
biopharmaceutical molecules approved in the clinic are currently produced in 
mammalian expression systems (263), 70% of which are produced using CHO cells 
(360). The main reason for the success of this cell line lies in the ability of these cells 
to adapt to serum free culture conditions, efficient post-translational modifications 
compatible and bioactive in humans, and compliance to FDA criteria and 
regulations (264). Since the well-established anti-TNF Adalimumab was produced 
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using CHO, we adopted this expression system as the standard approach for scFv-Fc 
expression. The IgG-like construct was readily produced by CHO cells and secreted 
in the medium directed by the IgG leader sequence. A yield of up to 20 mg/L could 
be achieved using high density cultures of CHO-s cells in suspension using serum-
free medium. This yield however, is far from optimal when yields of more than 10 
g/L have been reported for industry productions. A possible way to increase the 
production efficiency could be the use of shaker incubators allowing a continuous 
re-suspension of cells during culturing, increasing cell growth and protein 
production. This system could be easily applied to laboratory based productions. An 
additional strategy could be the use of hollow fiber bioreactors that can house 10-
100 times higher cell density than conventional T-flasks. In this system, small tube-
like filters create a semi-permeable membrane filtering nutrients and waste 
material allowing high cell density, continuous cell culturing and long term protein 
production (361). However, although this system is available for small and large 
scale productions, it requires specialised equipment. Another way of addressing 
yield efficiency would be engineering of the expression vector. Simple integration of 
UCOE sequences, characterised by methylation-free CpG islands upstream of the 
promoter sequence, preventing heterochromatin formation and transgene 
silencing, have shown to significantly increase scFv-Fc antibody production in CHO-s 
cells, providing long term stable expression of the exogenous antigen (348). 
Finally, synovium specific reactivity was confirmed via IHC on arthritic 
synovial tissue sections with comparable efficiency to the parent scFv A7. However, 
the gained avidity did not seem to substantially increase the binding capacity of 
scFv-Fc antibody. Analysis of the scFv A7 sequence revealed the presence of two 
glycosylation sites within the CDR2 and CDR3, specifically N-S-T and N-A-S 
respectively. Presence of N-glycosylation sites within the antigen recognition 
regions can seriously impair binding capacity and potentially influence 
pharmacokinetic properties and should therefore be avoided (362). Furthermore, 
bacterial scFv expression does not include glycosylation, introducing an additional 
variable for the scFv-Fc construct. Removal of the glycosylation consensus sequence 
can be easily achieved via site-directed mutagenesis; however, modifications in 
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such critical regions can alter the specificity of the antibody and therefore require 
scrupulous screening to confirm retention of original targeting capacity. 
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7.1.2 Characterisation of scFv A7 reactivity  
 The reactivity of the soluble scFv A7 antibody was previously proven in vivo 
in the SCID mouse transplantation model, showing preferential homing specificity 
for the human arthritic synovium compared to the normal human skin and mouse 
tissues (230). ScFv A7 was also shown to specifically target the microvasculature of 
both RA and OA human synovium in vitro with no detectable reactivity with normal 
human skin. As already mentioned in section 4.6, the targeting of both RA and OA 
vasculature is not uncommon. A previously isolated peptide using in vivo phage 
display in the same SCID mouse model showed synovial homing specificity 
irrespectively of RA or OA origin (279). This can indicate the targeting of a synovium 
specific antigen or an antigen undergoing expression or up-regulation in arthritic 
disease and therefore shared by the two conditions. Further investigations using 
synovium biopsies from patients with inexplicable knee pain that did not develop 
arthritic conditions in a 5 year follow-up survey (271), showed no reactivity with 
vasculature or other cell components within the tissue. This is of particular 
importance since it points toward the identification of an arthritic synovium specific 
antigen and therefore may lead to a possible diagnostic tool. 
It would be of interest to further characterise the prevalence and expression 
of the target antigen in different therapeutic stages of the disease, analysing tissues 
from patients not previously treated with DMARD or biologic agents to detect 
changes in expression patterns.  Additionally, screening patients with early or 
advanced arthritis would provide insights into whether the target antigen or scFv 
A7 may be used as a marker for early diagnosis of the pathology.  
Towards this aim we have performed a screen on tissue sections form OA 
and RA synovium characterised by varying degrees of immune cell infiltrates. Tissue 
samples can show low amount of infiltrating cells, diffuse infiltration with no clear 
distribution and aggregates of varying size that can present features of ectopic 
lymphoid structures (50). However, no significant difference in reactivity could be 
detected with A7. It is worth mentioning that the infiltration levels detected in the 
tissue sections are not representative of the entire synovium of a single patient and 
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different regions may present different phenotypes (50). In this light, the stimulus 
required for A7 target antigen expression may be independent of tissue cellularity 
or may distribute across the tissue and therefore migrate in adjacent regions. It 
could be speculated that the A7 target antigen expression is promoted by the 
inflammatory environment itself and therefore be non-disease specific. In order to 
shed light on this possible scenario, the reactivity of scFv A7 was evaluated in 
inflammatory bowel disease, a class of disease characterised by extensive 
angiogenesis and chronic inflammation (268). An additional reason for testing IBD 
lies in the fact that mucosal leukocytes are capable of binding to synovial vessels, 
causing arthritic complications in mucosal disorders or aggravating pre-existing 
arthritis, indicating a common migratory pathway (363, 364). All of the samples 
tested were negative for scFv A7 reactivity in the vascular compartment; however, 
3 Crohn’s disease and 2 colorectal cancer tissues showed confined reactivity to the 
muscular layer. Further, reactivity was tested in psoriatic skin and melanoma 
samples with associated colon and axillary lymph node metastasis showed a 
negative outcome. The arthritic synovium specificity of scFv A7 was further proved 
by screening a comprehensive panel of normal human tissue from various organs, 
where no targeting was detected with the vasculature or other tissue components. 
These results demonstrate that the expression of the epitope for scFv A7 is likely to 
be tissue specific and restricted to the microvasculature of the arthritic synovium.  
 The use of animal model of arthritis for testing antibody distribution, 
pharmacokinetics and possible biological effect would be an invaluable resource in 
the development of scFv A7 into a therapeutic agent for the treatment of 
rheumatoid arthritis. Collagen induced arthritis is a well-known and extensively 
studied model of the pathology, showing classical RA immunological and 
pathological features (272). However, despite the presence of an extensive 
angiogenesis, associated with T- and B-cell infiltrates and synovial hypertrophy, no 
reactivity could be detected with scFv A7. As already mentioned in section 4.6, this 
result could indicate the targeting of a human specific antigen with little homology 
to the murine counterpart. Screening of other models of arthritis in mouse or other 
species, with different triggering systems may identify a suitable alternative. 
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Collagen-antibody induced arthritis (CAIA) for example, exploits the same principle 
as CIA but it is characterised by more pronounced macrophage and 
polymorphonuclear cell infiltrates with no associated T- and B-cell response (365). 
Other models include Saccharomyces cell wall immunisation acting via TLR2 
stimulation, BSA-induced arthritis and TNF transgenic mouse models (365). While 
the identification of a suitable animal model of arthritis might provide a simple way 
of monitoring disease progression and A7 potency in vivo, the SCID xenograft model 
adopted in this project can be applied for the same purpose. Specifically, since the 
grafted arthritic synovium has been proven to maintain the phenotypic appearance 
of the in vivo rheumatoid tissue and maintained homeostatic and disease specific 
tissue response (231, 232), monitoring intragraft cellularity and cytokine expression 
would provide insights towards evaluation of the therapeutic properties of the 
tested molecule. 
Despite the impact that rheumatoid arthritis exerts both in personal and 
social life, in terms of life impairment with disability, associated morbidity and 
mortality, considerable health care cost and high investments from the 
pharmaceutical companies, to date, there is a paucity of specific synovial markers. 
The use of synovial specific markers for selective delivery of drugs to the synovium, 
may improve the levels of pharmaceuticals in situ, prolong the local activity and 
limit systemic side effects. Identification of synovial specific antigens may hence be 
an interesting avenue for the development of novel targeted therapeutics for 
treatment of arthritic disease. However, to date, only a few synovial markers have 
been reported. In this context, synoviolin/Hrd1, an E3 ubiquitin ligase has been 
shown to be involved in the pathogenesis of arthritis (366) through its antiapoptotic 
effects (367, 368). Although ubiquitously expressed in all human tissues, synoviolin 
protein expression is up-regulated in the endoplasmic reticulum of synoviocytes of 
patients with RA (366). Cadherin-11 has been shown to be important for the 
synovial tissue architecture, providing adherent junctions between fibroblast-like 
synoviocytes and hence support to the proliferating synovium. Specifically, 
prominent protein expression was detected in the lining of RA, OA and normal 
synovium and in rare cells in the sublining region (369). Although the complete 
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distribution of Cadherin-11 in adult human tissue is currently unknown, evidence 
suggest that the protein is ubiquitously expressed, rendering this protein not 
specific to the synovium (369-372). Finally, gene expression proﬁling studies have 
identiﬁed the TLE1 gene as an excellent discriminator of synovial sarcoma from 
other sarcomas (373). TLE proteins (human homologues of Groucho) are 
transcriptional co-repressors that inhibit Wnt signaling and other cell fate 
determination signals. Specifically, TLE has been implicated as a diagnostic marker 
for synovial sarcoma. However, although up-regulated in synovial sarcomas, TLE 
protein expression is found ubiquitously in human tissues (374-376). Further, 
expression of TLE in arthritic synovium has not yet been reported. In this light, 
currently, there is a dearth of markers specific to normal and arthritic synovium 
(Table 7.1).  
Here the development and characterisation of a scFv antibody was 
reported, which shows specificity for the stromal compartment of the 
microvasculature of arthritic synovium with undetectable levels of the target 
antigen in a broad spectrum of normal and disease human tissues. This suggests 
that the A7 antibody represents a more selective and specific marker for arthritic 
synovium than those mentioned above. ScFv A7 hence represents a strong 
candidate for targeted therapy of arthritic disease. 
 
Marker 
Presence 
in arthritic 
synovium 
Presence 
in normal 
synovium 
Presence 
in cancer 
tissues 
Tissue 
specificity 
Cellular 
localisation 
Activity 
Synoviolin Yes 
Not 
available 
Not 
available Ubiquitous Cytosol Protection from 
apoptosis 
Cadherin-
11 
Yes Yes 
Not 
available 
Ubiquitous Membrane 
Homophilic 
cell-to-cell 
adhesion 
TLE1 
Not 
available 
Not 
available 
Yes Ubiquitous Nucleus 
Transcriptional 
co-repressor 
scFv A7 
target 
Yes No 
Not 
available 
Arthritic 
synovium 
Cytosol 
Membrane 
Not available 
Table 7.1 Expression profile of synovial markers 
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The in vivo phage display approach used in this project was intended to 
selectively isolate a scFv antibody with high specificity for a microvascular 
determinant within the arthritic synovium. To this intent, the phage library injected 
intravenously in mice, would diffuse in the murine blood stream and reach the 
human vessels in the synovial grafts through the anastomoses between mouse and 
human vasculature. To ascertain which cellular compartment within the synovial 
microvasculature scFv A7 was binding to, a range of endothelial and stromal 
markers were used in immunohistological analysis. A panel of currently available 
vascular markers is shown in Table 7.2. CD31 is a platelet endothelial cell adhesion 
molecule normally found on endothelial cells, platelets and macrophages (282) and 
is primarily used to demonstrate the presence of endothelial cells; CD34 is a 
member of the transmembrane sialomucin proteins, expressed mainly in 
hematopoietic stem cells, endothelial progenitor cells and endothelial cells (377) 
and is employed as a marker for immature vessels; vWF is constitutively produced 
by the endothelium and megakaryocytes (280) and is used as a marker for 
endothelial cells in mature vessels. IHC stainings in a range of human tissues 
demonstrated a lack of correlation between scFv A7 antigen expression and the 
endothelial markers tested. Furthermore, a direct dual staining in RA synovium with 
scFv A7 and anti-vWF showed that the scFv A7 staining is not present in the 
endothelium.  
Regarding the vascular stromal compartment, endosialin (CD248) has 
recently been identified as a marker of mural (pericyte/smooth muscle) cells and 
fibroblasts associated with tumour vasculature (276, 277), however the expression 
detected in RA and OA synovium was not shared by the perivascular cells and 
showed a different profile compared to scFv A7. Additionally, smoothelin, a 
cytoskeletal protein, has been reported as a specific marker of differentiated 
(contractile) smooth muscle cells. In particular, smoothelin-A is found in viscera 
smooth muscle cells while the smoothelin B is found in the vascular smooth muscle 
cells in adult organs (378). In this context, it is unlikely that smoothelin is the target 
molecule for scFv A7 since the expression profile of these two antigens is different. 
Specifically, scFv A7 antibody does not show reactivity with the intestinal or 
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esophageal smooth muscle cells within the muscularis mucosa, where smoothelin A 
shows clear and strong reactivity (379, 380). Further, within the vasculature, 
smoothelin B is expressed in the tunica media of large and contractile vessels (378) 
and not the pericytes whilst scFv A7 exhibits reactivity with the pericytes as well as 
the smooth muscle cells of the microvasculature found in arthritic synovium. To 
date, expression of smoothelin in the arthritic joint has not yet been reported.  
NG2, α-smooth muscle actin and desmin are the most commonly used 
markers of perivascular cells. NG2 is expressed by pericytes but not shared by the 
smooth muscle cells, allowing a clear discrimination between the two populations 
(283). α-smooth muscle actin and desmin, are both important for muscle cell 
architecture and therefore are a shared feature of smooth muscle cells and 
pericytes (284, 285). Staining in arthritic human synovium tissues showed a similar 
staining profile between scFv A7 and the perivascular marker described above. A 
dual immunofluorescent staining in RA synovium with NG2 showed significant co-
localisation, therefore suggesting that the expression of the scFv A7 target antigen 
is confined to the perivascular compartment. This aspect is not in contrast with the 
principle of vascular in vivo bio-panning, since the presence of chronic 
inflammation, hypoxia and angiogenesis can facilitate extravasation of the phage 
clones during recirculation and allows the targeting of perivascular antigens. 
Further, since the in vivo selection guarantees the accessibility of the antigen in 
physiological conditions, it confirms the validity and potential of the selected scFv 
clone. In this regard, a scFv antibody fragment targeting the extra-domain A of 
fibronectin has been recently developed for RA synovium targeting (347). This 
antibody has been conjugated with the anti-inflammatory IL-10, showing promising 
results in animal models of arthritis and is now in phase Ib clinical trial, confirming 
the therapeutic potential of extravascular targeted therapy (347, 381). 
Comparison between scFv A7 and other markers of vasculature lies outside 
of the primary aim of this project and was not pursued further. 
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Marker Vascular localisation Tissue specificity Cellular localisation 
CD31 Endothelium Ubiquitous Membrane 
CD34 Endothelium Ubiquitous Membrane 
vWF Endothelium Ubiquitous Cytosol/soluble 
NG2 Pericytes Ubiquitous Membrane 
Desmin 
Pericytes 
Smooth muscle cells 
Ubiquitous Cytosol 
α-smooth muscle 
actin 
Pericytes 
Smooth muscle cells 
Ubiquitous Cytosol 
Smoothelin Smooth muscle cells Ubiquitous Cytosol 
Endosialin 
Pericytes 
Fibroblasts 
Ubiquitous Membrane 
scFv A7 
target antigen 
Pericytes 
Smooth muscle cells 
Arthritic synovium Cytosol/Membrane 
Table 7.2 Expression profile of best established vascular marker 
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7.1.3 Identification of scFv A7 target antigen 
From the data presented in chapter 4 and discussed in the above section, it 
is evident that scFv A7 and the target antigen may have potential as a therapeutic 
and/or diagnostic tool. In a scenario such as rheumatoid arthritis in which a specific 
and selective marker is not yet available, the identification of a tissue and disease 
specific antigen may have a profound impact. Unlike general antibody development 
strategies in which animal hosts are immunised with a known antigen to promote 
specific immunoglobulin production, this project started with the isolation of a scFv 
antibody from an in vivo screening. Although this strategy allowed the isolation of 
an antibody fragment with specificity for the natural environment of the target 
organ, the target antigen remains unknown. It is therefore one of the primary goals 
of this project to identify this antigen. 
Scarce availability of RA and OA synovium has been a limiting factor in the 
use of the diseased tissue as the primary source of the antigen. However, the data 
described in chapter 5 show a defined perivascular staining in the synovium, 
representative of only a minor percentage of the total tissue. In this light, isolation 
of the antigen from tissue protein extracts might be limited by the target protein 
concentration. Cell lines were subsequently screened for antigen expression, in 
order to identify a suitable line to use as source of expressed protein to be applied 
to the conventional proteomic approaches. PC3 and IE7 cell lines showed reactivity 
with scFv A7 on the cell surface (although only on a minor percentage of the total 
population) and in the intracellular compartment. It is important to bear in mind 
that protein expression pattern can be altered following in vitro culturing conditions 
as a result of extrapolation from the three dimensional context of the native tissue 
(301, 302). Screening of umbilical cord tissue sections indeed proved the absence of 
endothelial staining with scFv A7 as was detected in HUVEC derived IE7 cell line. 
Interestingly, vascular staining was detected in in the perivascular compartment of 
the umbilical cord vein which may suggest that the target antigen for A7 displays 
the properties of an oncofoetal protein reactivated in disease conditions. Primary 
RA synovial fibrablasts were also found to be positive for scFv A7, providing an 
antigen source closely related to the pathology. 
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The classical proteomic approach using multiple detergents to enrich for 
specific class of proteins, followed by SDS-PAGE resolution and Western blotting, 
failed to provide a clear antigen candidate due to the presence of background 
bands detectable also with the control antibody. Furthermore, an attempt to enrich 
for the target antigen using IP pull-down, followed by SDS-PAGE resolution and 
Western blotting, did not shown a detectable reactive band. The requirement of a 
conformational epitope for efficient antibody-antigen binding may be the reason 
for the failure of the Western blot approach. Sypro® ruby protein gel stain in SDS-
PAGE resolved proteins following IP, could overcome the necessity of the antibody 
dependent detection in Western blot by marking all protein content and detect 
enrichment of a specific antigen. However, no protein enrichment was detected, 
suggesting low concentration of the target antigen in the cell lysate. 
The identification of a lysis buffer that showed scFv A7 reactivity when 
tested in ELISA, provided the necessary confidence for pursuing the IP strategy 
using the additional advantage given by the developed IgG-like format of A7. In this 
approach, protein A or chemically coupled beads were used to capture the A7 
antibody followed by incubation with the cell lysate and analysed in Sypro® ruby 
stained SDS-PAGE. Despite the increased avidity of the IgG-like format compared to 
the scFv molecule, no clear enrichment was detected. Some bands were showing 
increased intensity compared to the control IP and may therefore deserve further 
investigation. The IP procedure mirrors what happens in vivo between antibody and 
target antigen, forming immune-complexes with stability dependent on affinity and 
avidity effects between the two molecules. Surprisingly, only a minor percentage of 
commercial antibodies are able to efficiently immuno-precipitate when not 
developed for this purpose. In addition, the scFv A7 antibody isolated via phage 
display was not affinity maturated and it did not appear to have a high affinity 
interaction. This may be the reason why despite the increased avidity an antigen 
pull-down was not achieved. Since the antibody showed a strong staining of the cell 
surface in RASF, a possible solution could be to cross-link the antibody to the 
antigen directly on the cell surface using the BS3 cross-linking reagent prior to cell 
lysis and analyse the shift in size of the A7 antibody. Cross-linking the antibody to 
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the target will prevent fast dissociation and retain the antigen during IP procedure. 
A possible drawback is the concomitant cross-linking of adjacent proteins, 
potentially resulting in a confounding picture when analysed by SDS-PAGE. A more 
refined strategy could be the use of sulfo-SBED Biotin (sulfo-N-hydroxysuccinimidyl-
2-(6-[biotinamido]-2-(p-azido benzamido)-hexanoamido) ethyl-1,3'-
dithioproprionate) (382, 383). Sulfo-SBED biotin conjugated antibodies can be 
incubated with the cell target or protein lysates to stimulate binding. When 
exposed to UV light, the biotin is transferred to the bound protein within a 20 Å 
distance, reducing non-specific and broad cross-linking. The antibody-sulfo-SBED-
biotin-antigen complex can then be disassembled in reducing conditions, leaving 
the biotin attached to the target antigen. The protein can then be easily detected in 
western blot using HRP coupled streptavidin.  
cDNA library screening was also adopted for isolation of A7 target antigen 
using phage display technology. The library employed was not derived from 
synovium but rather from colon carcinoma, lung fibroblasts and pancreatic cells, 
and was shown to express nearly 18000 human genes (241). The use of phage 
display for target antigen screening was deemed possible by the retention of A7 
staining in IE7 cells treated for glycosylation inhibition. The outcome of the first 
phage screening indicated LTBP2 as a putative target antigen for scFv A7. 
Subsequent validation of the antigen in ELISA as a soluble protein or using a HEK-
293 trans-membrane expression failed to confirm the specificity. A second selection 
on scFv A7 and A7 scFv-Fc antibody provided alternative candidates, with 
GABARAPL1 and MLF2 as the most represented clones. However, phage ELISA assay 
showed contradicting results and since no correlation with arthritic synovium 
appeared evident the validation was not continued. Under-representation of the 
total phage output could be a reason for the failure of this technique. Massive 
sequencing using deep sequencing systems could potentially identify previously 
missed clones (241). As an alternative, the yeast-two-hybrid system could be used 
for the same purpose. Although the general principle remains the same, the use of 
a eukaryotic system would allow the screening of more complex proteins. The main 
concern however, is the efficient folding of the scFv antibody in the cytosolic 
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compartment, which may impair the binding capacity of the molecule. In the 
literature the successful use of this system for the identification of scFv antibody 
targets has been reported, providing a proof of concept for the intended 
application (297, 298). The limiting step for these techniques comes down to the 
cDNA library used. For this reason, the development of an arthritic synovium library 
could be very beneficial and many companies now offer custom library 
development as a service.  
Further, use of synthetic protein microarrays could be useful for target 
identification and have been successfully employed for antibody profiling in 
autoimmune diseases (299, 300). However, since protein arrays are able to house 
fewer proteins than the ones expressed by cDNA libraries, the protein content 
needs to be carefully selected and tailored to the necessity of each particular 
screening. Commercially available protein arrays usually contain a broad spectrum 
of human proteins and can be customised according to personal requests. Synovial 
proteome microarrays have been described in the literature (299), containing 
known common autoantigens, including citrullinated forms, and abundant synovial 
antigens. The use of such arrays may provide a more disease oriented assay and 
increase the chances of identifying the interacting protein. 
As described in section 7.1.2, the current vascular and synovial markers do 
not fit with the scFv A7 staining distribution across the synovium and other tissues. 
A literature survey however, unveiled a yet unknown protein with strikingly similar 
tissue distribution to the A7 antibody (315). This protein is known as the product of 
the C19 ORF 10 gene and has been shown to be overexpressed in RA and OA 
synovium. This protein represented the optimal candidate for the A7 target 
antigen. Validation of the antigen using expression of soluble protein in HEK-293T 
or as a trans-membrane protein has been controversial. Additional experiments 
need to be performed in order to clearly define whether this protein represents the 
long sought target. Specifically, expression of the protein in soluble recombinant 
format will allow the testing in ELISA to determine antibody binding affinity and 
could be used in competitive assays in IHC on RA synovium to show inhibition of A7 
targeting capacity. 
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The failing of the proteomic approaches and library screening performed so 
far can be attributed to low affinity of the antibody, high false-positive results due 
to non-specific interactions or to false-negative results due to low concentration of 
the target antigen in the lysates and testing material. However, the possibility 
remains that scFv A7 does not bind a protein but rather a lipid based molecule and 
therefore not detectable with conventional proteomic approach. Analysis of the 
lipidome in rheumatoid arthritis is not yet available but the capacity of lipids to act 
as autoantigens has been reported in autoimmune diseases (384). Further 
investigation with total lipid extract from cell lines, followed by thin layer 
chromatography and antibody probing could provide insights into whether the A7 
antibody binds lipids. 
In conclusion, the identification of the A7 target antigen did not provide a 
clear answer with the conventional proteomic approaches. Nonetheless, the 
isolation of the antigen remains a pivotal point in the development of A7 as a 
therapeutic tool and will be further pursued. 
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7.1.4 Development of a novel tissue specific therapeutic 
 Development of tissue and/or disease selective drugs represents a unique 
opportunity to increase pharmaceutical potency and reduce systemic side effects. 
The possible strategies involve the identification of a molecule able to selectively 
inhibit the biological function of the target antigen or the isolation of a molecule 
with no direct effect but with the capacity to be used for targeted delivery 
approaches. Conceptually these two strategies are fundamentally different, with 
the first aiming at the development of an active compound with intrinsic 
therapeutic capacities, while the latter is aimed at the development of a molecule 
able to selectively localise in the target organ. In the latter strategy therefore, the 
effector function is delegated to a second molecule. This aspect confers a high 
versatility to the targeting agent. Imaging is one of the possible applications of a 
targeting agent, via conjugation with radionuclides, fluorophores or magnetic 
nanoparticles. For this purpose, the scFv format appears more suited for the task, 
due to the small size and short in vivo half-life which guarantees fast clearance and 
deep tissue penetration, translating into low systemic exposure (357, 359, 385). For 
therapeutic applications, targeting antibodies can be conjugated with a vast variety 
of effector moieties, including radionuclides, cytokines, loaded liposomes, active or 
pro-drugs, photosensitizers or active proteins such as full IgG or derivatives (386). 
Of note is the recent development of scFv antibodies directed towards splicing 
variants of fibronectin, specifically extradomain (ED) A and B, that have been 
successfully conjugated with effector molecules, retaining the targeting capacities. 
The L19 clone directed against the EDB was conjugated to IL-2 and TNF displaying 
potent anti-tumour activity in animal models and are currently in clinical 
development phase I and II (386-388). Furthermore, conjugation with 
photosensitizer agents demonstrated selective vascular occlusion as a result of 
treatment with red light in rodents with subcutaneous tumours (389). The F8 clone 
directed against the EDA was conjugated with IL-10, showing significant reduction 
of arthritis in CIA mouse models (347). More recently our group and collaborators 
demonstrated the successful delivery of IL-4 in vivo using a synovium targeting 
peptide in the xenograft SCID mouse model, and the selective accumulation of an 
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anti-C5 antibody fused to the same synovium targeting peptide in affected joints of 
rodent models of arthritis, further confirming the validity of targeted therapy in an 
arthritic context (136, 390). 
The A7 antibody described in this thesis was isolated in vivo with the 
purpose of identifying a scFv antibody with specificity for the microvasculature of 
human arthritic synovium. Indeed, the scFv A7 and A7 scFv-Fc antibodies proved to 
specifically target the vasculature in the arthritic synovium without detectable 
reactivity with normal human tissues or other disease conditions. In this light, the 
A7 displays all the requirements for a targeted delivery tool applied to rheumatoid 
and osteoarthritis. This is especially true since one of the key characteristic of a 
targeting agent is the accessibility of the target antigen when challenged in vivo. 
This feature is intrinsic in the in vivo isolation strategy adopted for the phage 
display screening and further confirmed in in vivo recirculation assays performed 
with the soluble scFv A7 (230). As a proof of concept and evaluate the capacity of 
A7 to act as a targeting molecule and develop a novel therapeutic agent in the 
treatment of rheumatoid arthritis, the A7 antibody was combined to the gold 
standard for anti-TNF therapeutics Adalimumab using a bispecific antibody strategy.   
Antibodies are still considered the molecules of choice for targeting 
applications due to the natural binding properties and established manufacturing 
processes. In addition, development of antibody screening strategies such as scFv 
phage display, allows fast isolation of clones of interest that can be readily 
engineered to introduce specific functions and properties. In this context, the 
bispecific antibody format combines the binding specificities of two independent 
antibodies, maintaining the structural and functional characteristics of a natural IgG 
molecule. As already described in section 1.3.3, bispecific antibodies are acquiring 
increasing interest from pharmaceutical companies with one FDA approved 
antibody and many other currently in clinical trials (205). Since a standard 
asymmetric IgG bispecific antibody combines two independent antibodies, two 
main issues need to be addressed to ensure optimal antibody production: correct 
light chain association and correct heavy chain heterodimerisation. Regarding the 
first aspect, the correct pairing of heavy and light chains for both components is 
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pivotal to the formation of functional molecules. Use of species restricted heavy-
light chain pairing can provide better outcomes but it is not applicable to fully 
human antibodies (210). Another strategy involves the combination of antibodies 
with common light chains, overcoming the problem of erroneous pairing but with 
the shortcoming of not being applicable to pre-existing antibodies and requiring 
development of ad hoc molecules (391). Alternatively, Roche laboratories 
developed a platform called CrossMab characterised by CH1-CL domain inversion 
on one arm, providing a better pairing outcome with reduced non-functional side 
products (392). For the purpose of this study, the format adopted was the scFv-Fc 
IgG-like antibody which confers advantages over the conventional IgG structure by 
overcoming the issues addressed above. Specifically, by using scFv domains, the 
light and heavy variable regions are linked in order to prevent chain mis-pair and 
provide only functional antibodies with the desired specificity. In addition, the 
expression of heavy and light chains in a single peptide circumvents the need to 
ensure a 1:1 ratio between the expressed heavy and light chain. To address the 
second issue, the developed bispecific antibody carried the Y407T and T366Y 
mutations in the CH3 domains, resulting in preferential heavy chain 
heterodimerisation due to steric instability of the homodimeric counterparts (211). 
Although this technology was developed in the late 1990’s and is not therefore the 
most innovative strategy, it has the advantage of requiring minimal alteration of the 
Fc region, maintaining unaltered the Fc effector functions (211). In our hands this 
method allowed an efficient heterodimerisation of 85% following a simple 
purification step.  
Towards the development of a novel bispecific therapeutic for the 
treatment of rheumatoid arthritis and as a proof of concept for targeted delivery 
using A7, the anti-TNF antibody Adalimumab was chosen as the effector moiety to 
be coupled to A7. Adalimumab is a potent biologic agent in the treatment of 
rheumatoid arthritis characterised by considerable clinical success (described in 
section 1.3.2). However, high treatment cost, safety concerns and a high number of 
non-responder patients, indicate the need of improved therapeutic agents. In this 
light, the bispecific antibody developed in this work may provide a better safety 
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profile by reducing systemic exposure, increase pharmacological potency via 
accumulation of the active molecule at the site of interest and as a consequence 
reduced administration doses and related costs. A second important aspect 
considered while choosing Adalimumab resides on the fact that Adalimumab was 
originally isolated from phage display in scFv format (324). Reports in the literature 
show that Adalimumab maintains binding and kinetic properties as a scFv when 
compared to the commercial IgG format (336, 337), providing supporting evidence 
for the bispecific antibody design described here. The scFv-Fc format of 
Adalimumab showed TNF binding capacity with similar EC50 values and kinetic 
properties compared to the original antibody. In addition, the scFv-Fc antibody was 
biologically active rescuing L-929 cells from TNF induced cytotoxicity with an IC50 
value closely comparable to the parent antibody. The bispecific antibody 
A7/Adalimumab was readily produced by CHO-s cell line and showed both TNF and 
human arthritic synovium binding specificity. As already mentioned in section 6.4, 
the bispecific but monovalent nature of the A7/Adalimumab antibody is likely to be 
the reason for the slightly elevated IC50 compared to the commercial Adalimumab 
detected in the TNF cytotoxicity assay. It may be argued therefore that the reduced 
inhibitory efficiency of the bispecific antibody will work against it in vivo, possibly 
resulting in a reduced therapeutic efficacy. However, the synovial homing 
properties of A7 may provide a gain of function to the molecule and allow the 
selective accumulation in the site of interest, as has been reported for other 
synovium homing constructs (136, 390), conferring increased pharmacological 
activity by reducing the systemic and non-specific distribution. 
Bispecific antibodies reveal huge potential for therapeutic applications with 
an estimated market of 4.4 billion USD to be reached in the next 10 years (393).  In 
this light, the bispecific antibody developed in this project may provide proof of 
concept for antibody based delivery in arthritic synovium with the final aim of 
improving available therapeutics by addressing the safety concerns characterising 
anti-cytokine biologics. The A7/Adalimumab bispecific antibody construct showed 
unaltered TNF blocking capacity and synovial specificity that may allow reduction in 
the dosage and/or administration frequency, with the ultimate goal to reduce the 
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systemic exposure, achieve a better therapeutic index and decreasing health care 
costs.  
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7.2 Future directions 
 Identification and isolation of the target antigen remains a primary goal of 
the project. Standard proteomic approaches described in this work failed to 
produce reliable results, despite the presence of A7 reactivity on cell lines detected 
using immunofluorescent staining. Future work towards this goal can follow two 
main paths, involving engineering of the A7 antibody and more refined proteomic 
strategies. 
It is possible the affinity of scFv A7 for its target antigen may be the reason 
for the difficulties encountered in antigen identification. Conversion into an IgG-like 
format would have provided an increase in functional affinity (i.e. avidity) via 
formation of a bivalent molecule. However, the increased avidity did not result in a 
stronger binding to synovial tissues and subsequently did not translate into a more 
efficient IP. Although structurally similar, scFv-Fc and IgG differ mainly for the 
absence of the CL-CH1 region in the former molecule. This region is necessary for 
heavy and light chain stability via formation of a disulphide bond (153, 252) but can 
be efficiently substituted by a short peptide linking the VL and VH regions, without 
altering the Fc effector functions (234). This substitution results in approximately 30 
kDa size reduction and shortened arm span. This last aspect may be relevant in the 
context of antigen binding when high clearance is required to accommodate the 
antigen. In this context, a native IgG format might provide the necessary flexibility 
to allow simultaneous binding of both arms and increase binding capacity. scFv 
conversion in IgG format is a well-established procedure commonly adopted for 
scFv antibodies to be developed into therapeutic agents (394). Specifically, 
commercially available vectors can be employed to fuse the VL and VH regions to 
the CL and CH1-CH2-CH3 domains respectively. This strategy however, will 
substantially alter the Fv structure and, as performed for the scFv-Fc construct, 
careful screenings on reactive synovial tissue will be required to confirm 
preservation of specificity. 
As already mentioned in section 7.1.1, the scFv A7 carries two putative N-
glycosylation sequences located in the CDR2 and CDR3 regions. Glycosylation in the 
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variable region is fairly common among natural IgGs, preferentially in the CDR2 
region, and can introduce unforeseen variables in the antibody properties, 
influencing binding capacity and pharmacokinetics (362). Since the scFv antibody 
was produce in bacterial hosts, the N-glycosylation was initially not incorporated in 
the molecule but became evident in the scFv-Fc construct expressed in CHO cells, 
characterised by a higher apparent molecular weight when compared to similar 
constructs. The expected improved performances of the scFv-Fc format may 
therefore be partially neutralised by the presence of glycosylation in the site of 
antigen interaction. In order to assess the influence of the two glycosylation in the 
binding capacity, the A7 scFv-Fc could be treated enzymatically with PNGase F and 
compared with the untreated antibody. However, enzymatic treatment is subjected 
to site accessibility and may result in uneven cleavage. A second potential strategy 
may be site directed mutagenesis in order to substitute the asparagine residue and 
disrupt the consensus sequence. The IgG variable domains, especially the CDR 
regions, are extremely delicate and small changes in the amino acidic sequence can 
substantially alter binding capacity and antigen specificity. This key aspect is 
exploited by B cells themselves during affinity maturation in a process defined as 
somatic hypermutation (395). In this specific case however, the binding to the 
target antigen needs to be preserved in order to maintain synovial targeting. A 
possible way of tackling this problem would be to apply conservative mutations to 
the consensus sequence, removing key amino acids and replacing them with amino 
acids showing either similar chemical properties or similar steric burden (396). 
Specifically, the asparagine, present in the NXS/T sequence, is a polar uncharged 
amino acid in physiological conditions, containing an amine group in the side chain. 
This amino acid could be substituted with glutamine without altering its chemical 
properties (396). Glutamine is also a polar uncharged amino acid with an amine 
group but carries an extra methylene group compared to asparagine. In a less 
conservative approach, the asparagine could be substituted with the closely related 
aspartic acid, with the advantage of maintaining a similar side chain size. However, 
this substitution would introduce a negative charge in the CDR region with potential 
deleterious effects. 
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Once identified the target molecule, the antibody could be further 
optimised via affinity maturation to obtain a reagent with both high affinity and 
high specificity. In order to do so, the antibody could undergo random mutagenesis 
using error-prone PCR (397) or look-through mutagenesis in which primers are 
designed in order to constitute a small library with random substitutions with 
selected amino acids in the CDR regions (337). The newly created libraries can then 
be screened using display techniques, such as phage display, ribosome display or 
yeast surface display, to detect clones with improved binding kinetics (362).  
Indeed the observed low affinity may be related to the inefficient IP of 
scFvA7 and A7 scFv-Fc when tested with protein extracts from reactive cell lines. As 
introduced in section 7.1.3, chemically cross-linking the antibody to the antigen on 
the cell surface may preserve the immune-complex and facilitate the isolation of 
the target antigen from the total protein pool. However, in order to limit the cross-
linking to the nearest protein, the sulfo-SBED biotin reagent with a 20 Å range of 
interaction would guarantee a minimum degree of non-specific cross-linking and 
provide more robust results (382, 383). The possibility of detaching the antibody 
using reducing conditions would allow the identification of the interacting protein 
free from the immune-complex. Alternatively, the cross-linking could be performed 
on synovial tissue sections, preferably non-fixed frozen sections, in order to adopt 
the best possible source of target antigen. In this instance, the conjugated antibody 
could be incubated with the tissue section, similarly to the way in which IHC 
staining is performed, and cross-linked using UV light. Following efficient cross-
linking, the tissue would be scraped from the glass slide and solubilised, obtaining 
total protein extract and simultaneously releasing the antibody from the target. The 
presence of biotinylated target antigen could then be detected by Western blot 
with streptavidin-HRP reagent. Finally, identity of the putative interacting antigen 
would be identified using mass spectrometry following resolution of protein 
content in 2D gel electrophoresis and excision of relevant protein spot (398). 
Screening of protein expression libraries would provide an alternative route 
for target antigen identification. Screening of a phage expression library however 
was not successful and failed to reveal reliable target candidates (described in 
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section 5.3). The main limitation in such an approach relies on the library used. 
Indeed, in the absence of a rheumatoid synovial library, the use of a human 
placental library would increase the chances of identifying the A7 target since it 
represents the most generic library available and the application has been proven in 
several studies (399, 400). Screening of protein microarrays could offer a valid 
alternative, with the advantage of the availability of human synovial arrays. 
Specifically, a human rheumatoid synovial protein array has been developed at 
Stanford University in Professor Robinson’s laboratory and could be used to identify 
reacting proteins with A7 antibody (299). This strategy could provide a more 
disease oriented approach although limited by relatively low protein diversity and a 
restriction to known antigens. 
Finally, in order to evaluate the biological activity of the bispecific 
A7/Adalimumab antibody in an in vivo context, the xenograft SCID mouse model of 
arthritis could be employed in order to mimic the human arthritic synovial 
environment (231, 232). Since the scFv A7 antibody failed to demonstrate reactivity 
in the CIA mouse model, the human synovial milieu in this approach would provide 
the best chances of demonstrate biological functionality of the A7 antibody. 
Specifically, the bispecific A7/Adalimumab antibody would be injected via the tail 
vein in SCID mice bearing human synovial xenograft. Subsequently, the synovial 
xenografts will be harvested, evaluating the effect on cellularity within the tissue, 
processed for IHC to detect the presence of antibody and for QT-PCR to analyse 
gene expression of pro-inflammatory cytokines such as TNFα, IL-1β and IL-6 (73), an 
approach which has already proved successful in testing the effects of Infliximab 
(data not published). In parallel, the bispecific E2/Adalimumab and A7 scFv-Fc 
antibodies could be used as negative control molecules and the original 
Adalimumab antibody would serve as a positive control, collectively allowing a 
direct comparison of the in vivo biological efficacy of the newly developed bispecific 
antibody and the gold standard TNF blocker therapeutic.  
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7.3 Final conclusion 
 Rheumatoid arthritis is a relatively common disease worldwide with 
substantial impact on the life of affected people (18). With a 1% incidence rate it 
also represents a significant market share with growing interest and investment 
from pharmaceutical companies (137). However, despite the advent of biological 
agents in the management of rheumatoid arthritis, true treatment-free remission is 
still difficult to achieve and 20-40% of the patients do not respond to the available 
therapeutics (138, 139). Furthermore, the biologic agents currently approved are 
targeting inflammatory cytokines or immune cells, in an attempt to dampen the 
inflammatory response and limit the damages that occur during chronic 
inflammation. At the same time however, targeting the downstream effects rather 
than the leading cause of the disease exposes the patients to higher risk of 
developing infections, due to the systemic activity of such therapeutic agents. In 
this light there is therefore the need to develop new compounds with higher 
potency, broader efficacy and improved safety profiles.  
 In this thesis the characterisation of a scFv antibody isolated following in 
vivo phage display selection is described. The scFv A7 showed specificity for the 
human arthritic synovium with no detectable reactivity with normal synovium or 
other human tissues, suggesting that the target molecule for A7 may have 
applications as a biomarker and/or immunotherapeutic target in arthritis. The 
selective arthritic synovium binding capacity confers to the A7 antibody unique 
properties that can be exploited for the development of diagnostic or therapeutic 
agents. Towards this end, a novel bispecific antibody combining the anti-TNF 
properties of Adalimumab and the synovium targeting capacity of A7 was 
developed, providing proof of concept for antibody based pharmaco-delivery of 
existing therapeutics in an arthritic context, potentially allowing reduction in the 
dosage and/or administration frequency, with the ultimate goal of reducing the 
systemic exposure, achieve better therapeutic index and decreasing related health 
care costs. 
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With growing interest from pharmaceutical companies over bispecific 
antibody constructs (393), mostly deriving from the success obtained in the field of 
cancer therapy (205), the work presented in this thesis represents an innovative 
therapeutic development with potential impact in the therapy of rheumatoid 
arthritis. 
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Development of a Novel Recombinant Biotherapeutic With
Applications in Targeted Therapy of Human Arthritis
Panagiotis Kamperidis,1 Tahereh Kamalati,1 Mathieu Ferrari,1 Margaret Jones,1 Toby Garrood,1
Malcolm D. Smith,2 Soraya Diez-Posada,3 Chris Hughes,1 Ciara Finucane,1 Stephen Mather,1
Ahuva Nissim,1 Andrew J. T. George,4 and Costantino Pitzalis1
Objective. To isolate recombinant antibodies with
specificity for human arthritic synovium and to develop
targeting reagents with joint-specific delivery capacity
for therapeutic and/or diagnostic applications.
Methods. In vivo single-chain Fv (scFv) antibody
phage display screening using a human synovial xeno-
graft model was used to isolate antibodies specific to the
microvasculature of human arthritic synovium. Single-
chain Fv antibody tissue-specific reactivity was assessed
by immunostaining of synovial tissues from normal
controls and from patients with rheumatoid arthritis
and osteoarthritis, normal human tissue arrays, and
tissues from other patients with inflammatory diseases
displaying neovasculogenesis. In vivo scFv antibody
tissue-specific targeting capacity was examined in the
human synovial xenograft model using both 125I-labeled
and biotinylated antibody.
Results. We isolated a novel recombinant human
antibody, scFv A7, with specificity for the microvascu-
lature of human arthritic synovium. We showed that
in vivo, this antibody could efficiently target human
synovial microvasculature in SCID mice transplanted
with human arthritic synovial xenografts. Our results
demonstrated that scFv A7 antibody had no reactivity
with the microvasculature or with other cellular compo-
nents found in a comprehensive range of normal human
tissues including normal human synovium. Further, we
showed that the reactivity of the scFv A7 antibody was
not a common feature of neovasculogenesis associated
with chronic inflammatory conditions.
Conclusion. Here we report for the first time the
identification of an scFv antibody, A7, that specifically
recognizes an epitope expressed in the microvasculature
of human arthritic synovium and that has the potential
to be developed as a joint-specific pharmaceutical.
Rheumatoid arthritis (RA) is a chronic inflam-
matory disease that principally affects synovial joints,
causing disability with significant associated morbidity
and mortality (1,2). In RA, the synovium becomes
hyperplastic and locally invasive at the interface between
the cartilage and bone, resulting in the destruction of
articular cartilage and subchondral bone, leading to joint
damage and disability. Notably, in RA, the synovium
becomes heavily infiltrated by T and B cells, plasma
cells, and monocytes through the development of new
blood vessels (angiogenesis) (3,4). It is now clear that
synovial angiogenesis contributes significantly to disease
pathogenesis and progression (5,6) and may precede
other pathologic features of RA, since synovial hyper-
cellularity is sustained by an increase in the number
and density of synovial blood vessels (6–8). Further, not
only angiogenesis but also vasculogenesis may contrib-
ute to the increased vascularity observed in the RA
synovium (9), making the newly formed blood vessels a
particularly attractive therapeutic target for the manage-
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ment of inflammatory arthritis (10). In support of this,
blockade of inflammatory neovascularization has been
shown to lead to the suppression of synovial inflamma-
tion and proliferation and to an attenuation of synovitis
in RA (11).
The treatment of this condition has been trans-
formed in the last decade by the use of recombinant
antibodies targeting proinflammatory cytokines such as
tumor necrosis factor  (TNF) (12). However, despite
the obvious impact of such therapies, 20–40% of pa-
tients do not respond (13), sustained and high-
magnitude clinical response is achieved only in a minor-
ity of cases (14), and prolonged treatment-free remission
has not been obtained. Additionally, these therapies
exhibit several adverse side effects that make persistent
administration undesirable (14–16). Therefore, the de-
velopment of new agents that offer greater efficacy and
improved safety profiles remains an important goal for
the treatment of RA. In this context, tissue-specific drug
delivery systems for targeting and improving the reten-
tion of bioactive agents are particularly important, as
they could be used to achieve higher levels of pharma-
ceuticals at the site of therapeutic interference and thus
prolong local activity within the joint, thereby reducing
systemic exposure and toxicity. Recombinant, single-
chain antibodies lend themselves well to the develop-
ment of such targeted pharmacodelivery strategies.
To date, joint-specific targeting for the treatment
of arthritic disease remains an unmet clinical goal. In
order to address this, we have developed a synovial
xenograft model in SCID mice where functional vascular
anastomoses allow the delivery of agents targeting hu-
man synovial tissue to be assessed in vivo (17). Previ-
ously, we successfully used this model for in vivo peptide
phage display and imaging of synovial tissue (18,19).
Here, we have extended the use of this model system to
carry out in vivo single-chain Fv (scFv) antibody phage
display screening, in order to identify scFv antibody
clones with specificity for the human synovial vascula-
ture of the xenografts. We report for the first time the
isolation and characterization of an scFv antibody (A7)
that exhibits specificity for the microvasculature of hu-
man arthritic synovial tissue, and we discuss its potential
application as an innovative recombinant pharmaceuti-
cal agent for the treatment of arthritic diseases.
MATERIALS AND METHODS
Human tissue transplantation into SCID mice. Beige
SCID CB17 mice ages 4–10 weeks were used in this study.
Human tissues (synovium and skin) were transplanted sub-
cutaneously in a dorsal position distal to the shoulder joints
(2 transplants per animal) as previously described (20). Mice
were inspected daily, and animal work was performed under
a Project License (PPL 70-6109). Human synovial tissue was
obtained from RA patients or osteoarthritis (OA) patients
undergoing joint replacement. Human skin tissue was obtained
from patients undergoing cosmetic surgery. Informed consent
was obtained from all patients. Additionally, ethical approval
to use human synovial and skin tissue for research purposes
was obtained from the Ethics Committee (Local Research
Ethics Committee no. 05/Q0703/198).
In vivo selection of synovium-specific scFv phage. The
human scFv libraries I  J (Tomlinson I  J) (21) were kindly
provided by Dr. Greg Winter (Medical Research Council
Centre for Protein Engineering, Cambridge, UK). Synovium-
specific phage was isolated following 4 rounds of enrichment in
SCID mice carrying human arthritic synovial tissue and skin
tissue xenografts (18, 19). Selection and enrichment were
monitored by phage titration, and the integrity of scFv coding
regions from phage from the final round of selection was
assessed by polymerase chain reaction using LMB3 and pHEN
seq primers (see below). Clones that showed expression of
full-length scFv fragments were used to infect the nonsuppres-
sor strain Escherichia coli HB2151 for the production of
soluble scFv protein. One hundred colonies were selected and
analyzed for scFv expression by enzyme-linked immunosor-
bent assay for protein A and protein L binding (22).
DNA sequence analysis of scFv coding regions. The
DNA sequences encoding the scFv inserts of phage clones
from the final round of selection were determined using the
vector primers LMB3 (CAGGAAACAGCTATGAC) and
pHEN seq (CTATGCGGCCCCATTCA) (21,23). Sequencing
was performed using the Big Dye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems) on an ABI PRISM 3130
Genetic analyzer.
Production of soluble scFv antibodies. Single-chain Fv
fragments encoded by phage from the final round of selection
were expressed in E coli HB2151 as soluble, secreted pro-
teins and purified from bacterial culture supernatants by
affinity chromatography using protein A–Sepharose Fast
Flow Resin (GE Healthcare), as described previously (24).
Purified antibodies were analyzed by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and size-exclusion chroma-
tography on Superdex 75 HR10/30 columns (Amersham Bio-
sciences).
Biotinylation of scFv antibodies. Single-chain Fv anti-
bodies were biotinylated using the EZ-Link Sulfo-NHS-SS-
Biotinylation kit (Perbio Science). Briefly, purified scFv pro-
tein was diluted in 0.5–2 ml phosphate buffered saline (PBS),
added to a 20-fold molar excess of 10 mM Sulfo-NHS-SS-
Biotin, and incubated on ice for 1 hour. Biotinylated proteins
were subsequently purified using spin-column chromatography
(Perbio Science) according to the manufacturer’s instructions.
Iodination of scFv antibodies. Single-chain Fv antibody
fragments were radiolabeled with Na125I using the iodogen
method (25). Iodination reaction tubes precoated with iodogen
were used according to the manufacturer’s instructions (Perbio
Science). Typically, 25 g of purified scFv in 150 l of PBS
was radiolabeled to specific activities of 0.15–0.2 MBq/g. The
efficiency of iodination was evaluated by instant thin-layer
chromatography and typically found to be 90%. The purity
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of the labeled scFv was determined by size-exclusion high-
performance liquid chromatography.
In vivo localization of soluble scFv A7 antibody. Two
SCID mice bearing double xenografts of human arthritic
synovial and skin tissues (2 arthritic synovium and 2 human
skin grafts per animal) were injected with 6 g of biotinylated
scFv A7 four weeks after transplantation. Biotinylated anti–
hen egg lysozyme antibody, scFv HEL (22), was used as a
negative control. The biotinylated antibody fragments were
administered via the tail vein in a total volume of 200 l and
were allowed to circulate for 15 minutes, after which time the
mice were perfused under terminal anesthesia. The human
grafts along with murine tissues were excised and immediately
snap-frozen in liquid nitrogen for histologic examination. The
tissue-specific localization of soluble scFv A7 was examined by
immunohistochemical detection of biotinylated antibody using
avidin–biotin–horseradish peroxidase complex (Dako).
In vivo targeting capacity of iodinated scFv A7 anti-
body. Five double-transplanted SCID mice (2 arthritic syno-
vium and 2 human skin grafts per animal) were injected with
iodinated scFv antibody 4 weeks following transplantation.
Each animal was administered an injection, via the tail vein, of
200 l sterile saline containing 1.25 g labeled scFv with a
specific activity of 0.16 MBq/g. Mice were killed 4 hours or 24
hours after injection, and grafts as well as mouse organs were
collected for gamma counting. The results were corrected for
tissue weight and background radioactivity in the blood pool
and expressed as a percentage of the total injected dose.
Iodinated scFv HEL was used as an untargeted scFv control.
Immunohistochemical analysis. Slide-mounted frozen
tissue sections were fixed in ice-cold acetone. Paraffin-
embedded tissues were dewaxed and subsequently treated with
proteinase K (Dako) for 4 minutes at room temperature for
antigen retrieval. Slides were stained with 1 g of biotinylated
scFv A7 and visualized with avidin–biotin–horseradish perox-
idase complex using 3,3-diaminobenzidine chromogen. The
presence of human blood vessels in tissue sections was visual-
ized using mouse anti-human von Willebrand factor (vWF)
(Dako), followed by a horseradish peroxidase–conjugated anti-
mouse antibody (Dako). Rabbit anti-mouse CD31 (BD Bio-
sciences) and rabbit anti-mouse CD34 (Cambridge Bioscience)
were used to detect mouse endothelial cells in murine tissues.
An anti–-smooth muscle actin antibody (Sigma) was used to
visualize the stromal component of the microvasculature.
Sections were counterstained with hematoxylin, mounted with
Depex mounting medium (Dako), and analyzed using a light
microscope (Olympus). Images were acquired with CellP Soft
Imaging System version 1.2 (Olympus).
Immunofluorescence analysis. Slide-mounted frozen
tissue sections were fixed in ice-cold acetone prior to antibody
staining. Biotinylated scFv A7 reactivity was detected with
Texas Red–conjugated NeutrAvidin (Invitrogen). Mouse anti-
human vWF, mouse anti-human CD31 (Sigma), and rabbit
anti-NG2 antibody (Millipore) reactivity was detected using
goat anti-mouse and goat anti-rabbit antibodies conjugated to
Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen). Sections were
subsequently mounted in fluorescent mounting media
(Vectashield) with DAPI nuclear counterstain (Vector) and
Figure 1. Immunohistochemical analysis of single-chain Fv (scFv) antibody reactivity with
human arthritic synovial tissue. The reactivity of scFv antibody (scFv A7) with sections of
human arthritic synovial and skin tissue was examined using biotinylated scFv A7. Biotinylated
scFv HEL was used as an antibody negative control. The presence of blood vessels in tissue
samples was visualized with anti-human von Willebrand factor (vWF) antibody. Biotinylated
scFv antibodies were detected with avidin–biotin–horseradish peroxidase (HRP) complex, while
anti-vWF antibody reactivity was detected using an HRP-labeled antibody. RA  rheumatoid
arthritis; OA  osteoarthritis. Bar  100 m.
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examined using an Axioskop 2 microscope (Carl Zeiss). Im-
ages were captured by an AxioCam digital color camera using
KS300 image analysis software (Carl Zeiss).
Pearson’s correlation coefficient analysis. Velocity 5.5
imaging software (PerkinElmer) was used to perform thresh-
olded Pearson’s correlation coefficient analysis of images in
order to accurately quantify and correlate overlap of image
pixels from 2 different channels (26). A value of 1 indicates
complete pixel-to-pixel overlap of the pixels from the 2 chosen
channels. A value of 0 indicates no overlap or correlation of
pixels from 2 different channels, and a value of 1 indicates
complete disparity/exclusion of pixels from the 2 channels that
have been compared.
Statistical analysis. Results are expressed as the
mean  SEM. Parametric analyses were performed by unpaired
2-tailed t-test using GraphPad Prism software.
RESULTS
Isolation of an scFv antibody with binding spec-
ificity for human arthritic synovial tissue. In order to
select scFv fragments targeting the human synovial
microvasculature, 4 cycles of in vivo selection using the
human scFv libraries I  J (Tomlinson I  J) (21) were
conducted using mice with dual xenografts of synovium
(target) and skin (control) tissues. The composition of
recovered scFv fragments in the final round of in vivo
selection was assessed by examining the ability of 100
phage-encoding full-length inserts to transduce bacteria
for secreted antibody protein expression. The function-
ality of these clones was further confirmed by demon-
strating secreted scFv binding to protein A and protein
L. Of these 100 clones, 24 expressed secreted scFv
antibody at high levels and were subsequently shown
to encode the same scFv sequence. Notably, this scFv
sequence had already been identified in a previous,
independent, in vivo screen of the Tomlinson library,
using the same synovial xenograft model system (results
not shown). Thus, clone A7, an scFv from the group of
24 identical clones from the final screen, which showed
robust soluble antibody expression (1 mg/100 ml bac-
terial culture), was chosen for further studies.
Soluble scFv A7 protein was purified as a mono-
meric protein and used in immunohistochemical analysis
to assess binding specificity in human RA and OA
synovial tissues in comparison to that of skin, the control
tissue used in the in vivo selection process. We examined
15 OA and 8 RA synovial tissue samples and 5 skin
samples. As shown in Figure 1, scFv A7 exhibited
specific and strong reactivity with the microvasculature
of OA and RA synovial tissue. Importantly, scFv A7
exhibited no detectable reactivity with control human
skin tissue. The control, nontargeted antibody scFv HEL
did not exhibit binding to either synovium or control skin
tissue samples.
Single-chain Fv A7 antibody specifically binds to
arthritic synovial microvasculature. Following the dem-
onstration that scFv A7 exhibits strong reactivity with
the microvasculature of arthritic synovial tissue, we
sought to determine which cell types within the micro-
vasculature were recognized by this antibody. To do this,
costaining of RA synovial tissues was performed using
scFv A7 and the 2 endothelial markers vWF and CD31,
and the pericyte-specific marker NG2. As shown in
Figure 2, there was no overlap in the pattern of staining
observed in RA tissue stained with scFv A7 and vWF or
CD31. However, costaining with scFv A7 and the peri-
cyte marker NG2 showed complete overlap in the pat-
Figure 2. Characterization of cellular reactivity of scFv A7 within
synovial microvasculature. The reactivity of biotinylated scFv A7 with
cellular components of synovial microvasculature was examined by
dual staining of frozen human synovial tissue from RA patients and
compared with staining for the endothelial markers vWF and CD31
and the pericyte-specific marker NG2. Bound scFv A7 was detected
using Texas Red–avidin conjugate. Binding of vWF, CD31, and NG2
was detected using Alexa Fluor 488– or Alexa Fluor 594–labeled
secondary antibodies (green and red, respectively). Bar  20 m. See
Figure 1 for definitions.
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tern of cellular staining observed. This demonstrates
that scFv A7 recognizes an epitope localized to pericytes
and the stromal component of the microvasculature of
RA synovium.
In order to increase the accuracy and level of
confidence about the degree of colocalization, we used
Pearson’s correlation coefficient to provide a numeric
and nonsubjective analysis (27). The Pearson correlation
ranges from 1 to 1, whereby a correlation of 1
indicates complete overlap of pixels from 2 different
channels. A value of 0 indicates no overlap, and a
correlation of 1 indicates complete pixel disparity/
exclusion between the 2 channels being compared. Our
Pearson’s colocalization analysis of scFv A7 reactivity
(red pixels) and CD31 reactivity (green pixels) resulted
in a Pearson’s correlation of 0.07, demonstrating no
colocalization of scFv A7 and CD31 reactivity. Similarly,
Pearson’s colocalization analysis of NG2 reactivity
(green pixels) and vWF reactivity (red pixels) resulted in
a Pearson’s correlation of 0.01, demonstrating no colo-
calization of NG2 and vWF reactivity. However, Pear-
son’s colocalization analysis of scFv A7 reactivity (red
pixels) and NG2 reactivity (green pixels) resulted in a
Pearson’s correlation of 0.6, demonstrating significant
colocalization of scFv A7 and NG2 reactivity.
Single-chain Fv A7 antibody retains synovial
specificity in vivo. In order to examine the specificity of
scFv A7 targeting in vivo, SCID mice bearing arthritic
synovium (test tissue) and human skin (control tissue)
xenografts were injected intravenously with biotinylated
scFv A7 or biotinylated scFv HEL (as a negative con-
trol). As shown in Figure 3, after in vivo circulation,
biotinylated scFv A7 could be detected in the human
synovial microvasculature by simply adding avidin–
biotin–horseradish peroxidase complex to xenograft sec-
tions. In contrast, scFv A7 reactivity was not observed
with control human skin tissue xenografts. Additionally,
no detectable reactivity was observed with the control
scFv HEL antibody (Figure 3). To confirm the vascular
reactivity of scFv A7 in the positive grafts and to exclude
the possibility that the negative staining observed in
human skin grafts and mouse tongue are not due to an
Figure 3. In vivo targeting of scFv A7 to human arthritic synovial microvasculature. The ability
of scFv A7 to localize to human arthritic synovial microvasculature in vivo was examined by
injecting biotinylated antibody into dual-transplanted SCID mice bearing human arthritic
synovial and human skin xenografts. Immunohistochemistry was used to assess the reactivity of
scFv A7 with the microvasculature in the recovered xenografts. Biotinylated scFv HEL was used
as an antibody negative control. Mouse tongue tissue was used to assess cross-reactivity of scFv
A7 antibody. The presence of microvasculature within human tissue was visualized with
anti-human vWF antibody, while anti-mouse CD31 was used for mouse tissue. Biotinylated scFv
antibodies were detected with avidin–biotin–HRP complex, while anti-vWF and anti-CD31
antibody reactivity was detected using an HRP-labeled antibody. Bar  100 m. See Figure 1
for definitions.
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absence of vasculature, all tissues were stained for
human vWF and/or mouse CD31 (Figure 3). No cross-
reactivity with host mouse tissues was observed, as
exemplified by examination of mouse tongue tissue,
where microvasculature was clearly visible (Figure 3).
Taken together, these data further confirm the
synovium-specific reactivity of the scFv A7 antibody and
its capacity to reach its target in vivo.
In vivo targeting of arthritic synovial tissue by
scFv A7. To quantitatively assess antibody tissue speci-
ficity in vivo, we examined the ability of iodinated scFv
A7 to target human synovial tissue xenografts. Iodinated
scFv HEL was used as a nontargeted control antibody,
while human skin was used as control xenograft tissue.
Figure 4 shows the tissue-to-blood ratio of the percent-
age of the injected dose localizing in each tissue at 4
hours and 24 hours. These data demonstrate that 4
hours following injection, 3-fold more radiolabeled scFv
A7 was localized to the human arthritic synovium xeno-
grafts than to the human skin xenografts. Further,
despite an apparent fall in overall activity of scFv A7
in the synovium at 24 hours, significant differential
reactivity was still observed when compared to skin at
this time point. Overall, these data further confirm that
the scFv A7 antibody retains the synovial targeting
specificity of the parental phage clone in vivo.
Single-chain Fv A7 reactivity in normal and
inflamed human tissues. In order to further investigate
scFv A7 binding specificity over and above the original
targeted tissues, we examined the reactivity of this
antibody using an array for a comprehensive range of
normal human tissues. As shown in Figure 5A, scFv A7
did not exhibit reactivity with the various cellular com-
ponents of the tissues represented on this array. In
particular, no detectable reactivity was seen with the
microvasculature of organs such as the adrenal gland,
ovary, heart, ileum, and esophagus, all of which were
shown to be positive for vWF staining with evident
microvasculature.
Next we examined scFv A7 reactivity with the
microvasculature of normal human synovial tissue ob-
tained from subjects undergoing joint arthroscopy for
prolonged, unexplained knee pain that did not develop
into arthritic conditions during a 5-year followup survey
(28). The results presented in Figure 5B are represen-
tative of 11 samples and demonstrate that the microvas-
culature found in normal human synovium, as detected
by vWF reactivity, contains a stromal vascular compo-
Figure 4. In vivo targeting of human arthritic synovial tissue with 125I-labeled single-chain Fv (scFv) A7 antibody. The ability
of scFv A7 to preferentially target the microvasculature of human arthritic synovial xenografts in vivo was examined by injecting
iodinated scFv A7 (black) into SCID mice bearing dual synovial and skin xenografts. Graft tissues were examined by gamma
counting 4 hours (n  5) and 24 hours (n  6) after antibody administration. The results were corrected for tissue weight and
background radioactivity in the blood pool and expressed as tissue-to-blood ratios of the percentage of the injected dose.
Iodinated scFv HEL (gray) was used as a negative control. Results are expressed as the mean  SEM.   P  0.0079;
  P  0.0513 versus skin graft injected with 125I-labeled scFv A7, by unpaired 2-tailed t-test.
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nent as detected by -smooth muscle actin reactivity. In
contrast, scFv A7 showed no reactivity with the micro-
vasculature found in these synovium samples.
Finally, in order to establish whether the reactiv-
ity of scFv A7 is specific to the microvasculature of
arthritic synovium or a common feature of neovasculo-
genesis related to the presence of inflammation, we
examined scFv A7 staining in tissue samples from pa-
tients with Crohn’s disease (n 7) and psoriasis (n 5),
where the presence of microvasculature was detected
using anti-human vWF. The results presented in Figure
6 demonstrate that scFv A7 exhibits no detectable
reactivity with the microvasculature found in tissues
from patients with either Crohn’s disease or psoriasis.
Thus, these results demonstrate that the target epitope
for scFv A7 is absent from normal human tissues and
microvasculature and is not expressed in the neovascu-
logenesis seen in inflammatory conditions. Taken to-
gether, these results further support the conclusion that
scFv A7 is specific for the microvasculature found in
arthritic synovium.
DISCUSSION
Over the past decade, the therapy of RA has been
transformed through the application of recombinant
Figure 5. Immunohistochemistry of scFv A7 in normal human tissues. A, Assessment of reactivity of scFv A7 antibody with normal human tissues
using a paraffin-embedded whole-body survey tissue microarray. Bound biotinylated scFv A7 antibody was detected using avidin–HRP conjugate.
The presence of blood vessels in tissue samples was visualized with anti-human vWF antibody and an HRP-labeled secondary antibody.
Representative areas in selected samples at top (dashed circles) are presented at higher magnification at bottom. Bar  100 m. B, Reactivity of
scFv A7 with normal human synovial tissue. Sequential sections show blood vessels that stain with vWF and -actin. No reactivity is observed using
scFv A7 antibody. Images shown are representative of 11 independent samples examined. Arrows indicate the position of microvessels. Bar  50
m. See Figure 1 for definitions.
Figure 6. Reactivity of scFv A7 antibody with the microvasculature of
inflammatory tissues. The reactivity of scFv A7 with normal colon,
colon from patients with Crohn’s disease, normal skin, and psoriatic
skin was assessed. The presence of microvasculature was visualized
using anti-human vWF antibody. Biotinylated scFv A7 was detected
with avidin–biotin–HRP complex, while anti-vWF antibody reactivity
was detected using an HRP-labeled secondary antibody. Images shown
are representative of the 5 normal colon samples, 7 samples of colon
from patients with Crohn’s disease, 5 psoriatic skin samples, and 3
normal skin samples examined. Bar  100 m. See Figure 1 for
definitions.
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antibodies targeting inflammatory cytokines (24). How-
ever, despite the obvious impact of these agents, high-
magnitude responses and treatment-free remission re-
main elusive goals (29,30). Further, many patients
remain nonresponders or partial responders (14), and
within the responder cohort a loss of efficacy can be seen
over time, as can specific adverse effects (31,32).
The development of new therapeutics for RA,
with the ability to elicit greater clinical responses and
acceptable safety profiles, remains an unmet need. To-
ward this aim, we have used a human synovial xenograft
model established in our laboratory (19,20) to carry out
in vivo phage display selection of scFv antibodies with
specificity for the human synovial microvasculature. In
this model, synovial grafts implanted subcutaneously
into SCID mice remain viable and continue to express
human tissue–specific markers (17,20). Using this ap-
proach we have isolated and characterized scFv A7, a
novel human scFv antibody that efficiently and prefer-
entially targets the synovial microvasculature in RA, and
we have demonstrated that this antibody specifically
recognizes perivascular cells in this tissue. Abnormalities
of vascular morphology and angiogenesis in arthritic
synovium have been previously described at the macro-
scopic, histologic, and molecular levels (11,33). It is well
established that blood vessels of inflammatory tissue
lack the tight endothelial monolayer essential for normal
barrier function, resulting in increased endothelial per-
meability (leakiness) and extravasation of immune cells
to the extracellular space (34,35). In this context, given
that our in vivo phage screening strategy is against
human synovial grafts vascularized by permeable vessels,
the selection of an antibody that recognizes a stromal
vascular antigen is not surprising.
Our results demonstrate that the reactivity of
scFv A7 is specific to the microvasculature of arthritic
synovium, since the antibody does not exhibit reactivity
with the microvasculature or other cellular components
of normal human tissue from a spectrum of organs.
Further, expression of the scFv A7 epitope is not a
general feature of neovasculogenesis, since we detected
no binding to the microvasculature of the tissue from
patients with Crohn’s disease or psoriasis. These results
indicate that the expression of the epitope for scFv A7 is
likely to be tissue specific and restricted to the micro-
vasculature found in arthritic synovium rather than a
feature of the microvasculature seen in neoangiogenesis
or vasculogenesis in inflammatory diseases. The specific
reactivity of scFv A7 suggests that the target molecule
for scFv A7 may have potential as a biomarker in
arthritis and may also have applications as an immuno-
therapeutic target in the development of new strategies
for therapy of this condition.
Angiogenesis is an important and possibly a
primary event in the pathogenesis of the chronic inflam-
matory process of RA (36). Hence, targeting angiogen-
esis could play a part in a polypharmacy intervention
strategy for the treatment of arthritic disease (9,37–39).
In the course of angiogenesis, the associated tissue
remodeling leads to the expression and/or exposure of
molecules on endothelial and perivascular cells, which
are inaccessible, much lower in abundance, or undetect-
able in healthy adult tissues. For example, the oncofetal
extra domain B (ED-B) of fibronectin represents one of
the best characterized markers of angiogenesis (37) and
is abundantly expressed in many diseases including RA
(38,40). Moreover, antibody-mediated targeted delivery
of proinflammatory cytokines using L19, the human
antibody specific for ED-B (41), can result in a signifi-
cant increase in the therapeutic index of biopharmaceu-
ticals in animal models of cancer (42,43) and has re-
cently been evaluated for interleukin-2 (IL-2) and TNF
delivery in phase I and II clinical trials (39). Further, L19
together with F8, an antibody specific for the ED-A of
fibronectin, have been used to deliver IL-10 to inhibit
the progression of collagen-induced arthritis (38,44).
Most recently, 3 recombinant human antibodies specific
for matrix metalloproteinases 1, 2, and 3 have been
developed and are currently being evaluated for
antibody-based pharmacodelivery applications in arthri-
tis (45).
Taken together, these findings clearly demon-
strate the utility of perivascular and stromal targeting for
the development of ligand-based strategies for treat-
ment of arthritic disease. In this context, we have shown
that in vivo, scFv A7 can target the microvasculature of
arthritic synovium efficiently and is preferentially re-
tained on the target tissue for at least 24 hours after
systemic administration. These data provide functional
evidence for the potential use of scFv A7 as an agent to
target therapeutics to the arthritic joint.
Although vascular targeting research has mainly
focused on tumor angiogenesis, the development of
nononcologic applications has recently gained momen-
tum and is likely to become an important area of
pharmaceutical intervention. Over the last decade, a
spectrum of innovative bispecific antibody formats has
been described, with scFv fragments being extensively
used as fundamental building blocks to develop 13 novel
antibodies that are currently in clinical phase I and II
trials (46), as well as a spectrum of new candidate
antibodies with biologic potency (47, 48). As described
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here, scFv A7 represents a new building block for the
development of vascular targeting of biopharmaceuti-
cals, capable of selective accumulation at neovascular
sites in RA.
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